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Abstract 
Background 
Ethnic minority groups (EMGs), including South Asian and Middle Eastern 
populations, often have a high prevalence of chronic diseases. This may lead to co-
morbidities, multiple drug therapies and consequently medicine-related problems 
(MRPs). People from different cultural backgrounds may experience language 
barriers, or demonstrate different beliefs and experiences. These people may have 
different needs and expectations from health and pharmacy services which may 
affect their ability to use medicines effectively. It is acknowledged that EMGs have 
experienced inequalities in health and in accessing healthcare services. There have 
been many studies on health problems of EMGs especially regarding access to care 
but there has been little research which specifically examines medicines use. Thus, 
the aim of this study was to characterise and examine MRPs from the perspective of 
SA and ME patients and to identify reasons which may contribute to MRPs.  
Method 
The study was a cross-sectional study. Patients were from SA and ME origins, aged 
over 18 and prescribed three or more regular medicines. Patients were identified 
through previous medicine use reports (MUR), patient medication records (PMR) or 
when presenting with a prescription. The data were collected in 80 face-to-face 
semi-structured interviews in seven pharmacies in London using MRPs tool. 
Interviews were audio-taped; transcribed verbatim and analysed thematically using 
Gordon’s coding frame and Nvivo 10 software.  
Results 
Interviews were held with 80 patients. Final analysis showed the following types of 
MRPs that influenced adherence and informed decision-making among participants: 
adverse drug reactions and drug interactions; intentional non-compliance; 
cognitive, physical and sensory problems; and issues with concurrent use of herbal 
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and alternative therapies. Problems with drug-prescribing; lack of information; 
monitoring and review; repeat prescriptions; GP surgery and pharmacy service were 
also identified. Interviews revealed that many factors may contribute to MRPs 
occurrence and some appeared to be specific to SA and ME cultures. These factors 
comprised religious practices and beliefs, extent of family support, and travelling 
abroad back to patient’s home land or to take religious journeys. Perceptions of 
healthcare providers, difficulty consulting a doctor of the same gender, lack of 
referrals to specialised care, language and communication barriers, lack of 
translated resources, illiteracy, lack of involvement in the treatment decisions, lack 
of knowledge and understanding (e.g., problems with source, delivery, type and 
timing of information) may also contribute to the problems. However, other 
reported factors were similar to the general population.  
This thesis provided evidence that non-adherence to medications and poor health 
status among SA and ME patients is a significant problem of a striking magnitude. 
The current study also highlighted differences between SAs and MEs participating in 
the study and so far it is the only one to propose a tool that can be used in SA and 
ME populations to identify MRPs and to detect factors that may contribute to the 
problems. 
Discussion and Conclusion 
This study demonstrated that SA and ME patients have their own problems and 
needs with both medicine use and service access. It also highlighted the crucial role 
that patients play in the management of their own illnesses. By uncovering 
particular problems experienced by these groups the study can inform healthcare 
professionals to support SA and ME patients in the use of their medicines; for 
example, developing medication use review further and adding the specific issues 
that were reported by SA and ME groups. Development of pharmaceutical care 
plans specific for SA and ME groups is also recommended. Interventions tailored to 
patients’ needs and wants may also be required to improve medication use and 
service access.  
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Overview of thesis contents 
Chapter 1 – Introduction and background 
 
The introduction presents background information on chronic diseases, ethnic 
minority groups and medicine-related problems. The background information 
summarises the current knowledge in these areas and highlights the gaps in the 
literature and the importance of doing this research and finally presents a flow 
diagram on how this research project addresses the knowledge gap. This chapter 
shows that ethnic minority groups (EMGs) are increasing and they often have a high 
prevalence of chronic diseases. This may lead to co-morbidities, multiple drug 
therapies and consequently MRPs. People from different cultural backgrounds may 
experience language barriers, or demonstrate different beliefs and experiences. 
These people may have different needs and expectations of health and pharmacy 
services which may affect their ability to use medicines effectively. It is 
acknowledged that EMGs have experienced inequalities in health and in accessing 
healthcare services. There have been many studies on health problems of EMGs 
especially regarding access to care but there has been little research which 
specifically examines medicine use. 
 
Chapter 2 – Medicine use and medicine-related problems experienced by ethnic 
minority patients in the UK: a review 
 
The focus of this chapter was to review the published studies on MRPs in EMGs in 
the UK. The aim of this review was to establish type(s) and possible contributing 
factor(s) of MRPs experienced by ethnic minority populations in the UK and to 
identify interventions or recommendations to support these groups in their use of 
medicines. This review highlights that ethnic minority patients have their own 
problems and needs with regard to both medicine use and service access. Little 
evidence is known of what influences MRPs among ethnic minority groups, despite 
the increased diversification of populations in countries throughout the world. It 
was highlighted that one of the most striking reasons for the lack of progress in the 
research might be the absence of the patient’s perspective. Therefore, there is a 
need for further research to be done in this area and for these patient groups. This 
review has been published in the International Journal of Pharmacy Practice. 
 
Chapter 3 – Research context and methodology 
 
This chapter reports the theoretical framework of the main study and justifies the 
selection of particular measures and procedures to achieve the study objectives. It 
also describes the research design and methods used in this research for data 
collection to meet the aim and objectives of the main study. Finally, it reports the 
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outcomes of the preliminary study conducted to identify logistical problems for the 
main study. This study was a cross-sectional study. Patients were from SA and ME 
origins, aged over 18 and prescribed three or more regular medicines. Patients 
were identified through previous medicine use reports (MUR), patient medication 
records (PMR) or when presenting with a prescription. The data were collected in 
80 face-to-face semi-structured interviews in seven pharmacies in London using 
MRPs tool, 8-item MMAS, and EQ-5D-3L. Interviews were audio-taped; transcribed 
verbatim and analysed thematically using Gordon’s coding frame and Nvivo 10 
software. SPSS 21 software was used to analyse quantitative data. The pilot work 
indicated that the potential response rate for patients in the main study would be 
high, if the recommended steps to increase response rate in Chapter 3 were closely 
followed. Inviting patients when they presented in the pharmacy was the best 
method to recruit patients. The pilot also showed that the methods used were 
acceptable and workable for the main study. 
 
Chapter 4 – Recruitment, response rate and characteristics of the sample 
 
This chapter reports the recruitment and response rates of pharmacies and 
patients. It also involves a description of the characteristics of the participating 
pharmacies, the SA and ME patients participating in the interview, and the SA and 
ME patients who did not take part in the interview. Finally, it describes the 
challenges in the recruitment and data collection process. This chapter highlighted 
that, in order to facilitate recruitment of community pharmacies, in-person visits 
should be made to non-responding pharmacies. The present study also showed that 
SA and ME patients were willing to take part, unlike what had been reported by 
some of the previous studies. An approach to the patient in-person by a healthcare 
professional (HCP) whom the patient knows and/or by a researcher who speaks the 
same language might increase the response rate. This chapter also outlined that 
there is a need to address the challenges encountered during recruitment and data 
collection process when recruiting patients from the same origins. 
 
Chapter 5 – A description of the MRPs and the reasons that may contribute to 
MRPs and appeared to be similar to the general population from patients’ 
perspectives 
 
Chapter 5 reports the number and types of MRPs that were identified during the 
current study. It also describes the reasons that may contribute to MRPs from 
patients’ perspectives and appeared to be similar to the general population, along 
with direct quotes from participants’ interviews. The main finding of this chapter is 
that many problems that were identified in SA and ME groups were similar to the 
general population. All the MRPs identified may affect the safe use of medicines 
and medication adherence if not addressed. All the MRPs could be detected and 
prevented in the community by communicating with the patients, providing 
expanded services and reviewing patients’ records in the pharmacy. An 
independent decision-making process was followed by many participants in the 
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current study regardless of the medical advice. This resulted in participants 
empowering themselves not to take their medicines as prescribed. Thus, strategies 
for informing and empowering patients in treatment decision-making should be 
high on the policy agenda. There is also a need to implement changes at the 
primary care level, with the aim of improving the equity of access to primary care 
services for SA and ME patients. 
 
Chapter 6 – Contributory factors to MRPs that may be specific to SA and ME 
cultures 
 
Chapter 6 describes the reasons that may contribute to MRPs and were reported to 
be specific to SA and ME cultures, along with direct quotes from participants’ 
interviews. Interviews revealed that many factors may contribute to MRPs. Some 
factors appeared to be specific to SA and ME cultures which included religious 
practices and beliefs; extent of family support; and travelling abroad back – to their 
homeland or to take religious journeys. Perceptions of healthcare providers, 
difficulty consulting a doctor from the same gender, lack of referrals to specialised 
care, language and communication barriers, lack of translated resources, illiteracy, 
lack of involvement in the treatment decisions, lack of knowledge and 
understanding (e.g., problems with source, delivery, type and timing of information) 
may also contribute to the problems. Thus, HCPs should support patients by talking 
to them more openly and providing tailored advice and education in relation to 
their specific needs and wants to enable them to manage their medicines 
effectively. 
 
Chapter 7 – Comparing South Asian and Middle Eastern participants 
 
Chapter 7 describes the differences between SA and ME participants in terms of 
response rate, demographic details, medication-taking behaviour, and pharmacy 
and health service issues experienced by these two populations. Poor participation 
was detected among SA women. Looking at the demographic details, some 
differences were found between SA and ME groups in terms of age, religion, main 
language and year of coming to the UK. The principal distinctions in terms of 
medicine use and service access between the two groups were found in the 
following: the extent to which participants reported consulting a pharmacist, the 
absence of a pharmacist who speaks the same language among ME respondents, 
the use of multiple pharmacies, access to GPs and other services, the extent of 
family support/help with medicines, and medication-taking behaviour. This chapter 
has shown that each ethnic group might have its own distinct characteristics, 
problems and needs. Therefore, care and treatment for all needs to be culturally 
sensitive and delivered according to each individual’s wishes. 
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Chapter 8 – The adaptations made to the original MRPs questionnaire and coding 
frame for the use of SA and ME groups 
 
Chapter 8 provides a brief overview of the original MRPs questionnaire constructed 
and validated by Gordon.  This chapter also illustrates our findings in relation to 
each part of the tool in order to identify what additional issues were discovered 
among SA and ME groups which would not be captured by the original MRPs 
questionnaire. The purpose of this was to make recommendations for the tool to be 
valuable for the use in these populations and to offer recommendations for the 
coding frame. In summary, Gordon’s MRPs tool was adapted by the researcher with 
minor modifications mainly to capture the experiences and views of SA and ME 
patients regarding use of medicine and access to services and to address reasons 
that may lead to MRPs which are specific to these groups. The principal changes 
were in describing the extent of support provided to patients by their families 
(section 1), adding additional patients’ characteristics (section 2), providing 
additional prompts to capture the reasons for intentional non-compliance that are 
important to SA and ME groups (section 3), presenting additional prompts to 
capture the problems that are likely to face ME and SA groups in accessing 
healthcare services (section 5), describing patients’ perception of pharmacists’ role, 
pharmacy services and MUR service (section 5), and, finally, asking for 
recommendations or advice from patients in order to provide care that is better 
tailored to their needs. The revised version of this tool could be used as an 
instrument in the MUR for these patients to detect MRPs. In terms of 
recommendation for the coding frame, no changes should be made to the original 
coding frame apart from adding 11 new sub-categories that were identified in the 
current study. It is also recommended to review patients’ records in GP surgeries 
and pharmacies and to conduct home interviews in order to be able to identify a 
wide range of MRPs that are included in the coding frame. 
 
Chapter 9 – The perspectives of pharmacists on MRPs identified and 
recommendations made by the researcher  
 
Chapter 9 examines the perspectives of pharmacists on the MRPs identified and 
recommendations made to address medicine-related problems among SA and ME 
groups. The main purpose of this chapter was to validate the MRPs identified in the 
current study and to test the recommendations made. This chapter provides a 
theoretical framework for MRPs from pharmacists’ perspectives. It also supports 
developing MUR further and adding the specific issues that were reported by SA 
and ME groups to support these groups in their use of medicines. The findings also 
support the development of pharmaceutical care plans specific for SA and ME 
groups. The interviews with the pharmacists confirmed the presence of specific 
issues among SA and ME groups and highlighted the need to implement changes at 
primary care and community level, with the aim of addressing MRPs among SA and 
ME patient and supporting their needs and preferences such as prioritising 
medication use review to SA and ME groups, increasing patient education and 
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counselling, providing verbal and written information in patients’ preferred 
language and according to their needs and wants, and raising awareness of SA and 
ME cultures among HCPs. 
 
Chapter 10 – 8-item Modified Morisky Adherence Scale (MMAS)  
 
Chapter 10 assesses the extent of non-adherence among SA and ME patients using 
the 8-item MMAS. This chapter provided evidence that SA and ME patients (53/79, 
67%) had poor medication adherence using the 8-item MMAS. In the current study, 
the MRPs tool as well as the 8-item MMAS was used for the assessment of 
adherence to medications. Comparison of data from both methods revealed that 
what one method suggested was sometimes similar or different to or even 
conflicting with the other. Even sometimes when the two methods agreed, the 
participants appeared to have different incidents in mind when reporting their non-
adherence behaviour using these different methods. This implies that the 
usefulness of each method for the assessment of non-adherence to medications is 
limited when used solely. It is therefore recommended that data from one method 
should be assessed with reference to the other. What is missing from one method 
can be completed by the other. 
 
Chapter 11 – Discussion 
 
Chapter 11 discusses separately: (1) the main key findings on what is new; (2) 
personal reflections about the research; (3) strengths and limitations of the study; 
(4) implications of the results for practice and policy; (5) suggestions for future 
work; and (6) research contributions (i.e., how this thesis has contributed to the 
knowledge and understanding of MRPs among SA and ME patients). 
 
Chapter 12 – Conclusion 
 
Chapter 12 summarises and brings together the main areas covered in this thesis 
and also makes some recommendations. 
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Chapter 1 Introduction and background  
1.1 Chronic diseases 
Chronic diseases are also known as long-term conditions (LTCs) and life-long 
diseases/conditions (WAG/NPHS, 2006). Although chronic disease has been defined 
by many sources, there is no widely agreed definition. Chronic diseases are defined 
as “diseases of long duration and generally slow progression” (WHO, 2005) or 
as “diseases which current medical interventions can only control not cure by 
medication and other therapies. The life of a person with a chronic condition is 
forever altered and there is no return to normal” (DoH, 2004; DoH, 2008). 
According to Cheever et al. (2009) chronic diseases have been defined as “medical 
or health problems with associated symptoms or disabilities that require long term 
management of three months or longer.” (Cheever et al., 2009). In this study the 
definition of Cheever et al. has been employed because in it they recognised that 
patients with LTCs require “long term management” which may involve using a 
complex and wide range of medicines to manage these conditions and frequently 
may lead to medicine-related problems (MRPs).  
Long-term conditions include cardiovascular diseases (CVD) – mainly heart diseases 
and stroke – cancer, chronic respiratory diseases and diabetes (WHO, 2005; DoH, 
2008). There are many other chronic conditions and diseases that contribute 
significantly to the burden of disease on individuals, families, societies and 
countries. Examples include mental disorders, chronic kidney diseases, bone and 
joint disorders and genetic disorders (WHO, 2005).  
Across the globe, the burden of chronic diseases is increasing. The World Health 
Organisation (WHO) has estimated that 75% of the populations have at least one 
LTC (WHO, 2005). The number of people with chronic diseases is also rising in the 
UK. For example, there are around 15.4 million people (33.2%), or almost one in 
three of the population, with a LTC in England (DoH, 2008). In Wales, it was noted 
that 23% of adults reported having a LTC (WAG/NPHS, 2006). In Scotland, it was 
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indicated that, between 2005 and 2006, 23.6% of adults reported some form of LTC, 
health problems or disability (Scottish Government Social Research, 2007). These 
variations in prevalence of LTCs between England, Wales and Scotland are possibly 
due to several factors such as age of patients with LTCs, socio-economic status, 
lifestyle choices and rurality.  
LTCs are now the most common cause of mortality and disability in the world 
(WHO, 2005). It is estimated that 85% of deaths in the UK are from chronic 
diseases.  Within this, 36% of all deaths will be from cardiovascular disease and 7% 
from chronic respiratory disease (DoH, 2008). The World Health Organisation has 
identified that such conditions will be the leading cause of disability by 2020 (WHO, 
2005) and that, if not successfully managed, they will become the most expensive 
problem for healthcare systems (DoH, 2008).  
Both incidence and prevalence of chronic diseases are expected to increase in the 
UK (DoH, 2008). One of the main reasons for this is that the population of the UK is 
ageing and as people get older they are more likely to develop one or more LTC. For 
instance, the number of people in England with a LTC is set to increase by 23% over 
the next 25 years due to the ageing population (DoH, 2008). However, not all 
people with LTCs are elderly; for example some adults will have lived with a LTC 
from birth or childhood or may have acquired a LTC in adulthood. Others may have 
developed or exacerbated a LTC as a result of lifestyle factors which can contribute 
to the increase of LTC, such as unhealthy diet, excessive energy intake, physical 
inactivity, alcohol consumption and tobacco smoking (WHO, 2005). 
Living with a LTC has a significant impact on a person’s quality of life, independence 
and economic wellbeing. It is reported that patients with LTCs are very intensive 
users of healthcare services. For example, those with LTCs account for 31% of the 
population but use 52% of all GP appointments and 65% of all outpatient 
appointments (DoH, 2008). It is also estimated that the treatment and care of those 
with LTCs accounts for 69% of all primary and acute care budgets in England (DoH, 
2008). The majority of patients who have one or more LTC account for 49% of all in-
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patient hospital bed days (DoH, 2008).   The UK economy stands to lose £16 billion 
over the next 10 years through premature deaths due to heart disease, stroke and 
diabetes (DoH, 2008). Total long-term care expenditure in general is forecast to 
increase by 103% to £26.4 billion (DoH, 2008).     
In addition to the negative impact on individual sufferers, families and carers of 
patients with LTCs are also affected indirectly through additional care 
responsibilities undertaken (Francis et al., 2002). Tackling chronic disease is 
therefore a critical challenge in healthcare and 
The impacts of chronic diseases can be significantly reduced through chronic 
disease prevention and management efforts (Bromeling et al., 2005; Bromeling et 
al., 2008). While, in the past, many chronic disease prevention strategies have 
focused on interventions aimed at modifying individual lifestyle and behavioural 
risk factors associated with increased risk of chronic disease (e.g., smoking, diet, 
and physical activity), there is growing evidence that such approaches will have 
limited success. Research shows that community- and systems-level approaches 
that target the social, economic, and environmental root causes of poor health can 
be more effective at preventing chronic disease and can greatly improve the overall 
health of the population (Bromeling et al., 2008; Marmot, 2010).  
there is a huge benefit to the 
population and financial savings if health and social care communities try to find the 
best ways to help people manage their chronic diseases effectively, for which 
effective management depends on the appropriate use of medicines. 
Chronic diseases and disability are increasing throughout the world and affect 
people of all ethnicities (WHO, 2005; Jack et al., 2006). However, differences in 
prevalence rates of chronic diseases among various ethnic groups have been 
identified which indicate the presence of health inequalities within the society. 
Therefore, the next section will introduce the reader to the definition, prevalence 
and illness profile of ethnic minority groups and the experience of health 
inequalities among these groups in the UK.   
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1.2 Ethnic Minority Groups (EMGs) and health inequalities 
The concept ‘ethnic minority’ refers to many different ethnic groups of extreme 
heterogeneity. The concept is used for groups that share minority status in their 
country of residence due to ethnicity, place of birth, language, religion, citizenship 
and other (cultural) differences. It sets apart a particular group in both numerical 
and (often) socioeconomical terms. Members of these groups are considered to 
practise different cultural norms and values from the majority culture and (often) 
have a different mother tongue. Ethnic minorities vary in duration of stay and 
acculturation, and between different ethnic minorities there exist different degrees 
of access to the majority culture. The concept of ethnic minority includes groups 
from newly arrived immigrants to (minority) groups that have been a part of a 
country’s history for hundreds of years (Blais and Maı¨ga, 1999; Scheppers et al., 
2006). Four ways have been used to establish ethnicity in the UK. Firstly, parental or 
preferably grandparental origin. Secondly, self-identity (i.e., permitting people to 
assess their own identity, which is in keeping with the patient-centred approach of 
the UK). Thirdly, appearance, which has poor reproducibility and does not serve a 
scientific role (Oldroyd et al., 2005). Finally, visual inspection of forename and 
surname, which has been used in several published studies (Nicoll et al., 1986; 
Rashid and Jagger, 1992; Martineau and White, 1998; Jessa and Hampshire, 1999; 
Platt and Tann, 1999; Chan, 2000; Nanchahal et al., 2001; Bouwhuis and Moll, 2003; 
Fiscella and Fremont, 2006).  
The ethnic minority population in the UK grew rapidly in the post-World War II era. 
In 1951, the population numbered 80,000, growing to 500,000 in 1961, 1.5 million 
in 1971 and increasing further to 2.2 million in 1981 (McGarrigle, 2010). A large 
amount of primary migration occurred between 1948 and 1974. Since then, most 
growth in this population has been possibly due to natural increase, as over half of 
the Caribbean and Pakistani population in Britain are UK-born (McGarrigle, 2010). 
By 1991, the census recorded the minority ethnic population as numbering 3.1 
million or 5.5% of the total population, growing to 4.6 million or 7.9% of the total 
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population in 2001, and to 8.2 million or 13% of the total population in 2011 (ONS, 
2004; McGarrigle, 2010; ONS, 2011). 
The ethnic composition of the UK, based on 2011 census data, was more varied 
than ever before. There had been a dramatic increase in ethnic diversity in all 
regions (ONS, 2011). The 2011 census in England revealed the largest ethnic 
minority group (EMG) to be Asian or Asian British (6.9%) including Indian (2.3%), 
Pakistani (1.9%), Other Asian (1.4%), Bangladeshi (0.7%) and finally Chinese (0.7%). 
This is followed by Black or Black British (3%), Mixed Ethnicity (2%), Other Ethnic 
Group (0.9%) and finally White Irish (0.1%) (ONS, 2011). In general terms, the 
possible reason for the increasing proportion of ethnic minorities in the UK could be 
due to continued immigration and high birth rate in some ethnic groups (Memon et 
al., 2002) and possibly because some people may have been missed from the 2001 
estimates. 
The National Health Service (NHS) in the UK is facing challenges of demographic 
changes, technological advances, new diseases and increased consumer 
expectation and sophistication (Rawaf and Bahl, 1998). These mean increasing 
demands on health services, rising costs and considerable organisational changes to 
meet these challenges and demands. Thus, health authorities have to develop 
strategies for improving the health of their local population by understanding 
realistic needs assessments. The White Paper relating to the NHS highlights new 
responsibilities and roles for health authorities, trusts and primary care groups 
(Secretary of State for Health, 1997). Our healthier nation, the Green Paper, 
describes action by the government in partnership with local organisations to 
improve people’s living conditions and health (Secretary of State for Health, 1998). 
It puts forward specific targets for tackling some of the major killer diseases and 
proposals for local actions. 
The government’s public health agenda is set to tackle causes of illness and reduce 
inequalities in health (Rawaf and Bahl, 1998). The key determinants in health (e.g., 
education, income, employment, geographic region, housing, social exclusion, 
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pollution, minority status, age and gender) are important issues when talking about 
the health of EMGs (Marmot, 2010). Health inequities refer to the differences in 
health status among population groups that are deemed to be unfair, unjust, or 
preventable, as well as socially produced and systematic in their distribution across 
the population (Marmot, 2007). Inequality in health is based on complex social, 
cultural, and economic processes. 
The inequalities among the three million people (6% of the total population) in 
ethnic minority groups are very striking. Examples of these are the high proportion 
of manual classes in Pakistani and Bangladeshi populations in comparison with the 
White population. Unemployment is highest in Bangladeshi men, with 1 in 3 
unemployed. Unemployment in young adults of all EMGs exceeds that in Whites. 
There are marked ethnic differences in housing tenure. Over a third of Black and 
Bangladeshi households reside in accommodation rented from the local authority. 
Variations in housing conditions show dramatic differences between EMGs. Whilst 
2% of White households are overcrowded, 47% of Bangladeshi and 29% of Pakistani 
households are overcrowded (Rawaf and Bahl, 1998). It is estimated that the 
additional NHS healthcare costs associated with health inequalities are in excess of 
£5.5 billion a year (Marmot., 2010). 
EMGs often concentrate in the inner city and are clustered in particular areas. In 
some inner city areas EMGs comprise the majority of the population. The 2001 
Census found that nearly half (48%) of the total minority ethnic population lived in 
the London region, where they constituted 29% of all residents (ONS, 2004). By 
2031, 39% of London’s population is projected to be from an ethnic minority group 
(GLA, 2010). This compares with 32% in 2006 and 29% in 2001 (GLA, 2010). 
It is important to understand the diversity among EMGs. They are not one 
homogenous group. Each group has its own distinct characteristics and health 
status. Almost all ethnic minority populations have a younger age structure than the 
White group. However, the Pakistani and Bangladeshi groups have a much younger 
age profile than other EMGs. The variations in health status and disease patterns 
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among EMGs are very marked in some areas and are distinctly different from that 
of the general UK population. For instance (Rawaf and Bahl, 1998)
• Death rates from coronary heart disease among Asians aged under 65 years 
are more than 50% higher than the England and Wales average. 
: 
• The death rate from stroke among those aged 65 years who were born in 
the Caribbean is nearly twice as great as the England and Wales rate. 
• Perinatal mortality among Pakistani-born mothers is nearly twice the UK 
national average. 
• Sickle cell disease occurs most commonly in the African and African-
Caribbean populations. 
• Diagnosis of schizophrenia may be 3-6 times higher among African-
Caribbean groups than in the general population. 
• Rates of uptake of cervical screening among Bangladeshi women are less 
than half of those among the general population.  
• South Asians, in general terms, have a higher prevalence of chronic diseases 
including diabetes and cardiovascular disease (CVD) (Raleigh, 1997; Memon 
et al., 2002; Memon et al., 2003; Yusuf t al., 2004; NHS Health and Social 
Care Information Centre, 2005; Bhopal, 2007; Jayawardena et al., 2012) than 
the general population. They also have higher mortality and morbidity from 
such diseases than average (Raleigh, 1997; Memon et al., 2003), shorter life 
expectancies (Lee, 1998), and poorer health outcomes from these 
conditions than the majority of the population (Memon et al., 2003; Bhopal, 
2007). 
 
It is well documented that EMGs find it difficult to access healthcare services 
(Scheppers et al., 2006). Services provided are often not appropriate and language 
and cultural barriers prevent a useful dialogue between patients and healthcare 
professionals (HCPs), often leading to EMGs not receiving health advice or not 
having an understanding of NHS procedures (Rawaf and Bahl, 1998; Scheppers et 
al., 2006; Mead et al., 2009; Kontopantelis et al., 2010).  
People from many ethnic minority groups tend to perceive themselves as less 
healthy than those in the general UK population. In particular, those of South Asian 
origin reported ‘bad’ or ‘very bad’ health when they were asked to self-assess their 
current health status on a five-point scale (e.g., 15% of Bangladeshi men and 10% of 
Pakistani men) (NHS Health and Social Care Information Centre, 2005). The lowest 
prevalence of bad/very bad health was among Black African and Chinese men (4%). 
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As regards women, 14% of Bangladeshi and 15% of Pakistani women reported 
bad/very bad health. As with men, the lowest prevalence was among Chinese 
women (3%) (NHS Health and Social Care Information Centre, 2005). These 
responses suggested that, with respect to the perception of their own general 
health, people from minority ethnic groups considered their health to be worse 
than did the general UK population. This is possibly because some ethnic groups 
may be receiving lower standards of care in terms of poor access (Kontopantelis et 
al., 2010), lower uptake of screening (Naish et al., 1994), less use of antenatal 
services (Chan, 2000) and poor standards of communication when care is accessed 
(Chan, 2000; Mead et al., 2009), particularly when a consultation is conducted in a 
language other than their own (Roberts et al., 1996).  
With this background, health needs assessment must be comprehensive and take 
into consideration the determinants of health. The new NHS White Paper assigns 
clear roles to health authorities, primary care groups, NHS trusts, local authorities 
and the public in the health improvement programme (Secretary of State for 
Health, 1997). Some of the key areas that health authorities have undertaken 
include (Secretary of State for Health, 1997):  
• Assessing the health needs of the local population and implementing 
strategies for meeting those needs, in the form of a health improvement 
programme developed in partnership with all the local interests and 
ensuring delivery of the NHS contribution to it. 
• Increasing understanding among HCPs of the health and disease patterns of 
the EMGs. 
• Provision of appropriate information on health and health services for EMGs 
to increase their understanding of the health and disease patterns within 
their communities; they need to understand the action needed to prevent 
morbidity and mortality. 
• Use of ethnic minority media locally and nationally to promote health 
messages. 
• Development of alliances with local authorities, the voluntary sector and 
public agencies; key players will be individuals and organisations working 
closely with the EMGs.  
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Ethnic minority health should be part of mainstream service delivery. Commissioner 
development is an ideal mechanism for achieving this. Commissioners and 
providers can draw upon a number of Departments of Health initiatives, and HCPs 
and managers must (Rawaf and Bahl, 1998): 
• Involve stakeholders. 
• Improve available information. 
• Consult communities in-depth and more widely. 
• Set local targets and quality standards for ethnic minority health. 
• Build ethnic minority health into the mainstream of the organisational 
process of commissioning and provide programmes to take account of the 
needs of the EMGs. 
• Learn lessons from regular reviews of progress. 
 
The last Labour government commissioned Professor Sir Michael Marmot to 
undertake a strategic review of health inequalities in England post-2010. Its goal 
was to identify the evidence on health inequalities – including on putting evidence 
into practice – and to advise on possible measures to reduce health inequalities in 
the short, medium and long term (to 2020 and beyond) (Marmot, 2010). The review 
concluded that the fundamental drivers of inequalities in health are “inequalities in 
power, money, and resources”. The Marmot review recommended that one of the 
priority policy objectives should be to “improve community capital and reduce 
social isolation across the gradient”, noting that the “extent of people’s 
participation in their communities and the added control over their lives that brings, 
has the potential to contribute to their psychological well-being and , as a result, to 
other health outcomes”.  The review concluded by setting out an implementation 
framework to achieve reductions in health inequities along the social gradient, 
stating that “Without citizen participation and community engagement fostered by 
public service organisations, it will be difficult to improve penetration of 
interventions and to impact on the health inequalities.” (Marmot, 2010).  
The UK Coalition government’s public health White Paper has indicated its support 
for the recommendations of the Marmot Review and most of them are reflected in 
its strategy for public health, healthy lives, and healthy people (Secretary of State 
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for Health, 2010). This support is embedded in localism and the need to build local 
solutions through effective working between public health, the NHS, the wider 
public sector and civil society, supported by the advice and expertise of Public 
Health England and the local public health system. The drive to reduce health 
inequalities will be central to everything they do.   
Since the 1st
Management of chronic diseases and tackling health inequalities can be affected by 
medicine use- and service access- issues, which are referred in this thesis as 
medicine-related problems. Therefore, the next section will define MRPs, identify 
types of MRPs, and present contributory factors that may lead to problems and 
ways to solve and prevent MRPs. 
 April 2013, the NHS has been undergoing major changes in its core 
structure (NHS, 2013). The biggest changes have had an effect on who makes 
decisions about NHS services, how these services are commissioned, and the way 
money is spent. Some organisations such as primary care trusts (PCTs) and strategic 
health authorities (SHAs) were abolished, and other new organisations such as 
clinical commissioning groups (CCGs) were created. However, none of these 
changes will affect how patients access NHS services in England. These changes 
were made because ministers believe that GPs will be more responsive to the needs 
of patients as they have day-to-day contact with them; as a result, this will make 
the NHS more efficient and improve the quality of care.   
1.3 Medicine-related problems (MRPs) 
Drug treatment can effectively improve quality of life, prevent or alleviate 
symptoms, cure disease and finally arrest or slow a disease process. However, drugs 
are powerful and must be handled appropriately. In reality, this does not occur 
because medicines are often prescribed, dispensed or sold inappropriately (Lau et 
al., 2005; Laroche et al., 2007; Spinewine et al., 2007; WHO, 2010) or factors 
prevent patients from taking their medicines correctly or as prescribed (Smith, 
2000, WHO, 2010). It has been shown that inappropriate use of the drugs may give 
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negative health outcomes, such as increase morbidity and mortality (Buajordel et 
al., 2001; Laroche et al., 2007; Mannheimer et al., 2006; Viktil et al., 2006), reduce 
quality of life (Ernst et al., 2003; Viktil et al., 2006), and increase health expenses for 
the patient and for society (Mannheimer et al., 2006; Viktil et al., 2006, WHO, 
2010). 
Inappropriate use of medicines may raise the risk of the occurrence of medicine-
related problems (MRPs) (WHO, 2010). The following section will include different 
terminologies, definitions and classifications of medicine-related problems that 
have been reported in the literature. 
1.3.1 Terminologies, definitions and classifications of MRPs 
In 2004, Van Mil et al. provided a systematic review and critical appraisal of MRPs 
classifications for use during the pharmaceutical care process and research in 
pharmacy. Classifications were assessed according to a clear definition, published 
validation method, and results reflecting process and outcomes, usability in 
pharmaceutical care practice and a hierarchical structure (with main groups and 
subgroups). After searching the literature, Van Mil et al. found that there are 14 
classifications of MRP. This section will only discuss eight classification systems 
identified by Van Mil et al.’s article (Strand et al., 1990; Hanlon et al., 1992; ASHP, 
1996; Krska, et al., 2002; Granada Consensus II, 2002; Westerlund, 2002; NCC-MERP 
Taxonomy, 2003; PCNE, 2010); and two systems identified by a hand search were 
not included in Van Mil et al.’s article because they were published after 2004 
(Gordon et al., 2005; AbuRuz et al., 2006). An overview of MRPs classification 
systems is summarised in Appendix 1. 
Although it seems that the term drug-related problem (DRP) is the most widely 
used term in the literature (Strand et al., 1990; Hanlon et al., 1992; Westerlund, 
2002; Gordon et al., 2005; PCNE, 2010), different researchers give different 
terminologies for problems in pharmacotherapy such as medicine-related problems 
(MRP) (ASHP, 1996), drug-therapy problems (DTP) (Strand et al., 1990; Granada 
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Consensus II, 2002), medicine-therapy problems (MTP) (ASHP, 1996), medication 
errors (ME) (NCC-MERP Taxonomy, 2003), pharmaceutical care issues (Krska, et al., 
2002), and treatment-related problems (AbuRuz et al., 2006). 
MRP, DRP, DTP or MTP are terms that can be used to describe a situation where a 
drug results in consequences other than those intended. These terms can also 
describe a problem that may not lead to unintended consequences, such as an 
increased risk of potential problems. ME is mainly used in the world of health 
maintenance organisations and hospital pharmacy. However, this term 
concentrates more on the healthcare professionals (e.g., physician or nurse) as the 
person causing a problem. It also implies that kind of error can be avoided. The 
term ‘pharmaceutical care issue’ describes potential and actual types of MRPs, and 
identifies causes of MRPs and interventions that should be employed to solve actual 
and prevent potential MRPs. AbuRuz et al. (2006) argued that the term treatment–
related problems should replace the other terms that describe DRPs. This is because 
they believed that the term DRP limits the scope of pharmaceutical care to 
medicine-related care. For instance, untreated conditions (e.g., hypertensive or 
diabetic patients without education about drug therapy or without a prescription to 
treat the condition) are actually a treatment-related problem rather than a DRP.      
Despite the fact that DRP and MRP terms can be used interchangeably, in this thesis 
the term MRPs will be used rather than DRPs, because in the UK the term 
‘medicine’ is more preferred than the term ‘drug’ (Fernandez-Llimos et al., 2005), 
especially given that the word ‘drug’ may also refer to recreational drugs. In 
addition, both DRPs and MRPs refer more directly to the usually undesired outcome 
of drug therapy seen from the patient’s perspective, both actual and potential.  
As became evident from this literature review, definitions for MRPs vary; for 
example, some used a clear definition to address MRPs (Strand et al., 1990; ASHP, 
1996; Krska, et al., 2002; Granada Consensus II, 2002; Westerlund, 2002; NCC-MERP 
Taxonomy, 2003; Gordon et al., 2005; AbuRuz et al., 2006; PCNE, 2010), either a 
wide or a narrow definition; whereas others used no universally accepted definition 
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(Hanlon et al., 1992). The wide definitions of MRP that were employed aimed at 
capturing all sorts of problems as well as actual (i.e., when the patient taking the 
drug is exhibiting a known adverse event) and potential MRPs (i.e., where the 
patient is at increased risk of a known adverse event) (Strand et al., 1990; ASHP, 
1996; Westerlund, 2002; Gordon et al., 2005; AbuRuz et al., 2006; PCNE, 2010). 
Conversely, the narrow definitions of MRP aimed at capturing a specific problem 
such as ME (NCC-MERP Taxonomy, 2003). Some definitions acknowledged the 
patient perspective as the central focus for identifying, resolving and preventing 
MRPs as well as healthcare professionals’ perspectives (Strand et al., 1990; ASHP, 
1996; Westerlund, 2002; Gordon et al., 2005), whereas other definitions focused 
only on healthcare professionals’ perspectives for identifying, resolving and 
preventing MRPs (Hanlon et al., 1992; Granada Consensus II, 2002; Krska, et al., 
2002; NCC-MERP Taxonomy, 2003; AbuRuz et al., 2006; PCNE, 2010). 
It is believed that, when a broad definition is used, an increased number of MRPs 
can be identified. Thus, in this thesis a broad definition will be employed to address 
MRPs. The majority of MRPs classification systems that use a broad definition to 
address MRPs (ASHP, 1996; Westerlund, 2002; AbuRuz et al., 2006; PCNE, 2010) do 
not vary widely from the one originally introduced by Strand et al. (1990). In this 
thesis the definition of Gordon et al. (2005) will be used because it includes all 
aspects of MRPs and focuses on patients’ experience and perspective, which are 
very important in order to support the entire population in the use of medicines.   
All MRPs classification systems categorise the type of MRPs identified but very few 
have a hierarchical structure that separates problems from causes and 
interventions (AbuRuz et al., 2006; PCNE, 2010). Only four classifications have been 
validated (Westerlund, 2002; Gordon et al., 2005; AbuRuz et al., 2006; PCNE, 2010). 
However, all the classification systems were tested as to their usability in practice.  
In general terms, several MRPs classification systems have been identified from the 
literature but a lack of agreement concerning terminologies, definitions and 
classifications of MRPs has been noticed. This can probably be explained by the fact 
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that the activity of counselling patients is a new one for pharmacists. Consequently, 
many pharmacists are working to find the best practice and to create tools that 
support their way of practising. In addition, terminology, definition and 
classification system of MRPs used depends usually on the focus of the inquiry. As a 
result, a variety of different definitions, classifications, practices and tools emerge. 
However, it is generally agreed that a comprehensive, well-conducted and validated 
instrument is currently lacking (Van Mil et al., 2004; AbuRuz et al., 2006). 
From our perspective, a good classification system: (1) should have a clear 
definition of the MRPs; (2) it should also be validated and usable in practice; (3) it 
should be structured in a hierarchical way, clearly separate cause from problems 
and preferably also have an intervention section. The only three classifications that 
meet the first two criteria are PCNE, Gordon, AbuRuz systems. Although Gordon et 
al.’s system has no hierarchical structure, it will be employed as a guide to classify 
MRPs in this thesis. This is because this system includes all aspects of MRPs and 
focuses on both patients’ and healthcare professionals’ perspectives. In addition, 
this system does not only address medicine-related problems but also service-
related problems that many ethnic minority patients are experiencing. Moreover, 
the Gordon system is usable in practice and was tested among people from Black 
(Gordon et al., 2007) and South Asian origins (Sidi et al., 2009). Finally, PCNE and 
AbuRuz systems do not include patients’ opinions or perceptions in the 
classification process because they believed that patients’ therapy expectations and 
goals are the same as the professionals’, which may not be true for all patients.   
The literature search methodology for the Van Mil review was clearly specified 
including source of data, study selection and data extraction. In addition, critical 
evaluation of the DRP’s classification systems was obtained. Moreover, 
classifications were adequately assessed according to a clear definition, published 
validation method, and results reflecting process and outcomes, usability in 
pharmaceutical care practice and a hierarchical structure. However, Van Mil had 
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reported difficulties in identifying previous literature on MRP from databases, so 
there is a high possibility that some MRPs systems have been missed. 
The previous section has looked at the range of terminologies, definitions and 
classifications of MRPs. The following section will illustrate the possible causes of 
MRPs reported in the literature. 
1.3.2 Potential causes of medicine-related problems 
The most common potential causes of MRPs reported in the literature may include 
(Rupp et al., 1992; Aparasu et al., 2000; Sutcliffe et al., 2004; Chen et al., 2005; 
Curran and Bullock, 2005; Morgan and Figueoa-Muñoz., 2005; 
• Inappropriate prescribing. 
Laroche et al., 2007; 
Scheppers et al., 2006; Howard et al., 2008): 
• Altered medication-taking behaviours. 
• Communication failure. 
• Knowledge gaps. 
• Inadequate monitoring and review. 
• Difficulties in access and use of healthcare services. 
 
Prescription is the first stage in the medicines use process and prescribing errors are 
possibly the most serious of all types of medication errors. Unless a prescribing 
error is detected by another person involved in medicine use, such as the 
pharmacist dispensing the medicine or the nurse administering the medicine or the 
patient to whom the medicine was prescribed, incorrect medicines will be taken or 
given, with the risk of harm. Inappropriate prescribing (IP) is now considered a 
major public health issue, given its direct linkage to substantial morbidity, mortality 
and wastage of health resources (Spinewine et al., 2007) that result from adverse 
drug reactions (ADRs) (Aparasu et al., 2000; Laroch et al., 2006) and/or adverse 
events (AEs) (Viswanathan et al., 2005). 
Inappropriate prescribing (IP) 
There are various published definitions of prescribing errors but one that allows us 
to understand how errors occur and how they can be prevented is that by Dean et 
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al. (2000) who define prescribing error as follows: “a clinically meaningful 
prescribing error occurs when, as a result of prescribing decision or prescription 
writing process that is an unintentional significant (1) reduction in probability of 
treatment being timely and effective or (2) increases the risk of harm when 
compared with generally accepted practice”.    
Prescribing errors can either be as results of errors in decision-making or as a result 
of miscommunication during the prescription-writing process (Chen et al., 2005). 
Errors in decision-making can occur as a result of lack of knowledge about patients 
and their clinical status, or lack of knowledge of the drug being prescribed. Errors in 
the prescription-writing process can occur as a result of error of commission or 
error of omission. Errors of omission occur when information essential to filling the 
prescription was missing (e.g., drug, dose, or dosage form not specified on the 
prescription) (Rupp et al., 1992). Errors of commission consist of the prescriber 
incorrectly specifying the dosage regimen or strength of the prescription or the 
occurrence of therapeutic duplication (Rupp et al., 1992). 
Some ethnic minority patients may experience language barriers. The inability to 
communicate in what is not the ethnic minorities’ mother tongue may lead to poor 
communication which prevents physicians’ attempts at obtaining vital medical 
history easily, which may result in medical risk (e.g., ADRs) and possibly 
inappropriate prescribing if a misunderstanding occurs with regard to obtaining 
medical history. Thus, there is a high possibility that prescribing errors may occur 
more frequently in ethnic minority groups. Because these errors are theoretically 
preventable, HCPs should focus on the error prevention strategies in order to 
propose sytems of working that can be implemented by individual organisations to 
prevent future occurrences and to meet the needs of ethnic minority groups and 
improve the care of ethnic minority patients. 
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Compliance, concordance and adherence 
Altered medication-taking behaviours 
Compliance, concordance and adherence are the three most commonly used 
definition to describe medication-taking behaviours. The term ‘compliance’ was 
defined by Sackett and Haynes as  “the extent to which a person’s behaviour (in 
terms of medication taking, following a diet, modifying habits, or attending clinics) 
coincides with medical or health advice” (Haynes et al., 1979; Sackett, 1976a). 
Compliance is probably the most used term in searching the literature. However, it 
has received much criticism due its negative connotations, as some argue it implies 
a lack of patient involvement in the process (Vermeire et al., 2001). Compliance 
implies that patients have a passive role in their healthcare and that they should 
‘submit’ to their healthcare providers' orders in taking their medications or 
following other treatment regimens (e.g., diet, exercise, weight loss, etc.). Failing to 
‘comply’ is usually associated with blame, whether this blame is placed on doctors 
or patients (Vemeire et al., 2001). Therefore, terms like ‘adherence’ or 
‘concordance’ are now more preferred.  
The term ‘concordance’ is a UK-specific term which was introduced about a decade 
ago by the Royal Pharmaceutical Society of Great Britain. It focuses on the 
consultation process in which the doctor and patient agree on therapeutic decisions 
incorporating their respective views, and extends to involve supporting patients in 
medicine taking. It is argued that the term ‘concordance’ reflects the contemporary 
practice of medicine and healthcare provision, allowing greater responsibility for 
both doctors and patients to reach mutual agreement regarding therapeutic 
decisions (Royal Pharmaceutical Society of Great Britain, 1997). However, if 
agreement cannot be reached, the patients’ view should prevail. 
Although the term has gained much appeal because it respects patients' rights in 
deciding about taking their medications, it has been criticised for the moral and 
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ethical issues it raises. Horne and others in 2005 highlighted some of these 
criticisms as follows: 
• Concordance has a limited scope, dealing with prescribing-related 
consultations but not medication-taking behaviour. 
• Concordance implies that achieving concordance will improve adherence. 
However, this is an assumption that requires empirical evidence.  
• Concordance may raise ethical issues in circumstances where the patient, 
knowledgeably or unknowledgeably, refuses a life-saving treatment, or 
chooses a treatment which could result in self-harm or harm of others. This 
could occur when patients misinterpret likely risks or benefits of treatment, 
or when they have created false beliefs based on erroneous information. 
• Concordance does not address the balance between individual rights and 
responsibilities. 
 
The term ‘adherence’ implies that the patient is free to decide whether to adhere to 
the doctor’s recommendations and that there is no reason to blame patients should 
they wish not to follow the treatment (Horne et al., 2005). Unlike the term 
‘compliance’, ‘adherence’ is seen as more respectful of the role patients play in 
their own treatment plan. However, both terms, ‘compliance’ and ‘adherence’, 
were used interchangeably throughout this thesis. 
Extent of the problem of altered medication-taking behaviour 
A report commissioned by the NHS National Coordinating Centre for Service 
Delivery and Organization (NCCSDO) highlighted that reviews from different 
countries and across different disease conditions have consistently estimated that 
30-50% of prescribed medication is not taken as instructed (Horne et al., 2005). The 
same report emphasised that: “There is no evidence that the problem of non-
adherence has been solved by recent advances in the design and presentation of 
medicines or by the evolution of healthcare services that have tended to become 
more patient-centered”. 
Consequences of altered medication-taking behaviours 
Non-adherence is a major health issue resulting in missed opportunities for 
treatment effect, reducing health outcomes, and increasing mortality, morbidity 
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and healthcare costs due to relapse and complications (Hanlon et al., 2003; Gerber 
et al., 2010; Stavropoulou, 2011). For example, it has been estimated that poor 
adherence is responsible for an 80% increased risk of diabetes death and also 
responsible for 48% of asthma deaths, and an increased risk of death by 3.8-fold in 
the year following a heart attack (Elliot, 2009). According to the UK National Health 
Service (NHS), medicines are considered to be the biggest expenditure after staff 
and 71% of the medicine budget is spent in primary care. It is estimated that 
concurrent cost of unwanted or unused medicines exceeds £300 million annually 
(Trueman et al., 2010). Failure to take medicines as intended is therefore likely to 
result in relative therapeutic failure, disease progression, and the need for more 
aggressive treatments, which might further increase the risk of drug-induced 
problems. Unnecessary suffering, loss in productivity, and even premature death 
can also result from non-adherence to medications (Grymonpre et al., 1998). 
Avoidable medical expenses may also follow, due to hospitalizations and the waste 
of expensive medicines that are misused or unused (Royal Pharmaceutical Society 
of Great Britain, 1997).  
Barriers to appropriate medication-taking behaviours 
Numerous researchers have conducted systematic reviews to explore and evaluate 
the most common factors and reasons causing therapeutic non-compliance (Carter 
and David, 2005; Jin et al., 2008; Peeters et al., 2011; Marshall et al., 2012). These 
reviews were conducted in various medical conditions, and of patients from a wide 
range of countries. These factors were categorised as patient-centered factors, 
therapy-related factors, social and economic factors, healthcare system factors, and 
disease factors. For some of these factors, the impact on compliance was equivocal, 
but for other factors, the impact was contradictory and inconsistent. However, the 
included studies differed too much with respect to their study designs and the 
sample that was studied.  
In these reviews, there were several methodological challenges with respect to 
measuring medication adherence, diversity of settings and study designs that made 
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it very difficult to compare results of the existing reviews. None of these reviews 
discussed the barriers to medication adherence which were reported to be specific 
to SA and ME populations. For instance, the influence of socio-cultural or religious 
factors on medication adherence is not well recognised in current clinical practice. 
The lack of knowledge concerning medication adherence among EMGs in Europe is 
surprising; very few studies were found on SA population and none were found on 
ME population (Ens et al., 2013).  
A recent systematic review by Ens et al. (2013), which aimed at examining 
adherence to cardiac medication among South Asian patients, found that there was 
an absence of studies around adherence among SAs in the UK, a country which has 
a sizable South Asian population. In their review, thirteen papers were identified; 
most of the studies (n=10) were conducted in India and Pakistan. Migration from 
these countries has resulted in high proportions of South Asian individuals residing 
in countries around the world, such as the countries from which the remaining 
studies originated: Norway (n=1), Denmark (n=1) and Canada (n=1).  
Medication side effects, symptomless conditions, cost, fasting, travelling to birth 
country or homeland, forgetfulness and higher frequency of dosing contributed to 
non-adherence. In addition, South Asian immigrants faced language and 
communication barriers, which contributed to non-adherence. Difficulties in 
accessing healthcare system and medication were also associated with poor 
adherence. Lack of knowledge regarding the medications prescribed was a factor 
that decreased adherence. Family support was associated with better adherence. 
Another systematic review was conducted by Al-Qasem et al. in (2011) to establish 
the extent of non-adherence to medication regimens in Middle Eastern countries 
across different conditions and the reason for non-adherence. The review 
estimated that non-adherence rates among MEs ranged from 1.4-88%. The 
reported reasons for poor adherence were forgetfulness, side effects, concern 
about drug dependency, feeling well, medication was not helping them feel better, 
lack of education about illness and medicines, irregularity of follow-up, disbelief 
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about the value and need for medication, social stigma, complexity of drug 
regimen, cost problems, and inability to consult patients’ regular doctors (Al-Qasem 
et al., 2011).    
The findings of these reviews should not be generalised because many of these 
studies were conducted outside the UK and some were carried out among different 
ethnic groups, so the views, behaviours or experiences that were revealed from 
these studies may not reflect other ethnic groups or countries because peoples’ 
views, behaviours or experiences may vary from country to country and what may 
be true to one ethnic group may not be necessarily so to another. In addition, a 
small number of participants were involved in some of these studies – ranging from 
30 to 47 participants – which might not provide sufficient power to detect 
meaningful results. Finally, a number of the studies were carried out among first-
generation ethnic migrants and views, behaviours or experiences may differ among 
second- or third-generation ethnic minorities.  
These reviews have shown that there is a lack of studies examining adherence and 
reasons for poor adherence among SA and ME groups in the UK. There is some 
evidence to suggest that SAs are less likely than Caucasians to adhere to their 
medication regimen (Lai et al., 2011). There is also some evidence to indicate that 
non-adherence among ME group is considerably high (Al-Qasem., 2011). Thus, in 
our study we would like to measure rate of non-adherence among SA and ME 
groups and to know the reasons behind poor adherence in order to support 
patients and provide the appropriate recommendations that suit their beliefs and 
needs. This may be crucial to reducing the level of non-adherence in general, and to 
enhancing the possibility of achieving the desired healthcare outcomes. 
Patients can be under the care of multiple healthcare professionals within different 
settings and at the same time. Any stage of the medicines management process can 
thus be carried out by different individuals including prescribers, patients and their 
Communication failure  
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carer. For instance, medicines use reviews may not be done by the prescribers. A 
patient’s medication may be stopped by one prescriber and continued by another 
due to lack of information. For example, when patients are discharged from the 
hospital, drug regimens that were started and needed only in the hospital may be 
unnecessary continued by another prescriber, who is reluctant to communicate 
with the previous prescriber. Conversely, at admission to a healthcare facility, lack 
of communication may result in unintentional omission of a necessary maintenance 
drug. 
MRPs can result from communication failure between members of the patient’s 
healthcare team, and between healthcare professionals and their patients/carers. 
Continuity of care by effective communication is vital to ensure intended treatment 
plans are implemented and monitored. Communication failures can be observed 
when patients are transferred between different healthcare settings such as 
admission to hospital or between different specialists/wards in the same hospital. 
Failures in communication between healthcare personnel can threaten patient 
safety. Recent evidence suggests that ineffective or insufficient communication 
among health-team members is often a contributing factor that leads to medical 
errors, adverse events and preventable drug-related admissions  (e.g., medication 
errors) (Sutcliffe et al., 2004; Howard et al., 2008). 
Sutcliffe et al. (2004) conducted a qualitative study (i.e., semi-structured, face-to-
face interviews) to describe how faulty communication contributes to many medical 
mishaps. Resident doctors (n=26) reported a total of 70 mishap incidents that had 
occurred in hospital ranging from error in patients’ management (n=29), error of 
omission (n=26), error of diagnosis (n=24) and treatment (n=24) and error of 
comission (n=21). The aspects of ‘communication failure’ (n=30) and ‘practitioners’ 
knowledge gap’ (i.e., refers to the extent to which a practitioner’s medical 
knowledge is incomplete or inaccurate) (n=28) were the two most commonly cited 
contributing factors to medical mishap.  
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 The findings of Sutcliffe et al.’s study are consistent with other research showing a 
strong link between poor communication, knowledge gap and preventable drug-
related admissions (PDRAs) or medication errors (Howard et al., 2008). Howard et 
al. (2008) published results of a study exploring the causes of preventable drug-
related admissions (PDRAs) to hospital using semi-structured interviews and 
medical records review. The study had sixty-two participants, consisting of 18 
patients, eight informal carers, 17 general practitioners, 12 community pharmacists, 
three practice nurses and four other members of healthcare staff, involved in 
events leading up to the patients’ hospital admissions. It was found that PDRAs are 
associated with problems at multiple stages in the medication use process including 
prescribing, dispensing, administration, monitoring medication and patients seeking 
help for problems with medication. The main causes of these problems were 
communication failures (between patients and healthcare professionals and 
different groups of healthcare professionals) and knowledge gaps (about 
medications and patients’ medical and medication histories). 
Insufficient patient counselling about medication was an important communication 
problem between patients and healthcare professionals reported by the authors in 
Howard et al.’s study. Many patients indicated that they were reluctant to question 
healthcare professionals, especially GPs, about their medication. Some community 
pharmacists assumed that patients would have received medication counselling 
from the GP or other healthcare professional when obtaining their prescription and 
so did not counsel patients themselves. Other community pharmacists did not 
perceive medication counselling to be their role. Some patients indicated that they 
could not recall information which they had been given, or had difficulty hearing the 
information healthcare professionals gave. These important issues relating to 
communication underpinned patients’ knowledge gaps about medication, resulting 
in active failures by patients and carers in appropriately administering medication, 
monitoring medication, and seeking help for problems with medication (such as 
how to take the medication or how to respond to potential adverse effects).  
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In this study communication failure between professional groups was also reported 
by the authors. Although some community pharmacists recognised that 
prescriptions were potentially harmful, they indicated reluctance to question GPs 
because they had insufficient information about patients’ medical and medication 
history and because of the length of time taken to contact GP and previous 
experiences when the problems were raised with the GP. This study also revealed 
that the limited or incomplete information on discharge letters and delay in sending 
outpatients letters may restrict GPs in managing medications safely that were 
started by hospital doctors.  
Although Sutcliffe et al.’s and Howard et al.’s studies have similar conclusions, 
Howard et al.’s study may be considered to be of better quality than Sutcliffe et al.’s 
one because Howard et al.’s study considered the perspectives of patients and 
different healthcare professionals (i.e., GPs and community pharmacists) (total 
number=62) whereas Sutcliffe et al.’s evaluated only the views of resident doctors 
(n=26). In addition, Howard et al.’s study enhanced the validity of the collected data 
by triangulating the views of three key players in patients’ safety (i.e., GP, 
pharmacist and patient). Despite all the advantages of Howard et al.’s study, its 
findings should not be generalised because all the data were collected in the 
Nottingham area, which may not be representative of other primary care across the 
UK.  
Inadequate knowledge about patients’ medication and medical history among 
patients and healthcare professionals can lead to MRPs. Lack of access to patients’ 
medical history by community pharmacists may influence counselling provided with 
medicines supplied. Patients may also use more than one community pharmacy, 
disrupting the continuity of care provided. Healthcare professionals may be less 
knowledgeable about particular medicines and LTCs; thus contributing to 
inadequate monitoring for particular patients. On admission to hospital, lack of 
knowledge about recent changes in treatment can result in the re-initiation or 
Knowledge gaps 
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disruption of medication therapy if the patient is unable to contribute to the 
medication reconciliation process. After discharge from hospital, delays in sending 
outpatient letters and limited information in discharge letters mean that 
information is unavailable when needed and GPs have insufficient information to 
safely manage medication started by hospital doctors.  
As mentioned earlier, Howard et al. (2008) suggested that the main causes of 
preventable drug-related hospital admissions were not only communication failures 
but also knowledge gaps. In this study it was found that difficulties in accessing 
complex medical and medication histories in electronic patient records were 
associated with gaps in GP knowledge. Information about important risk factors for 
adverse events was easily lost in long electronic records, which may influence 
patient’s safety. GPs in this study were not alerted to some high-risk prescriptions 
because computer systems did not link patient diagnoses and blood test results to 
prescribed medication. It was also revealed that there was a lack of access to 
patients’ medical and medication history for community pharmacists, which may 
influence patient safety and medication counseling, and, even when medication 
histories were available in some community pharmacies, some electronic 
computers systems did not provide alerts to potential interaction, which means that 
sufficient information is lacking.  
GPs and community pharmacists sometimes had insufficient knowledge of the 
medication they prescribed, dispensed or monitored. Some professionals assumed 
that they knew enough to safely manage the medication without consulting 
reference sources. These findings were also supported by Sutcliffe et al.’s study 
(2004), which revealed that the practitioners’ knowledge gaps as well as 
communication failure were the two most commonly cited contributing factors to 
medical mishap.  
Patients’ poor knowledge about illness and/or medicines has also been reported in 
the literature. In some studies, participants reported they had little or inaccurate 
knowledge about illness and/or medicines (Thompson and Stewart et al., 2001; Lip 
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et al., 2002; Kessels, 2003; Lip et al., 2004; Gordon et al., 2005; Gordon et al., 2007; 
Opara et al., 2010; Al-Qasem et al., 2011; Samman and Chaar, 2013; Ens et al., 
2013). In other studies, participants reported that their doctors supplied them with 
insufficient information about illness and/or medicines (Thompson and Stewart et 
al., 2001; Gordon et al., 2005; Gordon et al., 2007; Jin et al., 2008; Kumar et al., 
2013; Samman and Chaar, 2013), or even conflicting information (Gordon et al., 
2005; Gordon et al., 2007). Moreover, a number of studies reported that patients 
often failed to recognise the seriousness of illness and importance of taking their 
medications and often underestimated these which may constitute a major barrier 
to their adherence to medication regimens (Dimatteo et al., 2000; Al-Qasem et al., 
2011). The findings from various studies showed that knowledge of patients about 
their illnesses and/or medicines was far from optimal. Therefore, in order to 
support ethnic minority patients, who are expected to have communication failure 
and knowledge gap problems, in managing their medicines effectively and safely, 
these two potential causes should be considered in our study.   
The goals of treatment monitoring and review are to ensure that the medicines are 
producing the intended effect, that they remain appropriate, and to detect any 
medicine-related problems. The extent of monitoring and review of medication 
therapy depends on the pharmacological profile of the medicine used, patient 
profile, severity and advancement of the LTC being treated. Healthcare 
professionals such as pharmacists, trained nurse and doctors are well placed to 
carry out monitoring and review of medication therapy. Monitoring drug use 
involves documenting the indication for a new drug; keeping a current list of drugs 
used by the patient in medical records; monitoring for achievement of the 
therapeutic goals and other responses to new drugs; monitoring necessary 
laboratory tests for efficacy or adverse effects; and periodically reviewing drugs for 
continued need. Lack of close monitoring especially after new drugs have been 
prescribed may increase risk of adverse effects and ineffectiveness. Criteria to 
Inadequate monitoring and review 
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facilitate monitoring have been developed as a part of drug utilisation review 
criteria and they focus, for example, on inappropriate dosage or duration of 
therapy, duplication of therapy, and possible drug-drug interactions.  
Sidi et al. (2009) and Opara et al. (2010) conducted face-to-face interviews in the 
United Kingdom to explore the South Asian community’s experiences of the MRPs 
they faced. The most common types of MRPs identified in these studies were 
information needs about medication, poor compliance and difficulty in 
remembering the names of their medication. These studies also found that patients 
of South Asian origin had a lack of regular monitoring and review, which may be a 
contributing factor for the lack of information they had about their medicines and 
the poor adherence which may consequently result in more MRPs. The results of 
these studies should be interpreted with caution because all the data were 
collected in the Bedfordshire area from South Asian patients, which may not be 
representative of other people from different ethnic backgrounds and different 
areas. In addition, the sample size of participants was too small to come to a clear 
conclusion (n=32 and 59) (Sidi et al., 2009; Opara et al., 2010).  In order to support 
the needs of ethnic minority patients, who are expected to experience health 
inequalities, in managing their medicines effectively and appropriately, lack of 
regular monitoring and review factors should be taken into consideration in our 
study.  
In the UK, as in other countries, the growth of various ethnic communities and 
linguistic groups, each with its own cultural traits and health profiles, presents a 
complex challenge to healthcare practitioners and policy makers in terms of 
achieving equitable access (Rashid and Rogger., 1992; Roberts et al., 1996; Chan, 
2000; Morgan and Figueoa-
Difficulties in access and use of healthcare services 
Muñoz., 2005; Szczepura, 2005; Gordon et al., 2007). 
Pechansky and Thomas (1981) suggested that the concept of ‘access’ described the 
‘degree of fit’ between clients and the healthcare system. The ‘degree of fit’ might 
be influenced by the acceptability, affordability, availability, accessibility and 
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accommodation of services. Pechansky and Thomas’s approach extends the 
concept of ‘access’ beyond measuring service availability, to take into consideration 
the different dimensions of the client-provider relationship such as personal, 
organisational and financial barriers, which are the most important factors that may 
affect access to healthcare services.  
They identified five relevant dimensions to the client-service interaction which are 
as follows:  
“(1) acceptability refers to attitudes and beliefs of users and providers about each 
other’s characteristics. Acceptability is about the relationship of clients’ attitudes 
about personal and practice characteristics of providers to the actual characteristics 
of existing providers, as well as to provider attitudes about acceptable personal 
characteristics of clients. 
(2) affordability applies to the cost implications to the patient in relation to need; 
this includes both direct and indirect costs and perceptions of value. It is about the 
relationship of prices of services and other costs to the clients’ income and ability to 
pay. 
(3) availability refers to the adequacy of supply given by the relationship between 
volume (i.e., clients) and type of services (provision) and volume (i.e., clients) and 
type of needs (demand). It refers to the adequacy of supply whether of physicians, 
dentists, other providers, or facilities such as hospitals, clinics and of specialised 
programmes and services. 
(4) physical accessibility is defined by the suitability of the location of the service in 
relation to the location and mobility of the patient (geographical and physical 
barriers). Physical accessibility is about the relationship between the location of 
supply and the location of clients, taking account of client transportation resources 
and travel time, distance and  cost. 
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(5) accommodation refers to the way services are organised in relation to the 
client’s needs and the patient’s perception of their appropriateness (opening times, 
booking facilities, waiting times). Accommodation is about the relationship between 
the manner in which the supply resources are organised to accept clients (including 
appointment systems, hours of operation, walk-in facilities, telephone services) and 
the clients' ability to accommodate to these factors and the clients' perception of 
their appropriateness.” 
Scheppers et al. (2006) published a systematic review of 54 articles to present an 
overview of potential barriers that may prevent ethnic minority patients from 
accessing healthcare services. The study identified a great number of potential 
barriers that occur at three levels: (1) patient level, (2) healthcare provider level and 
(3) system level (i.e., the organisation of healthcare services).  
The barriers at patient level were related to the patients’ characteristics: 
demographic variables (e.g., gender and marital status); social structure variables 
(e.g., ethnicity, education, social class and economic status, living conditions, 
lifestyle, family and social support, culture, duration of stay, familiarity with 
Western health practices, local language skills, communication, translation); health 
beliefs and attitudes (e.g., values concerning health and illness, perceptions and 
attitudes toward health services and personnel); personal enabling resources (e.g., 
immigration rules, income/financial means, health insurance, sources of advice and 
regular source of care, knowledge of health services and how to use them, available 
time and stress constraint); community enabling resources (e.g., availability and 
delivery of services, price of health services, transportation and travel time); 
perceived illness (e.g., perceived cause) and personal health practices (e.g., 
traditional remedies and self-treatment) (Scheppers et al., 2006). 
The barriers at provider level were related to the provided characteristics: skills and 
attitudes (e.g., medical procedures and practices, ethnic matching, skills, behaviour, 
communication style, style of providing information, bilingualism, translation, 
cultural knowledge, family involvement and religion/spirituality). The barriers at 
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system level were related to the system characteristics: the organisation of the 
healthcare system (e.g., referral system, opening hours, consultancy appointments 
and waiting time, the length of consultation and treatment and translation) 
(Scheppers et al., 2006). 
These potential barriers may offer a key explanation for disparities in access to 
health services by BME populations. The cultural barrier, for example, may limit 
utilisation of healthcare services among ethnic minority groups. The BME patients’ 
cultural perceptions about the severity of their symptoms, for instance, may act as a 
barrier towards urgency of seeking care, as their needs may be differently 
expressed. BME groups may present classical symptoms in a different way, which 
could result in misunderstandings, misdiagnosis, incorrect referrals or incorrect 
drug being prescribed.  In some cultures it might be seen that the ‘husband’ 
answers all the questions on behalf of the patient. Hence, the actual patient may 
not be given the opportunity to express her concerns and opinions with regard to 
her drug regimens. Patients from a particular culture may prefer to be treated by a 
medical provider of the same gender; this may be especially true for female 
patients and if the medical practice has no female doctor then this group of patients 
may become reluctant to seek help, resulting in late presentation and worsening 
their diseases. Other people would rather prefer to suffer in silence than access 
health services as they believe that their pain or symptoms are a punishment from 
God, and thus they do not want to interfere with God’s decision.  
Communication, language and literacy barriers are one of the major factors that 
may prohibit the use of health services or affect the use of medicines. Lack of 
language skills may affect communication between ethnic minority patients and 
healthcare personnel. The inability to communicate in what is not the ethnic 
minorities’ mother tongue may lead to discrimination; due to lack of a common 
language, ethnic minorities may struggle to express their inner feelings to ask 
questions or to present themselves or their families. Poor language skills also have 
an adverse effect on the confidence of the patient. This causes yet additional 
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emotional stress, discomfort, frustration and anxiety that often accompany medical 
consultations, with patients feeling neglected and isolated (Scheppers et al., 2006). 
Language difficulties may have a harmful effect upon the patient’s ability to 
understand completely proposed treatments and remedies. They also may prevent 
the physicians’ attempts at obtaining vital medical history easily, which may present 
medical risks if a misunderstanding with regard to obtaining medical history occurs. 
In such cases interpreting services are required in order to adequately diagnose and 
treat these individuals but, even if the interpreting services are provided, some 
ethnic groups may feel reluctant to use a professional interpreter because they do 
not want to reveal their confidential information to her/him. Differences in literacy 
might be another important factor which acts as a barrier towards accessing 
services. Although people may be able to speak English they might not be able to 
read it and, even if letters or patient information leaflets are translated, individuals 
may not be able to read their own language (Scheppers et al., 2006). 
Unfamiliarity with the NHS, unawareness of service availability or a lack of 
knowledge about the services can act as a potential barrier towards accessing 
services. When the ethnic minority patient has no knowledge of, for example, the 
function and availability of primary care workers other than physician, then the use 
of primary healthcare may be restricted and inappropriate to his or her needs 
(Scheppers et al., 2006). 
In general terms, Scheppers et al.’s review suggested that there are a great number 
of potential barriers that may affect access to healthcare services among ethnic 
minority patients, such as (1) ethnic background; (2) lower education level; (3) 
lower social and socioeconomic status; (4) insecure living conditions; (5) poor status 
of health due to, for example, drug addiction or bad eating habits; (6) lack of family 
or social support; (7) cultural perceptions about disease or symptoms; (8) short 
duration of stay; (9) lower level of familiarity with Western health practices; (10) 
lack of local language skills; (11) ineffective communication; (12) disapproval of 
translation by an interpreter; (13) price of healthcare services; (14) differences in 
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health belief between the patient and healthcare provider; (15) disapproving 
perceptions and attitudes with regard to health services and personnel; (16) lack of 
right visas and work permits; (17) lack of financial resources; (18) non-professional 
advice and lack of a regular source of care; (19) unawareness of service availability 
and lack of knowledge about the services; (20) time limitations because of 
commitments to family and work; (21) stressful situations; (22) regional 
disadvantages and high medical cost; (23) irregular public transport; (24) different 
perceptions of the severity of symptoms; (25) do-it-yourself home remedy, 
treatment and traditional medicine; (26) application of intrusive medical 
procedures with insensitivity to patient need; (27) absence of ethnic matching of 
patients and provider; (28) discrimination; (29) using complex medical 
terminologies and lack of translator; (30) lack of cultural knowledge about minority 
cultures; (31) non-family involvement and denying the aspect of spiritual and 
religious factors; (32) inconvenient clinic hours; (33) the prolonged process for 
obtaining an appointment and prolonged waiting time; are all factors and potential 
barriers that may limit utilisation of healthcare services (Scheppers et al., 2006). 
The reviewed studies in this article differed enormously in terms of ethnic group of 
participants, country of study, study setting, sample size and methodology used. 
Although this review is representative because it consisted of 54 articles published 
from 1990-2003 and the studies were carried out in different countries (n=11), 
different ethnic groups and care settings, the result of this review should not be 
generalised, because the potential barriers that were relieved may vary from 
country to country and from setting to setting and what is a barrier to one ethnic 
group may not be necessarily so to another. In addition, this review presents only 
journal articles. Moreover, only seven studies from the 54 were conducted in the 
UK. Furthermore, some of these barriers are universal problems while others are 
specific to a particular country, such as health insurance and referral. Finally, some 
of these factors affect ethnic minorities as well as the general population whereas 
others are specific to ethnic groups. Although this review did not indicate whether 
ethnic minority groups had more difficulties in accessing healthcare services than 
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the general population, it can be stated that people from ethnic minority 
backgrounds may possibly have more problems in accessing healthcare than the 
general population due to many potential factors that prevent them from utilising 
care. These potential barriers should be taken into account in order to be examined 
in our study and consequently inform healthcare providers to deliver the best 
services that can suit the expectations and needs of ethnic minority populations.  
This section has looked at the range of causes of MRPs reported in the literature. 
The following section will investigate pharmacist-based strategies to identify and 
resolve MRPs and the frequency of MRPs in primary healthcare settings.  
1.3.3 Identifying, resolving and preventing MRPs in primary care 
The frequency of MRPs in the community, as reported in the literature, is between 
2.5 - 65% (Grannas and Bates, 1999; Gordon et al., 2005; Gordon et al., 2007), 
including prescribing errors, adverse drug reactions and drug interactions, 
uncertainty and lack of knowledge about medicines, lack of monitoring and review, 
problems with access to services, non-adherence to medications, and cogntitive, 
physical and sensory problems (Rupp et al., 1992; Claesson et al., 1995; Green, 
1995; Goldstein et al., 1998; Westerlund et al., 1999; Paulino et al., 2004; Chen et 
al., 2005; Haugbølle and Sørensen, 2006; Hammerlin et al., 2007; Krähenbühl et al., 
2008). 
Many methods have been used to identify and quantify MRPs. These methods vary 
according to the following: definition and classification of MRP used, patient groups 
being studied, study design, sampling method, practice setting, documentation 
method, length of time for data collection and the number of data collectors.  
Pharmacists have an active role in identifying, solving and preventing MRPs. 
Pharmacists’ interventions have been documented and have proven to be a 
valuable contribution both in primary and in secondary settings (Paulino et al., 
2004). Pharmacists can identify and prevent MRPs using the following strategies:  
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• Patient medication records (PMRs) and prescription monitoring in 
pharmacies. 
• Patient medical record (notes) reviewing in GP surgeries. 
• Patient interview. 
• Patient medicine use review (MUR) report monitoring in pharmacies. 
 
Monitoring patient medication records (PMRs) and prescriptions is an intervention 
that can be used to identify, solve or prevent a MRP, especially one that is related 
to prescription errors, drug interactions and adherence issues. However, identifying 
MRPs requires access to the patients’ medical notes, full record of prescriptions, 
non-drug care and results from laboratory tests, which are only available at GP 
surgeries. The data stored on pharmacy records relies on the information as 
presented on prescriptions and information offered by patients. The information 
that appears on prescriptions corresponds to the information held on computerised 
medical histories in GP surgeries. Thus, prescriptions can be used to confirm the 
information held on GPs’ surgery records.  
Because patients in the UK can only use one GP surgery, all their full medication 
records are held on one site, which makes using the GP surgery record an 
advantage over using the pharmacy record. In addition to providing information on 
the name and dose of the prescribed medicine, GP surgery records can also provide 
data on the purpose for which the medicine was prescribed and the patient’s 
clinical status. This data is entered on patient records for each consultation that a 
GP has with a patient. However, patients who receive long-term medicines to treat 
chronic diseases frequently obtain treatment via repeat prescriptions from GP 
surgeries. Although using repeat prescription reduces the workload of GPs, it 
increases the potential for patients to receive inappropriate or unnecessary 
medication over long periods of time (Corbett, 1995; Goldstein et al., 1998). 
Because over 80% of medicines prescribed by GPs in the United Kingdom are repeat 
prescriptions, pharmacist reviews of repeat prescriptions have been used to 
identify, solve and prevent MRPs (Harris and Dajda, 1996; Zermansky, 1996; Granas 
and Bates, 1999).  
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The types of MRPs that can be identified using patient’s records in GP surgeries and 
pharmacies are sometimes potential problems and could be limited because the 
review is retrospective. However, if prescriptions are monitored as the patient 
presents with them to be dispensed at pharmacies, or on the same day that they 
are issued by GP surgeries, this may be more useful in identifying and solving MRPs 
because in the absence of the patients it is often unclear from pharmacy records or 
medical notes alone what the patients are actually taking and it would be difficult to 
decide if a medicine or dose is no longer needed or inappropriate (Grannas and 
Bates, 1999). Further to this, patient’s interview should be considered.     
Having knowledge about the patient’s total drug use as well as other factors 
influencing the patient’s use of medicines can help to identify or prevent actual and 
potential MRPs. Interviewing patients can establish exactly what medicines they are 
actually taking, how they use their medicines and how they store their medicines. 
This approach depends on the art of communication and questioning. Effective 
interviewing requires skills. The question regarding compliance, for example, should 
not embarrass the patient through the admittance that he/she ignored the 
healthcare provider’s instructions. Inquiring about occasional forgetfulness, on the 
other hand, does not seem so threatening and does not carry negative connotations 
(Fodor et al., 2005). The advantage of patient’s interviews is that interviewing 
patients, especially in their homes, will provide a useful method of collecting data to 
supplement medication reviews with regard to identifying MRPs. This is because in 
their own homes, patients feel more relaxed as they describe and elaborate on their 
medication- and illness-related experiences, considerations, actions and problems, 
meanwhile displaying the specific contents of their medicine chest. On the other 
hand, the sample size of the study is often limited when interviewing patients in 
their homes or in a designated place. Home interviews also can be costly and time 
consuming.  
Another strategy of identifying, solving and preventing MRPs is through the 
medicine use review (MUR) service in pharmacies. The UK government introduced 
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the medicine use review (MUR) and prescription intervention service (‘MUR 
services’) as an advanced community pharmacy service in April 2005 (Latif and 
Boardman, 2008). The purpose of MURs is to establish a picture of the patients 
understanding and use of prescribed and non-prescribed medications. The 
consultation with the pharmacist provides patients with an opportunity to ask 
about their medicines and identifies any problems they might be experiencing along 
with possible solutions. These reviews are conducted privately in a consultation 
area within the pharmacy and the report of the review is provided both to the 
patient and if necessary to their GP. MURs are modelled on the concept of 
concordance where, during consultations with pharmacists, patients are 
encouraged to become increasingly empowered in their own medicine-taking 
decisions in order to achieve the most effective use of medicines (Latif and 
Boardman, 2008). The MUR will help to identify problems related to side effects, 
drug interactions, poor patient knowledge of their medicines, and adherence issues. 
Several distinct approaches to reviewing patients’ medicines have been described in 
which the levels of patient engagement and clinical input vary. These can be 
conducted by a variety of healthcare professionals, ranging from the most basic 
unstructured opportunistic review through to a full clinical medication review that 
is conducted face-to-face with the patient and considers both the patients 
medicines and condition(s). MURs do not fit easily into these approaches in that 
there is a high level of patient engagement but absence of access to patient medical 
records limits the clinical input; however, MURs have been described as a ‘valuable 
addition’ to the medication review framework (Latif and Boardman, 2008).  
1.3.4 Community pharmacists’ role in pharmaceutical care 
Pharmacists in all practice settings have been encouraged to provide 
pharmaceutical care to identify, prevent, and resolve medicine-related problems 
and reduce negative medication outcomes. Pharmaceutical care has been defined 
as “The responsible provision of drug therapy for the purpose of achieving definite 
outcomes that improve a patient's quality of life.” (Hepler and Strand, 1990). A 
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patient-centered, outcomes-oriented practice requires the pharmacist to work in 
concert with the patient's healthcare team to promote health, prevent disease, and 
assess, monitor, initiate, and modify medication use to ensure that drug-therapy 
regimens are safe and effective.  
Studies have shown that pharmacists can reduce medication errors, improve 
patient outcomes, and decrease costs by providing patient-care services in a variety 
of settings. Pharmacists have contributed significantly to the development and 
implementation of intervention strategies to reduce MRPs experienced by patients 
(Royal et al., 2006; Holland et al., 2007; Hinchliffe, 2010). Possibly this is because it 
is expected of their profession to provide efficient pharmaceutical care and 
promote patient safety. With their expert knowledge and skills, as well as being 
accessible to the public, pharmacists are ideally placed to be professional advocates 
for preventing and solving MRPs on the front line of healthcare.  
Pharmacists’ involvement in the medication monitoring and review process has 
been tested in a number of studies. Hinchliffe (2010) published a systematic review 
to examine whether pharmacist-led medication review improves pharmaceutical 
care and whether it is clinically and cost effective. It was revealed that pharmacist 
medication review can improve adherence and reduce prescribing of inappropriate 
medicines and consequently reduce prescribing costs and potential adverse events 
or reactions. There was weak evidence that pharmacist medication reviews reduce 
morbidity and mortality. It was also found that pharmacist medication review is 
more effective where there is a good professional relationship between the 
pharmacist and the GPs and when the pharmacist has access to more patient 
information on which to base recommendations. 
The findings from Hinchliffe’s study agree with Royal et al.’s study (2006) and 
Holland et al.’s study (2007). In general terms, these studies have shown that 
pharmacist-led medication reviews may slightly reduce the number of prescribed 
drugs, and improve drug knowledge and adherence, but have no effect on the 
morbidity and mortality rates (Royal et al., 2006; Holland et al., 2007). These 
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systematic reviews and meta-analyses are considered to be well conducted with a 
very low risk of bias. The studies searched the most relevant key databases to the 
topic area (n=5-11). Two studies also searched for grey literature by website 
searching to identify further relevant studies (Royal et al., 2006; Hinchliffe, 2010). 
Reference list search and hand search were also carried out (Holland et al., 2007; 
Hinchliffe, 2010). A large number of search terms were used to identify relevant 
studies. Searches for relevant literature ranged from the period between 1981 in 
one study (Royal et al., 2006) and 2010 in another study (Hinchliffe, 2010). The 
number of identified studies ranged from 24-38. There was rigorous quality 
assessment and appraisal of all the identified studies. However, despite all strong 
evidence, there may be unpublished studies that may not have been included in 
these reviews. In addition, the setting for two of these reviews was primary care 
and their findings may be unlikely to be applicable to all healthcare settings, such as 
secondary care (Royal et al., 2006; Hinchliffe, 2010). 
For decades, pharmacists in the community setting have performed an invaluable 
service for patients and their communities by avoiding medication-related problems 
with the use of drug utilisation review and patient counseling. In England and 
Wales, the NHS community pharmacy contractual framework (contract) consists of 
three levels of services: essential services, advanced services, and enhanced and 
locally commissioned services. Pharmacy owners (contractors) must provide 
essential services, but they can choose whether they wish to provide advanced and 
enhanced services (PSNC, 2013). 
Essential services include (PSNC, 2013):  
• Dispensing: the safe supply of medicines or appliances. Advice is given to the 
patient about the medicines being dispensed and how to use them. Records 
are kept of all medicines dispensed and significant advice provided, referrals 
and interventions made.  
• Repeat dispensing: the management of repeat medication for up to one 
year, in partnership with the patient and prescriber. The patient will return 
to the pharmacy for repeat supplies, without first having to visit the GP 
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surgery. Before each supply the pharmacy will ascertain the patient’s need 
for a repeat supply of a particular medicine.  
• Disposal of unwanted medicines: pharmacies accept unwanted medicines 
from individuals. The medicines are then safely disposed of.  
• Promotion of Healthy Lifestyles (Public health): opportunistic one-to-one 
advice is given on healthy lifestyle topics, such as stopping smoking, to 
certain patient groups who present prescriptions for dispensing. Pharmacies 
will also get involved in six local campaigns a year, organised by NHS 
England. Campaign examples may include promotion of flu vaccination 
uptake or advice on increasing physical activity.  
• Signposting patients to other healthcare providers: pharmacists and staff 
will refer patients to other healthcare professionals or care providers when 
appropriate. The service also includes referral on to other sources of help 
such as local or national patient support groups.  
• Support for self-care: the provision of advice and support by pharmacy staff 
to enable people to derive maximum benefit from caring for themselves or 
their families. The main focus is on self-limiting illness, but support for 
people with long-term conditions is also a feature of the service.  
• Clinical governance: pharmacies must have a system  of clinical governance 
to support the provision of excellent care; requirements include: provision 
of a practice leaflet for patients, patient safety incident reporting to the 
National Reporting and Learning Service, conducting clinical audits and 
patient satisfaction surveys, acting upon drug alerts and product recalls to 
minimise patient harm, having cleanliness and infection control measures in 
place.  
 
Advanced services involve (PSNC, 2013):  
• Medicine use review (MUR) and prescription intervention service: the 
pharmacist conducts an adherence-focussed medicines review with the 
patient. The review assesses the patient’s use of their medicines and 
attempts to identify and address any problems they may be experiencing. 
Where necessary, a referral is made to the patient’s GP. The service aims to 
increase the patient’s knowledge of their medication and improve their 
adherence to the regimen. The MUR can be conducted on a regular basis, 
e.g., every 12 months, or on an ad hoc basis, when a significant problem 
with a patient’s medication is highlighted during the dispensing process. At 
least half of the MURs provided each year must be for patients who fall 
within one of the national target groups: patients with respiratory disease 
(e.g., asthma and COPD), patients recently discharged from hospital, patient 
taking a ‘high-risk’ medicine (NSAIDs, anticoagulants, antiplatelets and 
diuretics). MURs are conducted in a private consultation area, which ensures 
patient confidentiality.  
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• New medicine service (NMS): this service is designed to improve patients’  
understanding of a newly prescribed medicine for a long-term condition, 
and help them get the most from the medicine. The pharmacist will provide 
the patient with information on their new medicine and how to use it when 
it is first dispensed. The pharmacist and patient will then agree to meet or 
speak by telephone in around a fortnight. At this second stage of the service 
the pharmacist will discuss with the patient how they are getting on with 
their new medicine. Further information and advice on the use of the 
medicine will be provided and where the patient is experiencing a problem 
the pharmacist shall seek to agree a solution with the patient. A final 
consultation (typically 21-28 days after starting the medicine) will be held to 
discuss the medicine and whether any issues or concerns identified during 
the previous consultation have been resolved. If the patient is having a 
significant problem with their new medicine the pharmacist may need to 
refer the patient to their GP. The NMS is conducted in a private consultation 
area, which ensures patient confidentiality. 
• Appliance use review service: this service is similar to the MUR service, but it 
aims to help patients better understand and use their prescribed appliances 
(e.g., stoma appliances) rather than their medicines by (a) establishing the 
way the patient uses the appliance and the patient’s experience of such use; 
(b) identifying, discussing and assisting in the resolution of poor or 
ineffective use of appliance by the patient; and (c) advising the patient on 
the safe and appropriate storage of the appliance and proper disposal of the 
appliances that are used or unwanted. The service is conducted in a private 
consultation area or in the patient’s home. 
• Stoma appliance customisation service: this service involves the 
customisation of a quantity of more than one stoma appliance, based on the  
patient's measurements or a template. The aim of the service is to ensure 
proper use and comfortable fitting of the stoma appliance and to improve 
the duration of usage, thereby reducing waste.  
 
Enhanced services include minor ailments management, palliative care services, 
care home services, controlled drug, anticoagulation monitor, smoking cessation, 
alcohol screening, suerpvised administration (e.g., methadone) and weight 
management and obesity, out of hours services, supplementary and independent 
prescribing by pharmacists, medicines assessment and compliance support, etc. 
(PSNC, 2013).  
• The ethnic minority populations in the UK are growing substantially as a 
consequence of continued immigration and high birth rate. Not only the UK 
Key messages from Chapter 1 
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but also all countries over the world are diversifying in terms of ethnic 
makeup. Therefore, the needs and perspectives of different minority groups 
are of increasing importance to many countries as well as the UK. 
• People from many ethnic minorities tend to perceive themselves as less 
healthy than those in the general UK population.   
• Despite their heterogeneity, ethnic minorities in general often have a higher 
prevalence of chronic diseases including diabetes, cardiovascular disease, 
rheumatoid and respiratory disease for which effective management 
depends on the use of medicines. 
• The higher prevalence of chronic diseases among ethnic minority 
populations may lead to co-morbidities and multiple drug therapies and 
consequently MRPs.  
• Patients from different cultural backgrounds may be expected to have their 
own perceptions and beliefs, which will affect their use of medicines.  
• Ethnic minority groups are associated with communication and language 
barriers, and different experiences, needs and expectations than the wider 
UK population which may also influence their ability to manage their 
medicines effectively.  
• It is acknowledged in most healthcare systems that ethnic minority groups 
have experienced inequalities in health and in accessing healthcare services. 
There has been extensive research on health problems of ethnic minority 
groups, especially access to care, which can result in differences in health 
outcomes, but there has been little research which specifically examines 
medicines use. Also, evidence suggests that medicine-related needs may be 
poorly met for these groups. 
 
As the initial literature found limited exploration of MRPs in its broadest definition 
among patients from EMGs, a more comprehensive literature search was 
conducted and will be discussed in Chapter 2, comprising an electronic, as well as a 
manual approach. This was performed to identify type(s) and possible contributing 
factor(s) of MRPs experienced by ethnic minority populations in the UK and to 
identify interventions or recommendations to support these groups in their use of 
medicines. Although some factors might be similar in all patients regardless of their 
ethnicity, or cultural background, it is likely that other factors might emerge 
specifically in these groups, given their unique cultural and religious characteristics. 
A flow diagram of thesis content is illustrated in Figure 1-1. 
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Figure 1-1: Flow diagram of thesis content. 
 
STAGE ONE 
Literature Review: identification of issues of importance and relevant research within 
the field of MRPs  
 
STAGE TWO 
Systematic review: identification of previous work on MRPs in EMGs and gaps in the 
literature 
STAGE THREE 
Research context and methodology 
SATGE FOUR 
Commence Patients’ Interview 
STAGE SIX 
Commence Pharmacists’ Interview 
informed from patients’ interview 
 
STAGE FIVE 
Typical and a typical themes identified in the responses and presented in the results 
STAGE SEVEN 
Discussion and conclusion 
Chapter 2 – Systematic review 
66 
 
 
Chapter 2 Medicine use and medicine-related problems (MRPs) 
experienced by ethnic minority patients in the United Kingdom: a 
review. 
The focus of this chapter was to review the published studies on MRPs in EMGs in 
the UK. The aim of this review was to establish type(s) and possible contributing 
factor(s) of MRPs experienced by ethnic minority populations in the UK and to 
identify interventions or recommendations to support these groups in their use of 
medicines. Because the definitions of MRPs are wide and include problems ranging 
from prescribing errors through to obtaining supplies, monitoring for 
appropriateness and patient behaviours which influence their use, a broad 
definition of MRPs by Gordon et al. (2005) was used in this review to include all 
these aspects. Gordon et al. (2005) defined an MRP as “any problem experienced by 
a patient that may impact on their ability to manage or take their medicines 
effectively” (Gordon et al., 2005).  
Introduction  
2.1 Materials and Methods 
2.1.1 Data sources 
Electronic databases of PubMed, Embase, International Pharmaceutical Abstract 
(IPA) and Scopus were searched for the period from 1990 to 2011. Reference lists of 
retrieved articles and relevant review articles were manually examined for further 
relevant studies. A hand search of key journals: the International Journal of 
Pharmacy Practice, Pharmacy World and Science and the Annals of 
Pharmacotherapy was also performed.   
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2.1.2 Search terms and search strategy 
Identifying studies of MRPs experienced by ethnic minorities in the UK presented 
challenges. The review commenced with three main keywords: ‘medicine-related 
problem’, ‘ethnicity’ and ‘United Kingdom’. Lists of search terms associated with 
each keyword were generated from MeSH (medical subject heading) terms in 
PubMed and term mapping database in Embase (Ovid). MeSH terms and Map terms 
provide a consistent way to retrieve information that may use different terminology 
for the same concepts. Relevant terms were also handpicked from the literature 
during the course of the review (Van Mil et al., 2004; AbuRuz et al., 2006). 
Keywords not listed as MeSH or Map Terms were searched as phrases using the 
free text search mode. 
‘Medicine-related problem’ or ‘drug-related problem’ are not key words, MeSH 
terms or Map terms. Thus, a number of terms were required to describe problems 
related to the use of medications such as adverse drug reaction, adverse drug 
event, drug therapy problem and medication error. A further list of search terms 
was generated by referring to two key papers. The first article was a review on MRP 
classification systems by van Mil et al. (2004) which provided an overview and 
appraisal of classification of medicine-related problems for use during the 
pharmaceutical care process and research in pharmacy (van Mil et al., 2004). The 
second article by AbuRuz et al. (2006) aimed to develop and validate a tool to 
classify and assess MRPs in which an MRP was referred to as ‘treatment related 
problem’ (AbuRuz et al., 2006). These two articles had also reported difficulties in 
identifying previous literature on MRPs from databases. Each article suggested a list 
of search terms for ‘medicine-related problems’ (van Mil et al., 2004; AbuRuz et al., 
2006). The search terms reported by these articles include drug related problem, 
medicine related problem (van Mil et al., 2004; AbuRuz et al., 2006), drug therapy 
problem, treatment related problem, therapy related problem, medication error 
and pharmaceutical care issue (AbuRuz et al., 2006). The different keywords used to 
search for relevant articles in this review are presented in Appendix 2. 
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A further difficulty was the limited reporting of the ethnic profile of participants in 
previous studies. It has been argued that the under-representation of minority 
ethnic groups in studies may be because participants of ethnic minorities fail to 
understand the importance of the research process or they are unable to 
participate because of the language barriers (Harris et al., 1996). However, another 
possible explanation would be that some researchers have not received training or 
do not recognise the complexity or importance of incorporating the perspective of 
minority populations into their research and thus assume the cultural perspective 
or need of the majority in the conduct of their research (Rabionet., 2009). 
2.1.3 Selection criteria 
The articles were selected through titles and abstracts by the researcher. The 
criteria for relevant studies were: (1) involving people from an ethnic minority 
background and aged over 18, (2) relevant studies were those reporting types 
and/or potential causes of MRPs and/or interventions or recommendations made 
to address the problems or to support ethnic minorities in the use of medicines, (3) 
studies reported in English Language and conducted in the UK, (4) original research 
employing quantitative and/or qualitative methods as well as literature reviews. 
2.1.4 Process of data extraction 
Electronic databases were searched and duplicate articles were removed. All 
articles were reviewed manually by title, abstract and/or full-text for relevance. The 
reference lists of retrieved articles and relevant review articles were manually 
examined for further applicable studies. The key journals were also manually 
screened for further relevant articles. Full text manuscripts were retrieved either 
electronically or as hard copy for assessment. Information was extracted into a 
proforma which included: primary author name and date of publication, study 
design and study duration, participants’ age, setting, sample, type(s) and possible 
cause(s) of MRPs, intervention or recommendations to address the problems or to 
support ethnic minorities in the use of medicines. A flow chart of data extraction is 
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illustrated in Figure 2-1. Studies of medicine-related problems experienced by 
ethnic minority patients in the UK are attached as Appendix 3. 
 
 
 
 
 
 
    
 
 
 
  
 
 
 
 
 
Figure 2-1: Flow chart of data extraction. 
 
 
Does the title or abstract signify medicine-related problem (or other associated 
term)? 
Yes Unsure No 
Do the study 
participants indicate 
people from an ethnic 
minority background? 
Do the study 
participants indicate 
people aged 18 or over? 
Is this a study reporting 
(1) problems with 
medicine use or (2) 
problems with medicine 
use and service access? 
Is this a study reporting 
types and potential 
causes of MRPs as well 
as recommendations to 
solve MRPs? 
Check with my 
supervisors 
Relevant 
No 
Yes 
Include for full-text 
retrieval 
Exclude 
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2.2 Results 
The electronic database search retrieved a total of 145 titles, of which two were 
duplicates. Screening of titles, abstracts and/or full texts for the remaining 143 
identified that six were related to medicine-related problems (Chan, 2000; Morgan 
and Figueroa-Muñoz, 2005;
Figure 2-2
 McDowell et al., 2006; Ormerod et al., 2008; Opara et 
al., 2010; Tsang et al., 2010). Manual screening of the journals retrieved one article 
(Kumar et al., 2008) and a hand search of citations retrieved articles from the 
electronic database and journals lead to a further eight articles (Wheatly and Shelly, 
1993; Lip et al., 2002; Horne et al., 2004; Lip et al., 2004; Pardhan and Mahomed, 
2004; Gordon et al., 2007; Lawton et al., 2005; Sidi et al., 2009). Thus, 15 articles in 
total were included in this review. The summary of literature review search process 
is illustrated in . 
Twelve studies, from the fifteen, examined patients’ perspectives on, and 
experiences of, the use of medicines in terms of views and actions regarding illness 
and the use of medicines (Wheatly and Shelly, 1993; Chan, 2000; Lip et al., 2002; 
Horne et al., 2004; Lip et al., 2004; Pardhan and Mahomed, 2004; Lawton et al., 
2005; Morgan and Figueroa-Muñoz, 2005; Gordon et al., 2007; Kumar et al., 2008; 
Sidi et al., 2009; Opara et al., 2010). The remaining studies (n=3) examined 
medicine-related problems in terms of adverse drug reactions (ADR) (McDowell et 
al., 2006; Ormerod et al., 2008)  
The studies included: quantitative studies (n=6) (Lip et al., 2002; Horne et al., 2004; 
Lip et al., 2004; Pardhan and Mahomed, 2004; Kumar et al., 2008; Tsang et al., 
2010); qualitative studies (n=4) (Chan, 2000; Lawton et al., 2005; Morgan 
and 
or adverse events (AEs) (Tsang et al., 2010). 
Figueroa-Muñoz, 2005; Gordon et al., 2007); 
   
studies that combined 
quantitative and qualitative methods (n=2) (Sidi et al., 2009; Opara et al., 2010); and 
systematic reviews (n=2) (McDowell et al., 2006; Ormerod et al., 2008).  
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Figure 2-2: Summary of literature review search process. 
 
Data were collected in surveys (Lip et al., 2002; Horne et al., 2004; Lip et al., 2004; 
Pardhan and Mahomed, 2004), semi-structured interviews (Chan, 2000; Pardhan 
and Mahomed, 2004; Lawton et al., 2005; Sidi et al., 2009; Opara et al., 2010) or 
focus group interviews (Morgan and Figueroa-Muñoz, 2005). Fourteen of the 
studies were conducted among adult populations and one included all ages (Tsang 
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et al., 2010). The settings of these studies were GP practices (n=2) (Chan., 2000; 
Tsang et al., 2010), clinics (n=4) (Lip et al., 2002; Lip et al., 2004; Pardhan and 
Mahomed, 2004; Kumar et al., 2008), community pharmacies (n=2) (Sidi et al., 
2009; Opara et al., 2010), community centres (n=1) (Morgan and Figueroa-Muñoz, 
2005), and patients’ homes (n=3) (Chan, 2000; Lawton et al., 2005; Gordon et al., 
2007). The studies were carried out in the UK and a great number of ethnic 
minorities were involved such as South Asian (McDowell et al., 2006; Ormerod et 
al., 2008; Sidi et al., 2009; Opara et al., 2010; Tsang et al., 2010), Afro-Carribbean 
(Lip et al., 2002; Lip et al., 2004; Lawton et al., 2005; Morgan and Figueroa-Muñoz, 
2005; McDowell et al., 2006; Gordon et al., 2007; Ormerod et al., 2008), Chinese 
(Chan, 2000). Five studies, from the fifteen, evaluated MRPs among patients with a 
specific long term condition (Wheatly and Shelly, 1993; Lip et al., 2002; Lip et al., 
2004; Pardhan and Mahomed, 2004; Morgan and Figueroa-Muñoz, 2005
2.2.1 Type(s) and possible cause(s) of MRPs identified across studies 
). 
The MRPs identified by the literature search among ethnic minorities across the 
studies included limited knowledge of illness as well as its consequences and 
therapies (Lip et al., 2002; Horne et al., 2004; Lip et al., 2004; Pardhan and 
Mahomed, 2004; Lawton et al., 2005; Morgan and Figueroa-Muñoz, 2005; Gordon 
et al., 2007; Sidi et al., 2009), problems with not taking medicines as advised 
(Wheatly and Shelly, 1993; Chan, 2000; Lip et al., 2002; Horne et al., 2004; Lip et al., 
2004; Pardhan and Mahomed, 2004; Lawton et al., 2005; Morgan and Figueroa-
Muñoz, 2005; Kumar et al., 2008; Sidi et al., 2009; Opara et al., 2010), problems 
with missing clinical appointments (Pardhan and Mahomed, 2004), high risk of 
adverse drug reactions (McDowell et al., 2006; Ormerod et al., 2008), drug 
interactions and adverse events (Tsang et al., 2010), concern or fear of dependency 
or side effects of the drugs (Morgan and Figueroa-Muñoz, 2005; Gordon et al., 
2007), cognitive, physical and sensory problems affecting use of medicines Gordon 
et al., 2007), language and communication barriers (Chan, 2000; Sidi et al., 2009), 
lack of regular monitoring and review of medicines (Lip et al., 2002; Gordon et al., 
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2007; Sidi et al., 2009; Opara et al., 2010), problems with non-prescription 
medicines (Chan, 2000; Opara et al., 2010), and problems in use of, and access to 
healthcare services (Chan, 2000; Morgan and Figueroa-Muñoz, 2005;
The most frequently reported types of MRPs were: limited knowledge of illness, its 
consequences and therapies (Lip et al., 2002; Horne et al., 2004; Lip et al., 2004; 
Pardhan and Mahomed, 2004; Lawton et al., 2005; Morgan and 
 Gordon et al., 
2007). 
Figueroa-Muñoz, 
2005; Gordon et al., 2007; Sidi et al., 2009), and problems with not taking medicines 
as advised (Wheatly and Shelly, 1993; Chan, 2000; Lip et al., 2002; Lip et al., 2004; 
Pardhan and Mahomed, 2004; Lawton et al., 2005; Morgan and Figueroa-Muñoz, 
2005; Kumar et al., 2008; Sidi et al., 2009; Opara et al., 2010). These are common to 
other populations. However, in ethnic minority groups differing cultural perceptions 
or beliefs about health, illness, prescribed treatment and medical care may also 
impact on the use of medicines (Chan, 2000; Lip et al., 2002; Horne et al., 2004; Lip 
et al., 2004; Pardhan and Mahomed, 2004; Lawton et al., 2005; Morgan 
and Figueroa-Muñoz, 2005; Kumar et al., 2008). Ethnic minority groups have also 
been shown to have different experiences, needs, values and expectations of 
illness, prescribed treatment and medical care (Chan, 2000; Horne et al., 2004; 
Morgan and Figueroa-Muñoz, 2005). In addition, language and communication 
barriers have been identified in the literature as a possible contributory factor to 
MRPs (Sidi et al., 2009) as well as affecting the use of health services (Chan, 2000; 
Lip et al., 2002; Horne et al., 2004; Lip et al., 2004; Pardhan and Mahomed, 2004; 
Scheppers et al., 2006; Sidi et al., 2009). This is because some authors believed that 
lack of language skills may affect communication between ethnic minority patients 
and healthcare personnel. It is suggested that the inability to communicate in what 
is not the ethnic minorities’ mother tongue may lead to discrimination, due to lack 
of a common language, ethnic minorities may struggle to express themselves and to 
feel comfortable  asking questions (Scheppers et al., 2006). Language difficulties can 
have a harmful effect upon the patient’s ability to understand completely proposed 
treatments and remedies (Scheppers et al., 2006). They also prevent the physicians’ 
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attempts at obtaining vital medical history easily which may present medical risks if 
a misunderstanding with obtaining medical history occurs (Scheppers et al., 2006). 
Another factor that may cause a medicine-related problem identified in the 
literature included the difficulty in obtaining a suitable interpreter among friends or 
relatives (Chan, 2000) or relying on relatives or interpreters which may lead to 
information being lost or changed (Morgan and Figueroa-Muñoz, 2005). Religious 
influences (Wheatly and Shelly, 1993; Lip et al., 2002; Lip et al., 2004; Pardhan and 
Mahomed, 2004), high expectations and negative perceptions and attitudes 
towards healthcare services and healthcare providers have also been identified 
across the studies as a potential cause of MRPs (Chan, 2000; Morgan and Figueroa-
Muñoz, 2005; Opara et al., 2010). Lack of knowledge of the healthcare services and 
how to use them is also a further possible contributing factor for MRPs that has 
been identified, for example some ethnic minority patients have no knowledge of 
the pharmaceutical care role of pharmacists which may lead to lack of regular 
monitoring and review of their medicines (Chan, 2000; Opara et al., 
2010). According to the literature, underestimating patients’ desire for information 
which may be a consequence of a lack of awareness of the extent of patients’ 
decision-making regarding the use of their medicines and/or poor appreciation of 
their experience of MRPs (Gordon et al., 2007) 
2.2.2 Recommendations made to support ethnic minority patients in the use of 
medicines 
may probably cause MRPs. 
Some recommendations were made across the studies to support patients in the 
use of medicines. The recommendations involved providing patient counselling and 
education programmes about their disease, its management and medicines and the 
service available (Lawton et al., 2005; Morgan and Figueroa-Muñoz, 2005), 
providing an interpreter for ethnic minorities who cannot speak English, using 
pictorial flashcards to provide information for illiterate people (Pardhan and 
Mahomed, 2004), providing bilingual link-workers who explain reasons for regular 
appointments and provide encouragement and cultural bridge between healthcare 
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professionals and patients (Pardhan and Mahomed, 2004; Lawton et al., 2005), 
increasing involvement of ethnic minorities in decisions about healthcare provision 
and utilisation (Chan, 2000), involving patients in evidence-informed decision 
making for safer and more effective disease and medicine managements (Gordon et 
al., 2007). 
Further recommendations included improving provider-patients communication by 
understanding of cultural factors that inform their beliefs and practices but also 
that mechanisms are in place to ensure effective transfer of information (Lawton et 
al., 2005), encouraging pharmacists and patients to work together and share their 
experiences regarding the use of medicines and exchange information that will 
support patients achieving optimal outcomes from their medicines (Gordon et al., 
2007), encouraging effective reliable communication between secondary and 
primary care, surgeries, pharmacies and patients for the continuity of safe and 
effective therapy (Gordon et al., 2007), providing enhanced pharmaceutical services 
in area of health inequalities and to such minority groups (Opara et al., 2010). 
2.3 Discussion 
This review brings together the information in the current literature regarding 
medicine use and medication related problems experienced by ethnic minority 
groups in the UK. Our findings suggest that there was variability seen in type(s) and 
possible cause(s) of MRPs identified across studies as well as recommendations 
made to support these groups in their use of medicines, which may be explained by 
differences in purpose of the study, ethnic group of participants, definition of a 
medicine-related problem, different disease condition, study setting, methodology 
used and the duration of follow-up for problem identification. However, common 
issues such as access to care and cultural perspective arise across different ethnic 
minority groups. 
Identifying studies and key words on MRPs experienced by ethnic minority 
populations in the UK were challenging. Thus, there is a possibility that some 
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relevant studies were not included despite a thorough investigation. Secondly, to 
ensure a scientific evidence base this review includes only peer reviewed journal 
articles. As discussed above, some of the studies included in this review were either 
small with numbers of ethnic minority participants  (ranging from 17-44, with a 
median of 32 patients) (Wheatly and Shelly, 1993; Chan, 2000; Lawton et al., 2005; 
Morgan and Figueroa-Muñoz, 2005; Gordon et al., 2007; Sidi et al., 2009), or did not 
report the sample size (n=3) (Wheatly and Shelly, 1993; Opara et al., 2010; Tsang et 
al., 2010). The results are also limited by the short length of follow-up for problem 
identification (Chan, 2000; Horne et al., 2004; Lawton et al., 2005; Morgan 
and Figueroa-Muñoz, 2005; Gordon et al., 2007; Sidi et al., 2009; Opara et al., 
2010). A further limitation is that different terms and definitions were used to 
describe MRPs among the selected studies. For example, some studies used a wide 
holistic definition to identify MRPs (Gordon et al., 2007; Sidi et al., 2009; Opara et 
al., 2010) others used a narrow definition such as ADR (McDowell et al., 2006; 
Ormerod et al., 2008), ADE (Tsang et al., 2010) or adherence (Lawton et al., 2005; 
Morgan and Figueroa-Muñoz, 2005
There has been no holistic approach or systematic investigation of MRPs among 
ethnic minorities in the UK. This review highlights that ethnic minority patients have 
their own problems and needs with both medicine use and service access and also 
that some ethnic minority groups may be at higher risk of MRPs than the majority 
ethnic group (Lip et al., 2002; Lip et al., 2004; Pardhan and Mahomed, 2004; Lawton 
et al., 2005; McDowell et al., 2006; Ormerod et al., 2008). This is possibly because 
ethnic minority patients may experience more difficulties in accessing healthcare 
services, getting the correct diagnosis and medicine, being supported with the use 
of medicines and getting regular monitoring or review.  The full body of evidence on 
) or used no universally accepted definition 
(Chan, 2000; Lip et al., 2002; Horne et al., 2004; Lip et al., 2004; Pardhan and 
Mahomed, 2004; Kumar et al., 2008). Finally, this review focused on ethnic minority 
groups in the UK. Whilst some similarities and differences might be expected 
elsewhere, the extent to which findings are relevant to population groups in other 
countries, societies, settings and contexts is unclear. 
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the extent to which ethnic minorities have more or less MRPs than the majority 
ethnic group is lacking.  However, we can anticipate that ethnic minorities have 
their own perspectives and needs because of cultural and religious issues, language 
and communication barriers, previous experiences and different 
expectations. Recommendations made in the literature to support ethnic minorities 
in the effective use of medicines have not been evaluated. The recommendations 
need to be addressed to all stages including diagnosis of disease, safe and effective 
use of medicines, monitoring or review of their chronic disease and medication 
regimens. 
Differences in the use of medicines would be expected between different ethnic 
minority groups. However, this review clearly shows that articles on medicine use 
and medicine-related problems experienced by ethnic minorities in the UK are 
limited in number. As a consequence, it is not possible to separately identify MRPs 
from perspective of each ethnic minority group. Little evidence is known of what 
influences MRPs among ethnic minorities, despite the diversifying world in terms of 
ethnic makeup and expanding field of research in use of medicines. 
Therefore, there is a need for more studies that examine medicine related needs for 
ethnic minority groups to ensure we effectively serve the needs of all populations 
and that all groups are supported in their use of medicines. 
2.4 Conclusion 
There has been no holistic approach or systematic investigation of MRPs among 
ethnic minorities in the UK. However, this review highlights that ethnic minority 
patients have their own problems and needs with both medicine use and service 
access. Therefore, there is a need for further research to be done in this area and 
for these patient groups. This review has been published. 
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2.5 Implications for further research  
The findings from this review have wide-ranging and important implications for 
research community in the UK and beyond. For instance, researchers should include 
ethnic minority groups more in health research, and the research should be 
designed to identify and address the needs and perspectives of ethnic minority 
groups. Researchers should also ensure that ethnic minority groups fully 
understand what taking part involves, for example by generating translated 
materials and using interpreters when needed. Further research should be a priority 
internationally. Whilst many problems and solutions may be context specific, issues 
such as access to care and differing cultural perspectives which are common among 
ethnic minority groups in the UK may occur among ethnic minority groups living in 
other countries.   
• Medicine-related problems remain unresolved despite decades of research. 
It was highlighted that one of the most striking reasons for the lack of 
progress in the research might be the absence of the patient’s perspective 
(Gordon et al., 2005; Gordon et al., 2007).  
Key messages from Chapter 2 
• This review highlights that ethnic minority patients have their own problems 
and needs with both medicine use and service access. Little evidence is 
known of what influences MRPs among ethnic minority groups, despite the 
increased diversification of populations in countries throughout the world. 
Therefore, research in this area and in EMGs is needed to better understand 
and manage MRPs.  
• If no action is taken into account to address these issues and to support 
these patients, this will lead to poor chronic disease management and 
consequently more hospitalisation, comorbidities, and wasted resources.   
Therefore, research questions of the main study were: 
Q1. What are the different types of medicine-related problems (MRPs) 
experienced by South Asian and Middle Eastern populations with chronic 
diseases in primary care? 
Q2. What are the contributory factors of MRPs among South Asian and 
Middle Eastern populations? 
Q3. What resolution strategies can be employed to minimise the occurrence 
of MRPs? 
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2.6 Study aim and objectives 
From the review of the available literature, the aim of this study was to identify 
MRPs experienced by South Asian and Middle Eastern patients with chronic 
diseases in primary care and to evaluate contributory factors that influence MRPs in 
order to identify how patients may be supported in the use of their medicines. 
To achieve this aim eight objectives were set for the main study. These were: 
1. To explore and describe medicine and service use issues experienced by 
South Asian and Middle Eastern patients from their perspectives.  
2. To identify the frequency and different types of medicine-related problems 
(MRPs) experienced by patients of South Asian and Middle Eastern origins. 
3. To identify factors which may contribute to medicine-related problems 
experienced by South Asian and Middle Eastern patients. 
4. To offer a valuable tool that can be used in these populations as well as a 
revised coding frame.  
5. To describe differences between SA and ME participants in terms of 
response rate, demographic details, medication-taking behavior and 
pharmacy and health service issues experienced by these two groups. 
6. To evaluate the extent of non-adherence to medications using 8-item 
Morisky Medication Adherence Scale. 
7. To suggest recommendations to support patients in their use of medicines. 
8. To examine the perspectives of pharmacists on MRPs identified and 
recommendations made to validate the results and address these problems 
among SA and ME groups. 
 
The next chapter presents a research context and methodological approach that 
were used to answer research questions and achieve study objectives. 
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Chapter 3 Research context and methodology of medications use 
and medicine-related problems (MRPs) experienced by South Asian 
(SA) and Middle Eastern (ME) patients with chronic diseases in 
primary care in the UK    
This chapter consists of two parts. The first part, 3.1, reports the theoretical 
framework of the main study and justifies the selection of particular measures and 
procedures to achieve the study objectives. The second part, 3.2, describes the 
research design and methods used in this research for data collection to meet the 
aim and objectives of the main study. It also reports the outcomes of the 
preliminary study conducted to identify logistical problems for the main study. 
Introduction 
3.1 Theoretical or conceptual Framework, and rationale for the chosen research 
methods 
The literature review presented in Chapter 1 and systematic review in Chapter 2 
have discussed the background issues relating to this study and have revealed that 
the majority of the research in the field of MRPs has been provider rather than 
consumer led. There was also limited research involving SA and ME groups’ 
perspectives on MRPs and on how these problems might be addressed. Therefore, 
it seemed prudent to conduct semi-structured face-to-face interviews (i.e., MRPs 
questionnaire) and to use a thematic approach in order to reveal the MRPs 
experienced by SA and ME patients and address medicine-related needs of patients 
which might resolve MRPs. The advantage of using thematic analysis or content 
analysis approaches is that they identify commonalities and differences in 
qualitative data, before focusing on relationships between different parts of the 
data, thereby seeking to draw descriptive and/or explanatory conclusions clustered 
around themes or problems.  
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The literature search has also shown that there was an absence of articles that 
measure the extent of non-adherence to medication among SA and ME populations 
in the UK, a country which has a sizable SA population (Ens et al., 2013). The 
literature also reported that the SA population tends to perceive themselves as less 
healthy than those in the general UK population (NHS Health and Social Care 
Information Centre, 2005). Therefore, it seemed crucial to conduct surveys (i.e., 
EuroQol 5D-3L and 8-item Morisky Medication Adherence Scale) to assess health 
status and level of non-adherence among SA and ME groups respectively. This was 
because assessing health, level of adherence, medicine-related problems and needs 
of any population or targeted group is a necessary and crucial part of delivering a 
high quality of care to that population or targeted group. If no action is taken into 
account to address these issues and to support these patients, this will lead to poor 
chronic disease management and consequently more hospitalisation, comorbidities, 
and wasted resources.    
Rationale behind choosing a mixed-methods approach 
Approaches to assessing health, level of adherence, medicine-related problems and 
needs and rationale for the chosen methods  
The term ‘mixed-methods research’ has been used to describe those studies that 
combine quantitative and qualitative methods (Richey and Klein, 2007). This 
approach was supported by a statement emphasising the need for a mixed-method 
approach: “quantitative and qualitative approaches are more useful when used 
together than when either is used alone... [and] when combined, are likely to yield 
a richer and more valid understanding” (Richey and Klein, 2007). A mixed-methods 
approach was selected in this study to develop a great and a more complete 
knowledge and understanding of the MRP phenomenon, which is necessary to 
inform practice. This method is used when the researcher believes that neither 
qualitative nor quantitative data collection techniques alone are likely to answer 
the research questions so one method will inform the other, producing an insight 
and understanding not possible if either had been used alone (Smith, 2002; Bowling 
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and Ebrahim, 2005). Using a mixed-methods approach can result in better 
examining, explaining, confirming, refuting and/or enriching information. It can also 
result in better analysis and consequently better recommendations or actions 
(Smith, 2002; Bowling and Ebrahim, 2005). 
The mixed-methods approach has been employed in previous studies that 
examined medicine-related problems using patients’ interviews and case notes 
and/or pharmacy records reviews (Cunningham et al., 1997; Howard et al., 2003; 
Pirmohamed et al., 2004; Gordon et al., 2005; Sidi et al., 2009; Opara et al., 2010). 
The quantitative methods approach used in those studies aimed at quantifying or 
measuring a phenomenon in order to test theories, compare groups or make strong 
predictions. For example, a quantitative method approach has been used in the 
context of conducting research in the topic area of MRPs in order to investigate the 
frequency or prevalence of MRPs as well as to predict the risk factors for MRPs and 
to quantify the relationship between MRPs and clearly defined variables. In this 
study, the quantitative method was chosen to quantify the types and extent of 
MRPs. In addition, this method was selected to count the extent of non-adherence 
and to measure the health status of SA and ME participants.  
In contrast, the qualitative methods used in previous studies that examined 
medicine-related problems focused on understanding the meanings assigned to a 
phenomenon from perspectives, behaviours, experiences and feelings of individuals 
in order to verify descriptive information retrieved from case notes or pharmacy 
records or to generate hypotheses. In the context of conducting research in the 
topic area of MRPs, qualitative methods were used in order to understand the 
meaning assigned to MRPs from participants’ views, beliefs and experiences and to 
identify the possible factors that may contribute to the problems. The qualitative 
method in this study was chosen to explore medicine and service use issues and to 
identify factors which may contribute to the problems. 
The mixed-method approach to research is referred to as triangulation. 
Triangulation of several methods was necessary to achieve the study objectives in 
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this research. Semi-structured interviews, medicine use reviews (MUR) and patient 
medication record (PMR) reviews were all used in this study as a way of 
triangulation. The main advantage to the triangulation design is that it provides 
interpretation of the data and assigns meaning to the collected information (i.e., 
numbers can be used to add precision to words, pictures, narrative or, conversely, 
words, pictures and narrative can be used to add meaning to numbers) (Smith, 
2002; Bowling and Ebrahim, 2005). It can answer a more complete and broader 
range of research questions because the researcher is not confined to a single 
approach. It is also efficient because both types of data are collected at 
approximately the same time. Thirdly, each type of data collection can be collected 
separately by a member of the research team who is expert in the area. Finally, this 
method can provide stronger evidence for conclusion through corroboration and 
convergence of findings. The disadvantages of triangulation design are the amount 
of money, effort and expertise required to conduct this type of study are 
considerable because investigators should be expert in both types of data 
collections. Finally, results from the two data types may not agree, which may 
require the collection of further data to resolve the problem (Smith, 2002; Bowling 
and Ebrahim, 2005). In the current study, the purpose of the triangulation design 
was to obtain complementary data on the same topic in order to validate or 
address a set of related issues to gain a deeper understanding of the subject area. 
The information from semi-structured interviews, MUR and PMR reviews was 
collected simultaneously (i.e., at the same time) and then interpreted 
simultaneously in the research report (Smith, 2002; Bowling and Ebrahim, 2005). A 
specific form was used to obtain data from pharmacy records for each participant, 
see Appendix 4. 
Rationale behind choosing a face-to-face semi-structured interview method 
There are different methods in qualitative approach for data collection such as in-
depth structured, semi-structured and unstructured interviews which can include 
group discussion or focus groups, interviews, participant and non-participant 
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observational studies, oral and life histories, and analysis of textual and narrative 
sources such as reports, diaries, and film or television (Bowling and Ebrahim, 2005).  
Despite the diversity of methods and approaches involved in qualitative data 
gathering, interview in particular seemed to be the most appropriate method to 
meet the study aims and objectives of this research because interviews offer a 
flexible, practical, and relatively economical way of gathering research data. There 
are a number of advantages to this research method, such as: making it possible for 
the researcher to directly intervene in the research process; allowing the researcher 
to guide participants to talk about specific issues in a private context; and allowing 
the researcher to ask a number of participants the same broad questions on a 
particular theme (Bowling and Ebrahim, 2005). By using the interview method the 
researcher should be prepared to ask questions throughout data collection and 
analysis as well as to consider new issues that may be raised during interview in 
order to get a deeper understanding of phenomena of interest in their natural 
context. It can also clarify the diversity of meanings assigned by different 
participants to a certain concern or event (Smith, 2002; Bowling and Ebrahim, 
2005). 
Face-to-face interviews offer an advantage over the other methods of qualitative 
data collection. Qualitative interviews consist of three main types, namely 
structured, unstructured and semi-structured interviews. Each method serves a 
different purpose and therefore requires a different procedure. Firstly, structured 
or standardised interviews, which are normally used in quantitative or survey 
research and involve asking the same set of specific questions in precisely the same 
way to every research participant (Bowling and Ebrahim, 2005). Structured 
interviews consist of ‘closed’ questions. This approach is used when the 
researcher’s time is limited and there is a need to collect specific data in a 
comprehensive manner (Kvale, 1996). This approach is also used when the 
researcher wants to test a hypothesis or attempt to generalise beyond the 
immediate sample. It is not, however, an appropriate method within qualitative 
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research, where the aim is to uncover the meaning of events in the meaning of 
research participants (Bowling and Ebrahim, 2005). 
Conversely, unstructured interviews are entirely participant-led, which means that 
the research participants are allowed to tell their own stories, experiences, 
attitudes, behaviours, at length, in their own words with little intervention or 
direction from the researcher. The questions in this type of interview are open in 
order to search deep beneath the surface of superficial response. Despite the rich 
data that the unstructured interviews can offer, the approach has some 
disadvantages such as it generates large amounts of data that then need to be 
analysed; due to the time limitation a small number of participants may be 
included, which creates doubt about the representativeness of the data collected; 
there also may be greater possibility of interviewer bias; and this method is 
expensive and time-consuming and requires a particular set of approaches and skills 
(Bowling, 2002; Bowling and Ebrahim, 2005). Hence, for many qualitative health-
related research projects, the semi-structured interview is more likely to be used 
because of its efficacy in gathering research data (Bowling and Ebrahim, 2005). 
Mixed-method face-to-face semi-structured interview was chosen to be the most 
appropriate method to evaluate MRPs experienced by South Asian and Middle 
Eastern patients with chronic diseases from their perspectives and to identify how 
patients may be supported in the use of their medicines. This is because it is the 
most commonly used qualitative method (Pope and Mays, 2006). Semi-structured 
interviews consist of both ‘open’ and ‘closed’ questions, which are planned but 
flexible, in order to allow the participants to develop their own narratives or reply in 
their own words and give their opinion in depth and in full while the researcher 
controls the interview via a structured topic guide that is important to the research 
questions (Bowling, 2002; Bowling and Ebrahim, 2005). Semi-structured interviews 
allow the participants the opportunity to expand on areas which they feel are 
important, to uncover their ‘framework of meanings’ and thus enable complex 
issues to be examined and provide rich information in context (Britten, 1995). This 
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method also allows a wide range of views to be captured and the researcher can 
probe for more details or return to the same topic for clarification (Bowling and 
Ebrahim, 2005). In addition, semi-structured interviews can generate unexpected 
findings which give valuable additional insight into the research topic and which 
may be left uncovered or missed if only quantitative methods were used (Smith, 
2002). Moreover, using a one-to-one approach makes the respondents more 
confident and comfortable to discuss or share any information, which may include 
sensitive topics such as discuss their disease and the problems they are having with 
its management (Bowling and Ebrahim, 2005). Furthermore, the response rate is 
higher with face-to-face interviews compared to postal questionnaires or telephone 
interviews (Harding et al., 2001; Bowling, 2002). This method also allows the 
researcher to gain both qualitative and quantitative data. Finally, tools that are used 
in semi-structured interviews can be modified to suit each individual (Harding et al., 
2001). The drawbacks of face-to-face interviews include being time consuming, 
expensive and subjective to both interviewer and respondent bias, having a small 
sample size and, finally, the information obtained is dependent on the skills of 
interviewer (Harding et al., 2001).  
Another qualitative method that can be used to meet the aim and objectives of this 
study is the focus group. Focus groups stimulate discussion, generate a breadth of 
ideas, focus on the most important topics raised, and explore insights in greater 
depth than traditional interviews (Bowling, 2002). They also allow the gaining of 
access to participants who are ‘difficult to access’, where literacy and confidence 
problems may exclude them from other individually-focused research studies. 
Focus groups can tackle sensitive topics in a supportive environment where a one-
to-one approach may become too ‘loaded’ (Bowling and Ebrahim, 2005). Sample 
size is high and the focus group method is enjoyed by respondents (Harding et al., 
2001).  
Despite all the advantages of focus groups, this method cannot be used in this 
study. This is because the medicine use and medicine-related problems topic may 
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involve complex and sensitive means of physical, psychological, spiritual, cultural, 
social aspects or dimensions in the lives of respondents, which may limit 
confidentiality and inhibit the deep exploration of respondents’ views (Harding et 
al., 2001; Smith, 2002; Bowling and Ebrahim, 2005). In addition, it is neither 
favourable nor usual for participants from SA and ME cultures to discuss their 
personal views and issues in front of strangers or in mixed gender groups, which 
may prohibit the deep exploration of participants’ views and perceptions. 
Moreover, this method is not suitable for participants who have limited physical 
activity and difficulty in travelling (Kirkevold and Bergland, 2007). Focus group 
studies also produce ‘messy’ data in comparison to other data collection methods. 
It may be time-consuming to analyse many transcripts and each group will naturally 
differ in terms of order in which they address specific issues and how they are 
discussed (Bowling and Ebrahim, 2005). A limited number of questions may be 
asked, conflicts may arise, a skilled interviewer is needed and, further, this method 
is expensive and difficult to control (Harding et al., 2001). Finally, a researcher 
combined three group interviews with ten individual interviews in an exploratory 
study of elderly women’s perceptions of control, health and aging. It was found that 
more in-depth results were generated from individual interviews compared to focus 
group interviews and in the group discussion not all the participants were able to 
comment on all issues (Mitchell, 1996).    
Survey, which is one of the quantitative methods that can be used to collect data, is 
considered appropriate for this study to assess extent of non-adherence and to 
measure health status of SA and ME participants. It was used because it is less 
expensive, is a quick process, has a large sample size and is a guarantee for 
anonymity of participants (Harding et al., 2001).   
Having chosen the appropriate methods for data collection, the next step was to 
determine the most appropriate tools or questionnaires to meet the research aim 
and objectives.  
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Rationale behind choosing the MRPs questionnaire from Gordon et al. (2005)  
In order to assess MRPs from the patients’ perspective, a semi-structured tool 
which included an adapted version of the MRPs questionnaire for Gordon et al. 
(2005) was employed. The MRPs questionnaire (English and Arabic versions) is 
available as Appendix 5. 
The Gordon et al. (2005) MRPs screening tool was developed based on the previous 
literature for the identification of MRPs. The reasons behind choosing this tool in 
particular were because this tool is short and practical and it employs a broad 
definition of MRPs: “any problem experienced by a patient that may impact on their 
ability to manage or take their medicines effectively” (Gordon et al., 2005) and, 
when a broad definition is used, an increased number of MRPs can be identified. In 
addition, to our knowledge this is the only tool available that is designed as a semi-
structured interview. Other researchers usually identify MRPs through patients’ 
medication review and not through patients’ interviews. This tool consists of closed 
and open questions with probes to help identify whether, from the patient’s 
perspective, they believe they have any MRPs by obtaining systematic information 
and detailed explanation and clarification (Gordon et al., 2005). It also provides a 
structured framework in which quantitative data could be obtained. It also seeks to 
explore factors and events leading to MRPs from the patient’s perspective. The 
open questions and the in-depth nature will enable a detailed documentation of 
MRPs from patients’ perspectives. Moreover, this tool was developed to be brief 
and easy to apply. Moreover, the screening tool includes questions regarding not 
only medicine use but also service access and, because ethnic minority groups are 
known to experience barriers to service access, this tool seems to be appropriate to 
identify what problems and barriers these groups are having with service use or 
access (Gordon et al., 2005).  
This interview will also discover from the patients’ perspective what services or 
facilities will help to prevent future MRPs. It will seek to discover if services and 
facilities currently in place are effective from their perspective, if they are aware of 
Chapter 3 – Research context and methodology 
89 
 
these services and how often they access these facilities. This tool has shown that it 
can be used in a range of settings to identify MRPs. Finally, the MRPs questionnaire 
is a valid tool and is able to correctly distinguish between patients with at least one 
MRP and those identified with no MRPs (for 83% of the cases). This tool is also 
reliable. The reliability of the procedure for categorising the MRPs was evaluated by 
assessing the level of agreement between three independent assessors. Two 
assessors agreed with 100% of the categorisation and one with 99% of 
categorisation (Gordon et al., 2005). This tool was also tested for its usability in 
practice in people from White, Black (Gordon et al., 2005) and South Asian origins 
(Sidi et al., 2009; Opara et al., 2010). The advantage of this tool over the medication 
review instrument used with patients present in pharmacies or surgeries is that this 
tool is able to identify a wide range of MRPs regarding the lack of opportunity to 
discuss MRPs, problems with monitoring and review of medicines, problems with 
process for obtaining repeat prescriptions through GP or pharmacy, and problems 
with pharmacy or surgery services use (Gordon et al., 2005). The MRPs 
questionnaire and coding frame is divided into five sections which involved 
questions regarding medicine and service use (Gordon et al., 2005): 
(1) Use of prescription and non-prescription medicines (About your medicine).  
(2) Personal characteristics including age, sex, country of birth, ethnic group, 
and whether or not they live alone (About Yourself). 
(3) Number of hospital admissions including accident and emergency, 
consultations as an outpatient or with private healthcare professional in the 
past five years (About the illnesses for which you take your medicines). 
(4) Self-reporting non-compliance (intentional and unintentional) with 
prescription medicines and the nature and frequency of their non-
compliance (More about your medicine).  
(5) Details relating to contacts with, and consultations at, the pharmacy and 
surgery (About your GP surgery and pharmacy visits).  
 
The MRPs were classified into the following categories using Gordon’s coding frame 
(Gordon et al., 2005): 
(1) ADRs and drug interactions. 
(2) Intentional non-compliance. 
(3) Cognitive, physical and sensory problems. 
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(4) Problems with non-prescription medicines. 
(5) Drug-prescribing problems. 
(6) Problems with monitoring and review of medicines. 
(7) Lack of information or opportunity to discuss MRPs or concerns. 
(8) Problems with process for obtaining repeat prescriptions through the 
surgery or the pharmacy. 
(9) Problems with services from the surgery or the pharmacy. 
 
For more detailed information about the questionnaire and coding frame please see 
Chapter 8. 
Rationale behind choosing self-reported Morisky 8-item Medication Adherence Scale 
(MMAS) (2008) 
The Morisky 8-item tool, which is a self-report tool, was selected in this research to 
evaluate the extent or rate of non-adherence to medication among South Asian and 
Middle Eastern patients in order to recommend the required intervention for 
improving adherence especially with the increasing need for long-term adherence 
to treatment. The MMAS questionnaire (English and Arabic versions) is available as 
Appendix 6. 
Various self-report tools have been used for studying adherence behaviours and 
associated health beliefs and attitudes in both general and specific patient 
populations but there is no ‘gold standard’ measure of medication adherence (Kim 
et al., 2000). The most commonly used measure of medication adherence in the last 
20 years is perhaps the 4-item original Morisky scale (Lichtenberg, 2010). The 
Morisky 4-item scale questionnaire was developed by Morisky and colleagues in 
1986 to measure medicine-taking behaviour in hypertensive patients (Morisky et 
al., 1986). The measure has been found to have adequate internal consistency (α = 
0.61), sensitivity (81%), and specificity (44%) but has shown poor psychometric 
properties (Morisky et al., 1986). Morisky and his colleagues (2008) created an 
expanded version (8-item) of this measure called the Morisky Medication 
Adherence Scale (MMAS). The additional items were added to better capture 
barriers surrounding adherence behaviour especially in that the new scale is able to 
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distinguish between intentional and unintentional non-adherence (Morisky et al., 
2008). The tool was validated using a sample of 1367 low-socioeconomic status 
minority respondents with hypertension (mean age 52.5, SD 12.2 years). It was 
found that the MMAS was reliable (α = 0.83), sensitive (93%), and specific (53%) in 
detecting non-adherence with favourable psychometric properties (Morisky et al., 
2008). 
All questions on the 8-item MMAS are answered on a ‘yes’ or ‘no’ scale except 
question number 8 which is answered on a ‘Never/Rarely’, ‘Once in a while’, 
‘Sometimes’, ‘Usually’ or ‘All the time’ scale. Each ‘no’ answer to items 1-7 receives 
a score of 0 and each ‘yes’ answer receives a score of 1. Question number 8, which 
asks participants to rate the difficulty remembering to take all their medicines is 
scored as follows (never/rarely = 0, once in a while = 1, sometimes = 2, usually = 3, 
all the time = 4). The coding instructions were given to the researcher as follows 
(Morisky et al., 2008): 
• Items 1-4, 6, 7, 8 should be reversely coded as follows each ‘no’ answer 
receives a score of 1 and each ‘yes’ answer receives a score of 0 except 
question number 5 where a ‘no’ answer receives a score of 0 and a ‘yes’ 
answer receives a score of 1. Question number 8 is scored as follows 
(never/rarely = 4, once in a while = 3, sometimes = 2, usually = 1, all the time 
= 0). This was done to make the scale range from low to high scores being 
equivalent to low to high adherence. 
• Item 8 was standardised by dividing this item by 4. 
• The total scale ranges from 0 to 8. 
• The MMAS scores can range from 0 to 8, which have been categorised as 
high, medium and low adherence (MMAS score of 8, 6 to <8, and <6, 
respectively). 
 
The Morisky 8-item tool was selected for measuring adherence because it is a self-
report method. The self-report is conducted by asking patients to self-report their 
medication-taking behaviour. Self-report assessments of patient adherence 
continue to be the most commonly used measure because they are quick, easy to 
administer, least equipment intensive, acceptable to patients, valid, reliable, can be 
used in large-scale studies, have the ability to distinguish between different types of 
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non-adherence, are inexpensive to obtain, and they can combine social, behavioural 
and situational factors involving revealing patterns of medicine use and what leads 
to non-compliance (Bosworth et al., 2006; Garfield et al., 2011). This measure is 
preferable because it is able to be administered in different ways, for instance, by 
post, by telephone, and face-to-face, and it is also suitable for both administration 
by an interviewer and for patient self-administration (Garfield et al. 2011). Self-
report measures have proven to be effective and efficient in determining and 
estimating medication adherence compared to the other methods of measuring 
adherence to medication (Garber et al., 2004; Krousel-Wood et al., 2006).  
Garber et al. (2004) reviewed the literature and evaluated the concordance of self-
report measures (i.e., questionnaires, interviews or diaries) with non-self-report 
measures (i.e., administrative claims, plasma drug concentration, electronic 
monitors, pill counts or canister weight, or clinical opinion) of medication 
adherence. It was found that the concordance of self-report and other measures of 
medication adherence varies widely based on the type of measures used. 
Questionnaires and diaries tend to have moderate-to-high concordance with other 
measures of medication adherence. However, interview-based self-reports are not 
concordant with electronic measures. Questionnaire and diary methods could be 
preferable to interviews for self-reported medication adherence (Garber et al., 
2004).  
Stephenson et al. (1993) compared self-report with other measures of adherence 
by conducting a systematic review. The review illustrated that most non-adherent 
patients can be identified by asking them about their adherence. It showed that 
asking patients about their adherence would detect more than 50% of patients with 
low adherence, with a sensitivity and specificity of 55% and 87% respectively. It was 
reported that it is essential to take into consideration that even when patients 
admit missing doses during previous days or weeks still they tend to overestimate 
their adherence rate by an average of 17%. However, the authors concluded that 
questioning patients about their adherence is the most reliable and valid way of 
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measuring adherence in clinical practice (Stephenson et al., 1993). Thus, self-report 
was chosen as a measure for non-adherence/adherence in this research.  
Despite all the benefits, there are a number of disadvantages to using self-report 
(Gochman, 1997; Vik et al. 2004). Firstly, patients may overestimate adherence or 
may underreport non-adherence. Secondly, self-report accuracy depends on the 
patient's cognitive abilities, social desirability and the honesty of his or her replies. 
Finally, using self-report to evaluate patients’ knowledge of the medications they 
have been prescribed and the dosing schedule provides little information as to 
whether the patient is adherent with the actual dosing schedule. However, it is 
believed that patients who report poor adherence to prescribed medications are 
likely to be telling the truth (Farmer, 1999; Haynes et al., 2002), which suggests that 
using this method may be helpful to reflect and detect true non-adherence, 
especially if it was used in conjunction with other available measures for assessing 
non-compliance, such as patient interviews. Using open questions during the 
patient interviews in a non-judgmental and non-threatening way, gives the 
participants the opportunity to give additional explanation about non-adherence 
(Farmer, 1999; Haynes et al., 2002).     
The 8-item MMAS tool has been validated for clinical practice in a number of 
studies and has been used to evaluate medication adherence across a wide variety 
of health conditions including cardiovascular disease, asthma, diabetes, HIV, 
osteoporosis, and depression and has been shown to be generally correlated with 
other measures of adherence (O’Donohue and Levensky, 2006) such as pill counts 
(Haynes et al., 1980), pharmacy records (Fairley et al., 2005), electronic monitoring 
(Schroeder et al., 2006), blood pressure control (Fleece et al., 1988) and virological 
outcome (Haubrich et al., 1999). This tool is suitable for measuring adherence in 
primary care because it is generic and not disease specific and it is suitable for 
patients taking a single medication or multiple medications for different conditions. 
This tool also has good predictive validity, in that individuals who scored in the high 
adherence range had a considerably better treatment outcome than those scoring 
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in the low adherence range as measured by the Medication Adherence 
Questionnaire (Morisky et al., 2008). Although the Morisky Scale does illustrate the 
ability to predict medicine-taking behaviour as well as outcomes, it was not formed 
to describe a patient’s long-term continuation of therapy, which is considered to be 
an essential factor in the long-term management of chronic diseases.  
The Medication Adherence Report Scale (MARS) (Horne, 1999) is another simple, 
valid and reliable tool for assessing adherence to medications. It has been used in 
several studies across a range of different illnesses (Barnes et al., 2004; Brown et 
al., 2005; Byrne et al., 2005; Grunfeld et al., 2005). The scale has been validated and 
showed favourable psychometric properties. In the validation study, the scale 
showed good internal reliability (0.67 to 0.90) when used across a range of diseases 
(asthma 0.83, diabetes 0.90, hypertension 0.67, and chronic pain 0.81). Two-week 
test-retest reliability was high (Pearson’s r=0.97, p<0.001). Concurrent validity was 
established by comparison of scores with another existing validated self-reported 
measure of adherence (Morisky et al., 1986) (Pearson’s r= 0.62, p<0.01). Construct 
validity was established by comparison with a validated measure of beliefs about 
medicines (Horne et al., 1999); higher levels of self-reported adherence were 
associated with stronger beliefs in the necessity of taking prescribed 
medications(r=0.33, p<0.01). Higher levels of self-reported adherence were 
negatively associated with stronger beliefs or concerns regarding taking prescribed 
medications (r=-0.30, p<0.01). Criterion related validity was established by 
assessment of blood pressure control among the hypertensive group; adherent 
patients showed better blood pressure control  than those who were non-adherent 
(χ2=4.24; df=1; p<0.05). The scale had a higher internal reliability than an existing 
validated self-reported measure, as measured by Cronbach’s alpha (Morisky et al., 
1986) (0.67 to 0.90 vs. 0.24, respectively).  
Despite all the advantages, the MARS had the drawback of allowing for assessment 
of adherence on a continuous scale and not a dichotomous division into 
adherent/non-adherent categories. In addition, the MARS was shown to be less 
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useful for distinguishing the type of non-adherence (intentional/unintentional) 
compared to direct self-report (29% vs. 43% respectively) (Alhaddad., 2010). 
Furthermore, the MARS fared worse at identifying non-adherence compared to 
direct self-report. In Alhaddad’s study, simple direct questioning of patients about 
their last episode of non-adherence that occurred within the last week was practical 
for assessing non-adherence to medication and a useful indicator of the type of 
non-adherence patients had. With direct self-report participants have the freedom 
to report any reason for their non-adherence, which can then be categorised by the 
researcher as intentional/unintentional or continuous/contextual/one-off 
(Alhaddad, 2010).  
Unlike MARS, which forced participants to rate five statements denoting non-
adherence to medications and with the exception of the first item ‘I forget to take 
them’ which clearly denotes unintentional non-adherence, and the third item ‘I 
decide to miss a dose’ which clearly denotes intentional non-adherence, none of 
the other items can be clearly said to be describing intentional or unintentional 
non-adherence. For example: the item ‘I alter the dose’ seems to denote intentional 
non-adherence but may also denote unintentional non-adherence if participants 
had to alter the dose for reasons outside their control, e.g., if they misunderstood 
dosage instructions provided. A further example is in the item ‘I take less than 
instructed’. This item seems to denote intentional non-adherence but may also 
denote unintentional non-adherence if participants took less than instructed – for 
example, because lack of manual dexterity prevented them from opening the 
medication bottle, or due to forgetfulness, etc. (Alhaddad., 2010). 
Non-adherers by direct self-report correlated better with non-adherence based on 
HbA1c levels than non-adherence based on MARS (kappa = 0.28 vs. kappa 0.24). 
When compared to HbA1c levels, direct self-report had a sensitivity of 48.5% for 
detecting non-adherence and a specificity of 93.3%, while MARS had a sensitivity of 
34.4%, and a specificity of 93.8% (Alhaddad, 2010).  
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Lavsa et al. (2011) evaluated the literature describing medication adherence scales 
to identify what is the best tool in identifying non-adherence. The literature search 
revealed five medication adherence scales which were the Morisky Medication 
Adherence Scale (MMAS), the self-efficacy for Appropriate Medication Use Scale 
(SEAMS), the Brief Medication Questionnaire (BMQ), the Hill-Bone Scale, and the 
Medication Adherence Report Scale (MARS). They found that MMAS is the quickest 
to administer, is the simplest for clinicians to score, and has been validated in the 
broadest range of diseases and among people from different ethnic background, 
unlike the other tools. MARS and the Hill-Bone Scale are difficult to score. In 
addition, MARS focuses on psychiatric populations whereas the Hill-Bone Scale is 
specific to hypertensive patients (Lavsa et al., 2011). 
On balance, as the 8-item self-report Morisky Medication Adherence Scale (MMAS) 
showed a good reliability and favourable psychometric properties and had been 
validated in a large patient population with chronic conditions, it was decided to 
use it for measuring participants’ adherence in the current study. The Morisky also 
had the advantage of allowing for assessment of adherence on a dichotomous 
division into adherent/non-adherent categories, which makes it easy to score, 
unlike MARs. 
Other common in-direct methods for assessing patient adherence to medications 
behaviourally are pharmacy and medical records review, pill counts, electronic drug 
monitoring, directly observed therapy and clinician assessment. Although a 
pharmacy database review can provide useful information on the exact regimen 
prescribed, the amount of medication dispensed and the timing of refills, pharmacy 
records will not be used as a main indicator of assessing adherence in this research; 
rather, this method will be used to support the accuracy of the primary method of 
assessing adherence since reviewing the pharmacy records method tends to be a 
less sensitive measure and can be difficult to use with patients who go to more than 
one pharmacy to refill prescriptions. In addition, this method gives us an indication 
of whether the patients dispense their medicines on time from the community 
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pharmacy but it does not tell us what happens on a daily basis at their homes. 
Another problem with this way of monitoring adherence is that some of the 
pharmacies may not have electronic patient records but hand-written records ones 
and consequently there is a great possibility of missing some of the information and 
data. Moreover, this method requires patient consent for release of records so, if 
the patient refuses, data and information will not be accessible. Finally, in order for 
this method to be reliable and to provide an integrated analysis of patients’ 
adherence behaviours, it should be matched with the medical record at the GPs, 
which is not achievable in this research. 
Pill counts involve measuring the amount of medication removed from the 
container (O’Donohue et al., 2005). For tablet and capsules, counting the number of 
pills is simple while non-unit-dosage formulations such as metered dose inhaler 
(MDI) and ointments, creams, gels, a change in weight of the carrier vessel can be 
used to indicate the number of doses used, but for many prescribed regimen this 
method is not available (O’Donohue et al., 2005). Although this method can be 
more objective than a report in that it does not rely on the patient's memory of 
missed doses, for clinical use this method is limited by the requirements for 
patients to bring in all of their medications and for clinical staff to take the time to 
count the pills. Additionally, this method does not provide information about the 
patterns of adherence or non-adherence, for example timing of doses and when 
doses are missed. Moreover, increased chance of dispensing medication from the 
container before a visit may occur if the patient knows medications will be 
measured (O’Donohue et al., 2005).  
Electronic monitoring devices record and store the date (and, for some devices, 
time) for each medication use and the data are transferred, using a communicator, 
to a computer for analysis (Myers and Midence, 1998). These devices are becoming 
more widely used (Myers and Midence, 1998). Electronic monitors are in most 
cases an objective, accurate and valid measure of adherence and, unlike the 
previously described measures, provide information on the pattern of medicine use. 
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However, this method is not without disadvantages. The opening of the container 
does not guarantee ingestion of the medication as the dose might simply be 
discarded and it does not account for the patient taking the appropriate number of 
pills (Horne et al., 2005). Ethically, patients have to be told in advance that their 
adherence behaviour is being monitored, with the risk that this might lead to 
temporary improvements in adherence as patients modify their behaviour to match 
the expectations of the observer (Horne et al., 2005). Moreover, electronic 
monitors cannot be fitted to many of the dosage forms and packaging used in 
routine care. Electronic monitoring is also expensive and it takes time to analyse 
data obtained and it does not provide information about the type of non-adherence 
(intentional or unintentional) (Horne et al., 2005). 
In addition to face-to-face or telephone interviews and questionnaires, diaries are 
another self-report measure of assessing adherence. Logs or diaries can track 
multiple behaviours including medication taking, exercise (type, frequency, duration 
and intensity) and diet (type, quantity of food consumed) and are intended to be 
completed on a daily basis (O'Donohue and Levensky 2006). They also can identify 
behavioural patterns and barriers. While daily diaries have high specificity for 
detecting treatment non-adherence, they suffer from problems of reliability and 
validity. Studies that compare written diaries to electronic monitoring show that 
diaries significantly overestimate adherence. In addition, patients can have 
difficulties in completing diaries and, as a result, there are often significant missing 
data or they are completed just prior to a clinic visit (O'Donohue and Levensky, 
2006).    
Direct measures for assessing medication non-adherence detect the presence of 
the drug in a person’s body using assays for the drug, its metabolite, or other 
biological markers in the urine, blood or other bodily fluids. Direct methods were 
not suitable to be used in this research because collecting serum, urine or blood 
samples to measure levels of a drug or its metabolites can be inconvenient and 
expensive for patients and, in addition, only a limited number of medicines can be 
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monitored by this way (Vermeire et al., 2001; Garfield et al., 2011). Direct measures 
are inappropriate for large samples and resources and are time consuming. A 
further disadvantage of using this method is that there is a great individual variation 
in drug absorption, the rate of excretion and metabolism, which makes it difficult to 
correlate drug concentration in urine or blood with adherence (O'Donohue et al., 
2005; O'Donohue and Levensky, 2006). Moreover, the patients may take their 
medication as prescribed for a day or two before their appointment, leading to drug 
levels that suggest better adherence than is the case. The ability of the direct 
methods to identify non-adherence depend on the accuracy of the test and the 
degree to which the patient was non-adherent before the blood or urine sample 
was withdrawn. Direct observation is practical only in hospitalised patients, single-
dose therapy and intermittent administration (O'Donohue et al., 2005; O'Donohue 
and Levensky, 2006). 
Rationale behind choosing the self-reported EuroQol EQ-5D-3L questionnaire 
Self-rated measures of health status and Health-related quality of life (HRQOL) 
capture the subjective evaluations of health and have been shown to be valid and 
surrogates for clinical outcomes. Numerous self-rated measures of health 
status/HRQOL have been developed, utilised and advocated by particular groups for 
different purposes. These instruments may be generic (non-disease-specific) or 
disease-specific. Generic instruments are designed to be applied across different 
populations and various types and severities of disease (Patrick and Deyo, 1989). 
Examples of various instruments available for the measurement of preference 
scores for current health comprise the EuroQol instrument, the Health Utilities 
Index Mark 2 (HUI2) or Mark 3 (HUI3), the Short form (SF-6D), the Quality of Well-
Being Scale (QWB), the 15D and the Disability and Distress Index. The EuroQol 
instrument, the HUI2 and HUI3 are three of the currently most used prescored 
preference instruments. In fact, Rasanen et al. have reported that the EuroQol 
instrument is the most used of any instrument. All three tools share features of 
ease of use, for instance, high completion rates and the ability to be filled out in five 
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minutes or less, and they have been used to assess preferences for a wide variety of 
diseases (Rasanen et al., 2006). Patients’ viewpoint of their health status is 
increasingly used as an important outcome measure of the impact of disease and 
the success of treatments. 
The EuroQol EQ-5D is a simple non-disease-specific questionnaire for evaluating 
and describing the HRQOL. This instrument was developed by a multi-centre, multi-
disciplinary and international group of researchers (EuroQol Group). It generates a 
health profile as well as a single index score of health-related quality of life.  It 
consists of five items relating to current problems in the following dimensions: 
mobility, self-care, usual activities, pain or discomfort, anxiety or depression. 
Responses in each dimension are divided into three ordinal levels coded (1) no 
problems, (2) moderate problems, (3) extreme problems. This part, called the EQ-
5D self-classifier, provides a five-dimensional description of health status, which can 
be defined by a five-digit number. For example, the state ‘11223’ indicates no 
problems in mobility and self-care but some problems with performing usual 
activities and moderate pain or discomfort, and extreme anxiety or depression. The 
EQ-5D self-classifier has also a visual analogue scale (EQ VAS) ranging from 0 ‘worst 
imaginable health state’ to 100 ‘best imaginable health state’. The EQ VAS records 
the participants’ self-rated health status on the day of the survey (EuroQol Group, 
2009). 
The reliability and validity of the questionnaire have been evaluated in various 
diseases and different patient populations and acceptable results have been 
obtained (Johnson et al., 1998; Johnson et al., 2000; Rabin and de Charro, 2001; 
Pickard et al., 2007; Szende et al., 2007; Dyer et al., 2010; Herdman et al., 2011). In 
addition, it was concluded in a review of the assessment of Quality of Life among 
older people, where a number of instruments were evaluated, that there was a 
good evidence for the validity, reliability and responsiveness of EQ-5D (Haywood et 
al., 2005). Validated translations are available for more than 102 languages 
including all South Asians and Middle Eastern languages. It has been used 
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frequently as an outcome measure in both clinical and healthcare services research. 
According to a recent systematic review, the EQ-5D is the most frequently used 
instrument to calculate quality-adjusted life years (Rasanen et al., 2006). Moreover, 
it is brief, acceptable for routine administration, and is being widely used in 
different countries by clinical researchers in a variety of clinical settings and a wide 
range of health conditions and treatments. It is designed for self-completion by 
participants and it is suitable for use in face-to-face interviews, telephone 
interviews or postal surveys (EuroQol Group, 2009). 
There is, however, some evidence of limited sensitivity/responsiveness of the 3L to 
small changes in health especially with patients with milder conditions (Janssen et 
al., 2008). Thus, to improve the instrument’s sensitivity to small and medium health 
changes and reduce ceiling effects, the EuroQol group developed EQ-5D-5L by 
increasing the number of severity labels to five levels in each dimension. 
Preliminary studies of the 5L measure in terms of reduced ceiling and floor effects, 
increased reliability and improved ability to discriminate between different levels of 
health (Janssen et al., 2008). Despite the advantages of using EQ-5D-5L over EQ-5D-
3L, it was decided to choose EQ-5D-3L to evaluate and assess health status for 
participants in this study because EQ-5D-5L is not available in all the languages that 
the participants in this study speak. In addition, EQ-5D-5L takes more time to fill out 
compared to EQ-5D-3L. Finally, dividing EQ-5D-5L into five levels – ‘no problems, 
slight, moderate, severe and unable to do’ – may make EQ-5D-5L more difficult to 
understand especially for ethnic groups that have clear language barriers.    
Various detailed measures can be used to assess health-related quality of life such 
as SF-36, the Quality of Well-Being Scale (QWB), and the Health Utilities Index (HUI). 
Our aim in the present study was just to give a general indication about the broad 
health status of SA and ME populations to enable us to describe these populations 
and not to determine whether MRPs contribute to the quality of life – in which case 
we would have required a very detailed and sensitive measure. Thus, the EuroQol 
was used because it is brief, can give a general indication about the health status of 
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our populations and is available in the required languages. The EQ-5D-3L 
questionnaire is available as Appendix 7.  
In summary, there are many different tools that were considered in the present 
study to explore MRPs, assess non-adherence to medications, and measure health 
status. Although there is still no gold standard MRPs questionnaire, 8-item MMAS 
and EQ-5D-3L tool were selected due to the advantages represented in Table 3-1. 
Table 3-1: The tools that were selected in the current study to explore MRPs, assess non-
adherence to medications, and measure health status respectively.   
Selected tools Advantages Disadvantages 
MRPs questionnaire • Short, easy to apply, valid 
and reliable; 
• Has been used in different 
settings and populations; 
• Can identify a wide range 
of MRPs and reasons 
behind the problems. 
• Has not been validated in 
SA and ME groups. 
8-item Morisky Medication 
Adherence Scale 
• Most commonly used tool; 
• Valid and reliable in 
determining and 
estimating level of non-
adherence; 
• Quick, easy to administer, 
acceptable to patients; 
• Able to be administered 
through post, telephone, 
face-to-face interviews; 
• Has been used in different 
settings, conditions and 
populations; 
• Available in different 
languages. 
• May overestimate 
adherence or 
underestimate non-
adherence. 
EuroQol EQ-5D  • Most commonly used as 
health economic 
assessment tool; 
• Simple, non-disease-
specific for assessing 
general health; 
• Valid and reliable; 
• Has been used in different 
settings, conditions and 
populations; 
• Able to be administered 
through post, telephone, 
face-to-face interviews; 
• Available in different 
languages. 
• Has limited sensitivity to 
small changes in health in 
patients with milder 
conditions. 
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3.2 Methods 
3.2.1 Study design  
The study was conducted from January 2011 to June 2014. This was a cross-
sectional study that took a mixed-method approach using qualitative and 
quantitative methods. The qualitative method included conducting semi-structured 
interviews with the patients from SA and ME origins in community pharmacies to 
identify MRPs from the patients’ perspective using an adapted version of the MRPs 
questionnaire from Gordon et al. (2005). The quantitative method involved 
administering questionnaires to measure the extent of non-adherence and general 
health status in South Asian and Middle Eastern patients using the Morisky 
Medication Adherence Scale (8-items MMAS) (Morisky et al., 2008) and EuroQol 
questionnaire (EQ-5D-3L) respectively (EuroQol Group, 2009). A retrospective 
review of pharmacy records which included Patient Medication Records (PMRs) and 
Medicine Use review reports (MUR) was also used to complement and validate the 
results obtained from the face-to-face interviews and to provide additional 
information on the MRPs identified. The data were collected from May 2012 to 
October 2012. Table 3-2 shows a summary of the methods used to the fulfil 
research objectives.  
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Table 3-2: Summary of the methods used to fulfil the research objectives. 
Research objectives Methods Outcome measures 
To identify and categorise 
types of MRPs experienced 
by patients of SA and ME 
origins. 
(1) Semi-structured questionnaire 
using MRPs tool; 
(2) PMR and MUR review; 
(3) Thematic analysis using Gordon’s 
coding frame and Nvivo 10 software; 
(4) Statistical analysis using SPSS 21 
software. 
(1) Identifying and 
categorising MRPs; 
(2) Counting types and 
extent of MRPs. 
To identify factors that may 
contribute to MRPs. 
(1) Semi-structured questionnaire 
using MRPs tool; 
(2) Thematic analysis using Gordon’s 
coding frame and Nvivo 10 software. 
(3) Statistical analysis using SPSS 21. 
(1)  Identifying what are 
the possible reasons that 
may contribute to MRPs 
from patients’ 
perspectives. 
To offer a valuable tool that 
can be used in these 
populations as well as a 
revised coding frame. 
(1) Semi-structured questionnaire 
using original MRPs tool; 
(2) MRPs original coding frame. 
(1) An adapted MRPs 
questionnaire and a 
revised coding frame to 
be used in SA and ME 
patients. 
To compare between SA and 
ME participants in this study. 
(1) Semi-structured questionnaire 
using MRPs tool; 
(2) Thematic analysis using Gordon’s 
coding frame and Nvivo 10 software. 
(3) Statistical analysis using SPSS 21 
software. 
(1) To describe 
differences between SA 
and ME participants in 
this study. 
To evaluate the extent of 
non-adherence to 
medications. 
(1) 8-item MMAS. 
(2) Statistical analysis using SPSS 21 
software. 
(1) Counting extent of 
non-adherence. 
To suggest recommendations 
to support patients in their 
use of medicines. 
(1) From patients’ and pharmacists’ 
perspectives; 
(2) From researcher’s perspective; 
(3) Existing literature. 
(1) Suggesting strategies 
to identify, correct and 
prevent MRPs. 
To validate the results and 
address these problems 
among SA and ME patients 
(1) Commencing pharmacists’ 
Interview informed from patients’ 
interview to examine their 
perspectives on MRPs identified and 
recommendations made. 
 
(1) Valid results and 
applicable 
recommendations. 
 
3.2.2 Study setting 
The study was conducted in community pharmacies located in the following areas 
of London: Camden, Brent, Harrow and Westminster. Camden, Brent, Harrow, and 
Westminster PCTs were chosen as sites for this study because they provided a rich 
sample of patients from these communities, which may have important implications 
for the identification of a wide range of MRPs and needs (DoH, 2009; Brent PNA, 
2011; Camden PNA, 2011; Harrow PNA; Westminster PNA, 2011). In addition, most 
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of the areas in these wards were highly deprived, and when people live in areas 
with high levels of deprivation they tend to have inequalities in health, multiple 
long-term conditions, and difficulties in accessing the healthcare services and 
possibly in using their medicines (DoH, 2009; Brent PNA, 2011; Camden PNA, 2011; 
Harrow PNA; Westminster PNA, 2011). 
Brent and Harrow were two of only three boroughs in England where, for the first 
time, the number of EMGs exceeded the White groups (GLA, 2010). In 2011, Brent 
had the second highest percentages of EMGs (59.2%) and Harrow had the third 
highest proportions of EMGs (53.7%). Table 3-3 illustrates the number of SAs and 
other ethnic groups in Camden, Brent, Harrow and Westminster boroughs 
according to the Greater London Authority 2011 (GLA, 2011).  
Table 3-3: The number of SAs and Other ethnic groups in Camden, Brent, Harrow and Westminster 
boroughs according to the Greater London Authority 2011 (GLA, 2011). 
 Total 
population 
Indian Pakistani Bangladeshi Other SAs Other 
ethnic 
groups 
Total 
EMGs 
Camden 212,200 6,200 1,400 15,000 4,600 11,400 29.9% 
Westminster 219,000 9,700 2,300 5,300 7,400 16,200 29% 
Brent 279,700 55,000 12,600 1,100 18,600 13,000 59.2% 
Harrow 218,700 60,100 6,000 1,100 19,400 9,000 53.7% 
 
Having described the health authorities that were selected for this study, the next 
step was to decide the most appropriate setting to conduct the study. The primary 
care setting, and in particular community pharmacies, was the most appropriate for 
conducting this study. According to the DoH (2008) ‘‘primary care is the term for 
the health services that play a central role in the local community’’ (DoH, 2008). In 
the UK about 75% of all prescribed items are ‘repeats’. Repeats are items that can 
be issued without the patient seeing a doctor. As a result, patients are more likely 
to experience MRPs in primary care.  
The reason for choosing community pharmacies as research sites is because the 
community pharmacy is the place the patients go to in order to collect their 
medicines. On balance, the community pharmacy sites are well placed to address 
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and identify MRPs and they can provide this research study with primary care 
patients who could be accessed on a daily basis, especially as they may not have 
such a heavy workload as the GPs may have, and they usually have a private 
consultation room which allows the semi-structured interview to take place, in a 
quiet, confidential and peaceful environment.  
3.2.3 Study sample 
The present study aimed at accessing people of SA and ME origins who were using 
medications. Therefore, there were two stages of sampling strategy. Firstly, 
sampling strategy of pharmacies, and secondly sampling strategy of patients within 
the pharmacies. The study required face-to-face interviews with SA and ME groups 
in community pharmacies. Therefore, we purposively selected a number of 
pharmacies and then, due to low response rate, those who agreed to take part 
(n=7) self-selected and were approached. As regards sampling strategy of patients, 
a purposive sample of patients that met the inclusion criteria was sought at the 
beginning and then, we approached everybody who met the inclusion criteria and, 
finally, those who agreed to take part were approached. 
Sampling strategy 
Eligibility criteria 
A purposive sample of patients was sought based on inclusion and exclusion criteria 
as follows: 
Inclusion criteria: 
• Patients whose ancestries were from a South Asian or Middle Eastern 
background, irrespective of their place of birth. South Asian background 
included Indian, Pakistani, Bangladeshi or any other South Asian background 
whereas Middle Eastern background included Arab, Iranian, Turkish or any 
other Middle Eastern background. Patients were identified by visual 
inspection of forename and surname together and outward appearance, 
and ethnic identity was confirmed by the patient later on. 
• Patients on multiple medicines (i.e., prescribed three or more regular 
medicines for chronic diseases). 
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• Patients who were willing to take part and signed a consent form. 
• Patients aged 18 years old or above (no parental consent required). 
• Patients who spoke the following languages: English or Arabic. Those who 
could not speak any of these languages were also included through utilising 
a routine practice used by community pharmacists who provided services 
for South Asian and Middle Eastern patients who did not speak English. This 
involved a community pharmacist or other pharmacy staff who assisted in 
communicating with the patient during the interview. Where translation or 
interpretation was required, the interviews were validated by the research 
team which included speakers of Arabic, Farsi, Panjabi, Hindi and Urdu. This 
was done by playing back a sample of audio-recorded interviews to the 
research team member who spoke the same language as the patient. 
 
Exclusion criteria: 
• Patients who disagreed to take part. 
• Patients who had a clear language barrier. 
 
The reason behind focusing on the South Asian group in particular was because 
people from the Indian subcontinent tend to perceive themselves as less healthy 
than those in the general UK population (NHS Health and Social Care Information 
Centre, 2005). In addition, South Asians now represent the UK’s largest minority 
ethnic grouping (ONS, 2004). Half of the total minority population was South Asian, 
25% were African Caribbean and 15% were Mixed origin (ONS, 2004). Between 
2006 and 2031 the largest percentage of ethnic minority group increases are 
projected to be in the Chinese, Bangladeshi and Pakistani ethnic groups, which are 
expected to increase by 55%, 51% and 50% respectively (GLA, 2010). In fact, during 
the same period, the highest increase of Ethnic Minority groups is projected to be in 
the ‘Other’ ethnic group by 79% (GLA, 2010).  The ‘Other’ ethnic category in the 
Census form was not broken down to determine which specific ethnic groups it 
includes and also there was no tick-box for the Middle Eastern groups on the 
Census form; therefore, it is more likely that the Middle Eastern groups fall into the 
‘Other’ category especially because of political instability in the Middle East, which 
may increase percentage of immigration to the UK among these groups. There was 
also a further reason behind choosing Middle Eastern groups which is because 
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these groups are relatively new to the British society and very little is known about 
what influences the medicine-related problems among these groups.  
The researcher determined sample size when no new topics, themes and issues 
emerged from the interviews. If no new issue emerged, then a decision was made 
to stop the interview because saturation was reached. This was reached by 80 
interviews. However, issues of availability and willingness of subjects to take part in 
the study also affected the sample size.   
Sample size  
Patients for this study were recruited through community pharmacies. Therefore, 
there was a two stage recruitment process: (1) recruitment of community pharmacy 
sites and (2) recruitment of patients from the community pharmacies.  
Sample recruitment  
Recruitment of community pharmacies 
The PCT in Camden, Brent, Harrow, and Westminster were asked to provide the 
researcher with a list of community pharmacies located in their areas. The PCTs 
provided a list of the names, address and telephone numbers of all community 
pharmacies from their databases.  
From the list obtained, all the community pharmacies located in Camden, Brent, 
Harrow and Westminster boroughs were invited to participate in this study if they 
met the following criteria:  
• Pharmacies located in wards or areas which had a higher percentage of 
residents of SA and MEs ethnicities than the national average (i.e., 17.6% - 
75.5%). This information was taken from the Office for National Statistics 
2001 (ONS, 2004). 
• Pharmacies located in the most deprived areas in these boroughs (i.e., fifth 
in lower super output areas – LSOAs) and more deprived areas than the 
borough’s average (i.e., fourth in lower super output areas). This 
information was taken from the Office for National Statistics 2010 (ONS, 
2010). 
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• Pharmacies conducting Medicine Use Review (MUR), and thus having a 
private consultation room.  
• Pharmacies that were willing to collaborate and participate. 
 
The level of deprivation in Camden, Brent, Harrow, and Westminster boroughs was 
assessed using the National Index of Multiple Deprivation (IMD) which provides a 
comparative measure of the deprivation experienced by a population based on a 
basket of indicators which are combined to form the overall index. These indicators 
include poverty, unemployment, poor housing, lower educational attainment, 
environmental factors and others. The index provides a score for each output area 
and ranks areas relative to each other. The scores range from 1 to 5, and the higher 
score indicates a high level of deprivation (ONS, 2010). 
All those eligible pharmacies (n=94) were invited to take part in the study by 
sending an invitation letter and a summary of the research study. The invitation 
letter included a brief description of the study’s aim and objectives, study 
procedures, how they would contribute and what they needed to do. It also 
involved contact details of the research team and a reply slip with a pre-paid 
envelope for return to the researcher. A sample of the invitation letter and a 
summary of the study provided to the community pharmacists are attached as 
Appendix 8 and Appendix 9 respectively. 
Then, the postal invitation was followed up after two weeks by telephone. A 
personal visit was also made two weeks after the telephone follow-up to those 
pharmacies that did not provide an answer regarding whether to take part or not 
after being contacted by letter and telephone.  
Once the community pharmacies agreed to participate, a letter was sent by the 
researcher to thank them for responding (Appendix 10). After that, they were 
contacted by the researcher to arrange a visit to the responding pharmacies in 
order to discuss the study in more detail. 
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Recruitment of patients 
Patients’ recruitment was carried out by two methods in each pharmacy: 
1. Reviewing Medicine Use Review (MUR) reports and Patient Medication 
Records (PMRs) in the pharmacy: the community pharmacists did a 
retrospective review of MUR reports and PMRs over the previous six months 
to identify eligible patients. Once eligible participants were identified, the 
researcher invited them to take part by post. Each patient was provided with 
a prepared information pack which included an invitation letter signed by a 
pharmacist, a reply slip with a pre-paid envelope and a patient information 
sheet explaining: the purpose of the study, study procedures and how the 
study will be conducted, possible disadvantages and benefits from 
participating, confidentiality of the data, and the researcher’s contact 
details. If patients wished to take part, they were requested to return 
the reply slip in the pre-paid envelope 
2. Direct approach: Pharmacists, who were local and tended to know patients, 
identified eligible patients by looking at prescription and PMR record and 
they also used names as well as appearance to ensure that no eligible 
possible participants were missed from the study. The pharmacists 
approached eligible patients directly when they came to the pharmacy (e.g., 
for a prescription, OTC, consultation) and invited them to take part. Regular 
patients, who were known by the pharmacists to take three or more regular 
medicines, but presented with a prescription for a non-regular medicine or 
less than three regular medicines, were also invited to take part. Eligible 
patients were approached by the pharmacist before or after the pharmacist 
dispensed their medicines. When the pharmacist was busy, the researcher 
approached and invited certain patients after being told by the pharmacist 
that these patients were eligible. When the researcher was busy 
interviewing a patient and during the less busy sessions in the pharmacy, the 
pharmacist approached and invited other patients who came to the 
pharmacy to take part in the study. If patients agreed, they were referred to 
the researcher who provided a full explanation of the study both, orally and 
with a patient information sheet, and obtained informed verbal and written 
consents prior to commencing the interview. After obtaining informed 
consent, the interviews were conducted. Patient Invitation Letter, Patient 
provided to the researcher’s address 
or alternatively, if they required further information, they could email or 
phone the researcher. Adequate time duration (i.e., three weeks) was given 
to the patients to consider whether or not they wished to take part in the 
study. Patients who returned the reply slip were contacted by the 
researcher and a date and time were arranged for the semi-structured 
interview. A follow-up letter was sent to non-responders to remind them to 
take part. This was done after three weeks of sending the initial invitation 
letter and prepared information pack.  
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Information Sheet and Patient Consent Form are attached as Appendix 11, 
Appendix 12 and Appendix 13 respectively. 
 
If patients did not agree to participate in the study, they were asked if they did not 
mind giving a reason for declining. The total number of recruits and the number of 
respondents and non-respondents were documented.  
From May 2012 to October 2012, a one-day visit from 9 a.m. to 5p.m. every two 
weeks to each pharmacy was conducted to recruit and interview eligible patients. 
The interview took place in the community pharmacy consultation room or outside 
the consultation room and was conducted by the researcher. Before commencing 
the interview, the participants were given five minutes to read the patient 
information sheet, ask any question and sign the consent form. The researcher 
went through the information sheet and consent form with some participants who 
could not read or understand English. After that, the participants were assured by 
the researcher that there were no wrong or right answers and that the participants’ 
perspectives were the main interest of this study. The researcher emphasised that 
all the information that the participants would provide or any other information 
that the researcher would obtain about their medicines from the pharmacy records 
would be treated as strictly confidential and their participation would not affect the 
quality of care they received from healthcare professionals. Finally, the researcher 
reminded the participants that they could withdraw at any time and that the 
interview would be audio-recorded and their medication records held at the 
pharmacy would be looked at as a part of this study. Where patients disagreed with 
having their interview recorded, only hand-written notes were taken by the 
researcher. 
Data collection 
After giving their informed consent (verbal and written), an eligible patient was 
interviewed face-to-face by using three tools. The tools that were used were ones 
that have been used in previous studies and have been validated. These validated 
tools were: 
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• Adapted version of the medicine-related problems questionnaire (Gordon et 
al., 2005). 
• Morisky 8-item tool (Morisky et al., 2008). 
• EuroQol (EQ-5D-3L) questionnaire (EuroQol Group, 2009). 
 
Each interview took between 15 and 45 minutes and was conducted in one session. 
After completion of each interview, the researcher accessed the participants’ 
records in order to review MUR and PMR records.  The medicine information on 
each participant’s record was documented using a form. The results obtained from 
MUR records, PMRs in the pharmacy and semi-structured interview were analysed 
and MRPs identified were categorised using Gordon’s MRPs coding frame (2005).  
An expert panel consisting of three pharmacists was invited to make a final decision 
on the presence of a MRP and to assess the MRP categories. This was done by 
preparing a case summary or vignette (i.e., a short illustrative narrative or story 
connected with the topic under investigation) using information from pharmacy 
records and the semi-structured interview. Case vignettes enabled pharmacists to 
review individual cases with an MRP effectively and categorise MRPs identified. The 
expert panel was asked to tick whether they agreed or disagreed with the category 
within which each MRP was placed.  The pharmacists reviewed only 10% of the 
patients and they were verbally thanked for their contribution to the study. The 
pharmacists reviewed only 10% of cases because it is unlikely that the researcher, 
who detected and classified the MRPs correctly for 10% of the cases, will not be 
able to identify and classify the MRPs correctly for the rest of the cases. A flow chart 
of the design of the main study is illustrated in Figure 3-1. 
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Figure 3-1: A flow chart of the design of the main study. 
 
Harrow PCT Brent PCT Camden PCT Westminster 
PCT 
A list of community pharmacies located in these PCTs was provided, where all 
eligible community pharmacies were invited to take part 
The 7 pharmacies that agreed to take part were contacted by the researcher to 
recruit patients 
Patients were recruited by two methods in each pharmacy 
Retrospective review of MRPs and 
MUR reports in pharmacy by 
pharmacists 
Direct approach by pharmacists and 
researcher 
Consent was obtained: 
Semi-structured interview was 
conducted by the researcher using 
MRPs tool and 8-item MMAS and 
EQ-5D-3L in the community 
pharmacy 
 
Consent was not obtained 
The researcher reviewed MUR 
reports and PMRs in the pharmacy 
Preliminary filedwork was first conducted 
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3.2.4 Translation of the instruments and transcripts 
The researcher conducted the interviews in English or Arabic according to the 
participant’s preference. In the current study, the questionnaire’s source language 
was English and the target was English and Arabic languages. The Arabic version of 
the MMAS and EQ-5D-3L questionnaire was provided by their authors. The MRPs 
questionnaire was translated and validated through a three-stage process of 
questionnaire validation. This process involved translation, group validation and 
post-validation of the questionnaire as follows: 
Translation of the instruments 
a) The translation stage: the MRPs questionnaire was translated using a parallel 
blind technique which involves translation of the instrument into the target 
language (i.e., Arabic) by two translators (F.A. and F.K.) independently. Both 
translators are native speakers of Arabic and proficient in English, have health-
related postgraduate qualifications and research interviewing experience as well as 
being professionally trained and familiar with the concepts being examined in the 
study. The translation process consisted of the following: 
• Translations for individual items were compared with one another. 
• If translations were identical or nearly identical in such a way that caused no 
disagreement between the two translators, the item was accepted 
immediately. 
• In case of disagreement between translators regarding an item, they 
discussed their individual points of view of why an item should be translated 
in their suggested way. Preserving the meaning of the original English item 
was the aim and the decisive factor in reaching an agreement about a 
particular item. 
• If one translator accepted the point of view of the other, the translation of 
the latter was accepted and used. 
• If not, the translators suggested alternative translations of the item, and 
discussed their views in the same way described above until agreement was 
reached and differences were resolved. 
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This method had the benefit of speed and practicality as the two translators worked 
in parallel rather than in sequence. In addition, this method has the element of 
security as it allows checking of the work of both translators and therefore 
comparing between the two drafts to increase the confidence in the accuracy of the 
translation (Behling and Law, 2000). Only a few spelling mistakes and grammatical 
amendments were required when discrepancies were identified. 
b) The group validation stage: a group of native Arabic speakers was formed 
consisting of the researcher, a researcher pharmacist and a clinical pharmacist to 
review and critique the translated tool. The MRPs questionnaire was assessed by 
answering the following: 
• Explain your understanding of the meaning of each question in the 
translated questionnaire. 
• Compare these meanings with the original English version and discuss and 
comment on the equivalence (is it the same?) 
• Suggest alternative translation if it is felt that the translation is not suitably 
accurate. 
• Is the translation culturally appropriate in Arabic and does it make sense? 
 
The questionnaire was amended after the suggestions and comments of the group 
validation and was ready for the next stage.  
c) The post validation stage: to enhance the quality of translation, the random 
probe technique was used (Behling and Law, 2000). This was done by administering 
the final version of the target language questionnaire after the group validation 
stage, to a group of target language speakers (n=3) who were asked to explain what 
they understood from each translated question and why they responded as they did 
to each individual item.  They were also asked to comment on the questionnaire in 
general including layout, wording, ease of understanding, and ambiguities, etc. In 
addition, they were also requested to recommend a better way of expressing these 
items and give any comments on the content. Those people were native speakers of 
Arabic with no knowledge about the concepts being examined in the study. No 
changes or amendments were made after post-validation. 
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The MRPs tool was adapted and amended in line with the recommendations after 
the group validation stage (Gordon et al., 2005). This involved changing the 
following points in the questionnaire: 
(1) Research participants’ demographic details were moved from section 2 (at 
the beginning) in the original tool to a separate sheet in the adapted version. 
The demographic details were asked at the end of the interview. This was 
done to allow the researcher to collect the most importance information 
and data regarding medicine use and service access at the beginning of the 
interview from participants who may not complete the interview.  
(2) In the demographic details sheet, the question regarding country of birth 
was changed to include only ‘the UK’ or ‘other’. The ethnic group question 
was also modified to involve only people from ‘South Asian’ or ‘Middle 
Eastern’ background. Questions about main language, religion, qualification 
and current employment status were added to the demographic details 
sheet.  
(3) Additional prompts were added to question 3, section 1. Prompts were as 
follows: ordering or collecting your prescription from the surgery, ordering 
or collecting your prescription from the pharmacy, opening containers, 
reading labels, understanding or reading information, obtaining information, 
administration (e.g., breaking tablets, measuring, putting in eye drops, etc), 
advice on when to take or how much (especially for as needed medicines - 
prn), advice on need for medicines and/or on side effects, buying 
medication or other remedies for yourself, other, please describe). These 
prompts were added in order to identify in which way these patients have 
been supported (i.e., type of support they receive, by whom and how often). 
(4) Two questions were added to section 5; these were: ‘How well does the 
service at your local pharmacy works for you?’, and ‘
(5) The following question: ‘Which GP surgery and GP do you usually go to and 
consult?’ was moved from the beginning of the questionnaire to the end 
because it was not considered as important as the other questions at the 
beginning.  
Is there anything you 
think that your doctor, pharmacist or nurse could do more to help you 
better manage your medicines?’ 
(6) Some grammatical changes were made to the translated version without 
changing the underlying concepts and some spelling mistakes were 
amended. 
 
The interviews were digitally recorded and transcribed verbatim by the researcher 
in the participant’s language that was used during the interview. This was done in 
Translation of the transcripts 
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order to produce initial verbatim transcripts. If some participants provided further 
information after the recorder was switched off, hand-written notes were made by 
the researcher as soon as the participants had left. All the extra field notes were 
included in the transcripts, which were then ready for translation and analysis.  
The translation process of the Arabic transcripts into English involved the following: 
• Reviewing 10% of the Arabic audio-records by another bilingual person (F.K.) 
in order to check the accuracy of the initial Arabic transcripts produced by 
the researcher. F.K. reviewed only 10% of Arabic audio-records because it is 
unlikely that the researcher, who correctly translated 10% of the cases, will 
not be able to correctly translate the rest of the cases. 
• Translating 10% of the Arabic transcripts into English simultaneously and 
independently by the researcher and the second bilingual person (F.K.) to 
ensure validity of translation and to allow the true meaning of the 
participant’s experience to be properly conveyed in the English language 
(Lopez et al., 2008). 
• Comparing the two translations and resolving all inconsistencies by 
discussion and generating a final version from each transcript. The few 
amendments that were required were mostly a few spelling mistakes and 
grammatical amendments which, for example, involved changes in tense 
and plurality of words but the underlying concepts remained intact.  
• Thematic coding and analysis of the data by the researcher using Gordon’s 
coding frame and Nvivo 10 software. 
 
Some qualitative studies which were conducted in another language directly 
transcribed the interview data into English, instead of transcribing it in the local 
language and then translating it (Kapborga and Bertero, 2002; Pitchforth and Van 
Teijlingen, 2005). Direct transcribing into English has the possibility that interpreter 
bias may occur (Lopez et al., 2008). Twinn (1998) suggested that qualitative data 
should be transcribed in the participants’ original language in order to reduce the 
difficulties associated with the translation and interpretation of verbatim data 
(Twinn, 1998). Pitchforth and Van Teijlingen (2005) conducted a study with 
Bangladeshi women who had recently used emergency obstetric care and had 
limited formal education. Pitchforth and Van Teijlingen worked with a lay 
interpreter who conducted the interviews. The interpreter was not professionally 
trained but she had trained and worked with the research team for six months and 
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had research interviewing experience. The interviews were translated directly into 
English by the interpreter. Pitchforth and Van Teijlingen arranged for an 
independent bilingual interpreter to transcribe four interviews into English for 
quality assurance purposes. The review of the two transcripts revealed that the 
interpreter did not translate the Bangladeshi women’s responses but interpreted 
the data. In addition, the level of detail which was provided by the interpreter was 
markedly different from that of the independent bilingual interpreter. She omitted 
many details, which led to loss of some insights into the experiences and views of 
Bangladeshi women. Thus, in this study the interviews, which were conducted in 
Arabic, were directly transcribed into Arabic and then translated into English. 
3.2.5 Data analysis 
In the analysis, the qualitative and quantitative procedures were applied to achieve 
the study objectives. The quantitative analysis was employed to describe the study 
population whereas the qualitative analysis was applied to explore people’s own 
perspective of MRPs, to explain how they might arise and to describe reasons that 
may contribute to MRPs.  
Preparation and coding of quantitative data 
Quantitative Data Analytical procedures 
Before data analysis, the data from MRPs face-to-face semi-structured interviews 
and the pharmacies’ review were coded in accordance with Gordon’s coding frame 
(deductively). Gordon’s coding frame (Appendix 14) consists of nine main broad 
themes plus a number of sub-themes under each main theme. When a new 
problem, sub-code or sub-theme emerged from participant’s discussion and was 
not included in Gordon’s coding frame, it was added to the most appropriate 
category or theme in Gordon’s coding frame (inductively) and all the previous 
transcripts were checked for the relevance of this new code to ensure consistency 
and thoroughness of coding. Any theme that did not fit a pattern in the coding 
frame was analysed separately. Thematic content analysis was used to develop the 
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coding scheme in this study. Thematic content analysis is a multistep procedure 
that can be performed inductively, deductively or both (Boyatzis, 1998). The data 
were then transferred into SPSS version 20.  
In Gordon’s coding frame, each MRP was given a three-digit code. The first digit 
related to the category within which the MRP was placed, with numbers from 1-9. 
The second and third digits related to its position within the category.  
Data entry 
The data were entered in groups of variables as they appeared in sections on the 
interview schedules and assessment form. The data were checked for errors in two 
ways during the data entry. First, when codes for each variable were entered for 
each case, the data entered for previous variables were checked against the original 
information. Second, after entering a group of variables, SPSS frequency and 
descriptive statistics were run on each variable to review minimum and maximum 
values, mean, median and range. Data checking was also carried out after data 
entry was completed. Missing values, shown by blank cells, were examined against 
original data to identify any inconsistencies. Variables from approximately three 
cases from each pharmacy were then reviewed with the original data from the 
interviews to identify any discrepancies.  
Quantitative data analysis       
Quantitative data were analysed using the Statistical Package for the Social Sciences 
(SPSS) version 21 for Windows® to report descriptive statistics. Numerical data were 
intended to indicate the extent to which problems were common among 
respondents. Descriptive procedures were used to characterise and summarise the 
data set. Summary stats and cross-tabulation procedures were used to describe the 
characteristics of participants, compare characteristics of respondents and non-
respondents, and compare characteristics of participants who had more or less 
MRPs. A p value equal to or less than 0.05 was considered as conferring statistical 
significance. All statistical tests were two-sided. Descriptive statistics included 
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frequencies, means/standard deviations, medians/interquartile ranges as 
appropriate based on measurement level and distribution of the variable. T-test, 
Chi-square test and Mann Whitney test were used for the descriptive analysis. 
Statistical significance was set at 0.05.  
Continuous data were illustrated as the mean (standard deviation [SD]) and median 
(inter-quartile range [IQR]).The mean measures the centre of symmetric data 
whereas median measures the centre of non-symmetric (skewed) data. Standard 
deviation (SD) was used to measure the variability of data and the level of spread 
around the mean. Inter-quartile range (IQR) (i.e., 25-75th
Differences between two independent samples were assessed using the t-test or 
Mann-Whitney U test. The t-test is a parametric test that assumes that the sample 
under analysis is from a population with a specific normal distribution, unlike non-
parametric tests. The independent samples t-test measures the differences 
between the means using the SD. The t-test was chosen over a non-parametric test 
if there was a normal distribution with no marked skewness. If the distribution was 
skewed, the non-parametric (non-normal) Mann-Whitney U test was used. The 
Mann-Whitney U test makes no assumptions about the underlying distribution or 
the normality of the data.     
 centile values) was used to 
measure the variability of data and the level of spread around the median. 
Categorical data were demonstrated as percentages (proportions) of participants 
belonging to different categories for each variable. Normality of distribution of data 
was assessed by producing histograms to visualise the shape of normal curve and by 
producing the normal probability plots (Q-Q plot). Histograms and normal 
probability plots are easy to interpret, even with a small number of participants.  
The chi-square test organises two or more categorical variables in a contingency 
table. The formula is based on the assumption that the variables are independent. 
The Pearson’s chi-square (χ2) test was used to look for an association and to test 
whether the distribution of frequencies among the categories of one variable is 
independent of their distribution among the categories of the other variable. It 
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works by comparing the expected frequency in each cell of a 2x2 table with the 
observed result. For the 2x2 table, the chi-square test is valid when the total sample 
size is greater than 20 and if the expected frequencies for each cell of the 2x2 table 
are greater than five. In a case where the total sample size is 20 or less and if the 
expected frequencies for each cell of the 2x2 table are less than five, the Fisher’s 
exact test was used instead.  
Preparation and coding of qualitative data  
Qualitative Data Analytical procedures 
The qualitative data from the interviews were transcribed to produce typewritten 
data. Different approaches have been identified previously by researchers to 
analyse qualitative data (Ritchie and Spencer, 1994). In the current study, a 
thematic framework technique was used as a method for analysing qualitative data. 
Framework analysis was developed in the 1980s by researcher at the UK National 
Centre for Social Research particularly for policy or applied research in which the 
information requirement is known in advance (Ritchie and Spencer, 1994). 
Framework analysis is good at dealing with research that has specific questions, a 
limited time-frame, a predefined sample and ‘priori’ issues that need to be 
addressed. Although it may generate theories, the main goal of using it is to 
describe and interpret what is happening in a particular setting (Ritchie and 
Spencer, 1994).    
This analytical approach develops a thematic framework, which is used to classify 
and organise data according to themes, concepts and emergent categories. The 
framework identifies a series of main themes that can be further subdivided into 
related sub-themes. Each main theme is charted by completing a matrix (table) 
where each individual case has its own row and columns that represent the sub-
themes. The cells of the matrix contain relevant summaries from the data set and 
the charts can then be used to examine the data for patterns and connections.  
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In pharmacy practice and policy and in particular in the area of MRPs, thematic 
content analysis has been used to understand the meanings assigned to MRPs from 
perspectives, behaviours, experiences and feelings of individuals in order to identify 
how individuals may be supported in the use of their medicines (Gordon et al., 
2007; Sidi et al., 2009; Opara et al., 2010). It has been used because it allows 
inclusion of prior identified themes or concepts from previous literature as well as 
other themes or concepts that emerge during the coding process. In addition, it 
follows a well-defined procedure, which makes it possible for others to rework and 
reconsider ideas precisely since the analytical process is accessible, as it has been 
documented. 
Ritchie and Spencer (1994) identified six advantages for framework analysis as 
follows: 
• “It is generative or grounded: it is heavily based on, and driven by, the 
original accounts and observations of the people it is about. 
• It is dynamic: it is open to change, addition and amendment throughout the 
analytic process. 
• It is systematic: it allows mechanical treatment of all similar units of data. 
• Enables easy retrieval: it allows access to, and retrieval of, the original 
textual material.  
• Allows between and within case-analysis: it enables comparisons between, 
and associations within cases to be made. 
• Accessible to others: the analytic process, and the interpretations derived 
from it, can be viewed and judged by people other than the primary 
analyst.” 
 
The analysis process of the thematic approach comprises five different stages 
(Ritchie and Spencer, 1994). The first stage is to understand the data by reading and 
re-reading the text to gain an overview of richness, diversity and depth of these 
data. The next stage is to focus on the analysis by reviewing the purpose of the 
evaluation and how the data will be presented. The third step is to identify a 
thematic framework by developing sub-codes or sub-categories from both pre-
existing and emerging problems and organising them into coherent codes or 
categories. The fourth stage is to identify patterns and connections within and 
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between categories. The final stage is interpretation and bringing it all together by 
putting together key characteristics of data and mapping and interpreting data as a 
whole in order to address the key objectives of the research study (Ritchie and 
Spencer, 1994). 
Qualitative data analysis 
The following procedure was followed by the researcher when analysing the data. 
The data were processed and verbatim transcriptions of the patients’ interviews 
were made. The researcher read each interview transcript thoroughly to enable her 
to gain a sense of the whole experience for each respondent and be able to identify 
descriptions of experiences and themes within the data. Each response to a 
question was independently analysed and each patient’s responses to a particular 
question grouped together and reanalysed. The data were analysed thematically 
using Gordon’s coding frame. By analysing each section of the interview transcripts 
independently the researcher was able to identify the clear intention of a 
respondent’s answers to the interview questions and thus to draw out underlying 
meaning of the responses.  
Verbatim quotations were taken from the interview transcripts and used to 
illustrate the results. The quotations are use to confirm that the researcher’s 
interpretation of the data was based on evidence and was not impressionistic.  
Nvivo is a qualitative data analysis computer software package produced by QSR 
International (Silver and Lewins, 2010). Nvivo provides a range of tools for 
integration, organisation, exploration and interpretation of rich data records and 
information. This software was used in this study to (Silver and Lewins, 2010): 
• Integrate data: by sources, data storage and data preparation and importing 
data. 
• Organise data: by folders, collections, classifications and attributes. 
• Explore data: by annotating text, searching text and querying word 
frequency. 
• Interpret data: by annotating codes, using memos, sets and models. 
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• Interrogate data: retrieving data by opening a code, text search, matrix 
queries.  
 
Nvivo 10 software has advantages over the other qualitative softwares because it 
does the following (Silver and Lewins, 2010): 
• Allows the importation of additional audio and video file format. 
• Allows social media data (e.g., from Facebook, LinkedIn and Twitter) to be 
imported. 
• Allows web pages captured using NCapture to be imported as PDFs. 
• Enables the content of source material and memos to be spell checked. 
• Includes new reports which summarise coding (i.e., includes coded content 
as well as summary frequency information).  
• Analyses both numerical and non-numerical data. 
• Accommodates a wide range of research methods such as literature review.  
3.2.6 Reliability of the results 
Reliability refers to the extent to which the study findings obtained are reproducible 
(Smith, 2002). As argued by Yin (1989), reliability is achieved if the same procedures 
lead to the same conclusions when repeated. In this study, detailed information has 
been presented regarding the method of data collection, sampling procure, sample 
recruitment, and data analysis. From this information, the study could be 
reproduced and therefore shown to be reliable. However, this piece of work is 
essentially naturalistic and as such explores the thoughts, feelings and opinions of 
respondents at one point of time. In essence, this means that the same questions 
asked of the same people at varying times may elicit different answers. This is what 
is expected. The reliability of the study therefore lies in the reproducibility of the 
results and assumption that if the data were collected using identical techniques at 
exactly the same point in time the same results would be obtained, and if the data 
were analysed using the documented method of data analysis the same conclusions 
to the study would be drawn.  
To ensure the reliability of the data collected during the interview and the 
administration of the tools and the collection of pharmacy records, the following 
steps were undertaken by the researcher: 
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• The data collection process was clearly documented and research 
procedures were followed as per the data collection protocol during the 
research process.  
• A semi-structured interview technique was employed using prepared 
interview questions, including prompts and probes, to ensure respondents 
were invited to consider the same topics.  
• Only one researcher was involved in data collection and the interview guide 
was closely followed to reduce any possibility of bias and to eliminate any 
inconsistencies in the procedures.  
• These interviews were audio-recorded and at least 10% of them were 
checked for reliability by the expert panel. In order to simplify the 
assessment of the reliability of the MRPs categories, the second and the 
third digits of the MRPs codes were removed, leaving the first number of the 
code, which was the category number (from 1-9). The data relating to 
medicine, recruitment, interviews, patients’ characteristics, healthcare 
issues and MRPs were kept in the same Statistical Package for Social 
Sciences (SPSS) data editor file. A separate data was created (in another 
SPSS data editor file) to assess the reliability of the MRPs categorisation. To 
ensure the reliability of the coded transcripts, the expert panel, which 
consisted of three pharmacists, were asked to tick whether they agreed or 
disagreed with the category within which each MRP was placed by the 
researcher for 10% of the interviews. Then, the expert panel and the 
researcher met to compare the sets of coding and resolve any 
inconsistencies or disagreements. The disagreement between the expert 
panel and the researcher was then calculated based on cases of 
disagreement in MRPs (when totally different problems were identified) and 
cases of missed coding (when one of the raters missed coding a chunk of 
text while other one coded it). In cases where both raters coded the same 
problem but with different wording, this was not considered as 
disagreement. The inter-coder reliability was assessed using the following 
formula (Artstein and Poesio, 2008): 
 Intercoder relibility = Number of agreementsNumber of agreements + number of disagreements 
 
The inter-coder reliability was acceptable for 10% of the interview 
transcripts as all the values were 90% or more. Due to the high inter-coder 
reliability achieved after the eighth transcript, it was decided to stop the 
validity check after the eighth transcript. 
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3.2.7 Validity of the results 
Validity refers to the extent to which the study findings are a true representation of 
the issue examined (Smith, 2002). It has been argued that qualitative methods have 
inherit validity due to the capacity of the participants to discuss issues relevant to 
the phenomena without facing an agenda or structure (Smith, 2002). Although a 
semi-structured interview tool was used to elicit participants’ responses on a range 
of issues and views without influencing their responses since open questions and 
prompts were used to allow the participants to express further issues or add 
additional comments, the following steps were also undertaken by the researcher 
to ensure the validity of the results: 
• Forming the basis for the validation of this study by conducting literature 
and systematic reviews. These reviews considered previous research within 
the field of MRPs and EMGs, the aims and objective of these studies and the 
methodology used. Previous research was considered to help ensure that 
this study included all issues relevant to MRPs in EMGs. The reviews 
provided the researcher with guidance with respect to the choice of the 
study research method. The literature and systematic reviews highlighted 
areas of importance as regards MRPs among EMGs. These included issues 
such as patient knowledge about their medication, medication-taking 
behaviour during Ramadan and when travelling back to their home lands or 
to take religious journeys and taking non-prescription medicines, etc.  The 
literature and systematic reviews helped ensure that the data collection 
instruments covered all angles and topics relating to MRPs among EMGs.   
• Certain issues that were found in the literature were considered significant 
and questions about these issues included in the interview schedule, e.g., 
the issues of altered medication-taking behaviours in Ramadan. This process 
ensured that the data collection instruments had content validity – content 
validity being a measure that the data collection instrument covered all 
angles and domains of the topic under investigation.  
• Attending tutorials and reading books on conducting qualitative research, 
use of questionnaires, interviewing techniques and obtaining informed 
consent.   
• Pilot interviews were conducted to assist the researcher in her interview 
technique, to ensure that the data collection instruments covered all the 
relevant areas and that the interview questions were unambiguous to 
respondents.   
• Using Gordon et al.’s (2005) MRPs questionnaire which was developed after 
conducting a literature review and preliminary filedwork, which ensured the 
inclusion of all the relevant issues concerning the phenomena being studied.   
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• Assuring participants of the confidentiality and independence of the 
research in order to relax the participants and make them comfortably 
discuss any problems and give their true views related to the study.   
• Using follow-up questions. Participants were asked to report any non-
adherence using a quantitative scale followed by a qualitative description. 
They were also asked to report how frequently they consulted with HCPs, 
which was followed by a question about their last consultation. The follow-
up questions were employed to measure accuracy of the previous response.     
• The researcher ensured that the participants understood the questions and 
in cases where the participants gave an unclear answer to a particular 
question, the researcher repeated the answer given by the participant. 
• Using a variety of sources for data gathering (triangulation): the results 
obtained from pharmacy records (i.e., PMRs and MUR reports) and face-to-
face semi-structured interview will be triangulated. The triangulation 
method will bring together qualitative and quantitative techniques and 
check the findings from pharmacy records against face-to-face interview, 
thus enhancing their validity. However, the researcher may not be able to 
find the same thing twice from pharmacy records and face-to-face 
interview. In addition, the quantitative and qualitative components of this 
study may yield data on different phenomena, so they may not be compared 
to check the ‘validity’ of each other or they may contradict one another. But, 
even if this happens, triangulation has an advantage of providing different 
viewpoints and different pictures of the phenomenon under investigation, 
resulting in a more complete picture if quantitative and qualitative 
components brought together (Bowling and Ebrahim, 2005).   
• Comparing the results with existing knowledge of the subject in the 
literature, which is termed cumulative validity, as well as using argument 
validation in which the negative cases where views were inconsistent with 
the majority were also considered and explained (Smith, 2002). 
• Commencing interviews with pharmacists to check the validity of our 
findings.  
• Checking the relevance of a new code when it was added to ensure 
consistency and thoroughness of coding. 
• Having the expert panel review, validate and verify the research 
interpretations and conclusions to ensure that the results have not been 
misconstrued  (internal validity). 
• Using Nvivo software to ensure validity of the results by providing a 
systematic approach to data analysis.  
 
3.2.8 Sample representativeness 
An attempt was made to ensure that there was representation of all ethnic 
backgrounds listed in the protocol as well as representation of participants from 
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different demographic characteristics. This is to allow a range of perspectives to be 
identified.  
3.2.9 Generalisability 
Generalisability exists when our results and conclusions are applicable to other 
context, settings, or a larger population. Although this study was conducted in four 
different PCTs to include pharmacies and patients from different demographic and 
cultural backgrounds, the findings of the present study could not capture the 
perspective of patients who could not speak English or Arabic unless they had a 
translator, which may affect the generalisability of the study. In addition, this study 
could not capture perspectives of people from other ethnic backgrounds such as 
people from White, African or Chinese origin, which may also affect the 
generalisability of the study. It can be concluded that the data generated by this 
study is context-specific and is not generalisable to a wider population. In addition, 
the sampling strategy for the study used non-random sampling techniques and so 
the data generated may not be representative of the wider populations; however, 
the data do provide valuable insights into issues surrounding MRPs in SA and ME 
groups and how these problems might be addressed. The choice of pharmacy from 
where the patient population was recruited may also influence the generalisability 
of the study results. Overall, even though the study data may not be generalisable, 
it provides descriptive data which fulfil the study objectives and may be used as a 
starting point to inform further research.  
3.2.10 Ethical approval 
Ethical approval was sought from London City and East Research Ethics Committee 
(REC) and was obtained on 17
Application to the Research Ethics Committee 
th October 2011. Prior to obtaining ethical approval, 
the required documents were prepared. A committee meeting was scheduled on 
the 1st
Appendix 
 September 2011 and enclosed with a cover letter for review. The documents 
sent to the Ethics Committee comprised the following: REC application (
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15), protocol, MRPs interview schedule, MAAS and EQ-5D-3L questionnaires, letter 
of invitation to community pharmacists and letter of invitation to patients, 
participant information sheet and consent form, and other relevant documents. The 
researcher was advised by the Committee to attend the meeting to respond to the 
members’ questions and provide further explanation if required. Thus, the 
researcher and one of the supervisors attended the meeting.     
A response letter was received on the 09
Response to letter from the Research Ethics Committee 
th
Appendix 
16
 of September 2011 in which the 
Committee granted the study provisional opinion and asked the researcher to 
provide further information and minor changes to the documentation (
). The researcher included all the modifications requested by the Committee, 
further clarifications and requirements were met, and a response letter was 
provided to the Committee on the 12th Appendix 17 September 2011 ( ). A 
favourable ethical opinion letter was received on the 17th
Appendix 18
 of October 2011 subject 
to obtaining approval from the local research and development offices (R&D) and 
host organisations or pharmacies prior to the patients’ recruitment ( ).  
R&D approvals (
Application to the local R&D offices 
Appendix 19 and Appendix 20) were sought from North West 
London R&D office and North Central London R&D office and approvals were 
obtained on 8th February 2012, 14th March 2012, and 25th
Appendix 21
 March 2012 respectively 
( ). Prior to obtaining the R&D approvals, the required documents were 
prepared in order to apply to each R&D office separately. The documents sent to 
the R&D offices comprised the following: all the documents sent and approved by 
the Ethics Committee as well as the research and development (R&D) form, site-
specific information (SSI) form, letter of favourable opinion from the REC and other 
relevant documents.  
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Permissions were sought and granted from the developers in order to use the 
chosen questionnaires. Authorisation for the use of the MRPs tool, MMAS and EQ-
5D-3L questionnaires was obtained free of charge by email communication from the 
UCL School of Pharmacy, Donald Morisky and the EuroQol Office respectively. A 
copy of each questionnaire was provided by email.  
Ethical consideration 
A patient information sheet was provided to all eligible participants who wished to 
take part. The leaflet included the purpose of the study, other individuals from 
whom relevant information may be obtained, and how data would be collected, 
anonymised, analysed, and disseminated, and other relevant information. 
Informed written and verbal consent was obtained prior to commencing the face-
to-face interviews. The patients were reminded that they could withdraw from the 
study at any time without providing a reason.  
The interview was audio-recorded for verbatim transcription with the participant’s 
authorisation. For participants who declined to have an audio-recorded interview, 
only researcher field notes were taken. 
If a significant problem was identified in the course of the research, the patients 
were advised and encouraged by the researcher to consult their pharmacist or GP, 
or alternatively, if they preferred and with their permission and consent, the 
researcher spoke to the community pharmacist on their behalf. Then it was the 
responsibility of the community pharmacist to inform the patients’ GP. In the event 
that the patients did not want to inform their GP, then this matter was handled by 
the community pharmacists through their normal clinical practice (i.e., it was the 
clinical judgment of the pharmacists in that situation regarding whether they 
wanted to inform the patients’ GP when patient safety overrides patient 
confidentiality).  
Chapter 3 – Research context and methodology 
131 
 
Any information that was obtained from the patients or pharmacy records was be 
anonymised and treated as confidential information and kept in a coded format 
without the name of the patients and locked all the time in a designated cabinet for 
this purpose. Data were stored in the University College London (School of 
Pharmacy) computers where all files were password protected and only the 
researcher was allowed to access the data. Storage of the data was the 
responsibility of the researcher. Data will be stored for at least five years after the 
end of the study and will then be destroyed. The storage of the data during the five-
year period will be the responsibility of Prof. Felicity Smith. 
3.2.11 Pilot work and its impact on the development of the study 
The pilot work was conducted in three pharmacies for a total of three days. A one-
day visit from 9am-5pm in each pharmacy was conducted. The main objectives for 
the pilot study were as follows: 
• To obtain demographic details of community pharmacies to see whether 
they are different. 
• To check response rates in order to estimate the potential response rate and 
sample size that could be obtained for the main study. 
• To identify the best method and time to recruit patients as well as the most 
suitable place to interview patients. 
• To test the feasibility of methods (e.g., data collection forms, MRP tool, 8-
item Morisky instrument and EQ-5Q-3L questionnaire) and to ensure they 
were acceptable and workable for this study and for these patient groups. 
This was done by examining question order, length of the interview, 
rephrasing the questions to ensure clarity if required, and adding more 
prompts if needed. 
• To assess the feasibility to transcribe and analyse the data sets obtained 
from the interviews. 
• To assess the practicality of obtaining relevant information from pharmacy 
records and to assess what type of information can be retrieved from them. 
• To ensure that all the data were obtained to meet study objectives and to 
highlight whether any adjustments need to be made or reconsidered for the 
design of the main study. 
 
The characteristics of community pharmacies were collected and described in the 
recruitment, response rate and characteristics of the sample - Chapter 4. Patients 
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(n=7/11) were recruited and interviewed during the pilot work. A (63%) response 
rate was obtained. In order to increase response rate further, a few steps were 
suggested and undertaken, as follows:  
• Patients should be approached by a pharmacist first, when they come to the 
pharmacy. 
• Patients should be approached before the pharmacist dispenses their 
medicines. 
• Eligible patients who use the pharmacy regularly, but present with a 
prescription for a non-regular medicine or less than three regular medicines, 
and are known by the pharmacist to be eligible should be invited to take 
part. 
• When the pharmacist was busy dispensing medicines or consulting a patient, 
the researcher approached and invited patients to take part in the study. 
• If patients are of Arabic origin, they should be approached and invited by the 
pharmacist as well as the researcher – who is of Arabic origin – and provided 
with a full explanation of the study in Arabic. 
 
During the pilot work, patients were recruited through a pharmacy records review 
(MUR and PMR) method and a direct approach method. It was concluded that the 
direct approach method (i.e., inviting patients when they presented in the 
pharmacy) was the best and simplest method to recruit patients due to many 
reasons, as follows: 
• Asking the pharmacists to check their PMR and MUR records to identify 
eligible patients was time consuming and impractical especially for some 
pharmacies that had only one or two computers in the pharmacy or one 
pharmacist to go through pharmacy records, which caused disruption to 
routine practices. 
• Response rate (0%) was very poor when recruiting patients through 
pharmacy records. This was done by a pharmacist in each pharmacy (n=3), 
who carried out a retrospective review of MUR reports and PMRs over the 
previous six months to identify a list of patients’ names and addresses 
(n=10) in each pharmacy that matched both inclusion and exclusion criteria. 
The community pharmacists then invited individuals via letter and the 
response rate was 0%. The researcher sent a follow-up letter was sent to 
non-responders three weeks after sending the invitation letter, to remind 
them to take part, which also yielded a 0% response rate. 
 
It was noticed that the three pharmacies had not had particular busy hours during 
the day or a particular busy day during the week (i.e., they all varied); thus the data 
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were collected from 9am – 5pm with a one-hour lunch break in between (i.e., 1pm 
– 2pm). The best place for interviewing participants was inside the consultation 
room. For pharmacies that did not allow the researcher to use the consultation 
room either for safety purposes or because they busy almost all the time, a quiet 
and separate area in the pharmacy was used to interview patients. This was 
conducted to ensure that the routine practice within pharmacies was not affected 
whilst the research study took place. Pharmacy staff and patient acceptability were 
also required to ensure that the research was not intrusive. 
No changes were made in the content, wording, layout or order of the 
questionnaires after piloting them. They were workable, acceptable, and easy to 
understand and able to identify any problems experienced by patients regarding 
the use of their medicines. The only thing that was changed was the order of 
administering the questionnaires. The order was as follows respectively: MRP tool, 
8-item Morisky instrument and EQ-5Q-3L questionnaire and, finally, demographic 
details of participants. This order was chosen in order to collect necessary 
information that could not be obtained without interviewing patients face-to-face, 
such as their perspectives, experiences and behaviours using the MRPs semi-
structured questionnaire. If time allowed, the surveys were administered by asking 
questions directly to the participants in the interview but if time did not allow, the 
participants were asked to fill in the questionnaire at home and give it back to the 
community pharmacist in a sealed envelope or post it to the researcher’s address. 
The length of the interview varied depending on the participants’ answers. 
Transcription and preliminary analysis of the pilot data were performed and the 
results were able to meet the study objectives, and they were combined with the 
results of the main study section.  
Pharmacy records review was used to validate and identify potential MRPs such as 
DIs, non-compliance issues, dosage and dose frequency problems. These records 
were also used to know whether the patient had any problems with their repeat 
prescription or problem with ordering their repeat medication, such as mobility 
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issues and dependency on carer for obtaining repeat prescription. The following 
information was retrieved and assessed from the pharmacy records:  
• Current prescribed and non-prescribed drug therapy for the previous six 
months. 
• Patients’ knowledge of their medications, including what medications they 
are taking (e.g., the names, strengths, types of medications, reasons for 
taking medications, when to take them, how to take them, etc.). 
• Intentional compliance issues due to patients’ concerns about side effects or 
belief that their medications were not effective, which could result in poor 
compliance. 
• Non-intentional compliance issues such as difficulty using a product form, 
manual dexterity problems, memory problems, visual or hearing problems, 
and swallowing difficulties.  
• Type of suggestions made to a particular prescriber. 
 
At an early stage, all the data that were obtained met the study objectives and no 
major adjustments were made for the design of the main study. Testing of the 
method and tool under the conditions proposed for this research study clearly 
demonstrated, that despite the busy and demanding routines of any pharmacy, 
methods and tools could identify patients and the MRPs they experienced. 
• This study was a cross-sectional study.  
Key messages from Chapter 3 
• Patients were from SA and ME origins, aged over 18 and prescribed three or 
more regular medicines.  
• Patients were identified through previous medicine use reports (MUR), 
patient medication records (PMR) or when presenting with a prescription. 
• The data were collected in 80 face-to-face semi-structured interviews in 
seven pharmacies in London using MRPs tool, 8-item MMAS, and EQ-5D-3L. 
• Interviews were audio-taped; transcribed verbatim and analysed 
thematically using Gordon’s coding frame and Nvivo 10 software. SPSS 21 
software was used to analyse quantitative data. 
• The pilot work indicated that the potential response rate for patients in the 
main study would be high if the recommended steps in Chapter 3 to 
increase response rate were closely followed. 
• Inviting patients when they presented in the pharmacy was the best method 
to recruit participants. 
• The methods used were acceptable and workable for the main study. 
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Chapter 4 Recruitment, response rates and characteristics of the 
sample 
Low participation rates of ethnic minority population in research studies is a 
concern that has been raised (Heiat et al., 2002; Mason et al., 2003). However, 
there is absence of evidence that reports the reasons for lack of participation 
because many studies do not reveal the ethnicity of participants and do not 
sufficiently report the reasons for exclusion or ineligibility (Jolly et al., 2005). It is 
crucial to understand the reasons for non-participation; firstly because this will help 
to assess generalisability of the results by understanding the representativeness of 
the sample. Secondly, it may allow future researchers to obtain higher response 
rates and thus more representative sample from similar populations. Thus, this 
chapter addresses these questions and reports the recruitment and response rates 
of pharmacies and patients in relation to medicine use and medicine-related 
problems experienced by SA and ME patients with chronic diseases in primary care 
in the UK. It also provides a description of the characteristics of the participating 
pharmacies, the SA and ME patients participating in the interviews, and the SA and 
ME patients who did not take part in the interviews. This was done to identify the 
response rate and the reasons for non-participating and to describe the participants 
of the current study.  
Introduction 
4.1 Recruitment, the response rate and characteristics of the participating 
pharmacies and patients 
4.1.1 Pharmacies 
The methods used for recruiting community pharmacies were described in Chapter 
3. Ninety-four out of three hundred and thirty-five community pharmacies in 
Camden, Westminster, Brent, and Harrow met the inclusion criteria and were 
eligible to take part. All the 94 pharmacies were invited by sending an invitation 
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letter. After two weeks, an email was sent and a telephone follow-up was made to 
the non-responding pharmacies. A personal visit was also made to the rest of the 
non-responders two weeks after contacting pharmacies by email and telephone. Of 
the 94 pharmacies invited only seven agreed to take part (Response rate 7.5%) 
whereas 87 declined to take part in the study (Non-participation rate 92.5%). 
Shortage of full-time pharmacists, lack of interest, heavy workload, the lack of time 
as well as lack of payment and place to interview patients were the reasons that 
were given for non-participation. Six pharmacies agreed to participate after the 
researcher made a personal visit and one agreed after a telephone follow-up. The 
recruitment methods used and response rate of pharmacies in each PCT are 
illustrated in Table 4-1. Pharamcies’ visiting timetables by month is illustrated as 
Appendix 22. 
Three out of the seven pharmacies that agreed to take part are located in 
Westminster. Going to the pharmacies in person was the best method of 
recruitment (i.e., six out of seven) in comparison to recruiting pharmacies though 
invitation letter, email or telephone follow-up. Five of the seven pharmacies were 
independent pharmacies (single-handed). There were only two types of 
computerised systems used among seven pharmacies (i.e., PROSCRIPT and Next 
Phase). The number of pharmacies’ staff varied and ranged from four to 12 people. 
Staff members consisted of pharmacists (i.e., regular and/or locum), pharmacy 
technicians and counter assistants. Although all the seven pharmacies were 
ethnically diverse, South Asian staff represented the largest ethnic group and 
Gujarati was the most commonly spoken language in the pharmacies as well as 
English.  
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Table 4-1: The recruitment methods used and response rate of pharmacies in each PCT.  
Pharmacies 
(PHARMS) 
No. of eligible 
PHARMS 
No. of PHARMS 
approached by 
sending an 
invitation letter 
(IL) 
No. of PHARMS 
approached by 
sending an email 
(E) 
No. of PHARMS 
approached by 
telephone (Tel) 
No. of PHARMS 
approached by in-
person visit 
(V) 
No. of PHARMS 
agreed to take part 
The last method used 
to convince 
pharmacy to take 
part 
Pharmacies in 
Camden 
(n=72) 
21 21 6 18 2 1  In-person visit 
Pharmacies in 
Westminster 
(n=102) 
13 13 6 11 5 3  In-person visit 
Pharmacies in 
Brent (n=87) 
37 37 8 33 2 2  1 (Telephone) and 1 
(In-person visit) 
Pharmacies in 
Harrow (n=74) 
22 22 2 18 2 1  In-person visit 
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The number of customers entering the pharmacies varied where the highest was in 
pharmacy number 2 (n=277) and the lowest was in pharmacy number 6 (n=65). The 
pharmacies in Westminster served a larger population of Middle Eastern customers 
whereas the pharmacies in other PCTs served a larger population of South Asian 
patients. The number of prescriptions and prescription items dispensed by the 
seven pharmacies differed where the highest was in pharmacy number 2 (n=140 
and 307) and the lowest was in pharmacy number 6 (n= 62 and 136) respectively. 
All the pharmacies provided essential, advanced and enhanced services. No big 
difference was found between the services provided in each pharmacy. The number 
of MURs that each pharmacy undertakes each year varied between 50 and 400. All 
the seven pharmacies had a private consultation room but only five pharmacies 
allowed the interviews to be conducted in their consultation room. Only the 
interviews that were conducted in pharmacies number 2 and 4 were quiet and 
private where they could not be overheard by others. Although some of the 
interviews were conducted outside the consultation room or inside the consultation 
room but the door was not closed, careful attention was given to make sure that no 
one was close enough to overhear or affect the response given by the participant or 
the flow of the interview. Interviews were carried out between May and October, 
2012. The characteristics of participating pharmacies are shown in Table 4-2. 
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Table 4-2: Characteristics of participating pharmacies. 
Pharmacy code Pharmacy 1 Pharmacy 2 Pharmacy 3 Pharmacy 4 Pharmacy 5 Pharmacy 6 Pharmacy 7 
Location Camden Westminster Westminster Westminster Brent Brent Harrow 
Type of pharmacy Single handed Group 
pharmacy 
Single handed Single handed Group pharmacy Single handed Single handed 
Type of PMR system PROSCRIPT Next Phase PROSCRIPT Next Phase PROSCRIPT PROSCRIPT PROSCRIPT 
No. of pharmacy staff 5 12 8 8 4 4 6 
No. of pharmacists 2 (1:regular) and 
(1:locum) 
4 (2:regular) 
and (2:locum) 
3 (3: regular) 4 (1: regular) and 
(3: locum) 
1 (1: regular) 1 (1: regular) 3 (2:regular) 
and (1:locum) 
No. of technicians 1 3 2 2 2 2 1 
No. of counter 
assistants 
2 5 3 2 1 1 2 
Ethnicity of pharmacy 
staff 
Indian, 
Bangladeshi, 
White British 
Arab, Indian, 
Black African, 
White British 
Indian, Irish Indian, 
Bangladeshi 
Pakistani, Black 
African 
Indian, Afghani Indian 
Language of pharmacy 
staff 
 
English, Gujarati, 
Bengali 
Arabic, English, 
Gujarati, Hindi 
English, 
Gujarati, Hindi 
Guajarati, Urdu, 
Hindi, 
English, Bengali 
English, Urdu Guajarati, 
English, 
Farsi 
English, 
Gujarati, Hindi 
No. of patients 
entering the pharmacy 
in the first visit from 
9am-5pm 
71 277 195 84 769 65 74 
Total number of South 
Asians 
10 10 9 15 6 35 55 
Total number of 
Middle Easterners 
0 37 32 21 2 2 0 
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Table 4-2: Continued characteristics of participating pharmacies. 
 
Pharmacy code Pharmacy 1 Pharmacy 2 Pharmacy 3 Pharmacy 4 Pharmacy 5 Pharmacy 6 Pharmacy 7 
Total number of 
prescription 
62 140 92 125 83 62 95 
Total number of items 170 307 202 299 151 136 222 
Type of services that 
the pharmacy provides 
Essential Service, 
advance service 
[i.e., the New 
Medicine Service 
(NMS), Medicine 
Use Review 
service (MUR)] 
and enhanced 
service [i.e., 
minor ailments, 
emergency 
contraception, 
smoking 
cessation, BP 
test] 
Essential 
Service, 
advance service 
[i.e., NMS and 
MUR] and 
enhanced 
service [i.e., 
smoking 
cessation, 
supervised 
consumption of 
methadone] 
Essential Service, 
advance service 
[i.e., repeat 
request, delivery 
service, NMS and 
MUR] and 
enhanced 
service [i.e., 
smoking 
cessation] 
Essential Service, 
advance service 
[i.e., NMS and 
MUR] and 
enhanced service 
[i.e., minor 
ailments, 
supervised 
administration, 
administration of 
influenza 
immunisation, 
needle exchange 
services] 
Essential Service, 
advance service 
[i.e., NMS and 
MUR] and 
enhanced service 
[i.e., supervised 
consumption of 
methadone, EHC 
on PGD patient 
group directive, 
sexual health 
services, health 
M.O.T service, 
food intolerance 
testing] 
Essential 
Service, 
advance service 
[i.e., NMS and 
MUR] and 
enhanced 
service [i.e., 
smoking 
cessation, 
weight 
management, 
BP monitoring] 
Essential 
Service, 
advance service 
[i.e., NMS and 
MUR] and 
enhanced 
service [i.e., 
smoking-
cessation 
service] 
No. of MUR conducted 
in the pharmacy per 
year 
50 400 300 200 400 50 400 
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4.1.2 Patients 
The methods used to recruit the patients are described in Chapter 3. A total of 30 
patients were invited using MUR and PMR review method. Of the 30 patients who 
were sent an invitation letter to take part in the study, none responded (response 
rate 0%). After two weeks a reminder letter was sent to non-responders; two 
patients declined to take part and 28 patients did not respond.  
A total of one hundred patients were approached in the seven community 
pharmacies using the direct approach method. Eighty participants agreed and 
consented to participate in the study. The overall response rate from recruitment in 
the seven community pharmacies was 80%. Complete interviews were obtained for 
77 participants and three interviews were partially completed. Twenty patients 
declined to take part in the study, all of whom were asked to identify their ethnicity 
and to give a reason for non-participation. Generally, pharmacies with a high 
number of patients entering the pharmacy in the first day visit had higher response 
rates except pharmacy number 6.  
Table 4-3 shows that the lowest response rate was obtained from pharmacies 
number 1 and 7 and the highest was from pharmacies number 2, 3, 5 and 6. There 
could be many reasons for this; for example, in pharmacies number 5 and 6 the 
response rates were high because the regular pharmacist approached the patients 
first, explained about the study and encouraged patients to participate. Also, 
pharmacies number 2 and 3 were located in areas that serve a higher population of 
Arabs and because the researcher is of Arabic origin and speaks the same language, 
this facilitated the recruitment process and increased the response rates in these 
pharmacies. Pharmacies number 1 and 7 had the lowest response rates possibly 
because they were located in less busy and less densely populated areas than the 
other pharmacies.  
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Table 4-3: Number of recruits and response rate in each pharmacy.  
Number of Recruits a Responders Declined b Ineligible Response 
rate 
Full Partial   Responders 
x100/ 
(Responders 
+ Declined) 
Pharmacy 1 11 6 1 4 5 64% 
Pharmacy 2 18 16 0 2 1 89% 
Pharmacy 3 16 13 1 2 1 88% 
Pharmacy 4 10 7 0 3 3 70% 
Pharmacy 5 7 7 0 0 3 100% 
Pharmacy 6 19 15 1 3 2 84% 
Pharmacy 7 19 13 0 6 3 68% 
Total 
 
100 77 3 20 18 80% 
a Full responders completed the interview and partial responders did not fully complete the 
interview. 
b
 
 Ineligible patients did not fit the inclusion criteria and were not recruited.  
Characteristics of 80 participants obtained during the interviews (e.g., age, gender, 
ethnicity, country of birth, coming year to the UK, living arrangement, main 
language, religion, education, employment) were entered into a database in SPSS v 
21 and are illustrated in 
Responders 
Table 4-4. The mean age of participants was 58 years (SD 
13, range 18-83) and 49 (61%) were male. Sixty participants (75%) were 65 years or 
below. The majority described themselves as Arabs (n= 38, 48%) followed by Indian 
(n=26, 33%). Seventy-seven (96%) of them were born outside the UK, of which 49 
(61%) arrived in the UK in 1990 or before. Fifty-four (68%) were Muslims and 19 
(24%) were Hindu. Arabic was the most commonly spoken language among 
participants at 38 (48%) followed by Gujarati at 19 (29%). Most participants lived 
with one or more family members (n= 67, 84%). Participants were asked about their 
current occupation: 11 (14%) were currently self-employed or employed as full-time 
or part-time workers. The remaining were not currently employed – 24 (30%), 
retired – 28 (35%) or homemakers – 16 (20%). Participants were also asked about 
their education status: 29 (36%) had qualifications higher than high school, 35 (44%) 
had high school or lower qualifications and 16 (20%) had no qualifications. 
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Table 4-4: Characteristics of the 80 participants.  
Participants’ characteristics Statistic Results 
Age (years) Mean (SD) 58 (13.4) 
Range  18-83 
≤ 65 N (%) 60 (75) 
> 65 N (%) 20 (25) 
Gender   
Male N (%) 49 (61) 
Female N (%) 31 (39) 
Ethnicity   
South Asians N (%) 40 (50) 
Indian N (%) 26 (33) 
Pakistani N (%) 8 (10) 
Bangladeshi N (%) 4 (5) 
Sri Lankan N (%) 2 (2) 
Middle Easterners N (%) 40 (50) 
Arabs N (%) 38 (48) 
Iranian N (%) 1 (1) 
Turkish N (%) 1 (1) 
Country of birth   
The UK N (%) 3 (4) 
Other N (%) 77 (96) 
Year of arrival in the UK 
(years) 
Mean (SD) 1983 (15) 
Range 1956-2011 
≤ 1990 N (%) 49 (61) 
> 1990 N (%) 31 (39) 
Living arrangement   
Alone N (%) 13 (16) 
With others N (%) 67 (84) 
Main Language   
English N (%) 5 (6) 
Gujarati N (%) 19 (24)  
Urdu N (%) 6 (8) 
Bengali N (%) 4 (5) 
Punjabi N (%) 1 (1) 
Hindi N (%) 1 (1) 
Arabic N (%) 38 (48) 
Farsi N (%) 1 (1) 
Turkish N (%) 1 (1) 
Other N (%) 4 (5) 
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Table 4-4: Continued characteristics of the 80 participants. 
 
Participants’ characteristics Statistic Results 
Religion   
No religion N (%) 2 (2) 
Christian N (%) 3 (4) 
Hindu N (%) 19 (24) 
Muslim N (%) 54 (68) 
Other N (%) 2 (2) 
Education   
> High school N (%) 29 (36) 
≤ High school N (%) 35 (44) 
No education N (%) 16 (20) 
Employment   
Full-time worker N (%) 5 (6) 
Part-time worker N (%) 3 (4) 
Self-employed N (%) 3 (4) 
Unemployed N (%) 24 (30) 
Retired N (%) 28 (35) 
Homemaker N (%) 16 (20) 
Student N (%) 1 (1) 
 
The 80 participants reported using a mean of 8 POMs (SD 4, range 3-21) POMs. 
Figure 4-1 illustrates the number of prescription medicines used by interview 
participants. The majority of participants (61/79, 77%) were taking ≤9 medicines. It 
was not possible to identify the name and number of medicines for one participant 
because the medication history was not on the pharmacy’s PMR. 
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Figure 4-1: The number of prescription medicines used by interview participants (n=79). 
 
The medicines used by participants were confirmed by the researcher during the 
interviews and through pharmacy records review. Figure 4-2 shows the number of 
participants taking at least one POM from any BNF chapter. The majority of 
participants (n= 67) had at least one cardiovascular drug. Many participants were 
using a medicine for central nervous (n= 51), Endocrine (n= 49) and Gastrointestinal 
systems (n=41).  
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Figure 4-2: Number of interview participants having medicines from each BNF chapter. 
 
The number and types of medicines used by interview participants are tabulated in 
their BNF chapters in Table 4-5. The number and type of each medicine (medicine 
listed in its generic form) is shown for each BNF chapter. The total number and 
percentage of medicines from each BNF chapter is also shown. The highest number 
of medicines prescribed and used by participants were for the cardiovascular 
system in BNF chapter 2 (38%), followed by central nervous system in BNF chapter 4 
(n=18%) and endocrine system in BNF chapter 6 (n=17%). A wide range of 
medicines were prescribed for this sample which represented all classes in the BNF 
chapters; this means that this study had a broad and diverse range of participants. 
Their chronic diseases patterns (e.g., diabetes, cardiovascular diseases, respiratory 
diseases, rheumatoid diseases and central nervous system diseases) are similar to 
the ones identified in the literature in these populations (Sidi et al., 2009; Opara et 
al., 2010).   
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Table 4-5: Type and number of prescription medicines documented as used by the interview 
participants (n=79). 
BNF chapters and categories of prescription medicines (chapter 1-
5) 
Number (%) of medicines 
documented for interview 
participants 
Total medicines in BNF chapters 1-12 612  
1 Gastro-intestinal system 51 (8%) 
1.1 Antacids and other drugs for 
dyspepsia 
4 
1.3 Ulcer healing drugs 38 
1.6 Laxative 8 
1.7 Compound haemorrhoids 
preparations 
1 
2 Cardiovascular system 234 (38%) 
2.2  Diuretics 21 
2.3  Anti-arrhythmic drugs 1 
2.4 Beta-adrenoceptor blocking 
drugs 
24 
2.5  Drugs affecting rennin-
angiotensin  system, centrally 
acting antihypertensive, alpha-
adrenoceptor blocking drugs  
51 
2.6  Nitrates, calcium-channel 
blockers and potassium-channel 
activators 
38 
2.8 Oral anticoagulants 2 
2.9 Antiplatelet drugs 35 
2.12 Lipid-regulating drugs 62 
3 Respiratory system 32 (5%) 
3.1  Bronchodilator 15 
3.2  Corticosteroids 13 
3.3 Cromoglycates and related 
therapy 
3 
3.4 Antihistamines 1 
4 Central nervous system 108 (18%) 
4.1 Hypnotics and anxiolytics 11 
4.2  Antipsychotics 4 
4.3 Antidepressant drugs 32 
4.5 Treatment of obesity 2 
4.6 Drugs in nausea and vertigo 7 
4.7 Analgesics 45 
4.8 Control of epilepsies 7 
5 Infections 1 (0.2%) 
5.1 Antibacterial 1 
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Table 4-5: Continued type and number of prescription medicines documented as used by the 
interview participants (n= 79). 
 
BNF chapters and categories of 
prescription medicines 
(chapter 6-12) 
 Number (%) of medicines 
documented for interview 
participants 
6 Endocrine system 101 (17%) 
6.1 Drugs used in diabetes 84 
6.2 Thyroid and antithyroid drugs 4 
6.3 Corticosteroids 1 
6.4 Sex hormones 1 
6.6 Drugs affecting bone 
metabolism 
11 
7 Obstetrics, gynaecology, and 
urinary-tract disorders 
6 (1%) 
7.1 Drugs used for urinary retention 6 
8 Malignant disease and 
immunosuppression 
1 (0.2%) 
8.3 Sex hormones and hormone 
antagonist in malignant disease 
1 
9 Oral nutrition 38 (6%) 
9.1 Anaemias and other blood 
disorders (oral iron and 
epoietin) 
18 
9.6 Vitamins 20 
10 Musculoskeletal and joint 
diseases 
32 (5%) 
10.1.1 Non-steroidal anti-inflammatory 20 
10.1.3 Rheumatic disease process 
drugs 
4 
10.1.4 Drugs for treatment of gout 3 
10.2 Drugs used in neuromuscular 
disorders 
2 
10.3.2 Rubefacients and other topical 
antirheumatics 
3 
11 Eye 8 (1%) 
11.6 Treatment of glaucoma 2 
11.8 Miscellaneous ophthalmic 
preparation 
6 
12  Ear, nose, and oropharynx 2 (0.3%) 
12.1 Drugs acting on the ear 1 
12.2 Drugs acting on the nose 1 
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Table 4-6: Twenty-one most common medicines used by the interview participants. 
Name of medicine BNF chapter Number of participants 
using medicines 
Omeprazole 1.3 27 
Bendroflumethiazide 2.2 8 
Furosemide 2.2 8 
Bisoprolol 2.4 9 
Doxazosin 2.5 8 
Losartan 2.5 8 
Amlodipine 2.6 22 
Aspirin 2.9 27 
Atorvastatin 2.12 17 
Simvastatin 2.12 33 
Salbutamol 3.1 11 
Amitriptyline 4.3 11 
Co-codamol 4.7 11 
Paracetamol 4.7 18 
Calcichew-D3 9.6 8 
Colecalciferol 6.6 9 
Gliclazide 6.1 13 
Insulin preparations 6.1 14 
Metformin 6.1 36 
Folic acid 9.1 14 
Diclofenac 10.1.1 9 
 
The most commonly used medicines by participants as shown in Table 4-6 were 
Metformin (n=36), Simvastatin (n=33), Aspirin (n=27) and Omeprazole (n=27). 
Metformin is an oral antidiabetic medicine in the Biguanide class (BNF chapter 6). 
Simvastatin is a hypolipidemic medicine to control high cholesterol (BNF chapter 2). 
Aspirin is an antiplatletes medicine that helps to prevent heart attacks, strokes and 
blood clot formation in people at high risk of developing blood clots (BNF chapter 
2). Omeprazole is a proton pump inhibitor used in gastrointestinal disorders (BNF 
chapter 1). All the participants were taking tablets and/or capsules (79/79,100%) 
and a small number of participants were taking Insulins (14/79, 18%) and/or 
inhalers (13/79, 17%).    
The use of non-prescription medicines including OTC and herbal medicines was 
wide spread in South Asian and Middle Eastern participants. Forty-two participants 
reported using non-prescription medicines on a regular basis (once a year or more 
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frequently). The 42 participants were taking a mean of 2.0 (SD 1.4, range 1-5) non-
prescription medicines. The 42 participants were using 81 non-prescription 
medicines. The types of non-prescription medicines used by the 42 participants are 
outlined in Table 4-7. 
Table 4-7: Type and number of non-prescription medicines used by interview participants (n=42). 
Name of non-prescription 
Medicine 
BNF Name of Non-POM Number (%) of non-
prescription medicines 
used by interview 
participants 
Gastro-intestinal system 1 Gaviscon
Pepto-Bismol
® 
® 
2 
Respiratory system 3 Piriton® 1 
Central nervous system 4 Paracetamol [various 
products] 
22 
Aspirin 1 
Oral nutrition 10 Cod liver oil 13 
Multivitamin preparations 12 
Vitamin C 4 
Vitamin E 1 
Vitamin B6 1 
Garlic capsules 5 
Calcium supplements 3 
Musculoskeletal and joint 
disease 
10 Ibuprofen 1 
Heat or cold patches 1 
Eye 11 Visionace® 1 
Other  Cinnamon tea 2 
Chamomile 2 
Powder from Syria for 
weight loss 
1 
Harard 1 
Green tea 1 
Thyme 1 
Jancobilbola 1 
Ajwain 1 
Jeera 1 
Chinese oil 1 
Mithi 1 
Total non-prescription medicines 81 
 
Participants of all ages used non-POMs (mean 57, range 18-83 years). Both males 
(25/42, 60%) and females (17/42, 40%) used non-POMs. All but two participants 
were first generation. Almost an equal number of SA (23/42, 55%) and ME 
participants used non-POMs (19/42, 45%). The majority had no university education 
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(27/42, 64%) and used a small number of POMs (mean 7, range 3-17). Paracetamol, 
Cod liver oil and Multivitamins were most commonly used non-prescription 
medicines. Participants were using more prescription medicines compared with 
non-prescription medicines. However, the use of non-prescription therapies varied 
from one participant to another.  
Almost half or more than half of the participants reported problems in mobility 
(61%), usual activities (48%), pain discomfort (70%), anxiety and/or depression 
(47%) when they were asked to indicate their health status using EQ-5D-3L. Table 
4-8 illustrates the number of participants reporting problems in EQ-5D dimensions 
where moderate and extreme categories of each dimension were combined. Figure 
4-3 describes the distribution of health status scores as measured by EQ-5D-3L and 
the figure illustrates that the mean state of health was 60%. In 2011, the mean 
general health status for people living in England was 81.4% (ONS, 2011). This 
means that the majority of SA and ME patients had poorer health than the general 
population, which is consistent with the literature. Such results are not surprising in 
the light of previous national surveys from the UK and among other countries 
where scores of health status are worse in people of lower socioeconomic class and 
from ethnic minority groups (Bhopal, 2007). Some BME groups experience worse 
health than others. For example, surveys commonly show that Pakistani, 
Bangladeshi and Black-Caribbean people report the poorest health, with Indian, 
East African Asian and Black African people reporting the same health as White 
British, and Chinese people reporting better health (Bhopal, 2007).  
Table 4-8: Participant numbers reporting problems in EQ-5D dimensions for 79 participants.  
EQ-5D No problem 
N (%) 
Some or sever problems 
N (%) 
Mobility 31 (39%) 48 (61%) 
Self-care 53 (67%) 26 (33%) 
Usual activities 41 (52%) 38 (48%) 
Pain discomfort 24 (30%) 55 (70%) 
Anxiety/Depression 42 (53%) 37 (47%) 
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Figure 4-3: Mean self-rated health status of participants on visual analogue scale of EQ-5D-3L. 
Twenty patients were eligible but refused to take part in the study. All 20 patients 
declined, and were asked about their ethnicity and to give a reason for non-
participation. Fifteen were male and five were female; seven described themselves 
as Indian, six as Bangladeshi, one as Pakistani, four as Arab and two as Iranian. 
More South Asian (n=14) than Middle Eastern (n=6) patients refused to take part. 
The reasons for not participating in the study as reported by the non-participants in 
the pharmacies were family commitments and time constraints (n=10), having a 
hospital or GP appointment (n=6), not interested in the study (n=2) and feeling 
unwell (n=2). Feeling unwell means having a physical condition, hearing problem, 
visual loss or mental illness that would interfere with their ability to undertake the 
interview, read written materials or hear the questions.      
Patients who were eligible but declined to take part in the study and those who 
were ineligible 
Eighteen patients were ineligible to take part in the study. Ten of these patients 
were female and eight were male; nine described themselves as Bangladeshi, six as 
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Indian, two as Pakistani and one as Arab. Significantly more South Asian patients 
(n=17) were ineligible than Middle Eastern (n=1) patients. The most common 
reason given by the ineligible patients was language barriers (n=14) (i.e., inability to 
speak English or Arabic). Of those ineligible as a result of language barriers, eight 
described themselves as of Bangladeshi origin and 11 of female gender. The 
remaining patients (n=4) were not approached because either pharmacists 
perceived them as being unwell (n=2) or rude (n=2). The number of ineligible 
patients (n=18) was small and almost the same as the number of patients who were 
unwilling to take part (n=20). Thus, the method used to select eligible patients was 
successful.    
4.2 Challenges in recruitment and face-to-face interview of research participants 
Recruitment is a discussion between a possible participant and a researcher before 
initiating the consent process. It is possibly the most challenging part of a research 
study. It starts with the identification, targeting and enrolment of participants for a 
research study (Patel et al., 2003). Recruiting adequate participants is very 
important to meet the sample size and power of recruitments of the study and to 
adequately represent the target population (Patel et al., 2003). Recruitment and 
data collection challenges can disturb the research project, researcher and 
participants, and can reduce the ability to answer the research questions and 
achieve the study objectives. The following challenges were encountered during the 
recruitment and data collection in the current study:   
• When going through the patient information sheet, some patients did not 
understand the purpose of the study and some of them were reluctant to 
take part. 
Obtaining consent 
• Others were reluctant to sign the consent form despite agreeing to all the 
listed criteria; they did not understand the need for a signature and the 
importance of giving consent. They thought signing the form would bring 
additional responsibilities. 
• Some patients were unhappy to be audio-recorded but when the researcher 
explained the reason for audio-recording, they agreed.  
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• Many participants were reluctant to share their information or concerns 
with their pharmacist or GP because they thought that this would affect 
their current treatment regimens. 
• None of the participants declined to have their MURs or PMR records 
interrogated. Possible explanations for this could be that, unlike GP 
surgeries, pharmacies hold limited patient information, thus this was not a 
cause for concern; or, the pharmacist was present to personally validate the 
trustworthiness of the researcher.  
• Barriers were found in patients speaking English or Arabic less fluently. 
Others were able to speak English or Arabic but were unable to read or write 
the language. This led the researcher or the person presenting during the 
interview to translate or read the patient information sheet (PIS) out loud 
and consequently the interview took longer to complete.  
 
• Understanding what each question of Gordon’s tool was proposing was 
found to be difficult for some SA and ME patients. The researcher had to re-
phrase the question to be understood or add probes on several questions, 
which led to participants becoming annoyed. 
Data collection method 
• Using numerous tools (n=3) increased the researcher burden and made 
some participants feel frustrated and annoyed because of the length of time 
each instrument took to administer. 
 
• Identifying eligible participants through MURs and PMR records was 
challenging. This was because in almost all the pharmacies there were only a 
few computers, and these computers were used by the staff to dispense 
medicines almost all the time rather than to identify eligible patients. In 
addition, asking the pharmacists to identify eligible participants was difficult 
because they were busy all the time. Moreover, it was not easy for all 
pharmacists to identify participants’ ethnicity through PMR or MUR 
especially if the pharmacists were locums. 
Recruitment techniques 
4.3 Mean length of interviews, start time of the interviews and presence of other 
people during the interviews 
The mean length of the interviews for the 80 participants was 25 minutes (SD 8 
minutes, range 15-55, median 20 minutes). The mean of the interviews’ start time 
was 12 noon (SD 2 hrs, range 9.15am – 4.45pm, median 12 noon). Thirty-seven 
participants (91%) presented alone during the interview whereas seven (9%) were 
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with a family member. The researcher reminded the participants who presented 
with a family member about the importance of the responses being taken from the 
participants themselves. In the case where the family member gave his/her 
response, the researcher directed the question back to the participant and re-
emphasised the importance of the participant’s individual answers to questions.  
There were differences between SA and ME groups in the length and location of 
interview. For the SA, the mean length of the interview was 22.6 minutes (SD 6.9, 
range 15-45 minutes). The mean length of the interview for ME participants was 
26.6 minutes (SD 8.8, range 15-55 minutes). The duration of the interview for the 
MEs was significantly longer than the length of the interview for the SAs (t-test, 
P=0.026).  
The interview took a longer time to complete with patients who were illiterate in 
English or preferred to do the interview in their own language (e.g., Arabic 
participants). This is possibly because the researcher had to translate the patient 
information leaflet and the consent form into the participant’s own language. 
Additionally, Arab participants felt more comfortable to discuss their issues and 
needs openly in detail in their own language, which took more time than other 
participants who did it in their second language (i.e., English). Other participants 
also took more time to complete the interview not because of the language but 
because their ability to understand the reason and the depth of each question was 
poor and thus the researcher had to answer their queries and re-phrase the 
questions to the patients’ level of understanding. The length of the interview was 
associated with whether a participant was more or less likely to be identified with a 
MRP (t-test, P=0.029).  
The ME group also had significantly more privacy during the interview than the SA 
group (chi-square test, P=0.004). Twenty-five (63%) ME participants were 
interviewed in a private consultation room in the pharmacy whereas 28 (70%) of SA 
participants were interviewed in an open area in the pharmacy where the interview 
could be over heard. Conducting the interview in a private consultation room was 
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associated with whether a participant was more likely to be identified with an MRP 
(chi-square test, P=0.035). The longer the interview and the presence of a private 
environment may have meant that there was more time and a proper place to 
identify problems. These findings were consistent with Gordon et al.’s study (2007) 
which found that the length and place of the interview (i.e., home interviews) were 
associated with whether a participant was more likely to be identified with a MRP 
because patients feel more relaxed in their own homes and have more time to 
describe their medication- and illness-related experiences, concerns, problems and 
needs.  
• Visiting pharmacies in person was the best method of recruitment. 
Therefore, in order to increase the response rate, an in-person visit should 
be made to non-responding pharmacies two weeks after sending the 
invitation letter. 
Key messages from Chapter 4 
• The present study showed that SA and ME patients were willing to 
participate in the current study unlike what was reported by some of the 
previous studies.  
• Approaching the patient in-person by a HCP whom the patient knows and/or 
by a researcher who speaks the same language and/or is from the same 
culture might increase the response rate. 
• The language barrier should be addressed to overcome one of the major 
obstacles of the recruitment process that is beyond the patient’s control 
especially given that non-English-speaking patients might be more likely to 
experience MRPs. 
• Many challenges were encountered during the recruitment and data 
collection process; these challenges should be addressed and taken into 
account when recruiting patients from the same origins. 
• Strengths of the study include a diversity of participants’ characteristics, 
making these findings relevant for a wide range of ME and SA patients. 
• The longer the interview and the presence of private environment may have 
meant that patients are more likely to be identified with a MRP. 
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Chapter 5 A description of the MRPs and contributory factors to the 
MRPs that may be similar to the general population from patients’ 
perspectives 
This chapter is divided into two parts. The first part, section 5.1, reports the number 
and types of MRPs that were identified during the current study using the Gordon 
coding frame. It also examines in detail the individual MRPs within their categories. 
The second part, section 5.2, describes the reasons that may contribute to MRPs 
that may be similar to the general population, along with direct quotes from 
participants’ interviews.  
Introduction 
5.1 A description of the medicine-related problems documented at the interviews 
The MRPs were classified and grouped into four categories of medicine-use issues 
and five categories of service-use issues. The medicine-use issues were divided into 
four categories, which were ADRs and DIs, intentional non-compliance, cognitive, 
physical and sensory problems, and problems with non-prescription medicines. 
Service-related issues were divided into five categories which were drug-prescribing 
problems, problems with interface, monitoring and review, lack of information and 
discussion, problems with repeat prescriptions, and GP surgery and pharmacy 
problems. Table 5-1 outlines the number and percentages of MRPs identified in the 
current study.  
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Table 5-1: Number and percentage of MRPs identified for the 73 interview participants. 
Number (n) and percentage (%) of MRPs identified at the interviews 
MRP category  N % 
Intentional non-compliance 84 44 
Cognitive, physical and sensory problems 55 29 
Adverse drug reactions and drug interactions 44 23 
Problems with non-prescription medicines 7 4 
Total medicine-use issues 190 100 
GP surgery and pharmacy service problems 66 45 
Problems with repeat prescriptions 34 23 
Lack of information or discussion 24 16 
Drug-prescribing problems 19 13 
Interface, monitoring and review problems 5 3 
Total service-use issues 148 100 
Seventy-three participants were identified with a total of 338 MRPs (mean of four 
MRPs per participant), 190 (56%) of which were medicine-use issues and 148 (44%) 
were service-use issues. Intentional non-compliance, cognitive, physical and sensory 
problems, GP surgery and pharmacy service problems were most commonly 
identified at the interviews. These results may not be surprising, given that patients 
included in the current study had multiple chronic conditions, were taking a mean 
of eight medicines and were from ethnic minority backgrounds, thus placing them 
at high risk of MRPs. Seventy-three of 80 interview participants (91%) had at least 
one MRP. Figure 5-1 gives the number of interview participants having at least one 
MRP in each category.  
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Figure 5-1: the number of interview participants having at least one MRP in each category. 
Participants were grouped into those having medicine-use issues only (n=20), 
participants with service-use issues only (n=4), and those with medicine-use and 
service-use issues combined (n=49) (Appendix 24). Case studies were made for the 
73 participants assigned to at least one MRP at the interviews. Each case study was 
given a number corresponding to the identification number, a short description of 
the participant (age, ethnicity, gender, and names of medicines used) and the MRPs 
with which they were identified. 
5.1.1 MRP category 1 – Adverse drug reaction and drug interactions 
Problems classified as ADRs and DIs documented at the interviews consisted of: 
 101 Side effect                                                                                                                   42 
102 Hypersensitivity                                                                                                            1   
103 Drug-drug interaction                                                                                                  1 
Total adverse drug reactions and drug interactions                                                     44 
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ADRs and DIs constituted almost a quarter (23%) of the 190 medicine-use issues 
identified at the interviews. Thirty-three participants were identified with 44 ADRs 
and DIs.  The majority of these problems were side effects. Drug interactions and 
hypersensitivity were among the least common MRPs identified from this category, 
possibly because the use of computerised checks by physicians for drug interaction 
and hypersensitivity reduced the number of DIs and drug sensitivity identified in 
this study.  
Thirty-one participants who reported side effects revealed one or more symptoms 
relating to the use of one or more medicines. Some had experienced side effects in 
the past and others still did. When adverse reactions were revealed, most 
participants were certain about which medicines caused the side effect. Table 5-2 
lists the reported side effects mentioned by participants in the current study and 
the medicines causing reactions using their own words. Although the British 
National Formulary cites a wide range of side effects for medications, some patients 
attributed side effects that the BNF does not list. Feelings of dizziness, sickness, 
tiredness and stomach upset were the most commonly reported reactions. Drugs 
used in diabetes, lipid-regulating drugs, and drugs used
In relation to drug-drug interaction, there was a participant [Case 311-AR-F-45] who 
was prescribed a tricyclic antidepressant [Amitriptyline] and a selective serotonin 
re-uptake inhibitor [fluoxetine]. A patient already being treated with a tricyclic 
antidepressant may experience significant increases in plasma antidepressant 
concentrations (and possibly antidepressant toxicity) when fluoxetine is added 
(Preskorn et al., 1990). When concomitant use of selective serotonin re-uptake 
inhibitors (SSRI) and tricyclic antidepressant is required, the patient should be 
monitored for anticholinergic excess. Conservative dosing of the tricyclic 
antidepressant should also be considered. 
 in rheumatic disease were 
the most commonly recognised medicines as producing a high incidence of side 
effects.  
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Table 5-2: Number of participants reporting ADRs and the types of medicines involved. 
Number of 
participants 
BNF 
chapter 
Name of medicine Reported symptoms* 
1 1.5 Mesalazine Aches and pains 
1 2.4 Atenolol Headache 
1 2.5 Irbesartan Constipation 
3 2.6 Amlodipine Swollen legs and lethargy/ dizziness 
1 2.6 Nicorandil 
 
Dizziness 
1 2.9 Aspirin Stomach bleeding and itchy rash 
1 2.12 Atorvastatin Breathlessness or shortness of breath 
2 2.12 Rosuvastatin Muscle pain and weakness/ Skin pigmentations 
3 2.12 Simvastatin Hair loss/ stomach upset/ itchy spots around the 
tummy 
1 4.1 Diazepam Internal skin rash and itching 
1 4.1 Zolpidem Internal skin rash and itching 
1 4.4 Venlafaxine Dry skin and dry mouth 
1 4.8 Tegretol 
 
Indigestion 
3 6.1 Insulin Weight gain/ stomach upset and dry mouth/ 
feeling sweaty and tired. 
1 6.1 Gliclazide Abdominal pain and bloating and dizziness. 
8 6.1 Metformin Dizziness, loss of appetite and stomach pain/ 
weight loss/ abdominal pain and bloating/ 
constipation/ tachycardia and tiredness/ 
heartburn/ felling sick and noxious/ tiredness, 
legs’ weakness, stomach problem. 
1 6.1 Pioglitazone Rash 
1 6.1 Repaglinide Dizziness 
2 6.6 Alendronic acid Itchy rash/ fever, shortness of breath and 
abdominal pain 
1 7.4 Fesoterodine Dry skin and dry mouth 
3 10.1.1 Diclofenac Stomach ulcer/vomiting/ stomach pain 
1 10.1.3 Adalimumab 
(Humira®) 
Itchy rash and redness of the skin 
1 10.1.3 Hydroxychloroquine Headache, earache, vertigo and dizziness 
2 10.1.3 Methotrexate Felling sick and having dizziness, drowsiness and 
nausea/ mood changes and stress 
* Where more than one participant reported symptoms caused by a particular medicine, the 
different patients’ symptoms have been separated by a forward slash (/) 
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5.1.2 MRP category 2 – Intentional non-compliance  
Problems categorised as intentional non-compliance documented at the interviews 
comprised: 
201 Under-use of POMs                                                                                                       42 
202 Over-use of POMs                                                                                                          24 
207 Unsure of dosing                                                                                                              1 
208 Stop taking medicines                                                                                                     3 
209 Split dose when should be one dose                                                                            1 
212 Problems with dosage form                                                                                           4 
213 Taking daily doses all together at once when they should be split                         3 
214 Taking medicine at the wrong time                                                                              4                                                            
216 Taking someone's else prescription medication                                                         2 
Total intentional non-compliance                                                                                       84 
Intentional non-compliance accounted for almost half of the 190 medicine-use 
issues identified at the interviews. Forty-three participants were identified as having 
84 instances of intentional non-compliance. However, only 21 participants reported 
adjusting doses of their medicines when asked to self-report their intentional non-
compliance. Participants were given the opportunity to clarify their responses on a 
Likert scale. The Likert responses are illustrated in Table 5-3. 
 
 
Chapter 5 – Results (A description of the MRPs and contributory factors to the MRPs that may be 
similar to the general population from patients’ perspectives) 
163 
 
Table 5-3: Number and percentage of interview participants self-reporting the frequency of their 
intentional non-compliance using a Likert scale. 
Question on non-
compliance (intentional 
non-compliance and 
cognitive problems) 
Number (n) and percentage (%) of interview participants self-
reporting the frequency of their non-compliance using a Likert scale 
Never Rarely Sometimes Often Very often 
N % N % N % N % N % 
‘Some people do not 
always take their 
medicines according to the 
instructions, but adjust the 
dose according to what 
they think they need. Do 
you do this? 
59 74% 1 1% 14 17% 4 5% 2 3% 
Regarding adjusting doses of their medicines, the majority (74%) revealed that they 
never adjusted a dose of a medicine. The participant who reported ‘rarely’, offered 
an additional explanation which was mainly attributed to a side effect of a 
medicine. All but one participant who reported ‘sometimes’ gave additional 
information. The majority of reports (n=10) were based on reducing the daily 
prescribed dose. Two participants stated taking a medicine at the wrong time: one 
explained that this was because he had lack of understanding and information on 
when to take the medicine. The second participant reported taking two tablets of 
Adcal® at once in the morning when the medicine should be taken as one tablet 
twice daily; she declared that she did this in order to avoid forgetting her evening 
dose of Adcal®. Another two participants stated overusing the daily prescribed dose 
to control their symptoms. Participants who reported that they adjusted their doses 
‘sometimes’ adjusted the number of doses per month, for instance once, twice or 
three times a month. All the participants who reported ‘often’ offered an additional 
explanation. The majority of reports (n=3) were based on reducing the daily 
prescribed dose except one which was based on increasing the daily prescribed 
dose. Participants who revealed that they adjusted their doses ‘often’ adjusted the 
number of doses per week, for instance once, twice or three times a week rather 
than the recommended seven days a week. The two participants who adjusted their 
doses ‘very often’ omitted the medicines for periods of time. They offered an 
additional explanation which was due to a side effect of a medicine.   
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It can be seen that assessing patients’ adherence to their medication is not a 
straightforward task, as it is difficult to extrapolate a pattern between data from 
different methods. What a patient reported was sometimes different or even 
conflicting to what was identified by the researcher. For instance, based on the 
MRPs questionnaire, participant [Case 205-AR-F-57] reported that she ‘never’ 
adjusted a dose of a medicine; however, when asked about fasting, she revealed 
modifying the dose in Ramadan, which produced contradictory information. A 
further example is participant [Case 209-AR-M-49] who revealed that he ‘never’ 
adjusted a dose of a medicine. However, when asked more in-depth questions, he 
declared a delay in renewal of the repeat prescription after his supply of diabetic 
and BP medicines ran out on different occasions which made him take diabetic and 
BP medicines that were prescribed for his mother until he ordered a repeat 
prescription. This was considered by the researcher to be poor compliance. Thus, 
the researcher’s judgment was taken into account when reporting the percentages 
of compliant and non-compliant participants. It can be concluded that patients in 
this study did not perceive themselves as non-compliant individuals; rather they 
viewed themselves as being empowered people to manage their own health and 
healthcare and to decide what is the best for them. In general, the accuracy of self-
report behaviour is problematic. However, research suggests that people who say 
they do not follow treatment usually report accurately, but those who report that 
they follow treatment recommendations usually report inaccurately (Spector, 
1986). Table 5-4 shows the number of reports and types of medicines implicated in 
intentional non-compliance. 
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Table 5-4: Number of participants and types of medicines implicated in intentional non-compliance. 
BNF 
chapter 
Name of medicine 
implicate 
Under-
use 
 
Over-
use 
 
Unsure 
of dosing 
Stopped Split dose Problems with 
dosage form 
Taking daily dose at 
once 
Taking medicine 
at the wrong time 
Taking someone's 
else prescription 
medication 
 
 
(201) (202) (207) (208) (209) (212) (213) (214) (216) 
Number of participants 
reporting problem 
42 24 1 3 1 4 3 4 2 
6.1 Insulin 4     2    
6.1 Metformin 13 4     1 1 1 
6.1 Gliclazide  2      1  
1.6 Senna         1 
10.1.3 Hydroxychloroq-
uine 
 1        
2.5 Ramipril    1      
2.4 Metoprolol       1   
1.3 Omeprazole 4 1        
10.1.1 Ibuprofen 1 
 
        
4.3 Mirtazapin 1 1        
4.6 Prochlorperazine 1         
6.1 Pioglitazone    1      
10.1.1 Diclofenac 1     1    
7.4 Fesoterodine      1    
3.1 Salbutamol  3        
2.12 Atrovastatin 2 1  1    1  
2.12 Simvastatin  1      1  
1.3 Lanzoprazole 1 1        
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BNF 
chapter 
Name of medicine 
implicate 
Under-
use 
 
Over-
use 
 
Unsure 
of dosing 
Stopped Split dose Problems with 
dosage form 
Taking daily dose at 
once 
Taking medicine 
at the wrong time 
Taking someone's 
else prescription 
medication 
 
(201) (202) (207) (208) (209) (212) (213) (214) (216) 
2.6 ISMN 1         
3.2 Beclometasone 3         
9.6 Vitamins 1         
4.6 Betahistine 1         
4.7 Lidocaine 
hydrocortisone 
1         
4.2 Risperidone  1        
4.1 Diazepam  1        
4.1 Temazepam  1        
4.7 Co-codamol  1        
4.3 Amitriptyline 1 1        
9.6 Adcal-D3  1        
3.1 Salmeterol 1         
4.3 Fluoxetine 1 1   1     
3.2 Seretide 1         
6.6 Cholecalciferol + 
Calcium carbonate 
      1   
4.1 Zolpidem  1        
2.6 GTN  1        
2.5 Doxazosin   1       
2.4 Propranolol 1         
4.2 Quetiapine 1         
13.6 Azelaic acid cream 
and Tretinoin GEL. 
1         
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Drugs used for diabetes (BNF chapter 6.1), lipid regulating drugs (BNF chapter 2.12) 
and ulcer-healing drugs (BNF chapter 1.3) were most frequently involved in 
intentional non-compliance. Twenty-six participants were identified with 
medication underuse and 13 participants were identified with medication overuse. 
Both were mainly associated with use of anti-diabetic medicines especially 
Metformin. Users of anti-diabetic drugs described that they experienced dizziness, 
loss of appetite, stomach upset, weight loss or gain, abdominal pain and bloating, 
constipation, tiredness, sickness, and weakness when taking anti-diabetic drugs. 
Side effects caused by anti-diabetic drugs accounted for (14/42, 33%) of the total 
side effects. Experiencing side effects as well as patients’ perceived need for 
medication (i.e., controlled sugar level) were the most commonly reported reasons 
for non-compliance in the use of anti-diabetic medications in the present study. 
The wide range of issues categorised as intentional non-compliance in the current 
study showed the way in which some patients adjusted their medicines irrespective 
of the instruction and advice given by HCPs. Intentional non-compliance manifested 
in the form of changing dosage amount, frequency or time of day medicine was 
taken, discontinuing using prescribed medication, initiating taking someone else's 
medications for perceived common symptoms, combining treatments – such as 
medications shared among family and community members, over-the-counter 
(OTC) medications, medications brought from abroad/home countries, and herbal 
and other traditional medicines. 
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5.1.3 MRP category 3 – Cognitive, physical and sensory problems 
Problems categorised as cognitive, physical and sensory problems documented at 
the interviews consisted of: 
301 Forgetting to take medicine(s)                                                                                    39 
302 Difficulty opening containers/packs                                                                           10 
303 Difficulty reading labels                                                                                                  3 
304 Difficulty hearing instructions                                                                                       2 
305 Difficulty swallowing                                                                                                       1 
Total cognitive, physical and sensory problems                                                               55 
Forty-six participants were identified by the researcher with 55 cognitive, physical 
and sensory problems, the majority of which were cognitive problems (n=39/55, 
71%), which was consistent with what was reported by participants when asked to 
self-report their unintentional non-compliance on a Likert scale. The Likert 
responses are illustrated in Table 5-5. 
Table 5-5: Number and percentage of interview participants self-reporting the frequency of their 
unintentional non-compliance using a Likert scale. 
Question on non-
compliance (intentional 
non-compliance and 
cognitive problems) 
Number (n) and percentage (%) of interview participants self-
reporting the frequency of their non-compliance using a Likert scale 
Never Rarely Sometimes Often Very often 
N % N % N % N % N % 
‘People sometimes forget 
to take their medicines. Do 
you do this?’ 
34 42% 17 21% 18 23% 8 10% 3 4% 
Regarding forgetting to take medicines, again the majority (42%) reported that they 
‘never’ forgot. Similarly, the additional information provided by participants was 
alike and had a clear boundary, just like the additional information provided for 
adjusting the doses of their medicines. For 15 of the 17 who reported ‘rarely’ 
response, the responses ranged from once or twice a year to once or twice every six 
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months. Participants who revealed that they forgot their doses ‘sometimes’ forgot 
the number of doses per month, for example once, twice or three times a month. 
The eight participants who revealed forgetting ‘often’ defined this as once or twice 
a week and those (n=3) who reported forgetting to take their daily prescribed dose 
‘very often’ defined this as once or twice a day. Ten participants reported 
difficulties opening containers/packs, difficulties reading labels (n=3), hearing 
instructions (n=2) and swallowing (n=1). These problems can be potential obstacles 
to compliance.  
As regards cognitive problems, the majority of participants (n=36) did not specify an 
individual medicine, but reported forgetting all or any of their medicines at any one 
time. Only 10 participants of 46 reported forgetting to take a specific medicine. 
Lipid-regulating drugs (BNF chapter 2.12) were most frequently involved in 
cognitive non-compliance (3/10) because patients did not perceive the importance 
of adhering to medication that is used for preventive purposes and symptomless 
conditions. Statins were also the only medicine that was taken at night by those 
participants. 
5.1.4 MRP category 4 – Problems with non-prescription medicines 
Problems with non-prescription medicines documented at the interviews consisted 
of: 
402 Interaction with POMs                                                                                                3 
403 Contra-indication                                                                                                         1 
405 Lack of knowledge about non-prescription medicines                                         3 
Total problems with non-prescription medicines                                                         7 
Six participants were identified with seven problems with non-prescription 
medicines. One participant was prescribed Co-dydramol (containing Paracetamol) 
for pain in a hospital A&E department but also used over-the-counter (OTC) 
Paracetamol. The duplication of these two Paracetamols can potentially cause liver 
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injury. One asthmatic participant revealed taking Ibuprofen as an OTC medicine, 
which is contraindicated in asthmatic patients. She was prescribed Citalopram 
(SSRIs) and also took Ibuprofen. The risk of bleeding may increase when Ibuprofen 
is taken with SSRIs. Another participant declared taking Aspirin as an OTC medicine 
one tablet a day and he was also prescribed Etoricoxib for pain by his GP. 
Concomitant use of low-dose Aspirin with Etoricoxib may result in an increased rate 
of GI ulceration or disorder. Three participants could not recall the reasons for 
taking their OTC medicines. It was identified that all the six participants were aged 
65 or less than 65 (range 35-64 years). All were first generation and lived with their 
families; three out of six reported receiving information and advice on medicines 
from their families. In addition, all the six participants were using eight or less POMs 
(range 6-8 POMs). The findings showed that participants who were younger and 
used a small number of medicines might be more likely to be identified with non-
prescription medicines problems. However, this cannot be generalised as only six 
participants were identified with problems with non-prescription medicines. 
5.1.5 MRP category 5 - Problems with drug-prescribing 
Problems with drug-prescribing documented at the interviews consisted of: 
501 Drug missing from regime                                                                                       3 
502 Therapeutic duplication                                                                                           4 
503 Use of drug to treat adverse effect of another drug                                           6 
504 Inappropriate dose (too high or low)                                                                     1 
506 Drug should not be in the regime                                                                           1 
507 Inappropriate length of treatment                                                                         4 
Total drug-prescribing problem                                                                                     19 
Seventeen participants were identified with 19 drug-prescribing problems. The 
problems associated with drug-prescribing could have been caused by GPs or 
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hospital consultants. Table 5-6 shows the medicines implicated in the drug-
prescribing problems. Two participants (case 303-AR-F-53, case 713-IN-M-64) of the 
seventeen who identified with drug-prescribing problems were each identified with 
two drug-prescribing problems.  
In this study, (19/190; 10%) drug-prescribing problems were identified in SA and ME 
patients during pharmacy interviews, which is considered to be low. This is possibly 
because information such as blood results or patients’ medical histories was not 
available to allow full assessment of medication safety. Thus, the researcher had to 
rely on patient’s experience and information to make a judgment about whether 
the patient had a drug-prescribing problem.  
Table 5-6: The types of medicines associated with drug-prescribing problems shown for each 
participant.  
MRP 
code 
MRP category Case number BNF category Names of medicines 
involved 
501 Drug missing 
from regime 
202-AR-F-61; 
601-PAK-F-65; 
713-IN-M-64 
1.3 Omeprazole 
 
502 Therapeutic 
duplication 
311-AR-F-45 1.3 Ranitidine and Omeprazole 
504-PAK-M-81 4.7 Paracetamol and Co-
codamol 
713-IN-M-64 11.8 Celluvisc eye drops and 
Hypromellose eye drops 
107-OSA-M-57 1.6 Senna and Docusate 
503 Use of drug to 
treat adverse 
effect of another 
604-AR-F-52 4.6 and 12.1 Betahistin and Otomize 
603-IN-M-51 10.1.1 Diclofenac 
602-PAK-M-54 3.4 Antihistamine 
204-AR-F-45; 
306-AR-M-47 
1.3 Omeprazole 
305-AR-F-32 4.6 Metoclopromide 
504 Inappropriate 
dose 
701-IN-M-77 2.3 Amiodarone 
 
506 Drug should not 
be in regime 
507-AR-F-39 4.1 Zolpidem 
507 Inappropriate 
length of course 
207-AR-F-40 2.8 Warfarin 
303-AR-F-53 4.1 Zopiclone 
507-AR-F-39 4.1 Zolpidem 
303-AR-F-53 4.1 Diazepam 
404-AR-M-45 4.1 Temazepam 
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5.1.6 MRP category 6 – Interface, monitoring and review problems 
Problems with interface, monitoring and review documented at the interviews 
consisted of: 
602 Inadequate monitoring or review reported by participants                                    3                                                                                                                                                       
603 Inadequate transfer of information from hospital to GP                                         2                   
Total interface, monitoring and review problems                                                             5 
Five participants were identified with five interface, monitoring and review 
problems. Two of the three participants visited a GP or a nurse for consultations 
every four months or more frequently but they revealed that they were not 
adequately monitored or reviewed. One participant revealed that he sometimes did 
not consult a GP in a year. Two participants had concerns that information was not 
transferred from hospital to GPs.   
When asked about how often they consulted a GP or practice nurse at the GP 
surgery, all the participants consulted a GP (n=76) and the majority consulted their 
GP ≤6 months (n=67/76, 88%). Forty-six participants (60%) consulted a nurse and 30 
of them (65%) consulted the nurse ≤6 months. However, 30 (40%) participants 
reported that they never consulted a nurse. Although the majority of participants 
consulted a GP and/or a nurse every six months or more frequently, some reported 
inadequate discussion of their illness and medicines. Reasons for why there was a 
lack of discussion were highlighted by some participants, such as lack of time or 
doctors to review patients, bad relationship with doctor, lack of trust and 
confidence in healthcare professionals and healthcare system. 
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5.1.7 MRP category 7 – Lack of information or discussion 
Lack of information or discussion documented at the interviews comprised: 
701 Inadequate information on medicines                                                                       18                                                                                                                                                       
702 Inadequate information on illness                                                                                6                   
Total lack of information or discussion                                                                              24 
The researcher identified 22 participants with 24 problems associated with lack of 
information on illness or medicines. Lack of information was identified from 
participants’ descriptions of how they took their medicines. The 79 interview 
participants were asked to name or describe at least four of the POMs they used. 
The four POMs were randomly selected by the researcher. The reason for selecting 
only four medicines was because some participants during the pilot face felt under 
pressure to name all their medicines. In addition, the lack of time and appropriate 
place hindered asking patients about all their medicines. However, it is unlikely that, 
patients who know all the basic information on at least four of their medicines will 
not know about their other medicines which were not selected by the researcher. 
Patients were also asked about the purpose for which the medicine was prescribed, 
dosing frequency and length of time for which they had been using the medicine. 
Participants’ responses were compared with information on the names of 
medicines, and the dosing frequencies of medicines obtained from patients’ 
medication records available at the pharmacies. Table 5-7 shows the participants’ 
knowledge of their POMs.   
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Table 5-7: Number and percentage of participants reporting details of their prescription medicines 
(n=79). 
Details of 
medicine 
Number (n) and percentage (%) of MRPs interview schedule participants able to 
report details of prescription medicines 
All medicines 
(n=4) 
All but one 
(n=3) 
Half of 
medicines (n=2) 
None but 
one (n=1) 
None of the 
medicines 
(n=0) 
N % N % N % N % N % 
Name of 
medicine 
31 39 3 5 9 11 5 6 31 39 
Dosing 
Frequency 
of medicine 
61 76 12 15 2 3 2 3 2 3 
Purpose for 
which 
medicine is 
used 
62 79 7 9 5 6 4 5 1 1 
Length of 
time for 
which 
medicine 
has been 
used 
73 93 1 1 1 1 1 1 3 4 
When asked to name at least four of their medicines, only 31 (39%) participants 
were able to correctly do so. More participants were able to identify the correct 
purpose or give a description of the symptoms for which they were using their 
medicines – 62 (79%). In addition to this, 61 (76%) participants were able to recall 
dosing frequencies and 73 (93%) were able to recall the approximate length of time 
for which they had been using their medicines. In general, although the majority of 
patients could not pronounce or provide the names of their medicines, they knew 
their indication and dosing instruction when the name was pronounced or shown 
on the prescription by the researcher. However, participants in this study reported 
many problems with source, delivery, type and timing of information. 
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5.1.8 MRP category 8 – Problems with repeat prescriptions  
Repeat prescriptions problems documented at the interviews comprised:  
803 Run out of medicine and did not order anymore                                                      1                                                                                                                                                          
804 Medicines no longer used remain on form                                                                 2                
806 Delay renewals after supplies run out                                                                        31                                  
Total problems with repeat prescriptions                                                                         34 
The majority of participants revealed regular frequencies with which they obtained 
their prescriptions: every month (n=43, 54%), every two months (n=27, 34%) or 
every three months (n=4, 5%). Five participants revealed variable frequencies with 
which they obtained their prescriptions: two reported every 1-2 months and three 
reported every 4-6 weeks. In the interviews, various issues with prescribing and 
issuing repeat prescriptions were exposed in which 31 participants were identified 
with 34 repeat prescribing problems.  
5.1.9 MRP category 9 – GP surgery and pharmacy service problems  
GP surgery and pharmacy service problems documented at the interviews consisted 
of:  
901 Difficulty getting appointments to see GP                                                                 20 
902 Difficulty consulting the practice nurse                                                                       1 
903 Difficulty consulting the pharmacist                                                                             1 
905 Problems with pharmacy supplying medicines from various manufacturers       2 
906 Pharmacy never have complete stock                                                                         2 
907 No information leaflet supplied from pharmacy                                                       2 
909 Difficulty consulting the same GP                                                                                 8 
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910 Lack of hospital referral                                                                                                  5 
911 Long waiting time in GP                                                                                                 8 
912 The short length of consultation                                                                                 11 
913 The attitude of GP staff                                                                                                  6 
Total GP surgery and pharmacy service problems                                                           66 
Thirty-two participants were identified with 66 GP surgery and pharmacy service 
problems. Patients’ perceptions of and views towards their GP surgeries were highly 
negative. Many patients were unable to make appointments with their GP with the 
waiting times being too long and the consultation times being too short. Others 
were unable to see the same GP or a GP from the same gender.  
The previous part, section 5.1, reports the number and types of MRPs that were 
identified during the current study. The next part, section 5.2, describes the reasons 
which may contribute to MRPs that may be similar to the general population. 
5.2 Contributory factors to medicine-related problems that were identified to be 
similar the general population 
5.2.1 Concerns about and management of side effects 
The side effects had led participants to deal with and react to them in different 
ways; some respondents reacted more than ones to resolve the problem. 
Participants reacted by stopping taking their medicines or by modifying the way 
they took their medicines, others accepted and tolerated the side effects associated 
with their medicines and made no changes to their medications, and the rest coped 
with side effects by some other means. Some of their actions indicated altered 
medication-taking behaviour. These reactions were either self-guided or 
professionally guided. However, consulting a doctor did not always lead to adherent 
medication taking. 
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Some participants did not accept the side effects associated with their medicines 
and reacted by deliberately stopping/taking less of their medicines (i.e., reducing 
the dosage of their medicines or skipping taking tablets for a few days each week or 
each month) without consulting a doctor to avoid/relieve these adverse effects. 
These participants perceived the risk of taking their medicines to outweigh their 
benefits:  
“Doctor gave me the 5 gram [Ramipril], 3-4 year use it. This year I am 
not use this tablet 3-4 days now, 1 week I had some tummy, tomach, 
tomach… This tablet is problem!” [Case 601-PAK-F-65] 
“If I feel like I have a SE from a medicine, I try not to carry on, to see 
what the effect will be... For example, I have this one [Pioglitazone], 
when I take it I feel rash on my hands... I think this medicine is affecting 
my liver so I stopped it just to find out whether this tablet is the cause of 
the rash.” [Case 203-AR-M-63] 
Other participants in this study reported raising their concern to their doctor when 
experiencing a side effect. Their fears of side effects were large to the extent that 
they could not wait to find out if the reaction would disappear without consulting a 
doctor. Those who discussed the problem with their doctor reported that the 
doctor advised them both to cope with and tolerate the side effects of the medicine 
or advised them to stop taking the medicine or made some or no changes to the 
medicine. The changes made were reducing the dose, changing the medicine to 
another one, prescribing a medicine to treat the SE of the other or changing the 
dosage form of the medicine anticipating that the reaction would disappear. Table 
5-8 illustrates quotes supporting these findings. 
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Table 5-8: Quotes of participants highlighting some changes made to their medicines as a 
consequence of experiencing side effects with them. 
Changes made by 
doctors 
Quotes Patient 
Coping with side effect “Yes, especially with my BP tab Amlofedia 
[Amlodipine]... It happened recently a 
couple of weeks ago... I was lethargic and 
getting more swelling in my legs especially 
with hot or warm weather... I spoke to my 
doctor and he said this is a common thing... 
He told me to stick to this medicine and try 
to cope with it.” 
Case 603-IN-M-51 
Reduce dose “I also had a problem with the tab that has 
been reduced from 20 mg to 10 mg 
[Nicorandil]... I had dizziness so it was 
reduced by my consultant as well as my GP.” 
Case 709-IN-M-66 
Change from one 
medicine to another 
“I spoke to my GP and he didn’t believe me, 
he said ‘Don’t worry every medicine has a 
side effect’, but I started to feel unwell. 
Then, I spoke to the consultant and I told 
him ‘Listen, if you will not change the 
Tegretol for me, I will stop taking it’. Then, 
the consultant spoke to the GP and told him 
to change the Tegretol to this one here 
[Keppra]” 
Case 702-IN-M-57 
Prescribe a medicine to 
treat the side effect of 
another 
“I am honest with my doctor like this one 
(Diclofenac) I started using two years ago 
but I had vomiting and I felt unwell so I 
spoke to my doctor and I told him that I 
stopped taking it for a period of time so I 
was prescribed antiemetic drug 
[Metoclopromide].” 
Case 305-AR-F-32 
Change dosage form “Methotrexate I take it on Saturday and 
when I take it, I feel sick, drowsy and 
nauseated... They said that they will change 
the dosage form of Methotrexate from tabs 
to injection.”  
Case 204-AR-F-45 
Stop taking medicine “Because I had rash and I could not sleep 
from itching... I spoke to the rheumatologist 
and GP. They were suspicious that this is a 
SE of Humira® injection so they decided to 
stop it to see whether it is from Humira®.”  
Case 204-AR-F-45 
 
Some individuals reported that their doctors attributed their symptoms to 
imagination or age, dismissed the importance of their symptoms or said that a 
connection between the symptoms and the medicine was not possible. When 
reported side effects were belittled or dismissed by HCPs, some participants 
described how they accepted their doctor’s response, doubted their own 
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attribution and persisted with taking medicines rather than consulting a doctor a 
gain for the same problem because they balanced the unwelcome side effects 
against the reasons to take medications. Some balanced the unwelcome side effects 
against the positive experiences with a healthcare professional, which might involve 
advice from a healthcare professional: 
“I put my full trust in the doctor... If I am going to die in their hands, I 
don’t mind [laughs].” [Case 708-IN-M-65] 
“My doctor obviously would know better than me.” [Case 211-IN-M-59] 
Other participants balanced the unwelcome effects with perceived benefits of 
taking their medications. This might involve achieving a good outcome or feeling 
better when taking medications or preventing any possible harm when not taking 
medications: 
“When I take Methotrexate I feel stressed and I have bad mood… I have 
fears of side effects but I have to use my medicines, I have no other 
option... They make me feel better” [Case 401-AR-F-40] 
“I need to take my medicines as instructed to prevent any possible 
harm.” [Case 604-AR-F-52] 
In contrast, other respondents were sufficiently convinced of their own attributions 
and they went to seek advice from other sources that were in a position to give a 
recommendation or to change the prescription, such as other HCPs or pharmacists 
who were not involved in the original prescription:  
“When they gave me extra Insulin yesterday I was very upset and I came 
to here to speak to him [pharmacist] and he made me feel better. He 
told me it [Insulin] is necessary to control my sugar level… I only hope 
that I won’t gain weight with taking Insulin.” [Case 309-AR-F-44] 
One individual stated reporting side effect directly to the pharmaceutical company: 
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“I spoke to my GP and he didn’t believe me, he said ‘Don’t worry every 
medicine has a side effect’, but I started to feel unwell. Then, I spoke to 
the drug company that makes the Tegretol, and they said to me ‘Don’t 
listen to what GP says, stop the medicine and speak to your consultant’. 
Then, I spoke to the consultant and I told him ‘Listen, if you will not 
change the Tegretol for me, I will stop taking it’. Then, the consultant 
spoke to the GP and told him to change the Tegretol to this one here 
[Keppra] and he also prescribed this one [Omeprazole].” [Case 702-IN-
M-58] 
Another one revealed consulting a private doctor: 
“I saw diabetes specialist three months ago… I heard a lot about him 
and my brother recommended me to see him... Well, I was thinking that 
he can prescribe something else other than Metformin because 
Metformin that I am using causes weight loss. So, I was expecting that 
he can change it to something else... No, he kept everything as it is and 
told me that I have to take it.” [Case 604-AR-F-52] 
Another respondent skipped taking his medicine: 
“Metformin… I take two tabs three times a day but sometimes I alter 
the dose, do you know why? Because if I take every day six tabs I feel 
tired and weakness in my legs… At night time I always take two tabs but 
in the morning and in the afternoon I sometimes take one tab rather 
than two tabs... I discussed that with him but I know what is better for 
me… Cholesterol tab gives me too much problem... When I swallow it I 
can’t breathe... My doctor knows about this but he couldn’t find 
anything... So I have to balance and adjust the dose myself... Sometimes 
I take and sometimes I don’t.” [Case 103-BNG-M-45] 
In summary, the results of the current study indicated that concerns about 
unwanted effects of medication and how these weigh up against perceived benefits 
were of a major concern for participants from SA and ME backgrounds as well as in 
patients from all ethnic groups and across all chronic conditions (Carter and Taylor, 
2005). In the present study, doctors responded to patients’ complaints about 
medication side effects in a variety of ways: by educating patients, changing 
medication, reducing dose of medicine, treating the side effect by prescribing 
another medicine, changing the dosage form of the drug, telling patients that the 
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benefits outweighed the harm, saying that there were no alternatives or that side 
effects were to be expected. When reported side effects were belittled or dismissed 
or not solved by HCPs, some participants continued to take their medicine as 
instructed but others took an active decision and decided to seek further advice or 
to take action themselves to solve the problem either by skipping doses, adjusting 
doses and regimen or stopping the medicine rather than consulting a doctor about 
the same issue again, especially when side effects continued to interfere with a 
body part or life routines. The most common scenarios in this study were that 
participants recirculated many times before establishing a stable pattern of 
medication use.  
The problem is that many SA and ME patients in this study reported that they had 
not been told of commonly encountered side effects and what to do if a side effect 
is experienced, which made them more vulnerable to inappropriate medicine-
taking behaviour. The decisions that were made without support and advice of 
doctors could affect medication effectiveness and safety. Thus, informing patients 
about possible side effects and what actions to take in order to counter side effects 
should be mentioned by HCPs when prescribing a new medicine. Asking whether 
patients experience any unwanted SE and whether they make any changes to their 
medication due to SE should be reviewed every six months. Patients should be 
offered advice tailored to an individual’s experience, not necessarily about changing 
medication but at least advice that makes patients feel that their experiences, 
worries or fears are taken into account (Benson and Britten, 2006).  
5.2.2 Beliefs about severity of disease, control of its symptoms and perceptions of 
the need for medication 
Many participants reported taking the medication in response to their symptoms, 
severity of disease, and perceptions of the need for medication. Patients were more 
likely to comply or sometimes overuse their medication if they perceived their 
illness to be severe or serious and thus they might be more susceptible to the 
complication of the disease if left untreated, and that the benefits of complying 
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with their medications (e.g., preventing complications, symptoms relief) 
outweighed the barriers or risks of taking it (e.g., complexity, side effects, 
interference with life routine). In contrast, patients were less likely to comply with 
their medication if they perceived their condition to be less severe or with absence 
of symptoms or fluctuation or if no signs of improvement in symptoms had been 
noticed, and subsequently the barriers or risks of taking medication (e.g., 
complexity, side effects, interference with life routine) outweighed the benefits of 
complying with their medications (e.g., control symptoms or prevent future 
complications). 
Many participants used their medication intermittently to control their symptoms 
rather than using them continuously to control their symptoms. Some did not 
perceive their disease as a serious medical condition or a priority illness and 
consequently they reduced dose or dosing frequency or stopped medication for a 
while. For example, some patients disclosed under-using tablets when symptoms 
improved or they “felt better”: 
“I have been using antidepressant medicine for almost 12 years since I 
came to the UK. Nowadays I am trying to decrease taking 
antidepressant medicine if I don’t need it… I fed up with all medicines; I 
don’t want to swallow more medicines especially if they are not 
necessary.” [Case 201-AR-F-62] 
“Purple inhaler [Seretide] I use for asthma... two puffs at night... I don’t 
use it every night... Yes, almost every day... I don’t use inhalers, if I don’t 
have shortness of breath... Because they have side effects which I prefer 
to avoid.” [Case 313-AR-F-44] 
“Yes, sometimes when I feel I am OK, I stop taking my medicines. Yes, all 
my medicines. Once or twice a month… If I feel I am OK, I stop taking 
them for three or four days. That’s why my wife is bugging me and 
nagging all the time to make sure that I take them [laughs].” [Case 216-
AR-M-50] 
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At the same time, some frequency and/or dose increments were made by 
participants based on their need for the therapy, which was guided by the existence 
or persistence or worsening of symptoms: 
“Yes, sometimes when I feel unwell, I increase the antidepressant tabs 
Risperidone and Mirtazapine... Rather than taking one tab a day from 
each, I take two tabs a day from each... Once or twice a month... Last 
time I did it was a week ago.” [Case 215-AR-M-40] 
Some participants acknowledged using medication as preventive approach to keep 
the symptoms away or from getting worse for a while (e.g., short acting beta 2 
agonist):  “Ventolin I use it for asthma... I always carry it with me. I take 20 puffs 
[laughs]... I use it regularly just in case.” [Case 208-PAK-F-35] 
Others did not perceive the importance of adhering to medications that are used 
for preventive purposes (e.g., lipid-regulating drugs to lower blood cholesterol level 
or proton pump inhibitor to prevent ulcers): 
“Like my cholesterol tablet, when I feel I am all right, I stop taking it but 
then I feel unwell so I go back and take it as instructed.” [Case 303-AR-F-
53]    
“Lansoprazole they gave it to me because I had reflux problem in the 
past, now I don’t have reflux problems... I am OK, but I still take it 
because my doctor still prescribes it to me... I adjust the dose for the 
whole month. You can say for about a week and days... Last month, I 
stopped them for three days and then I carried on. I should not tell you 
these things [laughs].” [Case 609-OSA-M-80] 
Feeling of denial towards their diagnosis of illness was described by a couple of 
participants. It seems plausible that denial of the disease can lead to denying 
prescribed treatment, resulting in patients’ non-compliance: 
“I don’t have asthma. They are giving me asthma medication but I don’t 
take them because I don’t have asthma. I take them only when required 
because sometimes I have shortness of breath.” [Case 212-AR-M-80] 
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“I don’t think it [Isosorbide] is necessary but I do keep it for a couple of 
days to make myself relieved... Because Isosorbide I think they have 
given it to me by mistake. They thought I had angina and then they gave 
it to me and they won’t take it off... I don’t have angina.” [Case 609-
OSA-M-80] 
Perceptions of expertise with the illness and body awareness are another factor 
which emerged and might have interfered with patients’ adherence to their 
medications. Some participants reported that they were able to skip and alter doses 
of their medications because they became experts at their illness and became 
aware of their own bodies, which allowed them to sense what to do in certain 
situations based on their own feelings rather than the advice of a health 
professional. They reported that they can feel when they need to reduce or 
increase their doses of their medications as their own body would provide cues for 
action:  
“Well, it depends if I have strong pain, I take three tablets a day 
[Hydroxychloroquine] but if I don’t have strong pain, I take one tablet a 
day... I just know; you kind of become an expert with time.” [Case 604-
AR-F-52] 
“I should take 40 units of Insulin in the morning and 40 units in the 
evening before food. But 40 units are too much for me so I take 30 units 
in the morning and 20 units at night. If I take 40 units I feel unwell… I 
adjust the dose often... with Insulin only... Because sometimes at night I 
don’t eat so I don’t need a high dose of Insulin... You know what works 
for you.” [Case 213-AR-F-60] 
In relation to attitudes towards illness or its medications, there was evidence that 
participants exhibited several attitudes which may have implications for medication 
or treatment adherence. For example, some participants met the diagnosis of their 
illness with denial. This finding has been reported in qualitative studies (Hernandez 
et al., 1999; Lautenschlager and Smith., 2006) and may adversely impact patients’ 
adherence to their medications or treatment. While some were in denial, other 
participants faced the diagnosis of illness by downplaying the severity of the illness, 
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i.e., minimize the severity of their disease by not paying too much attention to it. 
This attitude has been reported to decrease adherence to medications (Hernandez 
et al., 1999). 
Perceptions of body awareness, i.e., participants’ feeling that they were able to 
sense what was going on in their bodies as it would provide them with specific cues 
for action (e.g., feeling depressed, shortness of breath, stomach pain), were 
reported and resulted in participants taking actions based on these cues (e.g., 
increasing or decreasing their doses of medications). This finding has been reported 
in the literature and was found to influence patients’ adherence to their diabetes 
treatment regimens (Hernandez et al., 1999; Vermeire et al., 2003). It is worth 
noting here that non-adherence as a result of body awareness does not necessarily 
result from poor knowledge but rather from a desire to maintain control over the 
body and to observe how one’s own body would function without medications. 
Findings of the current study also revealed other beliefs about medicines among 
participants such as the necessity of medications for the management of illness, 
ineffectiveness of medications for controlling symptoms, and harmfulness of 
medications and their potential for serious adverse effects. Healthcare providers 
need to elicit these beliefs and address them to ensure patients’ adherence to their 
prescribed medications. Patients who do not believe in the necessity of medications 
for managing their illness may not adhere to their medications, and may benefit 
from education and counselling from their healthcare providers to address this 
concern. Similarly, patients who believe that medications are harmful chemicals 
that can cause serious adverse effects may also benefit from reassurance and 
education by their healthcare providers. An explanation of the consequences of not 
taking the prescribed medications may also resolve these beliefs. However, it is 
important for this to be achieved in a subtle way to avoid raising patients’ anxiety.  
Although some patients in this study were well informed about their illness and 
treatments, they actively resisted complying with their prescribed treatments due 
to attitudes they hold towards illness and beliefs about medicines. These beliefs 
Chapter 5 – Results (A description of the MRPs and contributory factors to the MRPs that may be 
similar to the general population from patients’ perspectives) 
186 
 
and attitudes did not always influence adherence negatively. For example, severity 
of illness and worsening or persistence of its symptoms, necessity of medications 
appeared to influence compliance positively whereas denial of illness, symptoms 
improvement, asymptomatic condition, God-centred locus of control, perceptions 
of expertise with illness and body awareness, fears of side effects and drug 
dependence influenced compliance negatively. This shows that patients are not 
passive recipients of medical advice. Rather, they sometimes process this advice 
and develop their own way of taking their medications based on their 
circumstances or what makes sense to them. Thus, healthcare providers should 
respect patients’ autonomy, and accept that increasing compliance with prescribed 
recommendations is not as important as meeting patients’ individual priorities and 
needs. Patients need assistance and help to make informed choices and decisions 
about treatment. For example, there is a need to distinguish clearly between 
situations where changing the timing or quantity of medicine doses may be 
beneficial or do little harm and the situation in which there is a high possibility of 
adverse clinical outcomes.    
5.2.3 Cognitive, physical and sensory problems affecting the use of medicines 
Participants described how often and why they forget to take their medicines. They 
also mentioned how they behave when they forget their medicines and what 
strategies they used to remind them to take their medicines. Reasons as to why 
participants forgot to take their medicines differed between participants. Some 
patients had no specific reason for why they forgot to take their medicines: 
“I take them all out. Take this, take this, take this and then the phone 
rings, I walk off and when I am on the phone, I forget that I have not 
taken it.” [Case 208-PAK-F-35] 
Some participants used their fears of the side effect as an excuse for why they 
forgot to take this particular medicine: 
“Yes, often... Once or twice a week... Last time I did that was yesterday 
[laughs]... My wife puts them in front of me on the table when I eat my 
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breakfast and even though I pretend not to see them [laughs]... I don’t 
like taking them… They all have side effects.” [Case 216-AR-M-50] 
Other participants described how they became absorbed in their daily activities at 
home or at work and forgot particular doses of medicines: 
“Yes, sometimes. Say twice every six months... No, I just forget because 
obviously if I am rushing out to work, I put my pills in the box and if I 
forget to pick it up and put it in my hand bag, then I will miss the whole 
day.” [Case 608-IN-F-50] 
A patient reported that he found it difficult sometimes to remember taking his 
medication because of caring for his disabled wife: 
‘[laughs] afternoon, the lunch time tabs I do forget because I am 
running around, looking after my disable wife because I am her carer.’ 
[Case 613-IN-M-64]  
Some respondents reported that reason for forgetfulness was the inconvenience of 
taking a medicine at a prescribed time.  For example, those who were taking all 
their medications in the morning explained that they had trouble remembering to 
take the statins, because it was the only medicine that they had to take at night: 
“Once or twice a year... Mostly with Atorvastatin because this is the only 
medicine I take at night so I do forget.” [Case 605-IN-M-66] 
“Rarely... Once or twice a year... With Simvastatin because I fall asleep 
and then I remember that I didn’t take it.” [Case 211-IN-M-59] 
One participant reported that she was instructed to take Exenatide injection before 
meals, which was difficult for her to remember: 
“Often [laughs]... Only Exenatide injection because I need to take it 
before food and when I forget, I am not allowed taking it after food... 
This is what the nurse told me... I have to wait to the next dose… I forget 
two or three times a month.” [Case 310-AR-F-43] 
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Perception that medicine was unnecessary when symptoms were controlled or 
when the patient did not perceive or experience any benefit from taking it was 
illustrated by different participants in the following quotes: 
“Sometimes it happens... I forget the Insulin... I take the dose in the 
kitchen as usual and I cook the food... heat it up and then I forget 
whether I take it or not... To be on the safe side I take half the unit... I 
can’t take the full dose again because I may have hypos... Sometimes I 
forget to carry my Insulin with me when I leave home... Insulin is 
essential... I worry about it... I also sometimes forget evening dose of 
Insulin because of sleepiness... Tabs I might forget but I don’t care; I go 
to sleep even if I forgotten, they are not that important... For the 
tablets, I wait until the next dose and I take the instructed dose only... I 
don’t double the dose.” [Case 107-OSA-M-57] 
“I forget sometimes the ones that do not help me a lot like Diclofenac 
and Calcium tabs but Prednisolone and Methotrexate I have never 
forgotten them. Calcium tabs sometimes I take and sometimes I forget 
but my doctors insist that I should take it for my bones.” [Case 204-AR-
F-45] 
A participant declared forgetting to take Aspirin sometimes because this tablet is 
produced in a dispersible form and until it solubilises in water he may forget to take 
it:  
“Sometimes... Mainly Aspirin because I need to put it in water to first 
dissolve and I have to take the other medicines so while waiting for tab 
to dissolve I forget [laughs]... Once a month.” [Case 312-AR-M-50] 
Some participants admitted that forgetting to take their medicines resulted from 
polypharmacy and the vast number of tablets they were on as well as their belief 
that the disease was uncontrollable: 
“Sometimes... 4-5 times last month... With the disease I have and the 
plenty of medicines I take, I feel depressed and anxious so I forget.” 
[Case 209-AR-M-49]  
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Other participants revealed other reasons for forgetting such as stress, laziness, not 
having their medicines with them when travelling or being away from home. When 
forgetting a dose, participants tend to do the flowing: skip it and continue with their 
normal schedule, take the missing dose as soon as remembered, or double the next 
dose. Table 5-9 illustrates actions taken by participants when forgetting to take 
medicines. 
Table 5-9: Quotes of actions taken by participants when forgetting to take medicines. 
Actions Quotes Patient 
Doubling the dose “Once I took overdose of either 
Amitriptyline or Naproxen... I can’t 
remember which one was it... What I 
remember is that I took two or three extra 
tabs... I had to much pain... I took my 
instructed dose first but the pain did not 
relieve so I thought that I forgot to take my 
tabs so I took extra dose... I felt like there 
are pins and needles in my mouth and like I 
was walking on the air... My mouth was dry 
and my tongue was heavy.” 
[Case 311-AR-F-45] 
Taking medicines as 
soon as they remember 
“I might not take it in the morning but as 
soon as I see it, I take it. I don’t miss 
anything but I might not take it in the right 
time sometimes.”  
[Case 208-PAK-F-35] 
 
Missing the dose and 
waiting for the next dose 
“Now, if I forget, I prefer not to take them 
and wait for the next day than to take extra 
doses.” 
[Case 214-AR-M-45] 
Participants had developed different strategies to remind them to take their 
medicines; however, these strategies were not always successful. Some participants 
positioned their medications in visible places or left them in a particular room or 
table: 
“I put them in front of me or otherwise I forget.” [Case 604-AR-F-52] 
“No, I just put my box in front of me on a table beside my bed.” [Case 
214-AR-M-45] 
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Others got another person to remind them or ask them whether they remembered 
to take their medicines, usually a family member, which was the most commonly 
used strategy and was perceived as successful and efficient: 
“Yes, my wife does. She reminds me to take my medicines sometimes.” 
[Case 210-AR-M-55] 
“My mother and sister remind me to take my medicines.” [Case 205-AR-
F-57] 
Some other participants used aids such as alarm clocks, dosette box, and calenders 
as a reminder aid: 
“All my medicines I put in a box that says SAT, SUN, MON, and 
MORNING, AFTERNOON, EVENING so I take according to what I put in 
the box.” [Case 606-IN-M-81]  
“Alert in my mobile and my family remind me as well because I forget a 
lot.” [Case 303-AR-F-53]     
“I have got a little pad, I write down each day and I tick off them when I 
take my tabs… Twice a year [I forget].” [Case 710-IN-M-58] 
“Can’t remember when the last time I forgot [laughs]... I don’t have a 
good memory... With all my medicines... No, I just write it down on a 
piece of paper but sometimes I forget to see the paper [laughs]... Also 
my mum and dad remind me to take my medicines... Nearly every day 
[laughs].” [Case 105-TRK-F-33] 
The rest were taking their medicines at routine times such as eating meals, 
showering, or sleeping or waking up time to be able to remember to take their 
medicines: 
“I have difficulties remembering to take regular warfarin and other 
medicines... What I do is I put all the medicines together and I take them 
before I go to sleep... Even if I do that I sometimes forget.” [Case 609-
OSA-M-80]  
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Other participants revealed altering or changing the time for taking their 
medications to suit their daily routine and to prevent them from forgetting to take 
their medicines. A participant reported taking a tablet and a half from Metoprolol 
all at once in the morning rather than taking half a tablet three times a day because 
she felt it would be easier for her to take Metoprolol with her other morning BP 
tablets Bendroflumethiazide and Ramipril. Other participants stated that they 
altered the time of taking their tablets to the morning, with other medicines, rather 
than the evening so that it was easier for them to remember: 
“Simvastatin I take it in the morning. I take all my medicines in the 
morning because I forget if I leave it till night.” [Case 604-AR-F-52] 
“I don’t do that but what I do is that I take my Adcal two tablets in the 
morning rather than one tablet in the morning and one at night because 
in this way I will be able to remember it better. If I take both tablets in 
the morning, I won’t forget.” [Case 503-IRN-F-63] 
Other than forgetting to take medicines, there were barriers that may have 
prevented participants from taking their medications such as difficulties reading 
labels or leaflet because of the small font size on type. Other obstacles included 
difficulties swallowing big tablets and problems with hearing instructions or 
opening containers and blister packs, mainly because of arthritis pain. In all cases, 
patients described how they overcome these problems such as using hearing aids, 
reading glasses, and help from family members. Patients did not report these 
problems as reasons for missing doses. 
In summary, forgetting was the most frequently quoted reason for unintentional 
non-compliance by participants. It often resulted from distractions (e.g., busy life 
style, being a carer), fears of side effects, inconvenient time of taking a medicine, 
being away from the home/travelling, having too many medicines, misperceptions 
such as not perceiving the importance of adhering to medications when symptoms 
are controlled or when they are used for preventive purposes or symptomless 
conditions or when patients do not benefit from taking them, etc. Patients 
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developed different strategies to improve medication taking
5.2.4 Problems with repeat prescriptions  
 in which getting a 
family member to remind them to take their medicines was the most commonly 
used strategy. These strategies were perceived as sometimes successful and 
efficient in promoting medicine-taking behaviour.  
In the interviews, various issues with prescribing and issuing repeat prescriptions 
were exposed, in which 31 participants were identified with 34 repeat prescribing 
problems. These problems could have been caused by the GP surgery, pharmacy 
staff or participants. Most participants’ complimented the repeat prescribing 
process for the ability it provided to renew a prescription without face-to-face 
consultation with the GP or nurse. However, while this reduces the workload for the 
GP and is convenient for the patient, it does not provide the adequate control that 
is needed to ensure that every repeat prescription is still appropriate, effective and 
well tolerated, and that it is still being viewed and taken by the patient as intended. 
Infrequent therapy reviews may lead to failure to prevent, identify and solve 
medicine-related problems and medicine wastage, and may, thereby, have a 
negative impact on the effectiveness, safety or cost of the medications prescribed.  
The repeat prescribing process was criticised by some participants in this study. 
Different negative views and experiences were revealed; one of the problems was 
old medicines remain on the repeat prescription form, which made it difficult for 
some participants to identify their current medicines on their repeat forms and 
gave them the opportunity to order medicines that they were not currently 
prescribed, either to be used by themselves or by someone else. During one 
interview, the participant stated that it was difficult to identify medicines that he 
was taking currently on his repeat form because old medicines had not been 
deleted from the form and thus this caused confusions and complications for him 
[Case 606-IN-M-81]. It was identified that his wife had the opportunity to order and 
take Senna, which was no longer used by her husband because Senna had not been 
deleted from his form.  
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Although guidance on repeat prescribing issued by NHS Executive in 1997 advises 
that ‘no more than 6 repeat prescriptions should be made, or 6 months should be 
elapse, whichever is less, without reassessing the patient’s needs’ (NHS Executive 
HQ, 1997), a number of participants perceived the repeat prescribing process not to 
provide adequate control that is needed to ensure that every repeat prescription 
was still appropriate, effective, well tolerated and taken by the patient as intended:  
“Isosorbide I think they have given it to me by mistake. They thought I 
had angina and then they gave it to me and I do not know why they 
don’t take it off... But I still take it because my doctor still prescribes it to 
me... I adjust the dose for the whole month. You can say for about a 
week and days... Last month, I stopped them for three days and then I 
carried on. I should not tell you these things [laughs].” [Case 609-OSA-
M-80] 
“Salbutamol inhaler, I don’t need it but it is on my prescription… I collect 
it but I don’t use it.” [Case 502-AR-F-65] 
Thirty-one participants revealed that they had delayed taking their prescriptions to 
a pharmacy at least once after running out of supplies of medicines. Their reports 
varied from just once or twice ever to a number of occasions. Of the 66 participants 
with complete records available in the pharmacy, 51 (77%) participants’ responses 
agreed with pharmacy records and 16 (23%) participants’ responses did not agree 
with pharmacy records. A delay in issuing repeat prescriptions in the GP surgery 
was one of the reasons for the delay in taking prescriptions to the pharmacy after 
patients’ supply of medicines ran out. A patient specified that lack of integration 
between primary and secondary care together with a lack of communication 
between the various clinicians regarding medications that have been altered were 
the causes for such delay:  
“If I ask receptionists for something [medicine] in particular, even if I 
ticked it, they won’t give it to me... The hospital changes the doses and 
they may not know about it in time... So, I have to go and tell them that 
this is what the hospital done and then they will say okay we will issue it 
for you.” [Case 505-PAK-M-57] 
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Others demonstrated that the reason for slow issuing of repeat prescription was 
the time the GP surgery takes to generate prescriptions. It is well known that a 
repeat prescription should be ready to collect after two working days of requesting 
it but some prescriptions took longer to issue either because the doctor did not sign 
and pass them to the receptionist or because the receptionist claimed that the 
patients did not tick which medicine they wanted in their prescription as in the 
following quotes:     
“Yes, I usually have to borrow medicines before getting my repeat 
prescription... Mostly because the GPs have not passed it on or have not 
made the prescription ready, something like that… I was just trying to 
persuade him [pharmacist] to request my prescription from my GP so I 
don’t have to request it and deal with them every time.” [Case 503-IRN-
F-63] 
“You see these medicines in my repeat prescription, I have been running 
out of them for three days because when I went to the GP, they told me 
to leave the prescription and come after two days to collect it. After two 
days they told me that I did not tick which medicines I needed but this 
was not true I ticked all of them. Then, they told me to come after two 
days to collect my prescription...Why I have to come after two days? I 
have been waiting long enough… Today was the last day I have tablets; 
if I did not get my prescription today, I would not be able to take my 
medicines because of their fault.” [Case 402-AR-M-65]  
A further reason for delay in taking prescriptions to the pharmacy after patients’ 
supply of medicines ran out was because of forgetfulness. It was identified that the 
majority of participants who delayed taking prescriptions to the pharmacy did not 
take remember to take their medicines as instructed (18/31, 58%). It is likely 
therefore that patients who forget to take their medicines may also forget to take 
their prescription to the pharmacy after running out of medicines. It was even 
identified that 11 participants out of 31 (36%) delayed taking prescriptions to the 
pharmacy after their supply ran out, despite receiving help from their family 
members in ordering and collecting their prescription from the GP surgery and their 
medicines from pharmacy. This was possibly because the help was not regular. 
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Patients who did not have a problem with delay in taking prescriptions to the 
pharmacy were those who asked the pharmacy to collect and order their 
prescription from the GP surgery and to remind patients to come and collect their 
medicines from the pharmacy on a regular basis before running out. Two 
participants [Case 605-IN-M-66] and [Case 503-IRN-F-63] wished that their 
pharmacy would establish a service where it could order and collect prescriptions 
from the GP surgery every month so that the medicines would be ready for 
dispending without the need for the patient to go to the GP surgery.  
Another negative experiences regarding the repeat prescribing process was 
prescription length that was not tailored to the needs of the individual participant. 
For example, when asked about frequencies with which participants obtained their 
repeat prescriptions from GP surgeries, twenty patients reported obtaining them 
every month. Twenty-eight-day prescribing can adversely affect patient adherence 
with long-term therapies because patients anticipate running out of some 
medication before the end of the month. The following quotes showing problems 
with the 28-day repeat prescription: 
“Yes... Couple of times... three times last year... I forgot to order some 
of the medicines and I ran out so I had to come to the pharmacist and 
ask him to give these medicines...It happened because some medicines 
like Statin and Metformin has 28 tabs in the box not 30 so for two days 
you don’t have tabs... That’s why I missed it out.” [Case 709-IN-M-66] 
“Yes, sometimes I forget... But when I remember, I tell the pharmacy 
and the pharmacy gets it for me straight away. Because there are only 
28 tabs in the box and as you know each month has 30 or 31 days so I 
get less tablets.” [Case 703-IN-M-60] 
In summary, problems with repeat prescriptions and drug-prescribing may affect 
the safe use of medicines and medication adherence if not being addressed. These 
problems have shown that a review of patients’ records by pharmacists may be 
beneficial to patients. Providing services such as ordering medicines from GP 
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surgery and delivering medicines to patients’ homes by pharmacy staff may also 
help the patients.    
5.2.5 Problems attributed to access to, and organisation of, services 
Thirty-two participants were identified with 66 GP surgery and pharmacy service 
problems. Patients’ perceptions of and views towards their GP surgeries were highly 
negative. Many patients were unable to make appointments with their GP with the 
waiting times being too long and the consultation times being too short. Others 
were unable to see the same GP.  
Difficulty getting appointments 
The NHS plan states that patients should be able to access a HCP within 24 hours 
and a general practitioner within two working days. However, one of the most 
commonly reported problems was the difficulty getting an appointment to see a 
GP. Participants in the present study revealed that the booked appointment system 
was ineffective and inefficient because they were unable to see their GP in 
emergencies or they experienced barriers making regular appointments. Typical 
comments were: 
“It takes time sometimes to get an appointment for my GP. For 
example, once I fell down on my hand and all this part was blue, when 
they gave me an appointment, this part was back to normal... 
Sometimes I have to wait for two weeks possibly to see a doctor.” [Case 
201-AR-F-62] 
“I try to make appointments for my parent later in the evening but it is a 
hard job. I get the attitude of call at 3pm to say ‘Can I please make an 
appointment, the latest one in the evening’ and if I forget to call at 3 pm 
and I ring them up later, the appointments are gone. So I found out that 
was difficult and I can’t make appointments.” [Case 608-IN-F-50] 
Dialling the telephone number of the GP surgery over and over again without 
getting through and the short length of time given for patients to book a normal 
appointment were the biggest complaints reported by participants about the 
booked appointment system. As a solution, most participants preferred to use the 
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emergency appointment over booked appointment as it offers the patients the 
opportunity to see their GP or other HCP quicker and when required even if they 
were not experiencing a medical emergency and their problems did not count as an 
urgent appointment: 
“Yes... All the time [laughs]... Cos in my GP surgery if you want to make 
an appointment, you should wait two weeks to get an appointment... 
So, sometimes if you can’t wait two weeks, you have to call them and 
say ‘I need an emergency appointment.’” [Case 208-PAK-F-35] 
“Well, appointment time is a bit of a headache. You can’t get 
appointment. They tell you to call in the morning and you can’t get 
through. But I found a way. If you go there personally at 8am and then 
talk to them as say I want emergency appointment, you will have a 
chance to get one. But through the phone it is difficult. It is engaged, 
engaged, engaged because everybody is phoning and after 8:30 they 
won’t give you any appointment because the ½ hr window to book 
appointment has gone.” [Case 605-IN-M-66]  
Apart from difficulty getting though on the phone, the attitude of receptionists was 
also highlighted by some participants as a barrier for booking not only regular 
appointments but also urgent ones. They had to battle with receptionists and had 
to answer many questions in order to get an appointment: 
“Appointment time is a problem... You can’t get appointment when you 
need... and you can’t go to A&E unless it is something so serious... and 
to get emergency appointment you need to be asked lots of questions 
by receptionists, which is annoying.” [Case 101-BNG-M-48] 
“The only problem I have is the appointment time... Sometimes they 
said ‘We are full all this week’ so I have to argue and fight with 
receptionists and I have to answer all their questions to get emergency 
appointment.” [Case 306-AR-M-47] 
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Long waiting time in GP 
Besides difficulty getting appointments, long waiting times during visits was 
reported by many participants as a problem when accessing healthcare services, as 
outlined in the following quotes: 
“If your appointment is at 5pm, sometimes the doctor sees you at 6pm.” 
[Case 210-AR-M-55] 
“I am just not happy about the long waiting time inside the GP surgery 
and the difficulties for getting your appointment... Like my appointment 
today was 10.30 am but I was not seen until 11.15 am.” [Case 503-IRN-
F-63] 
The continuity of care issues 
Many patients in the present study wanted both quick access to and relationship 
continuity in practice. This was evident by the number of participants who 
preferred to consult only one doctor in this study (70/79, 89%). Not being able to 
see or consult one known and trusted doctor regularly was also seen as an obstacle 
for some SA and ME patients in having their medicine and healthcare needs met: 
“I can’t see my regular doctor always, which I don’t like.” [Case 313-AR-
F-44]  
“I don’t see my regular doctor every time; I have to repeat the same 
story to a new doctor, which annoys me.” [Case 401-AR-F-40] 
“My regular GP gives me enough time because he knows that I am 
depressed and I need time to express myself but if someone else 
replaces him during his holiday, he/she won’t give me enough time, 
which I don’t like.” [Case 204-AR-F-45] 
The reasons for not being able to consult their known regular doctors all the time 
were either because of unavailability or popularity of their GPs which made the 
majority of patients book appointments with them: 
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“We go to this particular doctor but we sometimes find it difficult to get 
an appointment with this doctor… He is very popular and it takes more 
than necessary sometimes to get appointment with him, possibly 10 
days.” [Case 613-IN-M-64] 
“My GP is an excellent person; everyone wants to see her... So when I 
call the receptionist, she tells me that my doctor is fully booked.” [Case 
310-AR-F-43] 
A further reason in difficulties establishing continuity of care was lack of regular 
doctors in the surgery:   
“I’ve never seen the same GP, they are all locums, they keep changing… 
So, yes it is a constant battle… They just need to employ one permanent 
doctor but they don’t [laughs].” [Case 208-PAK-F-35] 
“Yes, in my GP the doctors are always changing... Yes, I want to see one 
doctor only.” [Case 201-AR-F-62]  
It was identified that patients, who consulted more than one doctor were more 
likely not to take their medication as recommended (7/9, 78%). The findings also 
showed that discontinuity of care is associated with lack of information on 
medicines. Five patients out of nine (56%) who consulted more than one doctor 
were identified with lack of information. In addition, seven patients who consulted 
more than one doctor had been admitted to hospital at least once in the last five 
years and five patients had been admitted to A&E at least once in the last five years. 
Discontinuity of care also increased the chance of ADRs and DIs. Six patients out of 
nine (67%) who consulted more than one doctor were identified with ADRs and DIs. 
However, a clear conclusion cannot be drawn from a small number of participants. 
One participant reported that discontinuity of care could have caused an adverse 
outcome, as illustrated in the following quote: 
“One day my doctor [a name of a doctor] was a broad and I was 
coughing... The doctor who replaced her was very bad... I told him ‘I am 
coughing’. The screen in front of him should show him what I have, 
what medicines I take and everything. He gave me syrup for my cough... 
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When I went back home as usual I read package leaflet insert and it was 
written 'DO NOT TAKE THIS MEDICINE IF YOU ARE TAKING ATENOLOL 
OR METFORMIN' and as I told you these were the medicines that I was 
taking. So, what I did was that I didn’t take the syrup... When my regular 
GP came back from her holiday after two months, I took an 
appointment to see her for something... She opened the computer and 
she shouted ‘Oh, my God!! What did you do with this medicine?’... I told 
her ‘Don’t worry, I did not take it’. She said ‘What the hell... you 
could’ve died, if you took this medicine... It could have stopped your 
heart immediately.’” [Case 301-AR-F-54]       
In the last few years, particularly since the drive for rapid access and the large 
proactive GP workload encouraged by the Quality and Outcomes Framework (QoF), 
patients are finding it far too difficult to get as much relationship continuity as they 
would like (Campbell et al., 2009). Research evidence shows that continuity of care 
is associated with better understanding of health condition and treatment, 
medicine usage and adherence, uptake of immunisation and screening 
programmes, and with cost saving in prescribing, hospital admissions and referrals 
and use of A&E and overall cost of healthcare (Alison and Freeman, 2011). It is also 
associated with increased trust, security in doctor-patient relationship, and reduces 
unnecessary and harmful medical intervention (Alison and Freeman, 2011). 
Researchers have shown that positive patient enablement (feeling able to cope with 
their condition after a consultation) is closely linked to relationship continuity 
(Alison and Freeman, 2011).   In contrast, patients who experience discontinuity of 
care are more likely to discontinue treatment by not turning up for appointments or 
by not taking their medication as recommended (Alison and Freeman, 2011). 
Discontinuity of care may also increase the chance of ADRs and misuse of 
prescription medication by patients. 
Research has shown that patients most likely to benefit from seeing the same 
doctor are vulnerable in other ways (e.g., older, disabled, chronically ill, language 
problems and poor education). Therefore, the most deserving patient may find it 
difficult to get the continuity they want if success needs a forceful personality 
combined with excellent negotiating and communication skills (Alison and Freeman, 
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2011), which SA and ME in the present study may not have. In a recent review, 
results in two contrasting areas of England 2008-2009 demonstrated that, while 
overall the frequency of consulting a preferred doctor seemed good, there were 
geographical variations and difficulties related to age and to ethnic group (Freeman 
and Hughes, 2010).  
Mead et al. (2009) investigated why some ethnic minorities evaluate medical care 
more negatively and revealed that these patients reported the worst experiences of 
waiting times for an appointment and “continuity of care”, in comparison to other 
patient groups. The lack of organisation in the healthcare system, including doctors’ 
attitude towards patients, inability to make appointments on day of request and 
the inability of patients to express all their problems in a single consultation, reduce 
the level of continuous care given to patients with chronic diseases (Cowie et al., 
2009). Prentice and Pizer found that long waiting times are associated with poorer 
health outcomes, with mortality rate being the worst-case scenarios (Prentice and 
Pizer, 2007).  
In general, SA and ME patients have many expectations and needs from HCPs and 
healthcare services and negative perceptions may arise when these are not met. 
Thus, pharmacists and HCPs need to work together to reduce health and access 
inequalities experienced by SA and ME populations by encouraging and supporting 
continuity of care, listening to what patients say they want most, involving patients 
in plans for service changes, giving patients clear information on how to get an 
appointment with their preferred doctor, reviewing the process for booking 
appointment, promoting teamwork, internal communications and staff training, 
reviewing staff capacity and employment policies, looking for where things go 
wrong by using critical event reviews to share learning, and adjust policies and 
practice  (Alison and Freeman, 2011). The provision of appropriate healthcare 
facilities is crucial to enable patients’ access to healthcare services at all levels.  
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5.2.6 Miscellaneous 
Participants identified with intentional non-compliance were more likely to be 
younger (Mann-Whitney test, P=0.004). There were (35/60, 58%) participants aged 
65 or less than 65 who were identified with 65 intentional non-compliance 
problems. In contrast, there were (8/20, 40%) participants aged above 65 who were 
identified with 19 intentional non-compliance problems. The data also showed that 
there was a statistically significant difference between SA and ME participants in 
terms of age (t-test, P=0.000). The mean age of SA participants was 62.80 (range 51-
81 years) whereas ME individuals’ mean age was 52.58 (range 18-83 years).  
It was noticed in this study that not all patients want to share in making the 
decisions. For example, some elderly patients or those who are very ill tend to be 
more likely to want the doctor to decide and tend to be more compliant, possibly 
because they might have more concerns and worries about their health and 
treatment than younger patients. Other people, however, want to participate in all 
decisions about their care and expect their doctor to provide them with the 
necessary information to enable them to do so, such as people who are relatively 
young and healthy and in cases where the doctor did not involve them in the 
decision-making process, these patients may make an informed decision not to take 
medication as directed.  
Besides age, the level of education was more likely to affect patients’ compliance. 
Participants identified with intentional non-compliance were more likely to have a 
lower educational level (i.e., up to high school or up to 10th grade) (chi-square, 
P=0.043). The majority of participants for whom 66 intentional non-compliance 
were identified reported having a lower educational level (n=33/53, 62%). There 
were (10/27, 37%) participants who had a higher educational level (i.e., university 
or above) and were identified with 18 intentional non-compliance problems. 
Patients with a lower educational level (i.e., up to high school or up to 10th grade) 
(chi-square, P=0.021) were also more likely to be identified with GP and pharmacy 
service problems (chi-square, P=0.021). Participants (26/53, 49%) who had a lower 
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educational level were identified with 56 GP and pharmacy service problems 
whereas participants (6/27, 22%), who had a higher educational level were 
identified with 10 GP and pharmacy service problems. Poor education was more 
likely to affect health literacy, communication with HCPs, participation in decision-
making, compliance and access to healthcare for some participants in this study:  
“Actually my daughter is the person who orders, collects and brings me 
my medicines so she is the one that knows about my medicines... I don’t 
remember 75% of my medicines... I don’t know their names or when to 
take them or how many should I take because my daughter always 
prepares my medicines for me and helps me with administration... She 
knows better... She does everything for me... She takes me to the doctor 
and she tells me what he says... Yes, often [adjust the dose of her 
medicines]... Of course I do but my doctor does not know.” [Case 201-
AR-F-62] 
“My mother [Case 607-IN-F-75] complies very badly... She does it all the 
time with all her medicines… I tell her the information the doctor told 
me but she can’t understand the information given to her, she gets 
confused... She is illiterate and she can’t speak or read English… She 
relies on my father and myself in everything and if I am busy with my 
father because he had heart attack or whatever, then she gets left 
behind.” [Case 608-IN-F-60]    
“I don’t know their names [his medicines]... My doctor told me what 
each medicine is used for and I wrote on each box in Arabic what it is 
used for... My son helps me with everything, he is taking good care of 
me because he is educated and he knows better than me... He reminds 
me to take my medicines, he brings them to me... He gives me advice 
and information on my medicines... He comes with me to the GP 
because he speaks English and I don’t.” [Case 209-AR-M-49]    
Key messages from Chapter 5 
• Ninety-one per cent of SA and ME participants were identified with at least 
one MRP. This could support prioritising medication use review to SA and 
ME groups.  
• All the MRPs may affect the safe use of medicines and medication 
adherence if they are not being addressed.  
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• All the MRPs could be detected and prevented in the community by 
communicating with the patients, providing expanded services and 
reviewing patients’ records in the pharmacy. 
• Many problems that were identified in SA and ME groups were similar to the 
general population. 
• Concerns about unwanted side effects of medication and how these weigh 
up against perceived benefits; perceptions of severity of disease and control 
of its symptoms; cognitive, physical and sensory problems; difficulties 
related to access to care (e.g., appointment time, waiting time, length of 
consultation, continuity of care) were all reported factors that may 
contribute to the problems and may be similar to the general population. 
• There was inconsistency between what was identified by the researcher and 
what was reported by the patients when patients were asked to self-report 
their intentional non-compliance. Conversely, what was identified by the 
researcher and what was reported by the patients were similar when they 
were asked to self-report their unintentional non-compliance. This might 
mean that patients did not perceive themselves as non-compliant 
individuals; rather they viewed themselves as being empowered people to 
manage their own health and medicines and decide what the best is for 
them. Thus, strategies for informing and empowering patients in treatment 
decision-making should be high on the policy agenda. 
• It seems to be that there is a need to implement changes at the primary care 
level, with the aim of improving the equity of access to primary care services 
for South Asian and Middle Eastern patients in regard to appointment 
systems and making regular appointments, continuity of care, short length 
of consultations and long waiting times. 
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Chapter 6 Contributory factors to MRPs that may be specific to SA 
and ME cultures 
Introduction 
This chapter describes the reasons which may contribute to MRPs and were 
reported to be specific to SA and ME cultures, along with direct quotes from 
participants’ interviews.  
6.1 Religious practices and beliefs 
Ramadan is the holiest month in the Islamic calendar and Muslims abstain from 
eating, drinking and smoking from dawn to sunset. Annual Ramadan fasting is a 
fundamental religious right in Islam observed by adult Muslims. Ramadan fasting 
may mean changes in use of medicines among people of Muslim background. Some 
Muslim patients in the present study, who were able to fast in Ramadan, adjusted 
and made some alterations to suit their fasting. The alterations made included 
modifying the number of doses, time of doses and the time span between doses, 
and even the total daily dose. Some of these actions were taken without consulting 
a doctor and without seeking medical advice because patients thought that this 
would be temporarily (i.e., for one month) and thus there was no need to ask. They 
also reported that their doctors did not talk with them about fasting and medicine 
taking unless they asked.  
Ramadan tended to be an important factor which influenced adherence to 
medications among study participants but obviously different patients would 
describe their medication-taking behaviours in Ramadan in different ways. Most 
Muslim patients who were taking a single daily dose (e.g., evening dose) continued 
to take their evening dose after sunset (Iftar) whereas others who were taking their 
single dose in the morning, advanced this morning dose to before dawn (Sehri). 
However, a small number of participants revealed delaying the intake of the 
morning or afternoon dose to the evening. Many patients who were taking two 
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daily doses took the first one at the break of fasting and the second one before the 
beginning of fasting, in which case the dosing time and the time span between the 
doses are both altered: 
“I have no problem in Ramadan because the morning tablet I take at 
Sehri time and the evening tablet I take at Iftari time. At the moment I 
have no tablets that I take in afternoon so I have no problem.” [Case 
504-PAK-M-81]  
“I take my tablets with the Sehri and the Iftari time so it is possible to 
fast.” [Case 308-AR-F-55] 
Some patients who were prescribed more than two doses took the first dose in the 
early morning before fasting (Sehri time), and the second dose at dusk after 
breaking their fast (Iftari time) and the third dose was essentially ‘skipped’. A 
number of participants also reported that they were not adequately counselled by a 
HCP on how to adjust their medicines in Ramadan. Thus while fasting they changed 
their medicine use in different ways without necessarily discussing these changes 
with a HCP: 
“Well, in Ramadan, when I fast I don’t take all the doses as instructed. 
So, by the end of the month I have extra tabs. Because for example this 
year I fasted from 3.00 am to 9.00 pm so I had only six hrs to take my 
medicines. All the medicines I take I need to take them after food and in 
Ramadan I eat only twice in Sehri and Iftari time. But some medicines 
like Metformin I need to take it three times a day... So, in Ramadan I 
take only two tabs, one in Sehri and one in Iftari time unless I eat a 
heavy meal in Iftari time, then I take two tabs after food rather than 
one. I am not sure whether this is right or wrong. Nobody told me what 
to do in Ramadan!... No, I did not ask because it is only one month.” 
[Case 205-AR-F-57] 
“Because I have sugar the doctor gave me some tablets. In Ramadan, I 
take them [medicines] as instructed except Metformin which I miss only 
one dose so rather than taking one tablet three times a day, I take it one 
tablet twice a day. Well, I did not ask and no one bothered to tell me 
about it.” [Case 310-AR-F-43] 
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Talking to people about Ramadan and what they do enabled us to gain an insight 
into what people thought in terms of if there were other issues that influenced their 
medication-taking behaviours. Some people, for example, seem to believe that, 
whatever action they take to improve their health, it is going to be limited because 
they believe that are external factors that are important, one of which is ‘God’. 
Those who felt that their fate in terms of their health was dependent on God, 
described a tendency to leave everything up to God’s will, which might have a 
negative impact on their medication-taking behaviours, as illustrated in the 
following quotes: 
“In Ramadan I don’t take my medicines at all... I don’t care really about 
medicines... It is my faith... Everything is up to Allah… I even sometimes 
can’t wake up because I go hungry in Ramadan but I will not let it go 
because of this... no way... Yes, if I die with it... I don’t mind... Although 
Rasoul Allah [the prophet Muhammad] said look after your body but I 
don’t..., I ...., I ..., I love my Prophet [cries]… No, my GP does not know.” 
[Case 501-PAK-M-68] 
“Yes, I do make some changes in Ramadan… You know God is our 
saviour and protector... I have faith in God; he is to decide what's going 
to happen to me, whether good or bad, not my medicines... life and 
death is something that only God can control. Sometimes you see 
someone dying despite being completely healthy, and sometimes you 
see someone living despite being very ill... No one can tell what's going 
to happen to you other than God; whatever he wants, will happen.” 
[Case 206-AR-M-66] 
The alterations in medication-taking behaviours in Ramadan could change the 
efficacy and tolerance of many medicines since the toxicity and efficacy of many 
medicines may alter depending on the time of administration and this should be 
taken into consideration as an important factor influencing a drug effect or side 
effect or its pharmacokinetics. The National Institute for Health and Clinical 
Excellence (NICE) guidelines emphasise the importance of individualizing care on 
the basis of patients’ social, cultural and religious needs (Hui et al., 2010). Thus, 
HCPs should take patients’ views, concerns and preference into consideration in 
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order to prevent any changes being made. The inclusion of patient perspectives on 
medicine use during Ramadan is an example of counselling conducted on the basis 
of concordance and adherence. If required, HCPs should make appropriate changes 
in their patient’s dosage regimen according to the prescription components such as 
the schedule of administration, the route of administration, and interaction with 
food intake. If changes are not required, HCPs need to carry out some proper pre-
Ramadan month education and counselling in order to teach patients about how 
they can manage their medication regimen effectively in Ramadan. The provision of 
information packs that include advice on Ramadan fasting is also recommended and 
this can be made available at diagnosis and also at annual review (Hui et al., 2010). 
HCPs should help patients to make their own decisions and to obtain optimal 
benefits from their medicines. 
6.2 Travelling abroad/ being away from home  
The potential for altered medication-taking behaviours 
Families from ethnic minority groups often travel abroad, usually back to their 
homeland to visit their relatives. A number of participants were asked about how 
they managed their regimen when they travelled abroad and during holiday 
periods. Some made no adjustments to their medication and they took enough 
supplies with them to cover the duration of the stay by informing their doctor prior 
to their journey: 
“Whenever I travel I take with me two months’ supply because I don’t 
stay longer than two months.” [Case 705-IN-M-64] 
“I get to the doctor to give me another month’s supply so I usually take 
two months’ supplies with me.” [Case 710-IN-M-58] 
Other patients stayed longer than they meant to and did not have enough supply to 
cover the entire period and thus had to go back as soon as possible to ask for 
further supply: 
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“Yes, sometimes I stay more than I meant to and I don’t take enough 
medicines with me so I try to go back home as soon as possible.” [Case 
506-PAK-F-78] 
“Yes, once last year... I was on holiday and I’d been a way for five weeks 
and I came back and I have not realised that I would not have enough 
supply when I go back and I was short of three pills and I went to doctor 
and explained, I said ‘Please don’t let me wait for three days’ and they 
gave it to me straight away.” [Case 706-IN-F-62]     
Other participants only took their remaining number of tablets, irrespective of the 
length of the time they were going a way for, and they relied on the healthcare 
provisions of that country. This could raise a concern that participants could end up 
receiving dual therapy from a healthcare professional in the UK as well as following 
the regimen of a practitioner abroad, resulting in potential adverse drug reactions, 
especially given that HCPs in the UK have no or little knowledge of the level of care 
and quality of provisions available in South Asian and Middle Eastern countries: 
“I just take whatever tablets I have left... I just take the same box to the 
doctor there and he [doctor] gives me the same medicine.” [Case 210-
AR-M-55] 
“No, actually last holiday I went to India, so I brought a lot of medicines 
with me... When I run out I take from these medicines.” [Case 704-IN-F-
30]  
The issue of travelling or being away from home was not only limited to running out 
of medicine or receiving dual therapy, it also involved changing the way patients’ 
took their medications either because they forgot their medication before travelling 
or because they deliberately decided to stop their medications in such situations 
and resumed their intake once they got back home where their normal routine was 
resumed. Some ethnic groups, for example, travel to take religious journeys, such as 
Muslims who undertake Hajj or Umrah in the holy city of Mecca in Saudi Arabia. For 
Muslims, the Hajj is the fifth and final pillar of Islam. It occurs in the month of Dhul 
Hijjah, which is the twelfth month of the Islamic lunar calendar. It is the journey 
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that every sane adult Muslim must undertake at least once in their lives if they can 
afford it and are physically able. Umrah is a pilgrimage to Mecca, performed by 
Muslims, which can be undertaken at any time of the year. Travelling to Mecca and 
being busy with performing religious duties and finding spiritual alternatives may 
mean changes in use of medicines among people of Muslim background. Zamzam 
water, for example, has a significant value for Muslims who believe it will relieve 
sickness. Zamzam water is located inside the Holy Mosque at about 20 meters east 
of the Ka’ba in Mecca. One participant stated that when he goes for Hajj or Umrah 
to Mecca, he does not take any medicines with him because he believed that 
drinking of Zamzam water will control his disease and relief his symptoms without 
the need to take any medicine: 
“Well, I don’t go for holiday... the only place I go to is Saudi Arabia... 
When I go there, I don’t take any... Well, I rely on Zamzam water... 
because I read about it so much... No, I just don’t check my BP... I don’t 
check my diabetes... I don’t take any medicines... I eat what I like 
because this is my faith... If I feel bad, I drink plenty of Zamzam water... 
You met different Pakistani, right? [Laughs]... There are millions like 
me... Yes but I don’t tell the doctor, I tell nobody, only you.” [Case 501-
PAK-M-68]  
The potential for conflicting advice 
The issue of travelling abroad also included receiving inappropriate advice or 
information from a HCP abroad that contradicted the advice the patient received 
from a HCP in the UK, which affected the way patients took their medicines: 
“My consultant abroad told me it would be better if I stop Metformin... 
You are a healthcare professional and you should know that taking too 
many medicines may kill you... These are chemicals... I feel really 
scared... My GP in the UK  at the beginning gave me 500 mg of 
Metformin but after the heart operation I had, he increased the dose to 
850 mg twice a day and when I asked him to decrease  the dose to 500 
mg, he refused and said ‘I can’t until your blood sugar goes down’... I 
should take one tab in the morning and one tab in the evening but to be 
honest after what I heard I am now taking one tab only... My doctor 
doesn’t know about this.” [Case 210-AR-M-55] 
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He added: 
“I should take one tab a day [Atorvastatin]... 40 mg a day... But I take 
half a tablet a day... You write 40 mg a day, I don’t want problems with 
my GP... The consultant told me that this cholesterol dose is too high 
and you don’t need such a high dose... It may affect your liver and 
kidneys... When I was prescribed this medicine, I didn’t use it at all but 
for the last three years, I have been using half tab a day because there 
was an Iraqi doctor here in the UK, he told me ‘It is wrong to stop taking 
your cholesterol tabs.’” [Case 210-AR-M-55] 
In general, many medicines are readily available without a prescription in SA and 
ME home lands. Certain medications, such as laxative, Aspirin and antibiotic and 
others are commonly brought from patients’ home lands, kept on hand in homes 
and used by patients in the UK. This may lead to medication misuse, duplication of 
therapy and potential adverse drug reactions. A few participants (n=13/79, 17%) 
also reported travelling or being away from home as a reason for non-compliance. 
Thus, healthcare providers should ask patients about medicine-taking and obtaining 
practices during travel period, etc., and about other possible factors that may 
influence compliance and patients’ safety. For example, people with chronic 
diseases (e.g., diabetes) who are going for Hajj should have enough time to discuss 
it with a HCP and to consider a management plan for their illness. Pre-Hajj 
education seminars should be conducted. Travellers should take sufficient supply of 
their usual medicines and also carry a written record, giving the generic names, in 
case further supplies are needed.     
6.3 The extent of family support/help with medicines reported by participants 
Almost half (39/80) of the interview participants revealed that they received help 
with medicines and 41 (51%) revealed that they did not receive help. Of the 39 
participants who received help, six (15%) lived alone and 33 (85%) lived with at least 
one family member. Of the 41 who did not receive help, seven (17%) lived alone 
and 35 (83%) lived with at least one family member. The help with medicines was 
mainly from a family member (n=23), a pharmacy (n=10), or from a family member 
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and a pharmacy (n=6). None of the participants in this study received help from a 
formal carer or a friend. Twenty-seven (69%) received regular (i.e., daily, weekly, 
fortnight or monthly) help with medicines and 12 (31%) received help only when 
required.  
The extent of support reported by participants was different, ranging from 
undertaking one activity to being responsible for all aspects of medicine 
management. Assistance with ordering or collecting a patient’s prescription from 
the surgery or medicines from the pharmacy – 28 (72%) – was undertaken generally 
by a family member when the patient was feeling unwell or was busy. Providing 
assistance with taking or using medicines – 10 (26%) – such as opening containers 
or pulling out tablets, was undertaken principally because patients had a physical 
problem or functional impairment such as rheumatoid arthritis. Support with 
administration was sometimes formulation dependent; for instance, the 
administration of Insulin injection, eye or ear drops and the application of creams to 
the feet or back. Other forms of support included reminding the patient to take 
medicines on time – 17 (44%), obtaining and reading information – 20 (51%), and 
giving advice on medicines – 14 (36%) especially for those with limited English or 
literacy skills.  
Participants identified with intentional non-compliance were more likely to report 
receiving help with medication (chi-square, P=0.007). Participants who were 
receiving help with medication (n=27/39, 69%) identified with 57 intentional non-
compliance problems whereas those who were not receiving help with medication 
(n=16/41, 39%) identified with 27 intentional non-compliance problems. The reason 
for non-compliance was identified sometimes to be due to inappropriate advice or 
information provided to patients by their families. Some participants, for instance, 
reported relatives encouraging them to stop taking their medicines because their 
families perceived the harm of the medication in general to exceed the perceived 
benefit. A participant from an Arabic culture revealed that her family weighed up 
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the risks and benefits of medication, which influenced the amount of 
encouragement they gave to her to comply with her medicines’ regimen: 
“My sister and my mother advised me to avoid taking too many 
medicines. Like for example Fesoterodine they told me not to take it. I 
told them ‘The doctor gave it to me’ but they said ‘Don’t take everything 
doctor prescribes, each medicine has a side effect.’” [Case 205-AR-F-57] 
A second participant revealed a similar story: 
“Sometimes my son – but I don’t always listen to his advice because I 
can’t stop taking some of my medicines... If I stop taking my sugar 
tablets for example I will be in trouble... If I stop taking my BP tablets, 
my pressure will go up... If I stop taking my inhalers, I will get in 
trouble... If I stop taking my painkillers I will be in pain... My son always 
tells me not to take too many medicines, it is dangerous for me.” [Case 
406-AR-M-67] 
A third participant declared that she did not take her cholesterol tablet for two 
months because of her son’s advice, as he thought that it was unnecessary and 
therefore should be stopped: 
“My son said ‘Stop tablets, no more tablets’. First time doctor [a name 
of a doctor] give me 5 gram cholesterol and then go over 10 mg. My son 
lives in Pakistan, the middle one, every time he says ‘No take tablet, no, 
stop’. I am going to Pakistan, ticket booked. I stopped tablets, 
everything stopped. This medicine. I have stopped for two months, my 
tablets stopped. One day 10 o’clock, 11 o’clock I feel pain there and 
there and there and I take tablet and my daughter-in-law, she called my 
son and said ‘Hurry, mother not OK’. My son came and my face was a 
little bit yellow and straight away I go hospital; doctor said your BP and 
cholesterol very, very high.” [Case 601-PAK-F-65]  
Strong evidence suggested that social support from family and friends can help 
patients take medicines correctly (Vaglio et al., 2004; Lee S-Y et al., 2006). However, 
researchers studying behaviours and outcome among older adults have 
hypothesised that social support might buffer the negative consequence of patients 
with limited literacy (Lee S-Y et al., 2006, Johnson et al., 2010). Johnson et al. 
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concluded that social support was mainly associated with better adherence for 
patients with adequate health literacy but not with limited health literacy (P<0.05) 
unless patients with limited literacy have a trusted person in their lives in whom 
they can confide. The reason for this was that limited-literacy patients were less 
likely to ask healthcare providers questions and infrequently brought relatives with 
them to the pharmacy. The findings of these studies were consistent with our study, 
which showed that participants who received help with medication from a family 
member were more likely to be identified with intentional non-compliance. One of 
the reasons for this might be because they listened to inappropriate advice or 
information.  
A further reason for poor compliance identified in the present study was medical 
advice and prescription medication borrowing and sharing. Sharing prescriptions 
and medical advice among family members is commonplace (Avery, 2008). If a 
patient observes that a medicine successfully cured her condition or relieved her 
symptoms, she may associate the medication with that perceived effect and then 
willingly share the medicine with others who seem to suffer from the same 
condition. Patients may also resist throwing away medication that is no longer 
needed or has expired, believing it still has value and may be needed later. A 
participant reported sharing medicine(s) with his mother when interruptions in his 
supply occurred as both of them were prescribed medications for diabetes and 
blood pressure. Another participant revealed taking a medicine from her husband 
to manage a new symptom (i.e., constipation). Senna was discontinued by the GP 
recently but because there was a hoarding of Senna at home, this facilitated the 
husband sharing the ‘spare’ Senna with his wife. A further example was a lady who 
came to the pharmacy to ask for a further supply of Omeprazole tablets. The 
pharmacist told her that she had already been provided with a supply of 
Omeprazole but she claimed that she had run out because she was sharing this 
medicine with her father who was already prescribed Ranitidine (dual therapy). A 
participant [Case 203-AR-M-63] reported that if he wanted information on 
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medicines, he would ask his friends who were experiencing the same condition and 
taking similar medicines. 
Not only sharing medical advice and information on the risk of a medicine but also 
sharing advice and information on the risk of a medical procedure was identified 
among participants. In close-knit communities, people know each other well and 
the suffering of one member of the community may be quickly communicated and 
actually felt by others. One first-hand story of success or failure may likely be much 
more powerful in shaping perceptions than scientific information or statistical data. 
This is what happened with some patients in this study who had heard many stories 
of relatives or friends suffering from previous negative experiences with medical 
care such as post-surgical complications, poor medical treatment or experiencing 
side effects of medicines. This resulted in lack of trust, confidence and faith in 
patients’ healthcare professionals and the healthcare system in the UK. Due to this, 
a few participants turned to the private sector which they perceived to provide 
them with better care, better services, and better medications, as in the following 
quote: 
“I was afraid because one of my friends who had the same operation 
done to her in the past told me not to do it because it will leave a hole in 
my uterus. So, I got scared. I was also scared that some of the medical 
students will do the operation so I don’t want to do it… My friends told 
me that they do lots of mistakes... I went a year ago to [a name of a 
hospital]. For a consultation with Dr. [a name of a doctor] to ask 
whether I need to have an operation done to my uterus and to ask 
whether she can do it herself privately rather than doing it free in one of 
the NHS hospitals. She said she stopped doing operations now… I 
personally think that private hospitals provide better service and you 
get what you paid for. They are not as same as free hospitals that make 
lots of mistakes. In free hospitals, you see one doctor in the clinic and 
another doctor in the operation or maybe a medical student. That’s 
what makes mistakes.” [Case 205-AR-F-57]  
A participant revealed that she refused to take an injection to relieve arthritis pain 
in her knees and neck because of the experience of another person who suffered 
negative reaction when having this injection in the knees and neck: 
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“No, no, no only when needed... He gave me injection here and in my 
shoulder... He also wants to give injection in my back and my legs but I 
am scared... Because my niece took the injection in her back and she 
became very stiff like ‘wood’... She was hurt and could not move... So, I 
got scared.” [Case 201-AR-F-62] 
Supporting patients by giving incorrect advice or information or by sharing 
medicines or medical information can reduce adherence, complicate incorrect use, 
cause drug-drug interaction, lead to misuse or addiction, reduce care seeking, 
increase patient perception of ineffective treatment and harm the patient.    
To summarise, almost half of the participants received help with their medicines, 
mainly from family members. This study identified the considerable role of patients’ 
families in their disease management in general and in medication-taking in 
particular. Families were frequently quoted as an important source of support. For 
the majority of participants, this help was sought on a regular basis and in regards 
almost all aspects of medicine management. The support was mainly sought by 
participants with poor educational level and language barrier. From 39 participants 
who received help with medicines, 26 (67%) reported having a low level of 
education (i.e., high school or below) and all of them stated that they had a first 
language other than English. The majority of participants who received help with 
medicines were younger – age≤65 (n=32/39, 82%) – and were on ≤8 medicines 
(n=22/38, 58%), which means that old age and polypharmacy may not be reasons 
for seeking help.  
The effect of family on patients’ compliance and safety should not be ignored 
especially for patients from cultures that prize family interrelationship such as SA 
and ME cultures. SA and ME groups value family intimacy and have the advantage 
of cohesive and supportive family networks. In these cultures it seems more usual 
for a patient’s whole family (brothers, sisters, siblings, mother, father and 
sometimes cousins) to be over involved in treatment decisions. In Britain a doctor 
would expect to talk to the patient and his or her spouse only whereas, among 
Asian and Middle Eastern families, a family conference may be called especially 
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when serious matters need discussion. In some cases, the family’s influence 
determines whether or not the patients take the prescribed medicines or undertake 
a medical procedure. Families may have different attitudes, beliefs and perspectives 
regarding the risks, benefits and the value of medications. They may also have 
limited access to, and problem with interpreting, information which may have a 
direct impact on the patient’s compliance, especially for close-knit communities 
who know each other well and where the belief or perception of one member of 
the community may be affected by others.  
Illustrating the extent of support provided to patients and the reasons for the 
assistance to the healthcare professionals in regards to how carers and participants 
divide tasks and share responsibilities can help in optimising medicine use, 
improving health outcomes and medicine management, and preventing any 
possible MRPs that may occur due to involving carers in patients’ care.  
The result suggests that a family-centred approach to education by healthcare 
providers may be beneficial. It is therefore always important to ask patients during 
consultation to declare whether they receive help or assistance with their 
medication and to describe the nature of support provided, how often and in which 
circumstances or on which occasions help is needed, and whether the support 
obtained from these sources is accurate to promote proper use of medications. 
How family members view a medication, and the interactional relations between 
patient and family, should also become a vital question for clinical practice. The 
strong familial and social relations held within these societies can also be utilised by 
healthcare providers through involving family members in discussions and decisions 
about a patient’s treatment plan and consequently it can help establish a positive 
collaboration with the family that will translate to improve compliance and prevent 
any negative effect that may occur when involving an uninformed carer in a 
patient’s care.  
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6.4 Problems with use of non-prescription medicines 
The use of non-prescription medicines including OTC and herbal medicines was 
widespread in south Asian and Middle Eastern participants. However, the use of 
non-prescription therapies varied from one participant to another. Generally, non-
prescription therapies were used mainly to treat a condition or a symptom that did 
not require doctor supervision (i.e., minor ailments) and which was proven to be 
common, reasonably well-tolerated and safe like common cold and flu, cough, 
indigestion, pain, headache, diarrhoea, constipation and allergy. Participants also 
used non-prescription medicines to promote strength, enhance health and 
strengthen immunity. Others used non-prescription medicines as a second-line 
treatment rather than an alternative to a medicine for the treatment of major 
diseases such as diabetes and arthritis. Having competing beliefs in effectiveness of 
herbal remedies was evident with few participants, as illustrated in the following 
quotes: 
“Yes… I don’t know what they call it in English. ‘Mithi’ I don’t know... She 
might know [pharmacist]... You know mithi? I use mithi with garlic... For 
my arthritis... I got lots of pain… Once a day... My wife prepares it for me 
every morning… It relieved my pain quite effectively… Four years… Yeh, I 
have been using heat patches and ice patches for about ten years for my 
back pain and shoulder pain… Yes... All my wife does.” [Case 702-IN-M-
57] 
“I use Indian herb called Ajwain... What I do is I roast four or five pieces 
of Ajwain... Then I make it as a powder... I take quarter tea spoon of 
Ajwain and half a spoon of Jeera (i.e., Indian herbs) and mix them 
together. The, I mix this mixture with chopped garlic (one small piece) 
and cod liver oil (one tea spoon)... This is for one person... I chew it 
every day and after half an hour, I drink 2-3 glasses of warm water... It is 
very good for knee pain... I have been taking it for about three months.” 
[Case 615-IN-M-74]     
“I sometimes use Cinnamon along with my diabetes medications. No, 
only when I see my sugar level high... I take one spoon with milk at night 
or afternoon... I found it useful at lowering my blood glucose levels.” 
[Case 604-AR-F-52] 
Chapter 6 – Results (Contributory factors to MRPs that may be specific to SA and ME cultures) 
219 
 
Some participants were persuaded by their families or friends to use herbal 
remedies, although some of them did not have any idea about the ‘rational use’ of 
these medicines: 
“Yes... The thing is my wife buys them and makes some for me and 
herself in the evening... She takes in the evening five or six different 
things... Garlic tabs, Multivitamins, Cod Liver Oil and some tabs that are 
good for skin, hair and nails... I don’t want to take them but she gives 
me so I take... Because my wife asks me to take them [laughs]... Well, I 
suppose for good health.” [Case 107-OSA-M-57] 
“I do take garlic tabs... because they [people] said it keeps your 
cholesterol level low... I take also Omega 3 because I am vegetarian... 
Again, I’ve heard that Omega 3 is good for bones... Yes, garlic I take one 
tablet a day and Omega 3 I take twice a day.” [Case 603-IN-M-51] 
Others did not know that taking non-prescription medicine with their POMs can 
cause them harm such as ADR. One participant declared taking Aspirin as an OTC 
medicine concomitantly with Etoricoxib, which may result in an increased risk of 
gastrointestinal ulceration or disorder: 
“I take Aspirin 75 mg... No, no I buy it myself... This comes from 
experience and my friends’ advice ... One at night but not always say 
about five days a week... For about two years... I use it as a precaution 
to thin the blood.” [Case 203-AR-M-63] 
Those who used herbal remedies perceived that they are safe and have fewer or no 
adverse effects compared to Western medicines: 
“Some might say with herbal remedies, you might not get any benefit 
but you could never get harmed of it… It is completely safe.” [Case 107-
OSA-M-57] 
“When I get sick I try to treat myself with herbal remedies as much as 
possible, because these are natural things that can never cause harm. 
Unlike traditional medications, they are chemicals and they are full of 
adverse effects!” [Case 615-IN-M-74]     
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Unwillingness to take non-prescription medicines was expressed by a number of 
participants due to past negative experience, fear of any possible drug interactions, 
disfavour of increasing the number of tablets used, and doubts about the efficacy 
and safety of many complementary medicines and traditional remedies. 
In summary, SA and ME patients used non-prescription medicines mainly to treat 
minor ailments, to promote strength and enhance health. Only a few used them as 
a second-line treatment rather than an alternative to a medicine for the treatment 
of a major disease. Many patients in this study bought non-prescription medicines 
without consulting or informing a HCP and with encouragement from a family or a 
friend, which can be dangerous in some cases for sufferers of chronic diseases. 
Some non-POMs might affect the efficacy of prescription medicines in several ways 
and others might lead to toxicity. Not only might they result in MRPs and high rates 
of hospitalizations, but patients also might have an increased risk of mortality, 
depending on the type of remedies used (Dasgupta et al., 2006). Thus, pharmacists 
and HCPs need to question the use of alternative therapies when prescribing; 
awareness of these remedies and their potential problems and hazards needs to be 
raised amongst HCPs. Patients may end up receiving dual therapies from both 
Western remedies and traditional remedies, if both contain the same active drugs, 
which affects patients’ safety (Aslam et al., 2001).  
6.5 Problems with the source, delivery, type and timing of information, which 
may lead to lack of information and/or understanding about the use of 
medicines 
Twenty-two participants were identified with 24 problems associated with lack of 
information on illness or medicines. Participants in this study reported many 
problems with source, delivery, type and timing of information. 
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Problems with source of information 
Seventy-seven participants reported their source of information, of which 37 (48%) 
participants reported one source, and 40 (52%) reported more than one source. 
Figure 6-1 describes what patients reported as their sources of information. 
 
Figure 6-1: Sources reported by participants from which they obtained information about their 
medicines. 
Participants most frequently mentioned the GP (n=55), followed by pharmacists 
(n=31) and leaflets (n=27) as sources of information. The identification of the source 
was mainly driven by the language(s) that the patient and HCP can speak, followed 
by their views that a doctor is the only person who has acquired the knowledge and 
skills for providing information and solving any problem.  
Doctors 
Many patients from both ethnicities preferred to consult a doctor who speaks the 
language of their native country instead of English, and this was not dependent on 
English proficiency or literacy skills of patients. For example, a number of 
participants from both ethnicities with either limited or good English proficiency 
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identified a doctor who speaks the same language in particular to be their primary 
source of information. They explained that they can better describe their health 
problems to doctors who speak their own language and also better understand the 
information that was given to them especially given that most patients, even if they 
speak English, may not know medical terminology. Patients also expressed the 
belief that doctors from the same ethnicity shared the same language, social 
experiences and cultural beliefs, thus they were able to understand patients’ 
worries, concerns, problems, preferences and needs better: 
“When our regular doctor takes charge looking at our illness... I mean 
me and my wife... We are OK... That’s particular doctor is what we 
would like to see specifically... We know him long time ago… He is aware 
of our shapes, health and illness... He is also Indian and speaks the same 
language, which is very important to us.” [Case 613-IN-M-64] 
“He [GP] knows what you have and what medications you are on and 
what you need and also he is Pakistani and speaks the same language; 
that is the main thing.” [Case 504-PAK-M-81] 
The preference to consult a doctor who speaks the same language could be due to 
the fact that the majority of participants from both ethnicities were first-generation 
immigrants (77/80, 96%) and their first language was other than English (75/80, 
94%). Interestingly, the importance of consulting a doctor from the same ethnicity 
did not emerge for second-generation participants (n=3). This is possibly because 
the degree of integration and healthcare requirements varies between first- and 
second-generation immigrants (Macdonald, 2004). For example, a number of the 
first-generation participants in the present study had a restricted knowledge of the 
English language and a greater sense of isolation in terms of, for example, providing 
interpretation services, which made them prefer to see a doctor from the same 
ethnicity or, in a worst-case scenario, if patients could not access a doctor who 
speaks the same language they depended on their family or friend to act as 
interpreter, to provide them with information and sometimes to make decisions 
regarding their own care: 
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“My daughter orders and collects my medicines because I don’t speak 
English… She gives me information about my medicines… She [her 
daughter] asks the doctor usually and then she tells me what he says 
because I don’t speak English… She does everything for me.” [Case 201-
AR-F-62] 
“My son comes with me to the doctor because I don’t speak English… 
He helps me with everything because he is educated and he knows 
better than me... My doctor told my son and my son told me what each 
medicine is used for and I wrote on each box in Arabic.” [Case 209-AR-
M-49] 
Two participants, who were living alone, expressed dissatisfaction with the lack of 
interpretation resources provided by primary care health professionals, which 
hindered their ability to access information and to seek care especially given that 
they did not have a family member to act as interpreter: 
“I feel very annoyed because of the interpretation problem. This GP 
does not offer you a translator... They are very lazy when it comes to 
this. I complained my times to my doctor and I told him that I need 
interpreter and I can’t speak or understand English but he told me to 
bring a friend with me as interpreter but my friend is not always 
free...Sometimes I try for months to find someone to come with me as 
an interpreter.” [Case 402-AR-M-65]    
“I studied in another country so I don’t read or speak English. Even if I 
read, I don’t understand. What I understood is that they don’t like when 
a person doesn’t speak English. I don’t have any one to translate for me. 
Once I asked the consultant to have an interpreter to know how my 
situation was but he didn’t bring me one, which was annoying. The 
consultant told me that I have problem with my gallbladder; I thought 
that I have gallstones because I didn’t understand it in English.” [Case 
210-AR-M-55] 
The preference to consult a doctor from the same ethnicity was to the extent that 
some participants looked for and were willing to travel considerable distances to 
consult GPs who spoke their own language:  
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“My doctor is an Arabic person... He understands me and I understand 
him. Although my GP is a little bit far, I don’t want to change it.” [Case 
403-AR-F-60] 
Others were willing to wait for a long time to make an appointment or to see a 
doctor in the GP surgery who speaks the same language: 
“We [participant and his wife] go to this particular doctor but we 
sometimes find it difficult to make an appointment with this doctor and 
it takes longer than necessary sometimes to get an appointment, 
possibly 10 days. He is also Indian and speaks the same language which 
is very important for us.” [Case 613-IN-M-64] 
Many participants even revealed disappointment with the time spent during 
consultation with their doctor but they preferred to tolerate and adapt to this 
situation for the sake of seeing a doctor who speaks the same language: 
“The time I sped with him is not enough... Well, he doesn’t say that 
directly but from the way he behaves you can estimate that... He is 
Egyptian, that’s why I have to tolerate him... I can’t speak English.” [Case 
212-AR-M-80] 
“No, sometimes they don’t give you time and they said ‘You came today 
to discuss this thing only, if you want to discuss other thing you should 
book another appointment’ because every patient has to stay no longer 
than 10 minutes with their GP… I don’t mind as long as my doctor is an 
Arabic person.” [Case 202-AR-F-61] 
Despite the fact that many participants in the present study preferred to see a 
doctor from the same ethnicity, a few respondents who had a good level of English 
proficiency believed that the most important thing is to see a doctor who listens to 
and understands patients’ beliefs and concerns, and responds to their needs no 
matter of his/her ethnicity. The following quotes illustrated their beliefs: 
“Ten minutes only, no good… My regular GP is British... She doesn’t 
want me to talk too much... Sometimes if she is not there, I see a 
Chinese doctor... He is better than her... He listens and understands.” 
[Case 213-AR-F-60] 
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“I don’t care if I didn’t see my regular doctor, what I care about is to be 
understood and helped by the doctor I have appointment with.” [Case 
305-AR-F-32] 
When participants in the current study were unable to access or failed to receive 
sufficient information from doctor due to illiteracy, language barrier, unavailability 
of interpreter or for any other reason, some felt empowered and managed their 
own care and made active decisions without looking for information from other 
sources. For example, one participant reported that she had never been told that 
cholesterol tablets have to be taken for life as a secondary prevention of 
cardiovascular diseases and thus she actively decided to stop taking her medicine: 
“When I had high cholesterol, they gave me cholesterol tabs... When 
they checked my cholesterol after a few months, they told me that my 
cholesterol was back to normal... So I stopped the medicine for three 
months [laughs]... Nobody told me to stop or to carry on... The next 
blood test showed that my cholesterol was very high and the doctor 
asked me what did I do? [laughs]... I told him that I stopped the 
medicine... He told me to take it for life.” [Case 309-AR-F-44] 
The identification of the source of information was also dependent on patients’ 
views that doctor is the only person who has acquired the knowledge and skills for 
providing information and solving any problem. Patients from both ethnicities 
identified doctors as the preferred and the primary source to find trustworthy and 
reliable information on illness and medicines. Some of the responses demonstrated 
unquestioning trust in their doctors. Unquestioning trust is where patients agree 
with any decision the doctor makes with regards to the patients’ health or 
medication regimen. As well as seeking information mainly from doctors, 
participants (n=59, 76%) demonstrated that the first source of call would be their 
doctor if they experienced any problem with their medicines. Participants affirmed 
a strong dependence, confidence and trust in their GPs to provide accurate 
information, passively following instructions without further consideration: 
“[Laughs] Why would I read it [PIS]? There is no need... I agree with my 
doctor... He knows best.” [Case 612-IN-M-45] 
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“I go straight away to the doctor because he knows more about my 
medicines than anyone else.” [Case 701-IN-M-77] 
“I put my full trust in the doctor... If I am going to die in their hands, I 
don’t mind [laughs].” [Case 708-IN-M-65] 
“My doctor obviously would know better than me.” [Case 211-IN-M-59] 
“They [doctor and pharmacist] don’t give you too much information but 
they are the experts… So, just take it [Laughs].” [Case 211-IN-M-59] 
Despite their beliefs, the majority of patients who were identified as having lack of 
information or discussion revealed that their main source of information was GPs 
(15/22, 68%). Only five out of 22 (23%) regarded pharmacists as a source of 
information and three regarded PIL as a source of information. 10 out of 22 (46%) 
used more than one source of information. Despite using more than one source, 
almost half of the 22 identified with lack of information and discussion. This was 
possibly because the majority of them (7/10, 70%) reported family members or 
friends as a second source of information and this information may be incomplete, 
unbalanced and erroneous, as illustrated previously.  
Pharmacists 
Other than doctors, seven participants only regarded pharmacists as their primary 
source of information and 24 others reported pharmacists to be their second source 
of information after doctor. Participants who consulted pharmacists in general 
(31/78, 40%) had ambivalent views regarding pharmacists’ consultations. Many 
expressed negative viewpoints and reported that pharmacists were similar to 
doctors: they only provided the basic information regarding their medicines (e.g., 
how to take or use the medicine and therapeutic indication), whereas the more 
important and detailed information that patients needed and wanted to know (e.g., 
side effects that medicine might cause, how to cope with it, other medications that 
might interact with it, how long the medicine needs to be taken before it is 
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effective, consequences of missing dose, how effective is the medication in 
comparison to other medicines, new treatment coming onto market, how and 
when to stop their medication) were not provided unless patients asked:  
“Pharmacists know quite a bit on medicines like side effects and 
something like that, so if there is a clash between two medicines or an 
expected side effect, they should tell you from the beginning... That’s 
what I believe but they don’t do it.” [Case 709-IN-M-66] 
A second participant, who consulted a pharmacist for backup advice, reported that 
the pharmacist did not provide any help or assistance; rather, every time the 
pharmacist was approached for a problem he told the patient to consult his GP: 
“I talk to him but I talk to him friendly... Nothing to do with my 
medicines... I told you if any problem happened with my medicines, I 
would see my GP... My GP is better... I don’t want to put him 
[pharmacist] in trouble [laughs]... I talked to him so many times but he 
said ‘No, no, no it is better for you to see your GP’... So I see no point in 
talking to him.” [Case 406-AR-M-67] 
Participants who reported consulting a pharmacist revealed that this was partially 
because they could not consult a doctor who speaks the same language and thus 
they had to consult a pharmacist with whom they shared a language, as mentioned 
earlier, or because their doctors did not provide them with adequate information or 
time to ask questions, and thus patients valued any source of information to make 
informed decisions on how to manage their medicines effectively. Consulting 
pharmacists was not perceived as a substitute for receiving information from 
doctors but was seen as helpful.  
Participants who hold positive views on pharmacists’ consultation were more likely 
to be those who had their MUR conducted or were counselled and provided with 
information that was tailored to their needs and preferences when approaching 
pharmacists:   
“Once I asked them [pharmacists] about diabetic medications so a 
Lebanese pharmacist brought me to this room and told me information 
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which I wrote down in Arabic... My doctor speaks English so I take my 
son with me and he translates what the doctor says which I wrote down 
in Arabic.” [Case 209-AR-M-49] 
“Yes, he [pharmacist] always gives good advice about my medicines and 
my wife’s medicines like indication, contraindication, reaction with 
other tabs... This kind of specific information that the doctor would not 
give thoroughly... Like my wife, her doctor, the one we like to see most, 
is putting her on lots of changes and those changes are happening very 
quickly... Like they put her on new tabs and these tabs started giving her 
wheezing effect so I had to run to the GP to get some Ventolin and I had 
to run to here to have the Ventolin dispensed... Those contraindications 
between different tabs were not explained thoroughly by the GP... Since 
then I started asking the pharmacist about every changes me and my 
wife has.”  [Case 613-IN-M-64] 
In fact, pharmacists’ involvement or role in providing information seems to be little 
that performing their expected duties such as MUR was seen as an extraordinary 
service which was highly appreciated by many participants:  
“Yes, all... Before I was taking my medicines from a pharmacy in front of 
my GP surgery but for the last 2-3 years I’ve been coming to this 
pharmacy to collect my medicines... Because when I come to this 
pharmacy, there are some people the same as you, ask me about my 
medicines like whether this is the first time I take this medicine or 
whether I have side effects... They check and review my 
medicines...They give me advice and information more than any other 
pharmacy... That’s why I like to take my medicines from here more than 
any other pharmacy... Just to remind me and to give me more 
information which I might not know from my doctor.” [Case 205-AR-F-
57] 
“I wish that the pharmacist could speak to me more about my 
medicines, like last time I came to have two painkillers dispensed from 
here and the pharmacist told me not to take these two painkillers 
together because taking them together may harm me... So I was glad to 
know before using them.” [Case 213-AR-F-60] 
“The pharmacist here is my friend... Usually I ask him about my 
medicines and he gives me all the information I need... He is better than 
the GP [laughs].” [Case 107-OSA-M-57] 
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From the discussion with patients, it was evident that the majority of them (n= 
47/78, 60%) had never discussed any matters with their pharmacist. The reason for 
not consulting a pharmacist on issues regarding medicines was that some SA and 
ME patients hold views that pharmacists are only supplier of medication. To these 
participants, pharmacists are just people from whom patients collect their 
medicines, nothing more. They perceived pharmacists as not being responsible or 
capable of more than dispensing their medications and thus avoided 
communicating with them. These participants were convinced that it was the 
doctor’s duty to tell them everything they were supposed to know about their 
medications, especially given that doctors are the HCP who hold their medical 
records and prescribe medicines: 
“No... Never ever? No, I don’t talk to them [pharmacists]… I just take my 
medicines from here.” [Case 302-AR-M-83]  
“No, I don’t ask them [pharmacists] because I don’t think that’s the 
solution with the pharmacists so I contact the GP straight away... I just 
order and collect my medicines from here.” [Case 502-AR-F-65] 
In addition to the wider perception of pharmacists as just suppliers of medicines, 
which was held by both groups, the absence of a pharmacist or a staff-member 
assistant who speaks the same language as ME respondents distinguished the two 
groups. This was one of the reasons for not consulting a pharmacist among ME 
participants. Unavailability of a pharmacist or a staff member who speaks the same 
language as the patient may lead to lack of patient counselling and consequently 
poor patient satisfaction and adherence, especially given that much of the 
communication that takes place in the pharmacy is verbal. In this study there was 
one Arabic-speaking pharmacist among the staff and shifts despite the fact that 
four pharmacies out of seven were located in areas that are highly occupied by 
Arabic-speaking patients. One participant described her experience: 
“No, I take my regular prescriptions to a pharmacy in [a name of a 
street]. The pharmacist there is a wonderful lady. She is Lebanese... So, 
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you get the chance to ask her about your medicines in Arabic… This 
pharmacy does not have Arabic-speaking pharmacists… I come to this 
pharmacy [no. 3] only if I am in [a name of a street] to buy Panadol or 
some cosmetics.” [Case 301-AR-F-54] 
Another Arabic-speaking participant mentioned that she changed the pharmacy she 
used to collect her medicines to enable her to consult an Arabic-speaking 
pharmacist. She expressed satisfaction with the new pharmacy because the Arabic-
speaking pharmacist wrote instructions about medication use in Arabic on the 
medicine labels: 
“I have been coming to this pharmacy for a year because they have an 
Arabic pharmacist who translates and writes down everything in Arabic 
for us [participant and her husband]… I used to collect my medicines 
from [a name of a pharmacy] on the same road but they were all Indians 
and I could not ask to talk to them because I don’t speak English.” [Case 
403-AR-F-60] 
In all the seven pharmacies there was at least one Hindi-speaking pharmacist 
among the staff. Although there are several languages spoken among the SA 
population such as Urdu, Gujarati, Bengali, etc., Hindi is commonly understood by 
all the SA population, so accessing a pharmacist who speaks a similar language as 
the SA group was not an issue for SA patients in this study. However, it was claimed 
by an Indian pharmacist in one pharmacy that the unavailability of a Bengali-
speaking pharmacist in the pharmacy hindered the ability to conduct MURs for 
Bangladeshi patients.  
Pharmacists need to promote themselves more as an information source. This may 
be more successful if they make an effort to increase prescription medication 
counselling. This would confirm in patients’ minds that pharmacists have the 
knowledge to answer questions and that provision of prescription medicine 
information is a necessary part of their responsibilities (Thompson and Stewart, 
2001).  
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Patient information leaflet 
The third source of information was the patient information leaflet (PIL), which 
indicated that, despite the growth in use of audio, video, computer technology and 
the internet for providing information, the leaflet remained the most widely used 
method as a source information after doctors and pharmacists. However, the 
majority (53/78, 68%) did not like the idea of reading a PIL either because they 
found it to be to be long, difficult to understand, increased their anxiety and 
premature discontinuation of treatment, and contained complicated medical terms 
that were difficult to understand. Others revealed that their GPs and pharmacists 
provided them with necessary information and that there was no more necessary 
information the leaflet can add. The next excerpt illustrates problems described 
with PILs:  
“I got frightened sometimes when I read leaflet of some medicines 
especially their SEs... Lots of these medicines have got quite few SEs... 
Putting on weight was one of them and they also said you may have 
heart problem, kidney problem... Instead of curing these problems, you 
might get them [laughs].” [Case 107-OSA-M-57] 
“Not really because leaflet has some medical terms that are really 
complicated, difficult to understand and long to read.” [Case 202-AR-F-
61] 
“All the leaflets are the same. They all say dizzy, headache, vomiting. 
The reaction is all the same for all the tablets, they cover everything. It is 
no point really.” [Case 608-IN-F-50] 
Those who preferred to read the PIL revealed that the reason for this was to remind 
themselves of what had been communicated verbally by HCPs or because the PIL 
was the only source of information that can provide the patient with more detailed 
information about medicines that no HCPs provide, such as the recognition of 
adverse effects: 
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“I always read leaflet... I don’t use a medicine without reading the 
leaflet... I see SE because I use lots of medicines so I make sure they 
don’t interact... This kind of information, nobody tells you anything 
about it.” [Case 205-AR-F-57]  
“I always read the leaflet because I want to see what the SEs are... I just 
want to know if there is going to be any heart problems with the 
medications cos I suffer with anxiety and panic attacks so I try to stay 
away from medications that will trigger anxiety or panic attack and if I 
am taking it, it needs to be able to be used with Diazepam and 
Citalopram that I take... As long as I know that the two are compatible, 
that is fine.” [Case 208-PAK-F-35] 
Problems with type of information 
When asked about the information received about their medicines: (63/76, 83%) 
participants revealed that the information received on medicines was enough 
whereas 13 (17%) participants revealed that they required more information, of 
which the majority wanted the information to be on their medicines (n=10) and 
some required information on illnesses (n=2) and one wanted information on both 
illnesses and medicines. The 13 participants who required more information used a 
large number of POMs (mean 6). The range (3-11) showed that participants who 
used a small number of medicines also identified that they were not having 
adequate information or discussion. The majority of patients who wanted 
comprehensive information about medicines were those who experienced some 
adverse drug reactions (8/13, 62%) compared to the ones who have never had an 
experience. 
Discussion with participants in this study revealed that basic information (e.g., the 
name, indication, dosing instruction) on medicines was enough but the more 
detailed information (e.g., interactions with food or other medicines, commonly 
encountered side effects and what to do if a side effect is experienced) which was 
essential to support appropriate and safe medicine-taking was lacking. Many 
acknowledged the importance of more detailed information that is tailored to their 
own situation and needs and preferences, and it could be divided into information 
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on illness and/or medicines. Where illnesses were concerned, some participants 
were interested in disease diagnoses or prognosis: 
“I think I need more but not about my medicines, about the 
inflammation I have in my body... It is upsetting me a lot... The doctors 
thought that the red spots are acne but then they discovered that I have 
infection in my blood.” [Case 711-AR-F-18]  
Where medicines were concerned, the curiosity was mainly about side effects of 
treatment, followed by long-term safety, drug interactions and contraindications, 
new medicines available on the market and information on treatment alternatives. 
There was also more complex interest in medicines to know the pharmacological 
action of a medicine in the body and to know whether there was a cure for the 
disease or whether patients really required medicines. Participants voiced that they 
preferred to be warned about the side effects before medicines were prescribed 
and to be informed and updated about the dangers of taking medicines for the long 
term whilst taking medicines. The type of information respondents wanted about 
their medicines is consistent with the findings of some, but not all, previously 
published studies. Most have shown information on side effects of medication to be 
a priority of patients (Thompson and Stewart, 2001, Samman and Chaar, 2013).  
The data of this study showed that the more consultations with a hospital 
consultant, the more likely that participants would be identified with intentional 
non-compliance (chi-square, P=0.043). The majority of participants for whom 45 
intentional non-compliance problems were identified reported being under the care 
of a consultant (n=22/33, 67%). Those who reported that they did not have 
outpatient consultations (n= 20/46, 44%) were identified with 39 intentional non-
compliance problems. The data suggested that the more patients consult a HCP, the 
more they are likely to get information about their disease and treatment, and the 
more information patients get may impact on the fact that they do not want to take 
their medicines either because the information from different HCPs was conflicting, 
which may create confusion, or because the information was scary and caused 
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unnecessary anxiety, particularly in relation to side effects. One participant, for 
example, expressed dissatisfaction due to conflicting advice or information 
provided by her GP and her hospital consultant about stopping her Warfarin 
treatment, which left the patient feeling more confused and distressed and with no 
clear understanding of what action to take: 
“In September, my regular doctor was travelling; I saw another doctor. 
She told me that she called my consultant in the hospital and he told her 
that I should stop Warfarin. She told me ‘You should stop Warfarin, you 
have been taking it more than enough’. I took an appointment with 
another doctor just to double check whether I should stop it. He said ‘I 
can’t decide, I am not your doctor’. I told him to refer me to hospital for 
a scan and blood test just to check that there were no clots but he said ‘I 
can’t, I am not your doctor’. I stopped taking it for 20 days and when I 
was crossing the road, I fainted on the street. When I went to hospital, 
they said ‘Who told you to stop it? You shouldn’t have done that, how 
did you live 20 days without it?’ So, I was frustrated – what if something 
bad happened to me!” [Case 207-AR-F-40] 
Another participant who was under the care of a hospital consultant stated that the 
best way to become better informed is to look for information from a variety of 
sources and not to depend only on HCPs, who give you contradictory advice or 
information and make you more confused:  
“I think they [HCPs] give you enough for you to go and research stuff for 
yourself... Because one doctor will tell you one thing and another doctor 
will tell you another thing, which makes you more confused... You get 
the name... Then you can research websites, go to forums, talk to other 
people... This is what I do myself... Sometimes one doctor tells you that 
you need to take this tab because it is really beneficial for you and then 
another doctor will say ‘No, I don’t think you should take it because you 
are asthmatic.’” [Case 208-PAK-F-35] 
A third participant expressed the same concern that she was getting inconsistent 
advice from different HCPs: 
“I take information mainly from the rheumatology department in the 
hospital [a name of a hospital]... There is professor (a name of a person) 
and 4-5 other people with her... This professor is hard to see all the 
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times and the others I don’t trust... Because everyone says something 
different than the other so I don’t get any benefit from seeing them.” 
[Case 204-AR-F-45] 
A further participant reported that he received alarming information from his 
hospital consultant abroad about the side effects of taking Metformin and 
Atorvastatin which affected the way he took these two tablets:  
‘In [the name of the European Country], my consultant told me it would 
be better, if I stop Metformin... You are a healthcare professional and 
you should know that taking too many medicines may kill you... These 
are chemicals... I feel really scared... My GP in the UK  at the beginning 
gave me 500 mg of Metformin but after the heart operation I had, he 
increased the dose to 850 mg twice a day and when I asked him to 
decrease  the dose to 500 mg, he refused and said “I can’t until your 
blood sugar goes down”... I should take one tab in the morning and one 
tab in the evening but to be honest after what I heard I am now taking 
one tab only... My doctor doesn’t know about this.’ [Case 210-AR-M-55] 
He added: 
“I should take one tab a day [Atorvastatin]... 40 mg a day... But I take 
half a tablet a day... You write 40 mg a day, I don’t want problems with 
my GP... The consultant in the European country I told you about told 
me that this cholesterol dose is too high and you don’t need such a high 
dose... It may affect your liver and kidneys... When I was prescribed this 
medicine, I didn’t use it at all but for the last three years, I have been 
using half tab a day because there was an Iraqi doctor here in the UK, he 
told me ‘It is wrong to stop taking your cholesterol tabs.’” [Case 210-AR-
M-55] 
This result should be interpreted with caution because no figures were found to 
show the rate and/or content of counselling given by hospital consultants. Thus, 
how consultants interface with their patients and what type of information they 
provide has to be tested in future studies. This finding is inconsistent with other 
findings that showed that the more information that is given, the better is 
adherence (Maidment et al., 2002). It is well known that providing patients with 
information about prescribed medicines is essential to understand the benefit and 
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risks of medication and to facilitate their appropriate use (Horne, 2001). However, 
providing basic information such as how and why to take medicine does not 
guarantee the appropriate use of medication; rather the information should be 
tailored to meet the needs of the individuals (Peveler et al., 1999). People 
prescribed the same medicines may require different levels of information. For 
example, in this study some participants reacted by becoming actively involved with 
their treatment and seeking detailed information about aspects such as possible 
side effect of their medicine and how to cope with it. Others, in contrast, responded 
with more ‘avoidant’ coping strategies, for example, by thinking about their illness 
and medicines as little as possible or wanting others to ‘take charge’, and may find 
additional information unhelpful or even distressing. Thus, the quality of the 
information is more important than the quantity. The quality of information refers 
to the extent to which individuals perceive that information has met their needs 
and that they are satisfied with the information provided (Horne et al., 2001). 
Problems with timing and delivery of information 
Besides the content and type of information, also the timing and moment of 
providing information was seen as a barrier for meeting patients’ health and 
medicine needs. There were inconsistent views among participants regarding the 
appropriate time for providing information. Many participants reported that it was 
enough to provide verbal information on medicines at the time of diagnosis or first 
prescription whereas others wished the information to be repeated and updated 
regularly during routine consultations. Those who reported that the information 
should be given only on prescription of new medicines revealed that they knew the 
necessary information about their regular medicines as they had been taking them 
for several years. However, (11/63, 18%) participants who did not want more 
information on their medicines identified with lack of information.  
Participants who revealed that they wanted more information complained that 
information was provided only the first time a prescription medication was given or 
upon request: 
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“Usually yes when it is something new but with the ones that I have 
been taking on regular basis no.” [Case 503-IRN-f-63] 
“I think I need a bit more... Both medicines and heath... He [doctor] 
does but I need to ask to be given information.” [Case 105-TRK-F-33] 
Their preference for receiving information on a regular basis was explained as some 
participants described how their information desires may change depending on 
their experiences and needs. A participant said: 
“I would like to have regular blood tests and to be given up to date 
information to see what methotrexate is doing to my body because it is 
nice to know that you take a drug that does not destroy other parts of 
your body.” [Case 607-IN-F-62] 
A further reason was because of difficulties remembering verbal information. This 
was not purely because of older age since the majority of participants (12/13, 92%) 
who expressed their desire to have more information and their willingness for 
information to be updated and repeated were ≤65 years old. One younger 
participant, for example, reported her need for information to be repeated and 
updated: 
“I think I need a bit more. I don’t mind to be reminded or to be given 
new information… Both on medicines and health.” [Case 105-TRK-F-33] 
Forgetting information was mainly because of mode and delivery of information 
(e.g., providing spoken information rather than written instructions). It was 
identified that the way the information was delivered to many patients by HCPs was 
not tailored to their preferences and needs. Many patients indicated that the only 
medicine information they received was in the form of verbal dosing instructions 
which can be easily forgotten for some participants. In addition, patients had never 
been told about alternate forms of information and had never been given any 
written medicine information except the patient information leaflet (PIL). Even the 
PIL was not given to all patients. Two participants [case 206-AR-M-66] and [case 
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604-AR-F-52] reported that they had appealed to a technician pharmacist who 
refused to supply one of their medicines with a PIL. The technician claimed that in 
[(case 206-AR-M-66), the medicine was regular and thus there was no need to 
supply the patient with a PIL but in (case 604-AR-F-52)] the medicine was new and 
prescribed for the first time.  
Written instructions presented difficulties to some patients with low education or 
literacy and non-native speakers. It was identified that the majority of participants 
(10/13, 77%) who wanted more updated and repeated information had no 
university education and none of them had English as their first language. Doctors 
routinely take for granted patients’ ability to read and understand all types of 
health-related materials. In reality, many patients have difficulty communicating 
with their healthcare professionals and following up self-care instructions due to 
poor understanding of basic health vocabulary, limited background health, limited 
education and limited native-language skills. One participant reported that her 
illiterate mother [case 607-IN-F-75] did not receive information she needed in a 
useful format and thus did not have the necessary skills to take, analyse or use the 
information she was given to make the appropriate decision: 
“My mother [case 607-IN-F-75] complies very badly... She does it all the 
time with all her medicines… I tell her the information the doctor told 
me but she can’t understand the information given to her, she gets 
confused... She is illiterate and she can’t speak or read English. The 
doctor gives us only verbal information nothing more.” [Case 608-IN-F-
60]    
Those who had limited language or literacy skills reported relying on their family 
members to obtain information from GP surgery or pharmacy and interpreting 
English verbal or written information about medicines. They reported their 
disappointment with the amount of information available in their native language. 
A participant revealed that she would welcome leaflets in her own native language. 
This participant had to rely on her busy husband all the time to translate the 
information obtained from the patient information leaflet, which made her 
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husband frustrated and made her modify the way she took her medicines rather 
than asking her husband for further translation:      
“I get information from my husband because I can’t speak or read 
English so he reads the package insert and explains the information for 
me... I wish they could provide leaflets in Arabic so I can read myself 
without asking the help from my husband because he gets upset 
sometimes and says ‘Just take it’ [laughs]... I make some changes, for 
example, I try not to take my medicines if I don’t need.” [Case 313-AR-F-
44] 
In summary, in the current study there was a great demand or reliance on HCPs 
who speak the same language as the patient for information. There was also limited 
access to verbal and written information provided according to patients’ language 
skills and literacy levels. In addition, there was a desire for information to be 
repeated and updated during regular consultations. Thus, HCPs have responsibility 
and a duty of care to provide high-quality, tailored information (verbal and/or 
written) to patients to ensure their safe use of medicines. 
6.6 Perceptions of healthcare professionals and difficulties related to access and 
organisation of the healthcare system 
Difficulty seeing a practitioner from the same gender 
Seeing a male doctor was regarded by a few participants as another issue facing SA 
and ME female patients in considering their medicines and health needs and 
concerns. They felt uncomfortable talking to or being examined by a male 
practitioner:  
“I have problem with seeing my regular doctor... They change doctors; 
sometimes I see a male doctor and sometimes a female doctor... I don’t 
like seeing a male doctor; I feel more comfortable talking to a female 
doctor.” [Case 308-AR-F-55] 
“It is quite uncomfortable because it is not like a lady... I can talk to him 
but I can’t let him touch me for examination; I just don’t uncover.” [Case 
506-PAK-F-78]   
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Lack of emergency GP or nurse home visits 
Lack of emergency GP or nurse home visits was also mentioned as a barrier by one 
SA patient in having her medicines and health needs and concerns met. One 
participant, who was physically incapable of coming to the surgery and was 
transported by his full-time worker daughter to the surgery, complained that his GP 
in Brent did not offer home visits service, unlike his previous surgery in Barnet. His 
daughter justified that the reason behind this was due to living in an area with a 
high level of deprivation and full of ethnic minorities, unlike Barnet which is full of 
White British and is less deprived. She suggested that the GP surgery should provide 
special services for the elderly who need special care and attention, such as offering 
home visits to those who are unable to go to the GP surgery due to issues with 
mobility and general physical health. The following quote from the daughter 
illustrates the problem: 
“I do have difficulties with them because they are old people and I find 
that they [GP surgery] don’t make the effort to make my life easier for 
me, so for example I went to the GP surgery on the foot for my dad... 
The GP said ‘Come tomorrow morning to see the nurse’... What for? He 
just needs to pick up the phone and say to the nurse ‘I need you to go to 
[the patient’s address]; I’ve got a gentleman who is diabetic, unable to 
walk and needs to be seen’... So now I am going to take another day off 
just to see the stupid nurse... They make my life very difficult here in 
Brent but in Barnet [where they come from] it is more... It is a white 
area so the doctor there Mr. [a name of a doctor] came down many 
times to our house to see my father... So it is different.” [Case 607-IN-F-
75] 
Problems related to consultation times and relationship with doctor 
Many participants perceived that the discussion with the HCPs regarding the 
progress of their illnesses and reviewing of their medicines was inadequate. They 
found that the consultation time with the GP was rushed and they were not always 
listened to. This was voiced as a barrier for them to raise issues and concerns about 
their illness and medicines with their doctors, as illustrated in the following quote:  
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“No, they are just so busy. They don’t listen; just get you out in 10 mins. 
I’ve been told in that practice that my 10 mins are up and she [doctor] 
spent five mins looking at my computer record to find out who I am and 
then, just when I was about to tell my problem, she said ‘Your 10 mins 
are up, sorry; make another appointment’. So, I had left the practice in 
the past without actually saying what my problems were… I go only if I 
got a problem but nobody asks me how I am getting on... I think they 
are very busy and they don’t actually listen to you. They [doctors] are in 
and out.” [Case 608-IN-F-50] 
Some participants revealed that they could not ask questions or discuss more than 
one problem each visit because their doctors were very busy and had no time to 
spend with their patients: 
“No, they don’t give you time and they said ‘You came today to discuss 
this thing only, if you want to discuss another thing you should book 
another appointment because every patient has to stay no longer than 
10 minutes with his/her GP.’” [Case 202-AR-F-61] 
A participant illustrated that her GP surgery did not have enough doctors to do a 
proper monitoring or review for patients: 
“They [GP surgery] can’t employ more doctors or spend more time with 
the patients... This starts hurting us... There are only one or two doctors 
in my GP surgery... sometimes emergency or locum doctors who hardly 
know you... So those changes and stuff affect us.” [Case 613-IN-M-64] 
The findings from this study showed that patients who reported having inadequate 
time with their GPs accessed care more (hospital admission 6/11 [55%]; A&E 
consultations 8/11 [73%], emergency GP consultations 7/11 [64%]), had poor 
adherence (5/11 [46%]) ADRs and DIs (6/11 [55%]), and lack of information (8/11 
[73%]). More time means that there is time to listen to the patient, to arrive at a 
better understanding of the patient’s concerns and come to a more accurate and 
thorough diagnosis, to focus more on the patient and on the disease, and to have 
more time to work together to arrive at an acceptable treatment plan which may 
improve health outcomes. In contrary, not considering patients’ perspectives, 
wants, needs and preferences within the consultations and not involving them in 
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decisions about their treatment plan increased patients’ dissatisfaction and anxiety 
and influenced their adherence. One participant felt she was not taken seriously or 
treated as an individual. She felt that her GP held a stereotypical view of people 
who attempt suicide as crazy, which influenced her medicine-taking behaviour and 
interaction with her GP: 
“My only problem is with my regular GP... He doesn’t listen to me, he 
doesn’t make eye contact, he doesn’t do anything, neither a check nor a 
test... I have shoulder pain for more than a year and he did not do 
anything about it... There is a total ignorance on his behalf... No 
attention is given to me at all... The problem with my doctor is that he 
thinks that I am mentally affected and crazy... He doesn’t listen to me 
and this is what increases my anxiety and depression and when I go 
back home I take three tabs rather than one because I am so stressed 
from visiting.” [Case 507-AR-F-39] 
Another participant viewed his doctor as insensitive, inconsiderate, unsympathetic 
and disinterested in his actual needs and beliefs in the following quote: 
“I had my shoulder dislocated in 2001 because of the epileptic attack... 
Then, I was transferred to hospital... I told the consultant that my 
shoulder was dislocated but he didn’t believe me and he did nothing 
about it, just an X-ray and the X-ray showed nothing abnormal. The 
consultant told me that I had only lack of calcium so there was nothing 
to form my bones and he prescribed calcium for me... Since then my 
shoulder is hurting me on and on and on, so my sister told me to go to 
that person [the alternative medicine practitioner] because our friends 
went to him and they recommended him to us. Now my shoulder is 
completely gone out... My GP told me that they will do an operation for 
me to look at my shoulder but I refused because they are the people 
who messed it up in the first place; they didn’t believe me... If they 
looked at it at that time [2001] and gave me something to hold it in one 
position, I wouldn’t be in this position. All the time they were telling me 
that you were either fighting or you injured yourself.” 
He added: 
“I had indigestion because of using the Tegretol... I spoke to my GP and 
he didn’t believe me, he said ‘Don’t worry, every medicine has a side 
effect’, but I started to feel unwell. Then, I spoke to the drug company 
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that makes the Tegretol, and they said to me ‘Don’t listen to what GP 
says, stop the medicine and speak to your consultant’. Then, I spoke to 
the consultant and I told him ‘Listen, if you will not change the Tegretol 
for me, I will stop taking it’. Then, the consultant spoke to the GP and 
told him to change the Tegretol to this one here [Keppra] and he also 
prescribed this one [Omeprazole].” [Case 702-IN-M-57] 
A number of participants felt neglected and detached due to the lack of attention 
given by their GP and described their fears of not being supervised more closely and 
not even being referred to a hospital specialist despite their request, which led to 
frustration and exasperation. When a participant wanted to be referred, this may 
indicate a lack of trust in the competence and resources of primary medical care 
provider or a strong belief in the competence and resources of the consultants. One 
participant described her experience: 
“I demanded to be referred to see a hospital consultant and even then I 
got referred to a GP who is still struggling... If they [GP and nurse] have 
not got the skills to assess the situation, may be they can refer you 
faster to a specialist especially for the diabetic people because they 
have new drugs, new medicines, new access, new research.” [Case 608-
IN-F-50] 
Bad relationship and lack of trust in healthcare providers led some respondents to 
be less likely to listen to the doctor’s advice and subsequently less likely to adhere 
to their medicines. One participant revealed: 
“My mother complies very badly [Case 607-IN-F-75]... Mostly with her 
Metformin and Insulin... She does it all the time... I think my mother 
does not believe that the doctors know what they are doing. For 
example, with diabetes the team do not understand that she has other 
problems. They just look at her sugar level and say ‘Your sugar level is 
up or down’. They don’t understand that when she has stomach pain 
she’s got maybe gallstone. Every time she is in pain. She misses meals. 
So, her sugar is not controlled. Sometimes is high and sometimes is low. 
Plus she tends to have bigger meals at lunchtime than evening time but 
the doctor prescribed her a bigger dose in the evening. So, there is a lot 
of miscommunication on behalf of the team and not understanding the 
lifestyle of the patient. Because in our countries, I mean the hot 
countries, as you know we tend to eat bigger meals in the afternoon 
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than in the evening because it is hot and we are tired, but in this country 
they eat more at nighttime.” [Case 608-IN-F-60] 
Another participant who had a bad relationship with his regular doctor requested to 
have another ‘good’ doctor who can supply him with more information and conduct 
more regular monitoring and review. This bad relationship influenced his medicine-
taking behaviour, communication with his GP and information seeking. For 
example, this participant could not recall for what reason he was taking Bisoprolol, 
Atorvastatin and Furosemide. He also reported that he stopped taking Atorvastatin 
because he did not think it was necessary and revealed that he was reducing the 
dose of Metformin once or twice a month from two tabs a day to one tab a day 
(‘sometimes’ on the Likert scale): 
“I don’t like to go to the GP... Because my regular GP is Pakistani... 
When I told him that I smoke and drink alcohol, he started showing me 
the other face... He doesn’t listen to me and I don’t like him... I don’t 
understand his explanations about my medicines and he doesn’t give 
me any advice... Tomorrow I have to go to the hospital for ECG because 
I have chest pain so I asked to be referred... He didn’t bother to refer me 
even though I told him that I have chest pain... I need more information 
and I need a good doctor who can regularly review and check my 
medicines.” [Case 214-AR-M-45] 
Good communication (i.e., a sympathetic doctor interested in patient’s worries and 
expectations and who discusses and reaches agreement on the problem and 
treatment), partnership, enough information, additional time and staffing – all 
these factors can facilitate patients' desire to become more involved, engaged and 
responsible for decision-making for their own care. Even for those who did not want 
to be involved in their own care, trusting their doctors and nurses to care for them 
and to make appropriate treatment decisions, being able to ask questions and 
understanding how decisions were made is important.  
Patients’ participation in their own care is limited by many factors such as rejection 
of new patient role, lack of health literacy and lack of medical knowledge, lack of 
confidence in own capacities and type of decision-making required; for instance, 
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most participants want to participate in major decision-making (e.g., whether to 
undergo coronary bypass) but are less interested about minor decisions (e.g., 
prescription for their illness) (Longtin et al., 2010). In addition, the desire to 
participate in decision-making and to be involved in the treatment process is 
inversely proportional to the patient’s disease severity in most of the conditions. 
Other obstacles that may also hinder patients’ participation include older age, being 
a male, from low socioeconomic class and from ethnic minority background. Finally, 
patients who use alternative medicines might be more involved in healthcare-
related decisions, although these findings lack consistency between studies (Longtin 
et al., 2010). Among healthcare workers, the acceptance and promotion of patient 
participation are influenced by desire to maintain control, lack of time and type of 
illness. Primary care physicians were more likely to encourage patient participation 
than specialists. Additionally, non-White physicians were less likely to encourage 
patient participation (Longtin et al., 2010). It can be seen that there are many 
obstacles hindering participation in patients’ own care which are applicable to our 
study. By highlighting these barriers, HCPs can estimate what level of involvement 
patients can have, and how to address these barriers in order to support patients 
and encourage them to participate in their own care.     
Key messages from Chapter 6 
• The HCPs should be aware that fasting may mean changes in medication-
taking behaviours, and thus HCPs should support Muslim patients by talking 
to them more openly and providing advice in relation to their religious 
needs. The issue of altered medication-taking behaviours in fasting should 
be included in MUR. 
• HCPs should be aware that travelling abroad back to patients’ home land or 
to take religious journeys may mean altered medication-taking behaviours, 
duplication of therapy and potential adverse drug reactions among SA and 
ME participants. Therefore, HCPs should ask patients about medicine-taking 
and obtaining practices during travel period, etc., and about other possible 
factors that may influence adherence and patients’ safety. The issue of 
altered medication-taking behaviours during travel should also be included 
in MUR. 
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• Patients with chronic diseases who are going for Hajj should have enough 
time to discuss it with a HCP and to consider a management plan for their 
illness. Pre-Hajj education seminars should be conducted.  
• HCPs should be aware that family support may influence medication-taking 
behaviours. The result suggests that a family-centred approach to education 
may be beneficial. It is also important to ask patients during consultation to 
declare whether they receive help or assistance with their medication and to 
describe the nature of support provided.  
• How family members view a medication, and the interactional relations 
between patient and family, should also become a vital question for clinical 
practice.  
• The strong familial and social relations held within these societies can also 
be utilised by healthcare providers through involving family members in 
discussions and decisions about the patient’s treatment plan and 
consequently it can help establish a positive collaboration with the family 
that will translate into improve compliance and prevent any negative effect 
that may occur when involving uninformed carers in patients’ care. 
• A few participants revealed using non-prescription medicines as a second-
line treatment rather than alternatives to a medicine for the treatment of a 
major disease. Therefore, pharmacists and HCPs need to question the use of 
non-prescription medicines when prescribing and during MUR; more 
awareness of these remedies and their potential problems and hazards need 
to be raised amongst HCPs. 
• The pharmacists need to promote themselves more as an information 
source. This may be more successful if they make an effort to increase 
prescription medication counselling. This would confirm in patients’ minds 
that pharmacists have the knowledge to answer questions and that 
provision of prescription medicine information is a necessary part of their 
responsibilities. 
• There is a great demand or reliance on HCPs who speak the same language 
as the patient for information. 
• There is limited access to verbal and written information provided according 
to language skills and literacy levels. 
• HCPs have responsibility and a duty of care to provide high-quality, tailored 
information (verbal and/or written) to patients to ensure their safe use of 
medicines. 
• There is a desire for information to be repeated and updated during regular 
consultations. 
• Some participants felt unable to communicate their needs and were 
concerned about the lack of supervision received. The main features of the 
poor supervision were lack of time given to patients by HCPs to review their 
medicines or monitor their illness, lack of doctors, bad relationship with 
doctor, and lack of trust and confidence in healthcare professionals and 
system.
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Chapter 7 Comparing South Asian and Middle Eastern participants 
Introduction 
This chapter describes the differences between SA and ME participants in terms of 
response rate, demographic details, medication-taking behaviour, and pharmacy 
and health service issues experienced by these two populations. Poor participation 
was detected among SA women. Looking at the demographic details, some 
differences were found between SA and ME groups in terms of age, religion, main 
language and year of coming to the UK. The principal distinctions in terms of 
medicine use and service access between the two groups were found in the 
following: the extent to which participants reported consulting a pharmacist, the 
absence of a pharmacist who speaks the same language among ME respondents, 
the use of multiple pharmacies, access to GPs and other services, the extent of 
family support/help with medicines, and medication-taking behaviour. 
Response rate and demographic details 
An equal number of SA (n=40) and ME (n=40) patients participated in the study. 
However, the response rate was lower in SAs (40/54; 74%) compared to MEs 
(40/46; 87%). From the data SA women were less likely to participate in this 
research study compared to SA men and ME men or women. Almost equal numbers 
of (22/40, 55%) men and (18/40, 45%) women of ME origin participated in the study 
while only nine (22%) women from SA background participated in this study 
compared to 31 (78%) men. In this study, 18 of those patients who were 
approached were unable to participate and the most common reason for non-
participation was language barrier (n=14) (i.e., inability to speak English). Of those 
ineligible as a result of language barrier, eight described themselves as of 
Bangladeshi origin and 11 of female gender. Those of the female gender who could 
not speak English were more likely to be older women who have been living in the 
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UK for a longer time than other immigrants but did not learn English as they 
thought they would not need to use it.  
A second reason for poor participation among SA women may be due to the fact 
that the researcher is not from the same ethnic origin, which might cause SA female 
participants reluctance in taking part in the study. However, this was not the case 
for SA male participants. Researchers Fenton and Sadiq-Sangster (1996) found that 
SA women were more open to discuss their concerns, problems and needs when 
talking to researchers whom they saw as ‘one of us’. A further possible explanation 
for poor participation could be due to the fact that SA females access services less 
(Chew-Graham et al., 2002) and thus they may not come out to get their medicines. 
In this study, a number of SA women were eligible to take part but they sent their 
husband to order and collect their medicines from the pharmacy on their behalf, 
which hindered their recruitment.   
Women in immigrant Asian families can be very isolated. Some are discouraged 
from travelling alone on public transport and, as their husbands often use the 
household’s car for work, there is no easy way for them to access care, health 
education or language classes (Macdonald, 2004). A study in East London, for 
example, reported that many Bengali women are still presenting with very 
advanced stages of breast cancer. Another potential obstacle to SA women’s 
participation could be lack of permission or approval from extended family 
members since some women in the SA group may have to take their family 
members’ opinions or views into consideration before making decisions (Ibrahim 
and Ohnishi, 1997). Based on the findings, it seems that researchers may find it 
difficult to access this particular group of women and it may also mean that SA 
women may have service access issues due to cultural barrier. Results of statistical 
analysis in the current study showed that female patients were more likely to be 
identified with problems attributed to access to services (chi-square, P=0.009).  
Looking at the demographic characteristics of participants, some differences were 
found between SA and ME groups in terms of age, religion, main language and year 
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of coming to the UK. The data indicated that ME participants tend to be younger 
than SA participants (t-test, P=0.000). The mean age of SA participants was 62.80 
(range 51-81 years) whereas ME individuals’ mean age was 52.58 (range 18-83 
years). The data also suggested that ME participants were less likely to use English 
as their first language (chi-square, P=0.022) compared to SAs. Based on the findings 
of this study, the data also showed that ME participants were more likely to be 
relatively newcomers (t-test, P=0.000) (mean 1993, 1970-2011) compared to SAs 
(mean 1974, 1956-2001). Muslim participants tended to be more in the ME group 
(40/40; 100%) (chi-square, P=0.000) than the SA group (14/40; 35%).  
Both groups tended to have low socio-economic status in which participants from 
both ethnicities were less likely to have a university degree or to work. Thirty 
percent (12/40) of SA and 38% (15/40) of ME participants had a university or above 
qualification. Seventeen percent (7/40) of SA and 10% (4/40) of ME participants 
were working.  
The extent to which participants reported consulting a pharmacist 
From the discussion with patients, many (n= 47/78, 60%) reported that they had 
never discussed any matters with their pharmacist regarding their medicines but, 
for a small number of participants (n=7), the pharmacist was regarded as their 
primary source of information, and it tended to be that those who reported the 
pharmacist as their primary source of information were Indians. From the data, it 
seems that MEs (31/40, 78%) were less likely to consult a pharmacist on aspects 
and issues regarding their medicines (chi-square test, P=0.002) compared to SA 
participants (16/40, 42%), in which language might be one of the reasons for poor 
consultation.  
The absence of a pharmacist who speaks the same language among ME 
respondents 
In addition to the wider perception of a pharmacist as just a supplier of medicines, 
which was held by both groups, the absence of a pharmacist or a staff member who 
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speaks the same language as ME respondents distinguished the two groups. This 
was one of the reasons for not consulting a pharmacist among ME participants. 
Unavailability of a pharmacist or a staff member who speaks the same language as 
the patient may lead to lack of patient counselling and consequently poor patient 
satisfaction and adherence, especially given that much of the communication that 
takes place in the pharmacy is verbal. In this study there was one Arabic-speaking 
pharmacist among the staff and shifts despite the fact that four pharmacies out of 
seven were located in areas that are highly occupied by Arabic-speaking patients. 
One participant described her experience: 
“No, I take my regular prescriptions to a pharmacy in [a name of a 
street]. The pharmacist there is a wonderful lady. She is Lebanese... So, 
you get the chance to ask her about your medicines in Arabic… This 
pharmacy does not have Arabic-speaking pharmacists… I come to this 
pharmacy (no. 3) only if I am in [a name of a street] to buy Panadol or 
some cosmetics.” [Case 301-AR-F-54] 
Another Arabic-speaking participant mentioned that she changed the pharmacy she 
used to collect her medicines to enable her to consult an Arabic-speaking 
pharmacist. She expressed satisfaction with the new pharmacy because the Arabic-
speaking pharmacist wrote instructions about medication use in Arabic on the 
medicine labels: 
“I have been coming to this pharmacy for a year because they have an 
Arabic pharmacist who translate and write down everything in Arabic 
for us [participant and her husband]… I used to collect my medicines 
from [a name of a pharmacy] on the same road but they were all Indians 
and I could not ask to talk to them because I don’t speak English.” [Case 
403-AR-F-60] 
In all the seven pharmacies there was at least one Hindi-speaking pharmacist 
among the staff. Although there are several languages spoken among the SA 
population such as Urdu, Gujarati, Bengali, etc., Hindi is commonly understood by 
all the SA population so accessing a pharmacist who speaks a similar language as 
the SA group was not an issue for SA patients in this study. However, it was claimed 
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by an Indian pharmacist in one pharmacy that the unavailability of a Bengali-
speaking pharmacist in the pharmacy hindered the ability to conduct MURs for 
Bangladeshi patients.  
The use of multiple pharmacies 
It seems that ME patients were more likely to report using more than one pharmacy 
(chi-square test, P=0.019) compared to SAs. Eleven (27%) ME participants reported 
using more than one pharmacy and only six (15%) SA patients reported using more 
than one pharmacy. The reason for this as reported by participants was more likely 
to be due to unavailability of a pharmacist or a staff member who speaks the same 
language. SAs, partly, were more likely to use the same pharmacy, which may make 
the pharmacy a good place to support wider needs. These points are important for 
policymakers in considering how to address needs of people newly arrived in the 
country.    
Access to GPs and other services 
From the data, it seems that patients of ME origin were more likely to voice GP 
service problems (chi-square, P=0.023). There were (21/40, 53%) participants from 
ME background identified with 48 GP service problems compared to (11/40, 28%) 
participants from SA origin identified with 18 GP service problems. For example, as 
a consequence of not being able to book appointments to see GPs, it seems that ME 
patients were more likely to go for emergency GP consultations (chi-square test, 
P=0.000) and A&E consultations (chi-square test, P=0.043) and in some cases to 
seek help from the private health sector compared to SAs. Eighteen out of 35 (51%) 
ME participants had one or more emergency consultation(s) whereas only five out 
of 38 (13%) of SA participants had one or more emergency consultation(s) in the 
previous five years. Twenty-two out of 37 (60%) ME participants had one or more 
A&E consultation(s) whereas only five out of 27 (18%) of SA participants had one or 
more A&E consultation(s) in the previous five years. The following quotes illustrate 
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the patients’ preferences to go for emergency GP consultations or A&E consultation 
rather than waiting for regular appointments:   
“The problem with my GP is that if you want an appointment, you have 
to wait for at least two weeks... If I waited for two weeks, I might be 
recovered before seeing my GP... So I had to ask for emergency 
appointments or to go to the A&E.” [Case 214-AR-M-45] 
“Yes, every day I go to the A&E... For the same reasons: my legs, pain in 
my stomach and dizziness… I am not happy at all with my GP surgery, 
appointment is difficult to get, waiting time is long, the time I spend 
with my doctor is not enough.” [Case 303-AR-F-53] 
“Yes, I always go to the A&E when I have asthma attacks. When I have 
an attack I can’t wait, I need to see a doctor on the same day.” [Case 
402-AR-M-65]  
A participant went to the private sector because it offered quicker access to 
specialised care: 
“The operation I had in my spinal cord and the consultant I see are all 
private... I have BUPA private insurance so I can go anywhere I like... If 
people who live here want to have the same operation done, they have 
to wait in a queue for at least six months to get an appointment for the 
operation... For me because of the private insurance I didn’t wait at all... 
All the process went quickly and smoothly.” [Case 314-AR-M-61] 
The extent of family support/help with medicines reported by participants 
According to the data, ME patients (29/40, 73%) reported receiving more help with 
medicines (chi-square test, P=0.000) compared to SAs (10/40, 25%). The most 
commonly reported extent of support in both groups was with ordering and 
collecting prescription medicines followed by obtaining and reading information as 
well as giving advice on medicines. Six out of 10 SA participants reported receiving 
help from a family member with obtaining and reading information as well as giving 
advice on medicines. All those who reported such support were illiterate in their 
own language and had no or limited English skills. In contrast, 14 out of 29 ME 
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participants reported receiving help from a family member with obtaining and 
reading information as well as giving advice on medicines. The majority (9/14) of 
them had no university education and one had no education at all and four had 
university or above qualification. All reported having limited English proficiency, 
except three participants who had university or above qualification. Based on these 
findings, it seems that SA and ME patients were more likely to involve their families 
in obtaining and reading information as well as giving advice on medicines if 
patients were illiterate in their own language and had no formal education at all. 
The rest of the illiterate participants from both ethnicities (9/16) reported that they 
get information and advice from a doctor who speaks their native language and 
thus there was no need for family involvement in providing advice and obtaining 
information.   
Medication-taking behaviour 
ME participants were more likely to choose not to take their medicines as advised 
compared to SAs (chi-square, P=0.000). There were (31/40, 78%) participants from 
ME background who were identified with a range of intentional non-compliance 
problems (n=65). There were (12/40, 30%) SA participants identified with 19 
intentional non-compliance problems. Based on the findings, no obvious differences 
were found between SA and ME groups to explain the reasons why ME participants 
were more likely to choose not to take their medicines as advised compared to SAs. 
Key messages from Chapter 7 
• It is important to understand diversity among SA and ME groups. This 
chapter has shown that each ethnic group might have its own distinct 
characteristics, problems and needs. Therefore, care and treatment for all 
needs to be culturally sensitive and delivered according to the individual’s 
wishes. 
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Chapter 8 The adaptations made to the original MRPs questionnaire 
and coding frame for the use of SA and ME groups 
Introduction 
This chapter provides a brief overview of the original MRPs questionnaire 
constructed and validated by Gordon (Gordon et al., 2005); more detailed 
information on the tool can be found in Chapter 3. This chapter also illustrates our 
findings in relation to each part of the tool in order to identify what additional 
issues were discovered among SA and ME groups which would not be captured by 
the original MRPs questionnaire. The purpose of this was to make 
recommendations for the tool (section 8.1) to be valuable for use in these 
populations and to offer recommendations for the coding frame (section 8.2). 
8.1 Description of Gordon’s MRPs questionnaire and recommendations that 
should be made to the original questionnaire for the use of SA and ME groups 
Gordon’s tool was designed to identify patients who are experiencing MRPs. A 
literature review was undertaken to identify the range of problems associated with 
using medicines and to develop the MRPs tool. A broad definition of MRPs, “any 
problem experienced by a patient that may impact on their ability to manage or 
take their medicines effectively” (Gordon et al., 2005), was employed by Gordon to 
enable her to detect a wide range of problems. The screening tool was designed as 
a semi-structured interview, which consists of closed and open questions with 
probes. It identifies whether from a patient’s perspective or beliefs they have some 
MRPs (Gordon et al., 2005).  
The tool provides a structured framework in which quantitative data can be 
obtained such as patients’ characteristics, number of hospital admissions, 
consultations as an outpatient or with a private healthcare professional. It seeks to 
explore factors and events leading to MRPs from the patient’s perspective. It was 
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validated among patients prescribed a cardiovascular medicine, who were aged 
over 18 and were from White or Black ethnic origin in areas of London. Gordon 
validated the tool by collecting additional qualitative data from the home interviews 
to see if the tool identified patients with MRPs. The MRPs screening tool is divided 
into five sections which involve questions regarding patients’ medicines, the 
illnesses for which they take their medicines, medications use, service access and 
background information on participants (Gordon et al., 2005):  
Section 1 (About your medicines) 
Participants were asked in this section to recall the names, doses, dosing 
frequencies and purposes for which they used their prescribed and non-prescribed 
medicines. The question aimed to obtain information on what patients were taking 
to gain insight into patients’ knowledge of their medicines and to provide a basis for 
subsequent questions. This was cross-checked with pharmacy records. This also 
provided data to indicate any potential duplication of medicines, drug-drug 
interaction, under-dose and over-dose. The following problems emerged at this 
stage: lack of information on medicines, interactions, non-compliance, and 
problems with non-prescription medicines. The question asked: 
Q3. Can you tell me the names of the prescription medicines you take or use? 
If you are unable to tell me any names, please describe them to me. About 
each medicine: How many/much and how often do you take/use each day? 
Do you know what you are taking/using this medicine for? For how long 
have you been taking/using this medicine? What other medicines do you 
take or use? Abut each medicine: What is the name of the medicine? What 
are you using this medicine for? How often do you use this medicine? 
 
Participants were afterwards asked to report if they received help with their 
medicines to describe the nature of the help received. The question asked: 
Q4. Does anyone help you with your medicines?  Who is this person? How 
does this person help you? How often does this person help you? 
 
In Gordon et al.’s study (2005) only 19% (49/259) reported receiving help with 
medicines, mainly from family members. The nature of help was limited to 
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collecting prescriptions and dispensed medicines, reminding participants to take 
medicines and administering medicines to participants. However, our findings 
showed that almost half (49%) of interview participants reported that they received 
help with medicines. The help received was mainly from a family member and was 
regular (i.e., daily, weekly, fortnight or monthly). The extent of support revealed by 
participants was different, ranging from undertaking one activity to being 
responsible for all aspects of medicine management.  
Altered medication-taking behaviour was voiced by some participants in the 
present study as a consequence of family support. For instance, some participants 
received advice from their relatives to stop taking their medicines because their 
families perceived the harm of the medication in general to exceed the perceived 
benefit. Prescription medication borrowing and sharing among family members was 
also described. For example, an Indian woman came to the pharmacy to ask for a 
further supply of Omeprazole tablets. The pharmacist told her that she had already 
been provided with a supply of Omeprazole but she claimed that she had run out 
because she was sharing this medicine with her father who was already prescribed 
Ranitidine (dual therapy).  
Our findings indicated that family support is a clearly important issue in SA and ME 
populations. These families tend to play a considerable role in all aspects of 
patients’ medicine management which sometimes affected patients’ medication-
taking behaviour and safety. Therefore, in order to identify different issues in SAs’ 
and MEs’ family support and to be sure to establish all relevant information, 
additional prompts could be listed under this question. Prompts could be as follows: 
collecting prescriptions from GP surgery or medicines from pharmacy, buying non-
prescription medicine, reminding you to take your medicines, opening containers or 
pulling out tablets, administration, understanding or reading information, obtaining 
information, advice on medicines, and other, please describe. These prompts will 
enable us to identify in what way these patients have been supported (i.e., type of 
support they receive, by whom and how often, what patients say about the help 
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they get and how helpful it is). This may be effective in showing how carers and 
participants divide tasks and share responsibilities. This may also help in optimising 
medicine use, improving health outcomes and medicine management, and 
preventing any possible MRPs that may occur due to involving carers in patients’ 
care. 
Section 2 (About yourself)  
In the original tool, this section includes questions on characteristics of participants 
(e.g., age, gender, country of birth, ethnic group, and whether or not they live 
alone). The questions asked: 
Q5. May I ask how old you are? 
Q6. Where is your country of birth? In which year did you come to the UK? 
Which ethnic group do you consider yourself to belong to? 
Q7. Do you live alone or with others? 
 
Additional patient characteristics such as main language, ability to speak English, 
year of arrival in the UK, religion, qualification and current employment status were 
collected in the present study to describe the population further. This may also 
enrich the data by including the experiences and views of participants from 
different characteristics. Another reason for gathering this additional information 
was because people of different characteristics have been found to differ in their 
beliefs about health and medicines, medicine-taking behaviour and service use. For 
example, language barrier was voiced to be an issue in accessing healthcare 
services, reading and obtaining information by many participants who reported 
having limited English proficiency. A further example is that some Muslim 
participants pointed out that while fasting they adapted their use of medicines in 
different ways. Therefore, it is recommended that additional patients’ 
characteristics which appear to be important to SA and ME groups should be 
gathered.  
It is also advised that in the participants’ characteristics section the question 
regarding country of birth should be changed to include only ‘the UK’ or ‘other’. 
Chapter 8 – Results (The adaptations made to the original MRPs questionnaire and coding frame for 
the use of SA and ME groups) 
258 
 
Ethnic origin question should be modified to involve only people from ‘South Asian’ 
or ‘Middle Eastern’ background. Research participants’ characteristic details should 
be moved from section 2 (at the beginning) in the original tool to a separate sheet 
in the adapted version and the details of participants should be taken at the end of 
the interview. This would allow the researcher to collect the most important 
information and data regarding medicine use and service access at the beginning of 
the interview for participants who may not complete the interview.  
Section 3 (About the illnesses for which you take your medicines) 
This section illustrates the number of hospital admissions including accident and 
emergency, and consultations as an outpatient or with private healthcare 
professionals in the past five years. The question asked: 
Q8 . About the illnesses for which you take you medicines,  
In the past 5 year have you: 
a. Been admitted to a hospital? Yes/No. 
b. Attended or been taken to A&E/casualty? Yes/No. 
c. Called a GP as an emergency outside surgery hours (i.e., evening or 
weekends)? Yes/No. 
d. Called a GP or made an appointment as an emergency during surgery 
hours (i.e., daytime)? Yes/No. 
If yes, please tell me: Which year and month? For what reason? More about 
this. 
Do you:  
e. Attend hospital as an outpatient? Yes/No. 
f. See any other person privately for your health? Yes/ No. 
If yes, please tell me: Who you see? For what reason? How often? The last 
time you attended. 
 
The majority of participants in Gordon et al.’s study (2005) reported having no 
hospital admissions (149/250, 60%) or A&E consultations (164/251, 65%) in the past 
five years whereas in our study the majority of participants reported having one or 
more hospital admission(s) (n=43/78, 55%) or one or more A&E consultation(s) 
(39/76, 51%) in the past five years. The high use of hospital and A&E services among 
SA and ME groups might show poor access to primary care and might indicate that 
they have problems in understanding how healthcare works and how to navigate 
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their way around the primary care system. This question highlights differences in 
service use between these groups. It may reflect perceived access to care, and 
therefore it may reflect people finding out more about their medicines. This 
question can be extended to gather further information about problems in access 
that may impact on medication-related problems.  
Section 4 (More about your medicine) 
This section measures self-reporting non-compliance with prescription medicines 
and demonstrates the nature and frequency of patients’ non-compliance. 
Information was collected in this section on participants’ perspectives of their 
medicine-taking behaviour.  
Q9. Some people do not always take their medicines according to the 
instructions, but adjust the dose according to what they think they need. Do 
you do this? Tell me more about this?  
People sometimes forget to take their medicines. Do you do this? Tell me 
more about this? 
What problems have you experienced with taking your medicines? 
What would you do if you had a problem with taking your medicines? 
 
Various reasons were given by SA and ME patients for non-compliance with 
medications. Some reasons were very similar to the ones identified in Gordon’s 
study and other studies but others were reported to be specific to SA and ME 
groups such as religious practices and beliefs, cultural and social issues, language 
and communication barriers, etc. These reasons that are important to SA and ME 
individuals may not be captured using Gordon’s original tool. They were only 
captured when specific prompts about cultural, social and religious beliefs were 
introduced into Gordon’s tool. Therefore, it is recommended that, after asking 
closed and open questions in the original tool regarding non-compliance, prompts 
should be given to patients to capture reasons that are important to SA and ME 
groups such as Ramadan, sharing or lending medicines, advice from family or 
friends, use of OTC or herbal remedies, travelling abroad back to their homeland or 
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to take religious journeys, others please specify. Patients should also be asked to 
report the medicine and how they had changed their prescribed regimen.  
By using this method, more reasons which were reported to be particular to SA and 
ME groups can be examined as to why patients adjusted their prescribed regimens. 
The open question can be asked at the beginning in order to allow respondents to 
say what is really on their minds without being influenced by suggestions from the 
researcher and after that prompts can be given to throw light on reasons for non-
compliance that are particular to these populations which may not be captured by 
open questions.  
Section 5 (About you GP surgery and pharmacy visits) 
This section gives details relating to contacts with, and consultations at, the 
pharmacy and surgery. Participants were asked about the frequency of their 
consultations at the GP surgery (with a GP or practice nurse). They were asked in 
this section to report how often they obtained their repeat prescriptions. Their 
purposes for consulting the pharmacist and a question on whether they have ever 
run out of supplies of medicines were also included. A final question in this section 
was about patients’ sources of information on medicines and illnesses. At the end 
of the questionnaire, participants were given the opportunity to add additional 
comment on medicine- or service-related issues that were not covered during the 
interview. The following problems emerged at this stage: lack of information or 
discussion, problems with repeat prescription, problems with interface, monitoring 
and review, and GP surgery and pharmacy service problems. The questions asked: 
About your GP surgery and pharmacy visits 
Q10. How often do you usually consult / see your GP about your illnesses and 
regular medicines?  
Do you usually consult / see any other person employed at the surgery about 
your illnesses and regular medicines? Yes/ No. If yes, please tell me: who you 
see? For what reason? How often? 
How well does this arrangement at your surgery suit you? 
When was the last time you consulted / saw your GP or anyone else 
employed at the surgery about your illnesses or regular medicines?   
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Q11. How do you usually get your prescriptions from your GP surgery? 
How often do you usually get prescriptions for your regular medicines? 
Q12. You ever delayed taking your prescription to the pharmacy, after your 
supply of medicines has run out? Yes/No. If yes, tell me more about this. 
Have you ever talked to your pharmacist/chemist about any matters? 
Yes/No. If yes, please tell me what matters. 
Q13. What do you think about the information you are given on your 
medicines?  
Do you have enough information or would you like more? Enough/More. If 
more, what suggestions do you have to improve this? 
Q14.  Are there any further comments about your medicines that you would 
like to add? 
Do you have any questions that you would like to ask me? 
 
Some participants in the present study tended to answer ‘it is OK’ to the question 
‘How well does this arrangement at your surgery suit you?’ but, when additional 
prompts were given, participants started to express their opinion and views 
regarding the difficulties in accessing care. The most commonly reported difficulties 
from SAs’ and MEs’ perspectives included making appointment, waiting time, length 
of consultation, seeing the same GP and relationship with the GP. Other reported 
difficulties were particular to SA and ME groups such as seeing a GP from the same 
gender, language barrier and absence of an interpreter. Therefore, it is highly 
advised that, after asking the open question ‘How well does this arrangement at 
your surgery suit you?’, additional prompts might be provided such as making an 
appointment, waiting time, seeing the same GP, seeing a GP of the same gender, 
length of consultation, language and interpretation, relationship with GP, other 
please describe.  
The advantage of the open question is to allow respondents to express their views 
fully concerning the question, and the advantage of providing prompts afterward is 
to invite respondents to enter their thoughts on a specific matter that they may not 
remember or may not consider as a potential issue. Providing additional prompts 
will also enable us to capture the problems that are likely to face ME and SA 
participants in particular in accessing healthcare services. Careful attention must be 
taken not to ask leading questions when prompting the question.  
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It is also recommended that two questions should be added to this section; these 
are:  
Q. How well does the service at your local pharmacy works for you?” 
Have you ever had an MUR?  
Yes/No. If yes, please tell me more about your experience? (Prompts: 
purpose of the MUR, perceptions on the benefit and usefulness of MUR, 
affected knowledge or use of medicines, likes and dislikes about MUR, how 
to improve the service) 
Q. Is there anything you think that your doctor, pharmacist or nurse could do 
more to help you better manage your medicines?”.  
 
The first question will elicit responses describing patients’ perceptions of 
pharmacists’ role and pharmacy services to suggest recommendations on how 
pharmacy services should be developed and what services need to be implemented 
in order to address the needs of these populations. Such responses can describe 
patients’ perspective of pharmacy services and the value that they derive from 
them and show how these services are being contextualised with patients’ life 
world. Questions about advance services such as medicines use review (MUR), 
which is available now in pharmacies, can be included. These questions might help 
in identifying problems and addressing different issues such as patients’ lack of 
knowledge and understanding, and inappropriate use of medicines. The revised tool 
could be used as an instrument in the MURs.  
The second question should be added in order to obtain recommendations from 
patients’ perspectives to support them in their use of medicines and access to 
services and to make them more involved in their own care. This is important to 
develop services which are better tailored to patients’ needs.     
8.2 Differences in the types of MRPs identified between the present study and 
Gordon et al.’s studies, and the recommendations for the coding frame 
This section (8.2) aims to describe systematic differences in the types of MRPs 
identified between the present study and Gordon et al.’s studies in order to develop 
a revised coding frame (Gordon et al., 2005; Gordon et al., 2007). In order to do this 
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the data from MRPs face-to-face semi-structured interviews and the pharmacies’ 
review were coded in accordance with Gordon’s coding frame. When a new 
problem, sub-code or sub-theme emerged from a participant’s discussion and was 
not included in Gordon’s coding frame, it was added to the most appropriate 
category or theme in Gordon’s coding frame. Any theme that did not fit a pattern in 
the coding frame was analysed separately. Gordon’s coding frame consisted of nine 
main broad themes plus a number of sub-themes under each main theme. The nine 
broad categories comprise: 
ADRs and DIs 
An ADR was defined as type A (side effect) or B (hypersensitivity). If a participant 
reported a reaction or a symptom that was actually or potentially related to a drug, 
this was considered as an ADR. A drug interaction was defined as a symptom or 
pharmacological response related to a combination of medicines (Gordon et al., 
2005). The original MRPs categorisation sheet has six sub-categories (sub-themes) 
under problems with ADRs and DIs, as illustrated below; in the present study no 
data were captured for problems related to ‘drug-disease interaction’, ‘drug-
laboratory test interaction’ and ‘drug-food interaction’ because the researcher 
could not access patient medical records in GPs’ surgeries in order to identify such 
problems. In terms of recommendations, access to the patients’ medical notes, full 
record of prescriptions, non-drug care and results from laboratory tests, which are 
only available at GP surgeries, is required in order for these problems to be 
identified.  
1 ADR and DIs 
Type A ADR – side effect known 
Type B ADR – hypersensitivity 
Drug-drug interaction 
Drug-disease interaction 
Drug-laboratory test interaction 
Drug-food interaction 
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Intentional non-compliance 
Intentional non-compliance was looking at patients actively making decisions about 
how to use their medicines. Gordon’s original MRPs categorisation sheet had 12 
sub-categories under the problems with intentional non-compliance category. All 
these sub-categories were coded under intentional non-compliance but some 
would not be considered as intentional non-compliance, such as ‘incorrect order of 
using inhaler’.  
From the original coding frame, no data were captured for problems related to 
‘mixing different preparations in the same container’, ‘use of expired medicines’, 
‘inappropriate storage of medicine’, ‘use of POMs discontinued by GP’, ‘duplication 
of POMs’, ‘unsure of correct medicine to take’, or ‘incorrect order of using inhaler’. 
This was because patients were not interviewed with their medicines present. Thus, 
it is recommended that patients should be interviewed with their medicines present 
in order for these problems to be identified. Interviewing patients in their homes, 
for example, can establish exactly what medicines the patients are actually taking, 
how they use their medicines and how they store their medicines.  
Four additional issues were identified in the present study under this category and 
subsequently were added as sub-categories. They were ‘problems with dosage 
form’, ‘taking daily doses all together at once when should be daily divided dose’, 
‘taking medicine at the wrong time’, ‘taking someone's else prescription 
medication’. The new sub-categories are highlighted in red below and written in an 
Italic style and it is advised that they are included in the revised coding frame. 
2 Intentional non-compliance 
Under-use of POMs 
Over-use of POMs 
Duplication of POMs 
Mixing different preparations in the same container 
Use of expired medicines 
Inappropriate storage of medicine 
Unsure of dosing 
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Stopped taking medicines 
Split dose when should be one dose 
Unsure of correct medicine to take 
Use of POMs discontinued by GP 
Incorrect order of using inhaler 
Problems with dosage form 
Taking daily doses all together at once when should be daily divided 
dose 
Taking medicine at the wrong time 
Taking someone's else prescription medication 
 
Cognitive, physical and sensory problems 
Cognitive, physical and sensory problems were defined as any personal difficulties 
that may have led to participants managing their medicines ineffectively, such as 
dexterity, visual, hearing and cognitive problems (Gordon et al., 2005). Gordon’s 
MRPs categorisation sheet has four sub-categories under the cognitive, physical and 
sensory problems category. One additional problem ‘Difficulty swallowing’, which 
was reported in the present study, was highlighted in red and added as a sub-
category to category number 3.  
3 Cognitive, physical and sensory problems 
Forgetting to take medicines 
Difficulty opening containers/packs 
Difficulty reading labels 
Difficulty hearing instructions 
Difficulty swallowing 
 
Problems with non-prescription medicines 
Problems with a non-prescription medicine were defined as any issues with non-
prescription medicines that are bought by the patient, such as OTC and 
homeopathic medicines (Gordon et al., 2005). Four sub-categories were under 
‘problems with non-prescription medicines’ category. From the categorisation 
sheet, no data were captured for problems related to ‘use of expired medicines’ 
because this study was not conducted in patients’ homes to see whether they used 
expired medicines or not. One additional problem was identified in this category 
and subsequently was added as a sub-category to category number 4. ‘Uncertainty 
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about the indication for the drug’ was included since a few participants used non-
prescription medicines without knowing their indications.  
4 Problems with non-prescription medicines 
Over-use 
Interaction with POMs 
Contra-indication 
Use of expired medicines 
Uncertainty about the indication for the drug 
 
Drug-prescribing problems 
Drug-prescribing problems were any problems identified by the researcher or 
reported by the participant relating to the prescribing of their drugs, for instance 
therapeutic duplication or prescribing of an inappropriate dose or medicine 
(Gordon et al., 2005). Gordon’s MRPs categorisation sheet has seven sub-categories 
under the drug-prescribing problems category. From the categorisation sheet, no 
data were captured for problems related to ‘No directions given for medicine’. This 
was identified as a problem in Gordon et al.’s study (2007) when no label or 
directions were found on the medicine. This was not possible to be assessed in this 
study because no home visits were made to see whether there were directions 
written on medicine or not.  
5 Drug-prescribing problems 
Drug missing from regime 
Therapeutic duplication 
Use of drug to treat adverse effect of another 
Inappropriate dose (too high or low) 
Drug should not be in the regime 
Inappropriate length of treatment 
No directions given for medicine 
 
Interface, monitoring and review problems 
Any problem reported by the participant about the lack of review or monitoring of 
medicines and illnesses was considered as an MRP. Additionally, the researcher 
assessed the frequency of patient consultations at the GP surgery using the 
following criterion: any report of less than one annual consultation with a GP or 
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nurse was considered insufficient. Any problem associated with the prescribing of 
medicines between hospitals and GPs were included in this category. These 
problems involved, for instance, prescribing problems resulting from a discharge 
from a hospital stay or those resulting from the lack of information supplied to a GP 
for an outpatient under the care of a hospital consultant (Gordon et al., 2005). No 
changes were made to this section.  
6 Interface, monitoring and review 
Inadequate monitoring or review 
Inadequate transfer of information from hospital to GP 
 
Problems with lack of information or discussion 
Any problem identified by the researcher or reported by the participants about the 
lack of information provided or the lack of discussion from a HCP regarding 
medicines or illnesses was classified as a problem in this category (Gordon et al., 
2005). Gordon’s MRPs categorisation sheet has 3 sub-categories under the 
problems with lack of information or discussion category. The sub-category for 
problem related to ‘Inadequate discussion with 
doctors/nurses/pharmacists/hospital staff’ in category number 7 was renamed 
‘short length of consultation’ and added to category number 9 to give a better 
indication and description of the problem.  
7 Lack of information or discussion 
Inadequate information on medicines 
Inadequate information on illness 
Inadequate discussion with doctors/nurses/pharmacists/hospital 
staff 
 
Problems with repeat prescription   
Problems with the process for obtaining repeat prescriptions through the surgery or 
the pharmacy: a repeat prescription service allows a patient to obtain a further 
prescription without consulting a GP. Any problem that was associated with the 
repeat prescribing process and medicine ordering from the GP was categorised as a 
repeat prescribing problem (Gordon et al., 2005). Gordon’s MRPs categorisation 
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sheet has five sub-categories under the problems with repeat prescriptions 
category. From the categorisation sheet, no data were captured for problems 
related to ‘over-ordering and stored at home (hoarding)’ and ‘renew once only 
medicine’. This is because, in order for these subcategories to be identified, patients 
should be interviewed with their medicines present such as conducting home 
interviews rather than pharmacy interviews.  
8 Problems with repeat prescriptions 
Over-ordering and stored at home (hoarding) 
Ran out of medicine and did not order anymore 
Medicines no longer used remain on form 
Renew once only medicine 
Delay renewals after supplies run out 
Order repeat POMs for another person 
 
GP surgery and pharmacy service problems  
This category was defined as any problems with services from the surgery or the 
pharmacy perceived by participants (Gordon et al., 2005). Gordon’s MRPs 
categorisation sheet has 10 sub-categories under the GP surgery and pharmacy 
service problems category. From the categorisation sheet, no data were captured 
for problems related to ‘lack of synchronisation of pharmacy and GP surgery 
opening and closing times’. Five additional problems were identified in the current 
study and subsequently were highlighted in red and added as sub-categories to 
category number 9. They included ‘difficulty consulting a GP from the same gender’, 
‘problem with communication, language and translation’, ‘the short length of 
consultation’, ‘lack of referrals’ and ‘the attitude of GP staff’.  
9 GP surgery and pharmacy service problems  
Difficulty getting appointments to see GP 
Difficulty consulting the practice nurse 
Difficulty consulting the pharmacist 
Long waiting time in GP’s surgery 
Difficulty consulting the same GP 
Difficulty consulting a GP from the same gender 
The short length of consultation 
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Problems with pharmacy supplying medicines from various 
manufacturers 
Pharmacy never has complete stock 
No information leaflet supplied from pharmacy 
Lack of referrals 
Lack of emergency home visits 
The attitude of GP staff 
Problem with communication, language and translation 
Lack of synchronisation of pharmacy and GP surgery opening and 
closing times 
 
Key messages from Chapter 8 
• In summary, Gordon’s MRPs tool (2005) was adapted by the researcher with 
minor modifications mainly to capture the experiences and views of SA and 
ME patients regarding use of medicine and access to services and to address 
reasons that may lead to MRPs which are specific to these groups. The 
principal changes were in describing the extent of support provided to 
patients by their families (section 1), adding additional patients’ 
characteristics (section 2), providing additional prompts to capture the 
reasons for intentional non-compliance that are important to SA and ME 
groups (section 3), presenting additional prompts to capture the problems 
that are likely to face ME and SA groups in accessing healthcare services 
(section 5), describing patients’ perception of pharmacists’ role, pharmacy 
services and MUR service (section 5), and, finally, asking for 
recommendations or advice from patients in order to provide care that is 
better tailored to their needs. The revised version of this tool could be used 
as an instrument in the MUR for these patients to detect MRPs.   
• In terms of recommendation for the coding frame, no changes should be 
made to the original coding frame apart from adding 11 new sub-categories 
that were identified in the current study. It is also recommended to review 
patients’ records in GP surgeries and pharmacies and to conduct home 
interviews in order to be able to identify a wide range of MRPs that are 
included in the coding frame.  
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Chapter 9 The perspectives of pharmacists on MRPs identified and 
recommendations made by the researcher  
Introduction 
This chapter concludes the results section by examining the perspectives of 
pharmacists on the MRPs identified and recommendations made to address 
medicine-related problems among SA and ME groups. A regular pharmacist from 
each pharmacy (n=7) was asked by the researcher to be interviewed for 
approximately ten minutes on the telephone. Pharmacists were asked to discuss 
what their experiences and views were regarding MRPs for these populations. This 
was done to confirm the presence of MRPs or refute them or discover new issues. 
They were also asked to highlight recommendations on how these problems might 
be addressed. The main purpose of this chapter was to validate the MRPs identified 
in the current study and to test the recommendation made. 
9.1 The perspectives of pharmacists on issues specific to SA and ME groups that 
influenced adherence and informed decision making  
Seven pharmacists were approached; six agreed to take part. The response rate was  
86% (6/7). One pharmacist could not take part because she was on maternity leave. 
An interview schedule was developed by the researcher from the issues that were 
raised in the semi-structured interviews and were reported to be specific to SA and 
ME groups with regard to religious practices and beliefs, extent of family support, 
travelling abroad back to their homeland or to take religious journeys. Perceptions 
of healthcare providers, difficulty consulting a doctor from the same gender, lack of 
referrals to specialised care, language and communication barriers were also 
included. Statements were developed to represent these issues and to assess their 
relevance to SA and ME participants from pharmacists’ perspectives. Table 9-1 
shows these statements.  
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Table 9-1: Statements developed based on semi-structured data used in the MRPs questionnaire. 
Items developed based on semi-structured 
interview findings 
1=Yes, in 
the last 
week 
2=Yes, in 
the last 
month 
3=Yes, in 
the last 
year 
4=Never 
(1) Altering mediation-taking behaviours 
due to religious practices and beliefs (e.g., 
Ramadan and fasting and submission to 
God’s will in coping with illness and taking 
medicines). 
    
(2) Altering mediation-taking behaviours 
due to family support (e.g., giving advice 
on medicines, buying non-prescription 
medicines, obtaining information, 
understanding or reading information, 
borrowing and sharing medicines). 
    
(3) Altering medication-taking behaviours, 
getting medicines without a prescription, 
and/or receiving conflicting advice from a 
HCP when travelling abroad back to their 
home land or to take religious journeys. 
    
(4) Altering mediation-taking behaviours 
due to perceptions of healthcare providers 
(e.g., lack of trust or bad relationship). 
    
(5) Difficulty consulting a doctor from the 
same gender. 
    
(6) Lack of referrals to specialised care.     
(7) Language and communication barriers.     
 
Pharmacists were asked to rate their responses to each statement from 1-7 on a 
four-point Likert scale (1= Yes in the last week, 2= Yes in the last month, 3= Yes in 
the last year, and 4= Never). The frequency of responses to issues raised in the 
semi-structured interviews was assessed by the community pharmacists to check 
whether they were relevant to SA and ME participants by examining whether the 
community pharmacists experienced any of these issues with their SA and ME 
customers.  Figure 9-1 illustrates percentages of pharmacists’ responses to issues 
raised in semi-structured interviews. 
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Figure 9-1: Percentages of pharmacists’ responses to issues raised in semi-structured interviews. 
- All the pharmacists (6/6, 100%) agreed that SA and ME Muslim patients alter 
their medication-taking behaviours in Ramadan in different ways. They all 
reported experiencing this in the last year. The following quote illustrated 
this: 
“Nearer to Ramadan time mainly I experience those kind of erm… 
People coming in and when I question them or ask to do an MUR or 
something like that... I find out that they are not taking it or they do not 
know what to do... Like which medicine to take at what time... and some 
people just stop it... I’ve had that issue, yeah... Especially I am worried 
about the diabetics in this area and in Ramadan time they just change 
the dose totally.” [Ph1-IN-M] 
- Nearly two-thirds (67%) of pharmacists responded with ‘Yes, in the last year’ 
to the question ‘Have you encountered SA and ME patients altering their 
mediation-taking behaviours due to family support?’ Pharmacists reported 
that they have seen family members giving patients advice on medicines; 
buying non-prescription medicines for them; obtaining, understanding or 
reading information for patients; or borrowing and sharing medicines among 
each other, as indicated in the following quotes: 
0 1 2 3 4 5 6 7 
Religious practices and beliefs  
Family support 
Travelling abroad 
Perception of HCPs 
Difficulty consulting a doctor 
from the same gender 
Lack of referrals to specialised 
care 
Language and communication 
barriers 
Yes, in the last week 
Yes, in the last month 
Yes, in the last year 
Never 
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“We had lots of people coming in and buying things for their families – 
over-the-counter medications. I also had prescription medicines taken 
which is not totally understood.” [Ph1-IN-M] 
“I have come across many instances where people shared their 
medications and received advice from their family or friends.” [Ph3-IN-
M] 
“Oh, yeah, it is very common... I found a lot of people coming and say 
‘Oh like erm... my sister had this and then I tried it on and it 
worked.’”[Ph7-IN-F] 
- As for the issue of ‘altering medication-taking behaviours, getting medicines 
without a prescription, and/or receiving conflicting advice from a HCP when 
travelling abroad back to their home land or to take religious journeys’, 
nearly two-thirds (67%) of pharmacists responded by saying that they have 
experienced this issue among their SA and ME customers in the last year. 
Typical comments included: 
“Receiving conflicting advice does happen... I have experienced this as 
well from patients who have come with certain kind of belief in taking 
certain medications in a certain way... and then you find out [and say] 
‘No, no, no, this is a wrong advice’ and then they can get confused 
because I am giving them different advice from the place where they 
come from. Getting medicines from their homelands – that is happen as 
well because they have been prescribed medication from that country 
and they come here and been given different brand name but then we 
check it for them to find what it is and we find out the generic and we 
find out that there could be a problem with what they are taking in this 
country... I mean their regular medicines in this country.” [Ph1-IN-M] 
“I’ve seen people buying medicines abroad, absolutely not the right 
medicines, but they buy it by their will and they come here and 
sometimes you could be shocked why they are using these sorts of 
medicines.” [Ph3-IN-M] 
“Experience it in a sense that they do tell us when they go to their home 
lands; they feel much better and sometimes they say they don’t need to 
take their medicines.” [Ph6-IN-M] 
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- Half (50%) of pharmacists reported that they have experienced in the last 
year SA or ME patients altering their medication-taking behaviours due to 
perceptions of healthcare providers either due to lack of trust or bad 
relationship. However, about a third (33%) of pharmacists reported that 
they have never experienced this issue among their patients. 
- With regard to the statement ‘difficulty consulting a doctor from the same 
gender’, half of pharmacists (50%) have experienced this among their 
customers in the last year. However, about a third (33%) of pharmacists 
revealed that they have never encountered this problem among their 
customers. The following quotes illustrated this issue: 
“Mainly female patients but actually no, no, male patients as well I 
would say... Certain male patients they have got things that are a bit 
personal to them and they are reluctant to see other gender GP.” [Ph1-
IN-M]    
“I will not name the centre but it is a diabetic centre. Obviously female 
patients want to see a female doctor... They should provide this facility.” 
[Ph3-IN-M] 
- Half (50%) of pharmacists responded with ‘Yes, in the last year’ and half 
(50%) responded with “Yes, in the last month” to the statement ‘Have you 
ever experienced patients reporting lack of referrals to specialised care?’ 
“That is very often happen [laughs]... Happens almost every month I 
would say... Every month I have somebody like that coming in to say 
that they have had a problem for a long time and they would be better 
if they had been seen by a specialist in that field... Or maybe I would 
advise them to see a specialist in the field because they have been 
suffering from something so long and I ask them ‘Have you seen 
anybody else other than the GP?’ and they have not... Many of them 
have not seen anybody else and I say ‘Why not?’ They just say that they 
keep asking their GP and their GP is just keep giving repeat medications 
and keep telling them to do what they are doing and that is it.” [Ph1-IN-
M] 
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- As for the ‘Language and communication barriers’, half (50%) of pharmacists 
revealed experiencing this issue among their SA and ME customers in the 
last month and about a third (33%) in the last week. Typical comments were: 
“I actually had a GP consulting me because he knows we [pharmacy 
staff] talk certain languages so they actually phoned me to talk to a 
patient [laughs] and sort of translated the problem over... We are stuck 
sometimes when it comes to certain African languages which we don’t 
speak.” [Ph1-IN-M] 
“The biggest problem is the lack of communication which is language 
related... We notice that here [in the pharmacy]. Sometimes, we have to 
be very careful when we shout out a patient’s name to give him his 
medicines... Supposing that we have two Ali’s or two Muhammed’s in 
the pharmacy and they both say ‘Yes’ when we shout their names and 
we have to try to find out who is who, and when there is a language 
barrier, they both say ‘Yes’ to everything and it does not help.” [Ph3-IN-
M] 
In summary, the majority of pharmacists (4/6, 67%) revealed that they have 
experienced all the issues that were reported to be specific to SA and ME groups 
among their customers. The problem that was seen more frequently (i.e., weekly or 
monthly) was language and communication barrier followed by lack of referral to 
specialised care.  
9.2 The perspectives of pharmacists on recommendations made to support SA 
and ME groups in their use of medicines 
A part from the issues that were reported to be specific to SA and ME groups, the 
interview schedule also had recommendations which were made by the researcher 
based on the issues raised during the interviews to support these groups in their 
use of medicines. Pharmacists were asked to rate their responses to each 
recommendation on a Likert scale (1= agree, 2= agree to a certain extent, 3= 
disagree and 4= uncertain). Table 9-2 shows these recommendation and the 
responses made by the pharmacists. 
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Table 9-2: Recommendation made by the researcher and the pharmacists’ responses to these 
recommendations. 
Recommendations developed based on 
interview findings 
1= agree 2= agree 
to a 
certain 
extent 
3= 
disagree 
4= 
uncertain  
N N N N 
(1) These patients have complex needs 
and co-morbidities. Therefore, they 
should be a priority group to have an 
MUR. 
6  0 0 0 
(2) A check list, which involves the issues 
that were reported to be specific to SA 
and ME groups, should be included during 
MUR. 
6 0 0 0 
(3) The pharmacists need to promote 
themselves more as an information 
source by increasing prescription 
medication counselling (e.g., MUR). 
6 0 0 0 
(4) Proper pre-Ramadan and pre-Hajj 
month education and medical counselling 
should be encouraged. 
6 0 0 0 
(5) It is important to ask patients during 
consultation to declare whether they 
receive help or assistance with their 
medication and to describe the nature of 
support provided. 
2 2 2 0 
(6) Family members should be involved in 
discussions and decisions about 
treatment plan of patients. Also, how 
family members view a medication should 
become a vital question in practice. 
2 2 2 0 
(7) The preferred language spoken and 
read by the patient should be monitored. 
Where there is a need, letters to patients 
should be provided in different languages 
according to their needs and more 
multilingual staff should be hired in areas 
which have high percentage of SA and ME 
groups. 
6 0 0 0 
(8) Improving patients’ language-speaking 
literacy should be made through the use 
of audio material such as CDs, or visual 
materials (e.g., videos, cartoon 
instructions or pictorial diagrams). If 
written materials are required, they 
should use plain language at the fifth-
grade level or lower. 
6 0 0 0 
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Table 9-2: Continued recommendation made by the researcher and the pharmacists’ responses to 
these recommendations. 
Recommendations developed based on 
interviews findings 
1= agree 2= agree 
to a 
certain 
extent 
3= 
disagree 
4= 
uncertain  
N N N N 
(9) Adopting a patient-centred approach 
in delivering care is highly recommended, 
whereby doctors would involve patients 
as equal partners in all decisions about 
their treatment, especially in relation to 
medication selection and prescription. 
Eliciting patients’ priorities, identifying 
their expectations towards illness and its 
treatment and translating these into 
realistic objectives for the individual 
patient should be conducted. 
5 0 1 0 
(10) Religious, social and cultural beliefs 
and lifestyle priorities should be 
addressed and incorporated into patients’ 
medical records.  
6 0 0 0 
(11) Patients’ information on electronic 
databases should be accessed and shared 
among all healthcare providers involved 
in patients’ care. 
5 1 0 0 
(12) Increase patients’ education through 
a group session or lecture courses at 
clinics, GPs, community centres, local 
masjids and temples or through 
educational programmes via radio and 
television should be made.  
6 0 0 0 
(13) HCPs need to be educated in the 
differences when dealing with a multi-
cultural population. They need to be 
aware of the different social and cultural 
factors of the ethnic community and how 
it can influence their attitudes and 
behaviours towards complying with their 
medication regimen. 
6 0 0 0 
 
The frequency of responses to the recommendation made by the researcher was 
assessed by the community pharmacists to check whether they can address MRPs 
among SA and ME groups.  
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- The pharmacists agreed on almost all the recommendations. However, they 
had different views regarding recommendations made to support the 
following: involving family members in patient’s care, adopting patient-
centred care, and finally sharing patient information on electronic databases 
among HCPs involved in patient’s care.   
- Two pharmacists agreed that family members should be involved in 
patient’s care and thought that the elderly patients would benefit most from 
this involvement : 
“Of course, I think that both you and I came from the same culture, we 
recognise that [involving family members in patients’ care]... I think we 
always look after our parents, uncles and aunts... I think it is important 
because the younger generation is more knowledgeable about things.” 
[Ph3-IN-M]   
“It depends on the family member I think... If there is, like, an elderly 
person, then his/her son or daughter should be, like, involved... 
Because they don’t always understand what the doctor is actually 
saying but if you get like a younger person, then I don’t think they, like, 
[are] able to comprehend... I think it is better to give the patient an 
option whether he/she prefers it or not... That would be good.” [Ph7-
IN-F]    
However, two pharmacists disagreed with this statement and another two 
pharmacists did not feel strongly about this statement, and rated it ‘to a 
certain extent’ because they believed that this involvement would affect 
patient confidentiality. They commented that this recommendation would 
be beneficial to patients only if patients agreed on involving their family 
members in their own care: 
“There is an issue here because some of them they don’t want their 
family members to know... I would disagree with that... But if they are 
happy with their family to be involved then yes.” [Ph2-AR-M]   
“Why should we involve family members? Because some people don’t 
want their family to know what they are taking… But if the patient 
agreed, then this would be a good idea.” [Ph4-IN-M] 
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“Involving a family member is beneficial in a sense that if they don’t 
understand the language. Perhaps, the family members who are a bit 
coherent, then yes I would say so. But obviously on the other side we 
have to look at patient’s confidentiality... I that case, perhaps we may 
not be able to discuss it with family members.” [Ph6-IN-M] 
- As for adopting a patient-centred approach in delivering care, one 
pharmacist disagreed with this statement and believed that all the decisions 
should be made by HCPs only and not patients: 
“Erm... I don’t think it is a good idea because I think you should leave it 
to the professionals.” [Ph3-IN-M]   
The remaining pharmacists (n=5) agreed that adopting a patient-centred 
approach is crucial in delivering high quality of care: 
“Yes, strongly agree because especially in that type of people, they want 
to have an opinion in what they are treated on so I would definitely 
involve their views yes.” [Ph2-AR-M]   
- Accessing and sharing patients’ information on electronic databases among 
all healthcare providers involved in patients’ care was agreed among all the 
pharmacists except one who responded with ‘to a certain extent’. The 
pharmacists believed that this would be highly beneficial if patients agreed 
on allowing HCPs who are involved in their care to share the information 
among each other: 
“It will be highly beneficial to share the information but of course after 
obtaining patient’s consent.” [Ph2-AR-M]  
“Sharing patients’ information on medical records is a bit difficult again 
because of patients’ confidentiality... If approved by the patient and the 
medical professions between themselves then yes... So, it has to be 
patient-oriented approval.” [Ph6-IN-M] 
- As for improving language and illiteracy barriers, all the pharmacists agreed 
with recommendations number 7 and 8 and they also highlighted other 
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recommendations on how to improve language barriers for SA and ME 
groups. They supported hiring multilingual staff, generating labels and 
written instructions in the patient’s preferred language and providing 
instructions using graphic symbols for illiterate patients. Providing written 
information in the most commonly spoken languages in the UK for key drugs 
and key diseases such as cardiovascular, diabetes, and cancer was 
recommended. Also, developing a PMR system where pharmacists can print 
out labels in different languages was seen as helpful. The following quotes 
illustrate pharmacists’ recommendations on language barriers: 
“The good thing we have here is different people talking different 
languages so we are able to sort this out at least if it comes to language 
and understanding... Stickers on our labels might help as well... We use 
stickers on labels which are translated into Bengali language at the 
moment I have got... Say night, morning, afternoon or something like 
that of stickers I put on my packaging have helped a lot.” [Ph1-IN-M] 
“The main thing is the cultural and language barriers that need to be 
addressed more... Especially giving information or leaflet that is proper 
in the language of the patient... This will make it a lot easier... Especially 
the key drugs and key diseases like cardiovascular, diabetes, or even 
cancer now... If you have information leaflets targeted to this type of 
people it will be highly beneficial.” [Ph2-AR-M]      
“We start now hiring multilingual staff who speak the languages 
required for that area... Recently we also started printing labels in 
Arabic as well... What we could do is to have a multilingual PMR system 
where it is possible to print labels in any languages patients like... That 
might help a lot.” [Ph4-IN-M]   
“Providing patient information leaflets in different languages would be 
useful... One of the biggest problems is the language barrier... 
Recruitment of professionals in areas where they have those 
communities would be good and it is happening.” [Ph6-IN-M]  
“Provide an advice leaflet in different languages before the month of 
Ramadan or before the Hajj I think is good.” [Ph7-IN-F] 
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- All the pharmacists supported that SAs and MEs should be priority groups to 
have an MUR due to their complex needs and co-morbidities. All the 
pharmacists also agreed that a checklist should be included in the MUR 
which involves all the issues that were reported to be specific to SA and ME 
groups. For example, patients should be asked during MUR about their 
medication-taking behaviour while fasting. Asking patients about 
medication-taking and obtaining practices while travelling should also be 
included in MUR, etc. All the pharmacists also agreed that prescription 
medication counselling and MURs are just as important. A pharmacist 
commented: 
“MURs should be increased; not only that but I believe that pharmacists 
should always consult patients no matter what medicines they are 
taking... That will promote the knowledge that pharmacists do care.” 
[Ph4-IN-M]  
- All the pharmacists agreed with the recommendation “Proper pre-Ramadan 
and pre-Hajj month education and medical counselling should be 
encouraged”. 
- Addressing and incorporating religious, social and cultural beliefs and 
lifestyle priorities into patients’ medical records was agreed among all the 
pharmacists.  
- All the pharmacists agreed with the recommendation “Patients’ education 
should be increased through a group session or lecture courses at clinics, 
GPs, community centres, local masjids and temples or through educational 
programmes via radio and television”.  Typical comments were:    
“That will help break the barrier between healthcare and the cultural 
barrier.” [Ph2-AR-M]   
“A lot of people do go to community centres, meetings and things so 
this would be an excellent idea... I know lots of people go regularly to 
community centres almost every day and they like it... They like listening 
to this kind of lectures and discussions... You just have to make them 
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understand from the beginning that there would be no examinations 
[laughs] and make sure that they understand what it is all about... They 
just have to sit there and listen and do nothing... Make it clear before 
the start that this session is going to be about a lecture, you listen to it 
and you might get some information. If you want to ask questions feel 
free and if you don’t want to talk, you don’t have to say a word.” [Ph1-
IN-M]       
“We [pharmacists] are also taking part in the local library down here in a 
programme called health sessions where people come up to discuss 
with a health officer if they are diabetics or have health problems... I 
tried to be there to help them as well.” [Ph4-IN-M]  
“Within the community involvement, particularly where they go in 
groups to meetings or whatever. Perhaps, a professional of any kind – 
say a pharmacist, or a doctor, or whoever. Perhaps, the HCP can advise 
them a bit more and give a special talk on different subjects.” [Ph6-IN-
M]  
- As for increasing HCPs’ awareness of the different social, religious and 
cultural factors of the ethnic community groups and how they can influence 
their attitudes and behaviours towards complying with their medication 
regimen, all the pharmacists agreed with this statement; for example:  
“Strongly agree because if the pharmacists know these factors, it will 
make their life easier to communicate and deliver the message they 
want to different types of patients especially the group you are testing.” 
[Ph2-AR-M]   
In summary, all the pharmacists highlighted recommendations for supporting SA 
and ME groups in their use of medicines. Responses ranged from prioritising 
medication use review to SA and ME groups, increasing patient education and 
counselling, providing verbal and written information in patients’ preferred 
language and according to their needs and wants, and raising awareness of SA and 
ME cultures among HCPs.    
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Key messages from Chapter 9 
• This chapter has provided a theoretical framework for MRPs from 
pharmacists’ perspectives. 
• This chapter supports developing MUR further and adding the specific issues 
that were reported by SA and ME groups to support these groups in their 
use of medicines. 
• The findings also support the development of pharmaceutical care plans 
specific for SA and ME groups. 
• The interviews with the pharmacists confirmed the presence of specific 
issues among SA and ME groups and highlighted the need to implement 
changes at primary care and community level, with the aim of addressing 
MRPs among SA and ME patient and supporting their needs and 
preferences, such as prioritising medication use review to SA and ME 
groups, increasing patient education and counselling, providing verbal and 
written information in patients’ preferred language and according to their 
needs and wants, and raising awareness of SA and ME cultures among HCPs. 
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Chapter 10 8-item Modified Morisky Adherence Scale (MMAS) 
Introduction 
This chapter assesses the extent of non-adherence to medications among SA and 
ME patients using 8-item MMAS. Participants’ adherence/non-adherence to their 
medications was assessed using self-report in two ways: using interview data from 
MRPs questionnaire, and a validated measure for assessing adherence to 
medications, the Morisky Adherence Scale (MMAS). Assessment of non-adherence 
based on MMAS was based on the instruction of the scale’s authors, as detailed in 
the methods chapter, Chapter 3. According to the MMAS scores, participants’ 
adherence level was categorised as low (if MMAS score < 6), medium (if MMAS 
score 6 to <8) or high (if MMAS score= 8). The distribution of the 8-item MMAS total 
score showed that 26 (33%), 27 (34%) and 26 (33%) participants scored 8 (high 
adherence), 6 to<8 (medium adherence) and <6 (low adherence) respectively. In 
general, 53 (67%) participants were identified with poor adherence where medium 
and low adherences were combined. 
In addition to specifying the adherence level of participants, where these existed, 
non-adherence of participants was assessed using the MMAS data in two ways (as 
in interview data): 
Intentional/unintentional non-adherence: 
• Unintentional non-adherence by MMAS resulted if participants responded 
with a ‘yes’ to items 1, 4, or 8, which denoted forgetting medications either 
generally, in travel or due to finding difficulties in remembering to take all 
medications. 
• Intentional non-adherence by MMAS resulted if participants responded with 
a ‘yes’ to items 3 or 6, which denoted cutting back or stopping taking 
medication without telling the doctor because of feeling worse when taking 
medications or when feeling that illness was under control. 
 
Note: Items 2, 5 and 7 were not used to classify participants as intentional or 
unintentional non-adherers as the wording of these items hindered this:  
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• Item 2 (People sometimes miss taking their medications for reasons other 
than forgetting. Thinking over the past two weeks, were there any days 
when you did not take your diabetes medicine?) 
• Item 5 (Did you take your diabetes medicine yesterday?) 
• Item 7 (Taking medication every day is a real inconvenience for some 
people. Do you ever feel hassled about sticking to your diabetes treatment 
plan?) 
 
Table 10-1 lists 21 research participants and compares their non-adherence 
behaviours based on interview data and MMAS responses. It also categorises 
participants’ non-adherence along the intentional/unintentional dimensions, based 
on data from both the interview and the MMAS. From Table 10-1 it can be seen 
that assessing patients’ adherence to their medication is not a straightforward task, 
as it is difficult to extrapolate a pattern between data from different methods of 
adherence assessment (i.e., MRPs questionnaire, MMAS), which may provide 
conflicting classification/categorisation of patients’ non-adherence in relation to 
these dimensions. There were discrepancies about participants’ non-adherence 
when different methods of self-report were employed (i.e., MRPs tool and MMAS). 
What one method suggested was sometimes different to or even conflicting with 
the other. For instance, based on the MMAS, participant [601-PAK-F-65] was 
classified as both an intentional and unintentional non-adherer with a score of 3.5, 
as she admitted sometimes missing taking her medications for reasons other than 
forgetting in the past two weeks. She also found some difficulty in remembering to 
take her medications at times. She admitted that she cut back or stopped her 
medications as a result of feeling worse while taking them. She also reported 
stopping taking her medicines sometimes when her disease was under control. 
However, when the MRPs tool was used, the patient was found to be highly 
adherent to her medications. A possible explanation for that is that when the MRPs 
questionnaire was administered the patient was asked the questions in English, 
whereas when the 8-item MMAS was administered, the pharmacist helped the 
researcher and translated questions into Hindi for the patient, which may improve 
the patient’s understanding of the questions.    
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Table 10-1: Twenty-one participants’ adherence behaviours based on MRPs interview data and 
MMAS data. 
Participant Adherence level Intentional or unintentional non-
adherence 
Based on MRPs 
questionnaire 
Based on MMAS 
tool 
Based on MRPs 
questionnaire 
Based on MMAS 
tool 
101-BNG-M-48 High adherence  
(never, never) 
High adherence 
(8) 
Adherent Adherent 
102-PAK-M-65 Not high adherence 
(never, rarely) 
Low adherence  
(5) 
Unintentional Intentional and 
Unintentional 
104-BNG-M-57 High adherence  
(never, never) 
Medium 
adherence (7.5) 
Adherent Unintentional 
210-AR-M-55 Not high adherence 
(never, sometimes) 
Medium 
adherence (6.5) 
Unintentional Unintentional 
211-IN-M-59 Not high adherence 
(never, rarely) 
High adherence 
(8) 
Unintentional Adherent 
216-AR-M-50 Not high adherence 
(sometimes, often) 
Low adherence  
(3.5) 
Intentional and 
Unintentional 
Intentional and 
Unintentional 
302-AR-M-83 High adherence  
(never, never) 
High adherence 
(8) 
Adherent Adherent 
303-AR-F-53 Not high adherence 
(often, very often) 
Low adherence  
(1.25) 
Intentional and 
Unintentional 
Intentional and 
Unintentional 
308-AR-F-55 Not high adherence 
(never, sometimes) 
Medium 
adherence (6) 
Unintentional Unintentional 
401-AR-F-40 Not high adherence 
(never, sometimes) 
Low adherence  
(4.5) 
Unintentional Unintentional 
403-AR-F-60 Not high adherence 
(never, sometimes) 
Medium 
adherence (6.5) 
Unintentional Unintentional 
405-AR-M-64 High adherence  
(never, never) 
High adherence 
(8) 
Adherent Adherent 
501-PAK-M-68 Not high adherence 
(sometimes, never) 
Medium 
adherence (7) 
Intentional Unintentional 
505-PAK-M-57 High adherence  
(never, never) 
High adherence 
(8) 
Adherent Adherent 
507-AR-F-39 Not high adherence 
(often, never) 
Low adherence  
(4) 
Intentional Intentional 
601-PAK-F-65 High adherence  
(never, never) 
Low adherence  
(3.5) 
Adherent Intentional and 
Unintentional 
603-IN-M-51 Not high adherence 
(never, rarely) 
Medium 
adherence (7) 
Unintentional Unintentional 
605-IN-M-66 Not high adherence 
(never, rarely) 
High adherence 
(8) 
Unintentional Adherent 
702-IN-M-57 Not high adherence 
(never, very often) 
Medium 
adherence (6) 
Unintentional Unintentional 
705-IN-M-64 Not high adherence 
(never, sometimes) 
Low adherence  
(5.5) 
Unintentional Unintentional 
708-IN-M-65 High adherence  
(never, never) 
High adherence 
(8) 
Adherent Adherent 
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Even when both MRPs tool data and MMAS data were in agreement with regard to 
the categorization of patients’ non-adherence into a certain category (e.g., 
intentional/unintentional), it was noted that sometimes this classification was 
arrived at using different incidents the patient had in mind when responding to 
interview questions/MMAS items related to non-adherence. For instance, 
participant [216-AR-M-50] was classified as both an intentional and unintentional 
non-adherer combined, based on both MRPs tool and MMAS data. Despite this 
agreement in classification, based on the MRPs tool data, the patient was classified 
to be intentionally non-adherent because he had admitted changing the timing of 
his Simvastatin tablet from evening to morning. He also reported intentionally 
stopping taking his medicines once or twice a month for three or four days when he 
was feeling better (‘sometimes’ on the Likert scale). He revealed forgetting to take 
his medicines once or twice a week (‘often’ on the Likert scale). However, based on 
MMAS responses, the patient was classified to be intentionally non-adherent 
because he reported stopping his medications sometimes when he felt better. This 
might be because the MMAS items did not include anything that would represent 
the patient’s intentional non-adherent behaviour, so this aspect of non-adherence 
was not detected using the MMAS.  
The cases selected showed that the data from MRPs tool and MMAS were in 
agreement at detecting intentional, unintentional non-adherence and high 
adherence. For example, with 14/21 it was possible to detect intentional, 
unintentional non-adherence and high adherence.  
Summary of measurement of adherence to medications  
Measuring adherence using various patient self-reported methods is not direct and 
data provided by each method should be interpreted with caution, as different 
patients were sometimes categorised differently when different methods were 
employed. Thus, categorisation of patients using one method only may be 
incomplete, and should be evaluated with reference to the other.  
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It is worth noting that in the MRPs questionnaire patients were asked to recall their 
medication-taking behaviour by specifying a certain period of time unlike the 8-item 
MMAS, which asked patients to recall their medication-taking behaviour in general 
without specifying a certain period of time. Thus, it was expected that non-
adherence data would not be similar using each method and that there will be 
differences in participants’ answers. There were possible explanations for 
inconsistency between data from MRPs questionnaire and MMAS: 
• Item 2 and item 5 out of the 8-item of the MMAS are the only items that do 
specify a time period for patients to report their medication-taking 
behaviour. This might have made it easier for participants to report their 
behaviour when MMAS was used.  
• The MRPs questionnaire seems to be worded in such way to allow detection 
of the continuous forms of non-adherence where the patients continuously 
altered their medication use unlike MMAS scale items, which seem to 
neglect the continuous form of non-adherence and allow only detecting 
contextual forms of non-adherence. 
• Participants were asked about their medication-taking behaviour at two 
different points of time in the MRPs questionnaire and MMAS. Thus, they 
may have reported different incidences of non-adherence with different 
methods of self-report.  
 
It was found that the MRPs questionnaire was better at detecting intentional non-
adherence compared to MMAS because MRPs has an open question (i.e., Tell me 
more about this: what do you mean, the last time, why?) to allow participants to 
mention all the possible scenarios denoting intentional non-adherence unlike 
MMAS items that did not cover all possible scenarios indicating intentional non-
adherence.    
It is best to use two or more methods and compare them to assess non-adherence 
to medication based on self-report. What is missing from one method might be 
completed or better explained though the other. For instance, participant 501-PAK-
M-68 was found intentionally non-adherent in the MRPs questionnaire but 
unintentionally non-adherent in MMAS, so the patient is possibly a combined 
intentional and unintentional non-adherer. However, problems arise when 
adherence assessment from one method contradicts that of the other. For instance, 
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participant 601-PAK-F-65 was adherent based on the MRPs questionnaire but non-
adherent when MMAS was used, in contrast to participant 605-IN-M-66 who was 
non-adherent based on the MRPs questionnaire but adherent based on MMAS. As 
it is more likely that those who report non-adherence to medications are telling the 
truth compared to those who report adherence, it was decided that wherever 
participants admitted to committing non-adherence, whether in MRPs 
questionnaire or MMAS, they would be categorised as non-adherent.  
Limitations to use of the MMAS 
Several limitations were noted using MMAS in assessing non-adherence to 
medication in this study: 
• MMAS requires literacy. 
• The wording of questionnaire items may exacerbate this problem. For 
example, item 1 which measures forgetfulness should not be considered as 
a good indicator for assessing patient’s cognitive ability because the patient 
might remember to take his/her medicine but not to take the right dose at 
the right time. Question number 2 does not indicate clearly the reason(s) for 
not taking the medicine; for example was not taking the medicine because 
of intentional reason(s) such as developing side effects or because the 
medicine has low efficacy or was it because of unintentional reason(s) such 
as dexterity problems that lead to inability to open medication containers or 
use devices such as inhalers or injections or because of poor sight, hearing 
loss and swallowing problems. Question number 3 does not indicate the 
reason why the patient felt worse – was it because of developing side 
effects or because the drug was not efficacious and thus the symptoms were 
not controlled?  
A few participants seemed that they did not 
understand some of the questions despite different attempts to explain 
questions clearly. However, they still provided answers to them, which may 
have biased total scores. 
• Some items were not easily interpreted by participants or were interpreted 
differently by different participants, which may have biased total scores. For 
example some participants provided a ‘Yes’ response to item 1 in particular 
and they followed by mentioning that this had occurred very rarely. 
However, other participants provided a ‘No’ answer, and they followed by 
reporting that this had occurred very rarely because they thought that rarity 
of such an incident did not mean a ‘Yes’ answer. Thus, a five-point Likert 
scale may have been more appropriate to address problems like this, and 
allow for accommodation of the diversity of participants’ behaviours. 
Similarly, as for item 4, there was a problem of interpretation by different 
Chapter 10 – Results (8-item Modified Morisky Adherence Scale) 
290 
 
participants. For instance, some participants responded by a ‘Yes’ but 
mentioned that they had done so only once, whereas others responded by a 
‘Yes’, but mentioned that they did this continuously and on purpose and not 
because of forgetting. Although these participants responded by ‘Yes’, they 
were reporting entirely different types of non-adherence behaviour (i.e., 
unintentional and intentional, and contextual and continuous). As previously 
mentioned, a five-point Likert scale may have been more appropriate to 
address problems like this, instead of the rigid Yes/No responses provided 
by the MMAS. 
• Some items were not applicable to some participants but participants still 
gave responses to them for the sake of completing the questionnaire, which 
might have introduced bias. Examples of this were items 3 and 4. Item 3 was 
not applicable for some participants because they once stopped taking their 
medicines but for reasons other than feeling worse while taking them. 
However, they still provided a ‘Yes’ answer. Similarly, item 4 was not 
applicable for some participants who had never travelled abroad since they 
were diagnosed with their illness. However, they still provided a ‘No’ 
answer.     
• 
• Although the MMAS can detect both intentional and unintentional non-
adherence, it is difficult to specify the exact reasons why non-adherence 
occurred, apart from those that were explicitly mentioned by the items (i.e., 
forgetfulness, stopping or cutting back on medications because of feeling 
worse or feeling that diabetes is under control). As far as the 
continuous/contextual/one-off non-adherence dimension is concerned, the 
MMAS is not useful at detecting other than the contextual aspect of non-
adherence.  
The MMAS may over-estimate some of the issues leading to unintentional 
non-adherence. For example, 3/8 items are worded to capture whether 
patients ‘forget’ to take their medicine. However, the MMAS ignored other 
causes of unintentional non-adherence such as physical problems, poor 
sight, difficulty swallowing and lack of awareness which might interfere with 
medication-taking behaviour. As regards intentional non-adherence, the 
MMAS items are worded in such a way to allow identification of those who 
took less of their medications either when feeling that their condition was 
under control or when feeling worse. These items do not reflect all possible 
reasons for intentional non-adherence. The MMAS items also neglect those 
who may take more of their medications for whatever reasons.  
• As regards the total score of MMAS, some participants ended up having a 
medium non-adherence level despite having a nearly perfect score of 7.75 
out of 8.00 or ended up having a low non-adherence level despite having 
nearly medium non-adherence score of 5.75 out of 8.00. Implications of 
scoring a 0.75 (two decimal places) instead of 1 for item 8 are that these 
patients ended up having a medium adherence level or low adherence level, 
just like anyone else who scored low on two different items or low on four 
different items respectively.   
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Key messages from Chapter 10 
• The present study, provided evidence that SA and ME patients (53/79, 67%) 
had poor medication adherence using 8-item MMAS. 
• In the current study, the MRPs tool as well as 8-item MMAS were both used 
for the assessment of adherence to medications. Comparison of data from 
both methods revealed that what one method suggested was sometimes 
similar or different to or even conflicting with the other. Even sometimes 
when the two methods agreed, the participants appeared to have different 
incidents in mind when reporting their non-adherence behaviour using 
these different methods. This implies that the usefulness of both methods 
for the assessment of non-adherence to medications is limited when one is 
used solely. It is therefore recommended that data from one method should 
be assessed with reference to the other. What is missing from one method 
can be completed by the other.  
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Chapter 11 Discussion 
This is the first study that has explored and described medicine use and medicine-
related problems experienced by SA and ME patients with chronic diseases in 
primary care in the UK, providing novel evidence that medicine use and service 
access among these particular populations continues to be problematic across all 
chronic conditions, which may have life-threatening consequences. Up to date, 
there have been no studies that included the SA and ME patients’ perspectives on 
MRPs. The literature search has shown that there has been extensive research on 
health problems of EMGs, especially access to care, but there has been little 
research that specifically examines medicine use among SA and ME populations. 
Also, evidence suggests that medicine-related needs may be poorly met for these 
groups (Alhomoud et al., 2013).  
The current study also highlighted differences between SAs and MEs participating in 
the study and so far it is the only one to propose a tool that can be used in SA and 
ME populations to identify MRPs and to detect factors that may contribute to the 
problems. This research provided important data in this regard which would serve 
as the basis and frame of reference for future intervention studies aiming to 
improve medication use and service access among these particular populations. 
The extent of non-compliance with medications among SA and ME groups in the UK 
has also never been estimated before (Ens et al., 2013). So, this study is the first to 
measure the extent of non-compliance with medication among SA and ME 
populations in the UK using 8-item MMAS.  
This chapter discusses separately: (1) the main key findings on what is new; (2) 
personal reflections about the research; (3) strengths and limitations of the study; 
(4) implications of the results for practice and policy; (6) suggestions for future 
work; and (6) research contributions and how this thesis has contributed to the 
knowledge and understanding of MRPs among SA and ME patients. 
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11.1 Main key findings and implications of the results 
The current study found that pharmacies located in areas with a high percentage of 
South Asian and Middle Eastern people were unwilling to participate in the study 
(non-participation rate 92.5%). Visiting pharmacies in person was the best method 
of recruitment possibly because this method gave the pharmacists an opportunity 
to ask more questions about the study and to clarify their roles in it and to examine 
the face and attitude of the researcher. Thus, in order to facilitate recruitment of 
community pharmacies for future research, it would be preferable to make in-
person visits two weeks after sending invitation letters to the pharmacies and 
before receiving their response.  
The present study showed that SA and ME groups were willing to participate when 
invited and stayed engaged with the study when the barriers to their participation 
were appropriately addressed and when given full information about the study 
(response rate 80%). The reason for the high response rate in the current study was 
possibly because patients were approached by someone (i.e., pharmacist or 
researcher) who had the same ethnic background as the patients and spoke the 
same language. In addition, participants were made aware of the lack of research 
available in this area and among these patients groups. Finally, the response rate 
was high because of the greater involvement from pharmacists to approach 
patients and promote the research in their practice.  
This finding supports previous research which showed that the ethnic minority 
patients are not less likely and are possibly even more likely than the majority 
population to agree to take part in biomedical research. Wendler and colleagues 
found that the main obstacle to their participation lay in their reduced likelihood of 
being invited to take part in the studies. Their systematic review was conducted in 
more than 90,000 patients offered enrolment in 20 health research studies 
(Wendler et al., 2006).  
Other studies perceived that there was under-representation of ethnic minorities in 
all therapeutic areas and all types of clinical research. They reported multiple 
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obstacles influencing the participation of ethnic minority patients. The most 
important barriers were the fact that some ethnic minorities have greater distrust 
of the medical system and others had language barriers (Endocrine Society, 2007). 
Another study, by Hussain-Gambles et al. (2006), suggested that, in addition to the 
language barriers, other obstacles such as age, gender, social class, feeling of not 
belonging, and cultural and religious factors are equally likely to affect ethnic 
minority participation in clinical research. However, patients were motivated to 
participate in clinical trials that investigated illnesses’ prevalence in their 
community when they were informed that there was a lack of research available in 
this group of patients.  
Harris and Dyson (2001) suggested different stages to overcome barriers of the 
recruitment process including approaching patients at a suitable time (e.g., not 
when they are distressed or in pain), offering an initial description of the study 
creating opportunities to obtain the patient’s initial thoughts about the study, 
paying attention to patient’s responses to check the understanding of the study, 
and providing sufficient time to make a decision. A qualitative study was conducted 
by Sheikh et al. (2009) investigating the recruitment of South Asian patients in 
research. They found that the main key issues highlighted for recruitments were 
language and cultural differences and poor understanding of what research includes 
(Sheikh et al., 2009).  
An implication for this is possibly that researchers should include SA and ME groups 
more in research, and the research should be designed to identify the MRPs and 
address the medicine-related needs of these groups from their perspectives. 
Researchers should also ensure that these groups fully understand what taking part 
involves and why participation is important, by generating translated materials and 
using interpreters when needed. The patient being approached in person by a HCP 
whom the patient knows and/or by a researcher who speaks the same language or 
is from the same culture might also facilitate recruitment. Making participants 
aware that there is a lack of research available in this area and among these patient 
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groups might also increase response rate. Another implication is that the response 
rate of pharmacies and participants in the current research study could be used to 
predict the number of pharmacies and participants likely to be recruited in areas 
with similar characteristics. It could also give an indication of the frequency of 
patients most likely to be identified with MRPs in other pharmacies with similar 
characteristics.    
Careful attention must be given to the extensive paperwork as it may decrease the 
response rate by making some patients anxious and reluctant to participate. 
Although this did not affect patients’ response rate in the current study (80%), 
some participants did comment on the length of the interview. In addition, for the 
purpose of qualitative research, digital or tape recording used might be frightening. 
In this study, a few participants were anxious about digital recording, as they were 
not sure who would listen to their problems and complaints. However, the 
researcher reassured them that she would be the only one to listen to their 
recording. Thus, when doing further research among these ethnic groups, 
researchers should assure patients of confidentiality of data and explain the 
purpose of recording besides addressing any concerns to get a good response rate 
and obtain patients’ honest views.  
This study has shown that the definition of MRPs should be wide and not restricted 
because there are many factors associated with MRPs that need to be considered. 
The nine categories in Gordon’s coding frame were developed to integrate all types 
of MRPs reviewed in the literature, which comprised: (1) adverse drug reactions and 
drug interactions; (2) intentional non-compliance; (3) cognitive, physical and 
sensory problems; (4) issues with concurrent use of herbal and alternative 
therapies; (5) problems with drug-prescribing; (6) problems with lack of 
information; (7) problems with lack of regular monitoring and review; (8) problems 
with repeat prescriptions; (9) GP surgery and pharmacy service problems.  
Interviews revealed that many factors may contribute to altered medication-taking 
behaviours and informed decision-making among SAs and MEs. Some of these 
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factors appeared to be specific to these cultures, which included religious practices 
and beliefs (e.g., fasting and Ramadan, fatalism and submission to God’s will in 
coping with illness); extent of family support (e.g., advice on medicines, buying non-
prescription medicine, understanding or reading information, obtaining 
information, borrowing and sharing medicines); travelling abroad (e.g., back to their 
homeland or to take religious journeys such as Hajj or Umarh). Perceptions of 
healthcare providers (e.g., bad relationship and lack of trust); difficulties related to 
access and organisation of the healthcare system (e.g., difficulty consulting a GP of 
the same gender, lack of referrals to specialised care, problem with communication, 
language and translation, illiteracy); lack of involvement in the treatment decisions; 
and lack of knowledge and understanding due to lack of available information (e.g., 
problems with source, delivery, type and timing of information) may also contribute 
to the problems. However, many reported factors were similar to the general 
population such as concerns about unwanted effects of medication and how these 
weigh up against perceived benefits, perceptions of severity of disease and control 
of its symptoms, and difficulties related to access to care (e.g., appointment time, 
waiting time, short length of consultation, lack of doctors, difficulty consulting the 
same doctor). 
In terms of barriers specific to these particular populations, the current study 
provided evidence that Ramadan tended to be an important factor which 
influenced adherence to medications among study participants. A number of 
Muslim patients in the present study made some alterations to their medication-
taking behaviour to suit their fasting such as modifying the number of doses, time 
of doses and the time span between doses and even the total daily dose. Some of 
these actions were taken without consulting a doctor and without seeking medical 
advice. Patients also reported that their doctors did not talk with them about 
fasting and medicine taking unless they asked. This finding is consistent with those 
of Salti et al. (2004) who found that approximately 25-33% of Insulin or oral anti-
diabetic drug users changed their medication while fasting. Their study was 
conducted in 13 countries with the majority population being Muslim (Salti et al., 
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2004). A nother recent study also showed that Muslim patients adapted their use of 
medicines in different ways while fasting, for example by changing the time of 
intake or by skipping morning medicines (Mygind et al., 2013). In both studies 
patients did not always discuss these changes with HCPs. 
An implication of this is that HCPs should be aware that fasting may mean changes 
in medication-taking behaviours among Muslims, and thus HCPs should support 
Muslim patients by taking their views, concerns and preferences into consideration 
in relation to their religious needs to prevent any changes from being made. It is 
also important to individualise care on the basis of patients’ social, cultural and 
religious needs (i.e., specific medical advice must be provided to individual 
patients). If required, HCPs should make appropriate changes in their patient’s 
dosage regimen according to the prescription components. If changes are not 
required, HCPs need to deliver some proper pre-Ramadan month education and 
medical counselling in order to teach patients about how they can manage their 
medication regimen safely and effectively in Ramadan. The best way to educate SA 
and ME individuals should be in a group session at clinics, GPs, community centre 
and local masjids. Not only patients but also HCPs should undertake educational 
programmes about Ramadan and how to help patients achieve safer fasting. It is 
also recommended that the issue of altered medication-taking behaviours during 
fasting should be included in MUR.  
Participants in the present study reflected an attitude of fatalism and submission to 
God’s will in coping with illness, which might have an impact on their medication-
taking behaviours. Participants felt that their fate in terms of their health was 
dependent on God and they described a tendency to leave everything up to God’s 
will. This finding is in line with the literature where spirituality was reported and 
often shaped illness experiences and medicine-taking practices (Adams, 2003; 
Devlin et al., 2006).  
The potential for altered medication-taking behaviours or the potential for receiving 
conflicting advice from a HCP while travelling or being away from home either to go 
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back to their homelands or to take religious journeys such as for Hajj or Umrah was 
one barrier of particular importance and relevant for the SA and ME populations. 
Similarly, Ens et al. in their review found that SA patients tend to alter their 
medication-taking behaviours while travelling to their homeland or country of birth 
(Ens et al., 2013). This finding has important implications for raising the general 
awareness of SA and ME patients’ medication-taking and obtaining practices during 
travelling. For example, people with chronic diseases (e.g., diabetes) who are going 
for Hajj should have enough time to discuss it with a HCP and to consider a 
management plan for their illness. Pre-Hajj education seminars should be 
conducted. Travellers should take a sufficient supply of their usual medicines and 
also carry a written record giving the generic names in case further supplies are 
needed. 
A few participants reported taking non-prescription medicines to help manage their 
illnesses. These were perceived to have fewer or no adverse effects compared to 
other medications. Although the use of such remedies was not associated with non-
adherence to medications among the study participants, this has implications for 
healthcare providers as patients who use these remedies may not inform their 
healthcare providers, and thus run the risk of potentially serious interactions with 
prescribed medications, which may adversely impact their health. To avoid this, it is 
therefore essential for pharmacists and HCPs to question patients about their use of 
alternative therapies. More awareness of these remedies and their potential 
problems and hazards needs to be raised amongst HCPs.  
The extent of family support was identified in the current study as one of the 
factors that could lead to altered medication-taking behaviour. Almost half of 
participants received help with their medicines, mainly from family members. The 
current study identified the considerable role of patients’ families in their disease 
management in general and in medication taking in particular. Families were 
frequently quoted as an important source of support. For the majority of 
participants, this help was sought on a regular basis and in regards to almost all 
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aspects of medicine management. From 39 participants who received help with 
medicines, 26 (67%) reported having a low level of education (i.e., high school or 
below) and all of them had a first language other than English. The majority of 
participants who received help with medicines were younger age≤65 (n=32/39, 
82%) and were on ≤8 medicines (n=22/38, 58%). 
Strong evidence suggested that social support from family and friends can help 
patients take medicines correctly (Vaglio et al., 2004; Lee S-Y et al., 2006). However, 
researchers studying behaviours and outcome among older adults have 
hypothesised that social support might buffer the negative consequence of patients 
with limited literacy (Lee et al., 2006, Johnson et al., 2010). Johnson et al. concluded 
that social support was associated with better adherence for patients with 
adequate health literacy but not with limited health literacy (P<0.05) unless patients 
with limited literacy have a trusted person in their lives in whom they can confide. 
The reason for this was that limited-literacy patients were less likely to ask 
providers questions and infrequently brought relatives with them to the pharmacy. 
The findings of these studies were consistent with our study, which showed that 
participants who received help with medication from a family member were more 
likely to be identified with intentional non-compliance. One of the reasons for this 
could be due to inappropriate advice or information provided to patients by their 
families.  
A further reason for poor compliance identified in the current study was medical 
advice and prescription medication borrowing and sharing. Sharing prescriptions 
and medical advice among family members is commonplace (Avery, 2008). A 
qualitative study (Bolton et al., 2002) looking at medication management habits of 
residents from non-English speaking backgrounds (Chinese and Arabic) found that a 
significant proportion of these people practiced prescription medicine borrowing 
and sharing behaviour. Researchers identified a number of conditions that 
facilitated this behaviour such as sharing medicines with someone else if they had 
the same prescription or if they were a family member wanting the same 
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medicines. Patients borrowed medicines if they had run out of prescription 
medicine in the short term. Patients also lent their medicines if they wanted to help 
a friend or kept leftover medicines for ‘next time’. Studies also identified that 
patients asked their GP for the same medication that a family member had been 
prescribed. Most of these findings were similar to those of an American study 
(Goldsworthy et al., 2008).  
These results provide further support for the fact that the effect of family on 
patients’ compliance and safety should not be ignored especially for patients from 
SA and ME cultures. The result suggests that a family-centred approach to 
education by healthcare providers may be beneficial. It is therefore important to 
ask patients during consultation to declare whether they receive help or assistance 
with their medication and to describe the nature of support provided, how often 
and in which circumstances or occasions help is needed and whether the support 
obtained from these sources is accurate to promote proper use of medications. 
How family members view a medication, and the interactional relations between 
patient and family, should also become a vital question for clinical practice. The 
strong familial and social relations held within these societies can also be utilised by 
healthcare providers through involving family members in discussions and decisions 
about patients’ treatment plans and consequently this can help establish a positive 
collaboration with the family that will translate to improve compliance and prevent 
any negative effect that may occur when involving uninformed carers in patients’ 
care. Educational programmes via different media sources such as radio, television, 
and lecture courses are recommended and might be more useful within the SA and 
ME cultures. These can also help to correct the misconceptions and alter patients’ 
attitudes that have the potential to result in intentional non-adherence to 
medications among SA and ME patients.      
Participants in this study reported many problems with source, delivery, type and 
timing of information in having their medicine use and needs met. As regards 
source, 37 (48%) participants reported seeking information from one source in 
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which the doctor was the most frequently mentioned as the source of information. 
The rest of the participants (40/77, 52%) reported seeking information from more 
than one source in which the doctor remained the primary source of information.  
The identification of the source was dependent on patients’ views that doctor is the 
only person who has acquired the knowledge and skills for providing trustworthy 
and reliable information and solving any problem. Some of the responses 
demonstrated unquestioning trust in their doctors. Various studies reported that 
some SA and ME patients have unquestioning trust in their doctors in which 
patients agree with any decision the doctor makes with regard to their health and 
medication regimen (Thompson and Stewart, 2001; Bolton et al., 2002; Rashid, 
2010; Opara et al., 2010, Samman and Chaar, 2013). The reason for their belief may 
be the ‘high regard’ they hold for them or their limited options. For example, in this 
study patients who were unable to communicate in English were restricted to the 
opinions of doctors who speak the same language and thus are highly reliant on 
them.  
The problem with consulting only the doctor is that doctors do not always offer 
sufficient time and attention when patients want to ask questions and thus patients 
may stop asking and not take their medicines as instructed (Samman and Chaar, 
2013). Insufficient time spent with doctors may be linked to doctors being seen as 
too ‘busy’ or the consultation time being taken up by administrative tasks. Some 
patients in this study felt empowered and managed their own care and made active 
decisions without looking for further sources of information when they were unable 
to access or failed to receive sufficient information from their doctor.  
It was also identified that many patients from both ethnicities preferred to consult a 
doctor who speaks the language of patients’ native country instead of English, and 
this was not dependent on English proficiency or literacy skills of patients. They 
explained that they can better describe their health problems to doctors who speak 
their own language and are also better able to understand the information given to 
them, especially given that most patients even if they speak English may not know 
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medical terminology. Patients also expressed the belief that doctors from the same 
ethnicity shared the same language, social experiences and cultural beliefs; thus 
they were able to understand patients’ worries, concerns, problems, preferences 
and needs better. Different studies reported that patients tend to prefer physicians 
who are of their own race/ethnicity even if they are able to speak perfect English or 
are not first generation (Saha et al. 1999; Garcia et al. 2003), and also tend to use 
more healthcare and are less likely to postpone care when they have physicians 
who are of their own race/ethnicity (LaVeist et al., 2003). Race-concordant visits are 
longer and characterised by more positive effects (Saha et al. 2000). Shared 
language, social experiences and cultural beliefs may also drive some of the 
preferences to consult a doctor from the same ethnicity (Schecter et al., 1996; Saha 
et al., 1999). One study reported that, even if patients are not satisfied with GPs’ 
counselling, they prefer to consult a GP from the same ethnic origin, especially 
patients who are unable to speak or read English fluently (Samman and Chaar, 
2013).  
Patients also report higher satisfaction when they are able to choose their provider 
(LaVeist and Nuru-Jeter 2002). Kulwicki et al. (2000) found that non-culturally and 
linguistically diverse HCPs treat all patients similarly without attention to cultural 
needs. Schnittker and Liang (2006) concluded that racial/ethnic concordance 
promotes better encounters mainly among patients who prefer concordance. Thus, 
practices should give patients opportunities to choose their own doctor according 
to their preference if possible. However, it is not always possible to provide a HCP 
who speaks the same language as the patient.  
Another problem was that the majority of patients (60%) had never discussed any 
matters with their pharmacist especially among ME individuals. The reason for not 
consulting a pharmacist on issues regarding medicines was that some SA and ME 
patients hold views that pharmacists are only supplier of medication. They 
perceived pharmacists as not being responsible or capable of more than dispensing 
their medications and thus avoided communicating with them. These participants 
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were convinced that it was the doctor’s duty to tell them everything they were 
supposed to know about their medications, especially given that doctors are the 
HCPs who hold their medical records and prescribe medicines.  
The findings of the current study are similar to those of Thompson and Stewart 
(2001) and Samman and Chaar’s (2013) studies. Thompson and Stewart (2001) 
conducted a study to explore the culturally and linguistically diverse older 
population’s opinions on information received about medicines. The majority of 
participants including ME- and SA-language speakers identified GPs (90%) as the 
main source of information followed by pharmacists (57%). Pharmacists were most 
often seen as a supplement to the GP. Only occasionally were pharmacists seen as 
first point of contact. In patients’ opinions, the GP was the responsible person to 
tell them information about their medicines. Those who consulted pharmacists for 
advice perceived that this was mainly to query the GP’s information, while those 
who did not consult pharmacists reported that they were not interested in further 
information, either because they had enough or because they were concerned that 
they would get conflicting advice from doctor and pharmacist (Thompson and 
Stewart, 2001). The limitation of this study was that the proportion of older ME- 
and SA-language speakers was too small. A more recent study showed that Arabic-
speaking general practitioners followed by Arabic-speaking pharmacists were 
identified as the main source of medicines and disease information among older 
Arabic-speaking Australians (age>65 years) who were unable to speak or read 
English fluently (Samman and Chaar, 2013).  
A further reason for not consulting a pharmacist especially among ME respondents 
in this study was due to the absence of a pharmacist who spoke the same language 
as the patient, which may lead to lack of patient counselling and consequently poor 
patient satisfaction and adherence, especially given that much of the 
communication that takes place in the pharmacy is verbal. Unavailability of a 
pharmacist who speaks the same language as the patient hinders the patients’ 
ability to access information (Samman and Chaar, 2013). The evidence from this 
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study suggests that 
Some research has highlighted difficulties in accessing Arabic-speaking pharmacists 
(Quine, 1999). Thompson and Stewart (2001) advised of the benefit of having a 
register of pharmacists who speak languages other than English. Brown et al. (2007) 
suggested that patients prefer physicians with whom they share language and/or 
cultural concordance, to the extent that they are willing to pay more or travel a 
considerable distance to obtain racial/ethnic concordance in the physician-patient 
relationship, which improves care (Saha et al., 1999, LaVeist and Nuru-Jeter, 2002, 
LaVeist et al., 2003). This could also apply to the pharmacist-patient relationship but 
such positive relationships are less likely to occur when an area does not contain 
enough pharmacists of a given race/ethnicity to serve local patients who are of 
concordance with the corresponding race/ethnicity. In a qualitative study 
conducted among different ethnic groups to explore ethnic differences in attitudes 
to medicines and medicines-taking (Bassett-Clarke et al., 2012), lack of familiarity 
with pharmacy staff due to an increasing use of locum pharmacists and a younger 
generation of pharmacists with a different communication style translated into less 
discussion with pharmacists and therefore less opportunity to give and receive 
information. 
there was a great demand or reliance on HCPs who speak the 
same language as the patient for information. Thus, the preferred language spoken 
and read by the patient should be monitored. More bilingual staff should be hired 
in areas with a high percentage of SA and ME groups. 
Participants who consulted pharmacists had ambivalent views regarding these 
consultations. Many expressed negative viewpoints and reported that pharmacists 
were similar to doctors: they only provided the basic information regarding their 
medicines (e.g., how to take or use the medicine and therapeutic indication) 
whereas the more important and detailed information that patients needed and 
wanted to know such as side effects and how to cope with them were not provided 
unless patients asked. Participants who reported consulting a pharmacist revealed 
that this was partially because they could not consult a doctor who speaks the same 
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language and thus they had to consult a pharmacist with whom they were sharing a 
language, as mentioned earlier, or because their doctors did not provide them with 
adequate information or time to ask and thus patients valued any source of 
information to make informed decisions on how to manage their medicines 
effectively. Consulting pharmacists was not perceived as a substitute for receiving 
information from doctors but was seen as helpful.  
The pharmacists, therefore, need to promote themselves more as an information 
source. This may be more successful if pharmacists make an effort to increase 
prescription medication counselling. This would confirm in patients’ minds that 
pharmacists have the knowledge to answer questions and that provision of 
prescription medicine information is a necessary part of their responsibilities 
(Thompson and Stewart, 2001). For example, in the current study participants who 
hold positive views on pharmacists’ consultation were more likely to be those who 
had their MUR conducted or were counselled and provided with information that 
was tailored to their needs and preferences when approaching pharmacists. 
One of the significant research findings from this work was that the more patients 
consult a HCP, the more they are likely to get information about their disease and 
treatment, and the more information patients get may impact on the fact that they 
do not want to take their medicines either because the information was conflicting 
from different HCPs, which may create confusion, or because the information was 
scary and caused unnecessary anxiety, particularly in relation to side effects. This 
result should be interpreted with caution because no figures were found to show 
the rate and/or content of counselling given by hospital consultants. Thus, how 
consultants interface with their patients and what type of information they provide 
has to be tested in future studies. This finding is inconsistent with another finding 
which showed that the more information that is given, the better is adherence 
(Maidment et al., 2002). It is well known that providing patients with information 
about prescribed medicines is essential to understand the benefit and risks of 
medication and to facilitate their appropriate use (Horne, 2001). However, 
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providing basic information such as how and why to take medicine does not 
guarantee the appropriate use of medication; rather, the information should be 
tailored to meet the needs of the individuals (Peveler et al., 1999). People 
prescribed the same medicines may require different levels of information. For 
example, in this study some participants reacted by becoming actively involved with 
their treatment and seeking detailed information about aspects such as possible 
side effect of their medicine and how to cope with it. Others, in contrast, responded 
with more ‘avoidant’ coping strategies, for example, by thinking about their illness 
and medicines as little as possible or wanting others to ‘take charge’, and may find 
additional information unhelpful or even distressing. Thus, the quality of the 
information is more important than the quantity. The quality of information refers 
to the extent to which individuals perceive that information has met their needs 
and are satisfied with the information provided (Horne et al., 2001). 
Besides the source, content and type of information, also the timing and moment of 
providing information was seen as a barrier for meeting patients’ health and 
medicines needs. There were inconsistent views among participants regarding an 
appropriate time for providing information. Many participants reported that it was 
enough to provide verbal information on medicines at the time of diagnosis or first 
prescription whereas others wished the information to be repeated and updated 
regularly during routine consultations for many reasons: firstly, patients’ 
information needs may change according to their situation and experiences. 
Secondly, 40-80% of medical information provided by HCPs is forgotten 
immediately. In addition, almost half of the information that is remembered is 
incorrect (Kessels, 2003). There are three basic types of explanation for why 
patients forget verbal information. First, HCPs using difficult terminology; second, 
the mode of information (e.g., spoken versus written); and, third, factors related to 
the patient such as low education or specific expectations (Kessels, 2003).      
It was identified that the way the information was delivered to many patients by 
HCPs was not tailored to their preferences and needs. Many patients indicated that 
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the only medicine information they received was in the form of verbal dosing 
instructions, which can be easily forgotten by some participants. In addition, 
patients had never been told about alternate forms of information and had never 
been given any written information about their medicine except for the patient 
information leaflet (PIL), which is always in English. Even the PIL was not given to all 
patients. Houts et al. suggested that written information is better remembered and 
leads to better treatment adherence (Houts et al., 1998). 
Written instructions, however, presented difficulties to some patients with low 
education or literacy and who were non-native English speakers. It was indentified 
that the majority of participants (10/13, 77%) who wanted more updated and 
repeated information had no university education and none of them had English as 
their first language. Doctors routinely take for granted patients’ ability to read and 
understand all types of health-related materials (Kessels, 2003). In reality, many 
patients have difficulty communicating with their healthcare professionals and 
following up with self-care instructions due to poor understanding of basic health 
vocabulary, limited background health, and limited education and native-language 
skills (Kessels, 2003).  
Those who had limited language or literacy skills reported relying in their family 
members to obtain information from GP surgery or pharmacy and interpreting 
English verbal or written information about medicines, which they described as 
inconvenient. Participants also reported that family members may lack the 
necessary skills to fully communicate their message to the doctor or the doctor’s 
advice to the patient. It is possible that family members also felt embarrassed to ask 
sensitive questions and overwhelmed when relaying bad news or were no longer 
available for interpreting owing to work and family commitments (Weissman et al., 
2006). Untrained family members’ inability to adequately read and speak Arabic or 
English may compromise the patient’s health owing to a lack of training, medical 
vocabulary or health literacy required to understand and communicate information 
accurately (Weissman et al., 2006). Patients who did not have a family member to 
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act as an interpreter reported that they were not even provided with any other 
interpretation resources by primary care health professionals despite their request, 
which hindered their ability to access information and to seek care. Other 
researchers have found medicine and disease information targeting ME or SA 
languages speakers to be deficient (Kulwicki et al., 2000; Girgis and Ward, 2004).   
Where communication problem exist, patients are less likely to consult about their 
ill health in the first place; the lack of a shared language can hinder the 
development of trust, increase the likelihood of healthcare staff failing to recognise 
the complexity of problems and decrease patients’ adherence to medical 
recommendations (Rivadeneyra et al., 2000). Interpreting may involve distortions: 
details may be omitted, statements added, concepts substituted, and complicated 
responses simplified or condensed (Jentsch, 1998). An interpreter may not speak 
the same dialect as the patient, while class differences and the interpreters’ own 
perception of their role reduce effective rapport with patients and hinder faithful 
interpretation. Confidentiality can be a concern for patients when interpreters are 
drawn from a small local community (Plunkett and Quine, 1996). In addition, the 
patient’s competence and control over communication are downgraded, patients 
are likely to make fewer comments and the ones which they do make are more 
likely to be ignored, the presence of a third party can disturb the flow of the 
consultation, and communication becomes indirect and more complicated 
(Rivadeneyra et al. 2000).  
Direct communication with bilingual professionals may well be preferable, although 
this clearly depends on the professionals’ own consultation and communication 
skills (Baker et al. 1998). For many patients, trained interpreters are not available 
when they are needed. This may occur if there are small numbers of patients from a 
particular community in an area, if appointments are made at short notice and 
interpreters are already committed elsewhere, or if the numbers of interpreters 
available are too low to meet demand (Brooks et al. 2000, Chamba and Ahmad 
2000). Other approaches have been developed in order to address some of the 
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shortcomings. Simultaneous translation, the approach used at international 
conferences, has been found to involve more utterances by both clinicians and 
patients than sequential interpreting and is more accurate (Hornberger et al. 1996). 
This method can, however, be more stressful for the interpreter. More readily 
available are telephones interpreting services (Jones and Gill 1998), but their cost 
can deter frequent use. Calling on nursing or administrative staff may appear to be 
a practical alternative, but such staff rarely have formal training or the skills that are 
needed; errors in translation can be common and topics that embarrass the 
translator may be omitted (Elderkin-Thompson et al., 2001). 
It is well known that patients require information to empower them in their 
medicine-taking practices (Patel and Dowse, 2013). Determining patient 
information needs and health information-seeking behaviour is a patient-centred 
approach. If information needs and wants of patients do not match the information 
given by HCPs, decrease in self-management, self-care and adherence to 
medication as well as increase in dependency on healthcare services may occur. 
Thus, HCPs have responsibility and a duty of care to provide high-quality, tailored 
information (verbal and/or written) to patients to ensure their safe use of 
medicines. ME or SA languages speaking health literacy can be improved through 
the use of audio materials such as CDs, or visual materials such as videos, cartoon 
instructions or pictorial diagrams (Samman and Chaar, 2013). Even patients who 
read well often prefer non-written materials including straightforward picture 
books, videotapes or multi-media presentations. If written materials are required, 
they should use plain language at the fifth-grade level or lower. Health educators 
stress that people of all literacy levels prefer materials that are simple and easy to 
understand. Because many standard patient education materials are written at a 
high school or college level, they are often inaccessible to patients (Parker, 2000). 
Providing simple, accessible materials could reduce their fear of disease and 
treatment, empower them to take greater control over personal health, increase 
their options and allow their decisions to be more conductive to their health 
(Samman and Chaar, 2013). It has been reported that personal interaction in the 
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form of counselling or group sessions might be more successful than simply handing 
out pamphlets; these may be useful as a reference or refresher of patients’ 
knowledge but should not substitute ongoing patient education and follow-up. 
The current study has shown that MRPs can be identified during the daily routines 
of community pharmacists. The Government has outlined plans on how the role of 
pharmacists should be extended in primary care, including a policy framework by 
which community pharmacists can be involved in prescribing and the provision of 
medicines’ management and medication review services. This would help the 
pharmacist to play an active and effective role in the management of medicines and 
help to reduce the number of patients who consult GPs about their medicines. 
Many studies have reported pharmacists’ ability of working with GPs in areas of 
medicines’ management and detection of MRPs.  
SA and ME patients have little regard for the role of the pharmacist when it comes 
to managing their medication regimen; patients consider that the doctor holds 
more knowledge and revealed that they would only consult a doctor with any 
health issues (Aslam et al., 2001). Patients need to be educated about the role of 
pharmacies, and how pharmacists can help in case of side effects, minor ailments 
and any other health query. If patients are able to understand the role of 
pharmacists, the number of GP appointments will be significantly reduced and the 
GP will be able to spend more time with patients with more severe cases. 
Consequently, access to healthcare services will also be improved as patients will be 
consulting the right HCP for the right problem. This will effectively reduce the 
current burden on the NHS and health costs will be considerably reduced, allowing 
PCTs to spend more money on other areas of healthcare (Aslam et al., 2001). More 
importantly, findings of the present study highlighted the need for greater 
involvement of pharmacists in the care of SA and ME patients through much-
needed patient education and counselling. With patient counselling pharmacists are 
in a great position to identify and correct any false beliefs patients might have 
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about medications and address any concerns they might have to make sure they 
have a better understanding of their medications. 
Pharmacist should be encouraged to do MUR to patients to help patients manage 
their medicines more effectively. During this review pharmacists also can provide 
patients with appropriate information and advice about their medicines. The NHS 
community pharmacy contract details three levels of pharmaceutical care services: 
essential, advanced and enhanced services. Essential services such as dispensing 
were provided to SA and ME patients. However, evidence of provision of advanced 
services including medicine use reviews was lacking. This standard of care was not 
met for most of the patients interviewed. Most patients limited their interaction 
with community pharmacists to the re-supply of prescribed medicines or 
recommendations to treat minor ailments. Pharmacists can review patients’ 
medication records held in the pharmacy and target MUR at those at risk of 
experiencing MRPs. However, in practice there is still an ongoing debate about the 
profitability of an incentivised MUR service, where the objective is to meet target 
levels and not necessarily to focus on patients who are most in need of MUR 
(McDonalds et al., 2010). Concerns over GPs’ indifferent attitudes to patients’ MUR 
reports and feelings of territorial encroachment may discourage the provision of 
this service to relevant individuals (McDonalds et al., 2010).            
This finding can inform the development of strategies to improve SA and ME 
patients’ understanding of their medicines and diseases and ultimately their quality 
of life. These strategies may lead to decreases in costs to patients and the British 
government through efficient health service delivery and better focused 
programmes. GPs and pharmacies in areas where non-English speaking residents 
are numerous should employ interpreters and bilingual staff, and utilise software to 
translate labels into variety of languages (Samman and Chaar, 2013). 
Some participants in the present research study, who revealed that they frequently 
consulted a GP and/or nurse, still thought that their illness and medicines were not 
sufficiently reviewed. Reasons for why there was a lack of discussion were 
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highlighted by some participants, such as lack of time and doctors to review 
patients, bad relationship with doctor, and lack of trust and confidence in 
healthcare professionals and healthcare system. 
Some participants found that the consultation time with the GP was rushed and 
they were not always listened to and they could not ask questions or discuss more 
than one problem each visit. Those who reported to have inadequate time with 
their GPs accessed care more (i.e., emergency GP consultations), had poor 
adherence and lacked information. More time means that there is time to listen to 
the patient, to arrive at a better understanding of the patient’s concerns and come 
to a more accurate and thorough diagnosis, to focus more on the patient and on 
the disease, and to have more time to work together to arrive at an acceptable 
treatment plan which may improve health outcomes. In contrast, not considering 
patients’ perspectives, wants, needs and preferences within the consultations and 
not involving them in decisions about their treatment plan increased patients’ 
dissatisfaction and anxiety and influenced their adherence. For several years GPs 
have found that consultation times are pressured and patients have expressed 
dissatisfaction with the time available with their doctors in satisfaction surveys (Hill 
and Freeman, 2011). Research showed that longer consultations are associated 
with better outcomes. More time means that there is time to listen to the patient, 
to arrive at a better understanding of the patient’s concerns and come to a more 
accurate and thorough diagnosis, to focus more on the patient and on the disease, 
and to have more time to work together to arrive at an acceptable treatment plan. 
This is shared decision-making. Where patients feel listened to, and have had their 
own views taken into account, they are more satisfied with the time they had with 
their doctor. 
A number of participants felt neglected and detached due to the lack of attention 
given by their GP and described their fears of not being supervised more closely and 
not even being referred to a hospital specialist despite their request, which led to 
frustration and exasperation. When a participant wanted to be referred, this may 
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indicate a lack of trust in the competence and resources of the primary medical care 
provider or a strong belief in the competence and resources of the consultants. Bad 
relationship and lack of trust in healthcare providers led some respondents to be 
less likely to listen to the doctor’s advice and subsequently less likely to adhere to 
their medicines. 
Patients' desire for participation in decision-making and participation in other 
aspects of care differed between participants. Some patients expressed their desire 
to become more involved, engaged and responsible for decision-making for their 
own care. This can be facilitated through partnership, communication, information, 
and additional time and staffing. Even for those who did not want to be involved in 
their own care, trusting their doctors and nurses to care for them and to make 
appropriate treatment decisions, being able to ask questions and understand how 
decisions were made is important. Little et al. (2001) studied patient preferences 
for a patient-centred approach to consultation in primary care and the results 
strongly showed that partnership and communication (i.e., a sympathetic doctor 
interested in a patient’s worries and expectations and who discusses and reaches 
agreement on the problem and treatment), health promotion, a positive approach 
(i.e., being definite about the problem and when it would settle) and interest in the 
problem’s effect on patient’s life were the key elements of patient-centred 
healthcare that patient wanted. If patients did not receive these elements, they 
were less satisfied, less enabled and may suffer greater symptom burden and use 
more health service resources (Little et al., 2001).  
Longtin et al. indicated that patient participation in their own care is limited by 
many factors such as rejection of new patient role, lack of health literacy and lack of 
medical knowledge, and lack of confidence in own capacities and type of decision-
making required; for instance, most participants want to participate in major 
decision-making (e.g., whether to undergo coronary bypass) but are less interested 
about minor decisions (e.g., prescription for their illness) (Longtin et al., 2010). In 
addition, the desire to participate in decision-making and to be involved in the 
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treatment process is inversely proportional to the patient’s disease severity in most 
of the conditions. Other obstacles that may also hinder patients’ participation 
include older age, being a male, from a low socioeconomic class and from an ethnic 
minority background. Finally, patients who use alternative medicines might be more 
involved in healthcare-related decisions, although these findings lack consistency 
between studies (Longtin et al., 2010). Among healthcare workers, the acceptance 
and promotion of patient participation are influenced by desire to stay in control, 
lack of time and type of illness. Primary care physicians were more likely to 
encourage patient participation than specialists. Additionally, non-White physicians 
were less likely to encourage patient participation (Longtin et al., 2010). It can be 
seen that there are many obstacles hindering participation in patients’ own care 
which are applicable to our study. By highlighting these barriers, HCPs can estimate 
what level of involvement patients can have and how to address these barriers in 
order to support patients and encourage them to participate in their own care.     
11.2 Personal reflections about the research 
In qualitative research, it is important for researchers to understand and be aware 
of their own positions in the research process and how their personal 
characteristics and/or experiences might have influenced choices made in the 
research process, their understanding of the research participants, the 
phenomenon under study, or both, and ultimately, the knowledge constructed. It is 
now accepted that cultural, social, professional, biographical, and personal 
characteristics influence what is perceived, experienced, interpreted and reported. 
Consequently, reflexivity about the research process is considered an important 
task of qualitative researchers: 
“Without such reflection the outcomes of the research process are 
regarded as "characteristics of objects," as "existing realities," despite 
their constructed nature that originates in the various choices and 
decisions researchers undertake during the process of researching”. 
(Mruck and Breuer, 2003) 
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Reflexivity is the process of looking both inward and outward with regard to the 
positionality of the research and the research process (Shaw and Gould, 2001). It is 
also part of the production of knowledge (Blaxter et al., 2006). Clearly, researchers 
will always have an effect on the setting and the people they are studying since they 
have their own knowledge about these and data collection may be modified by 
their presence. They also play an important part in analysing and interpreting the 
data that is produced. In short, researchers cannot avoid having an impact on the 
process of research (Kosygina, 2005).  
In this section I will reflect on how my personal characteristics and background may 
have influenced the research process and findings. I believe that my personal 
characteristics, in terms of gender, religion, culture and professional background 
have put me at a distinctive place, which proved advantageous in terms of 
facilitating the research process. However, my personal characteristics and 
background may have also potential negative impacts on the findings in which the 
results might be biased by my gender, religion, culture and professional 
background.  
As a Middle Eastern researcher, I felt that I was perceived by the research 
participants as an ‘insider’, someone who shared the same cultural norms and 
belief system of the Middle Eastern community. I believe that this has placed me at 
an advantageous position which facilitated the research process in so many ways, 
for example, it enhanced co-operation and easier recruitment. I also felt that, as a 
result of my cultural background, participants felt an immediate connection and 
were happy to disclose and share information with me. This was apparent as some 
ME participants when they talked to me they used the word ‘we’ for ME group. This 
was also evident as some participants made their feelings explicit in terms of my 
cultural background: 
 “You are our daughter, we have to help you” 
“You make us and the Arabic culture very proud. God bless you!” 
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In addition, it might have also made it particularly easier for ME participants to 
interact freely and encouraged them disclose and share their feelings, worries and 
concerns about MRPs and needs. ME interviews lasted longer and produced more 
information on issues regarding medicine use and service access. This may be the 
result of MEs talked in their own language, or may be related to both interviewee 
and interviewer being of the same culture.  
I believe also that my Muslim faith had an influence on the participation rate and 
the research process. I always wore Islamic dress (hijab) which might have 
influenced the participation rate among Muslims from both ethnicities. Sharing the 
same faith with the majority of my participants I felt helped to create an instant 
connection between us, and the talk of God and Islamic values and beliefs painted 
most interviews. Nevertheless, the expectations of being a practising Muslim may 
have had a minor drawback with respect to participants revealing practices that 
might be judged as sins in the Muslim faith, such as the intake of alcohol. Only one 
participant admitted to consumption of alcohol, and I felt from the tone and facial 
expressions that he was not at ease to disclose such information.  
My gender role as a female had a potential influence on the research process. In ME 
culture, there are defined gender-roles, which people are supposed to play and live 
by. Females are not supposed to mix with or talk to males, unless necessary. I was 
aware of that issue from the outset of my research and wondered whether there 
would be a problem recruiting and talking to male participants. I was afraid that 
males may not welcome or feel comfortable talking to me (as a female) about their 
disease, medications, etc. in sufficient depth and sincerity to allow the aims of the 
research to be achieved. However, after the pilot study with five participants in 
which four of them were male, my worries resolved as I was able to engage with 
male participants in a professional way that it was easy for them to share their 
stories with me. At the end of data collection, the analysis of interview transcripts 
showed that I was able to gather data of similar quality and depth from the male 
participants as that of female participants. 
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Nevertheless, there was an issue which might have been brought about due to my 
gender as a female and might have been disadvantageous in the research. 
Specifically, when I asked participants questions related to certain type of 
medicines or certain type of conditions, these were often not fully, freely or directly 
discussed. This is possibly due to the intimacy of the issue, complicated by my 
gender as a female. Discussing sexual problems and medicines for such problems 
are considered culturally inappropriate and embarrassing, particularly with 
someone of the opposite sex, even if that person is a healthcare provider. 
As an unmarried young female researcher, I utilised the device of fictive kinship to 
neutralise cross gender relations. I used fictive kinship terms such as ‘brother’ or 
‘sister’ when speaking with participants, especially with male interviewees who 
were closer to my age. This is a common practice among Muslims because it means 
that each one deals with the other with respect and as socially neuter (Al-
Makhamreh and Lewando-Hundt, 2008). I also had a concern about interviewing 
male interviewees in private consultation rooms, and thus I conducted the 
interviews in an open area in the pharmacy or in a private consultation room by 
leaving the door slightly open or pulling up the curtains. This was important 
because of issues of safety, reputation and culture. However, this could have also 
been negative due to lack of privacy from other clients. 
Despite being an ‘insider’ as a ME researcher, I was also ‘an outsider’ to the 
research participants, as I was unfamiliar with the life and contexts of patients who 
had a long term condition. This might have had an influence on how they might 
have perceived me, and consequently, behaved towards me. Therefore, I had to 
find a balance between being sensitive and responsive to the issues and concerns 
participants raised in a way to allow them to share their stories, and yet not 
influencing what they had to say in any way.  
In terms of my identity as a researcher, I chose to introduce myself as a PhD student 
and a pharmacist. Therefore, participants might have suspected an association 
between myself and their healthcare providers. Consequently, they might have 
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concealed critical information fearing that I might share it with their healthcare 
providers, ultimately influencing the care they would receive. However, participants 
were assured that the information they provide was confidential and would not be 
shared with their healthcare providers. I believe this helped to put participants at 
ease and the amount of criticism to healthcare providers assured me that, to some 
degree, participants trusted in me and provided me with their true accounts of how 
they felt about their healthcare providers. 
Despite being an ‘outsider’ as some of the patients talked to me by saying “us and 
you” locating me as a young and healthy person, I was an ‘insider’ from another 
perspective: that of a carer of my parents.  My father and mother had more than 
one chronic condition and were using more than 3 regular medicines. My 
experience as a relative and carer of my father and mother inevitably shaped my 
views on MRPs among people of Middle Eastern culture. It allowed me to approach 
the study with some knowledge (i.e., having ‘cultural intuition’ and insight) about 
the subject and to address certain topics more easily or even be aware that I should 
address them. Sharing the experience diminished the distance and affected 
interviewees’ expression. They sometimes left sentences unfinished, acting under 
the assumption that “you know how.....” (e.g., inability to speak English and get 
interpreter). I knew too well what they were talking about as I had many relatives 
and friends with limited English proficiency. Because of my insider position, I had to 
be constantly alert and rigorously reflect on how my presence and how I am shaped 
the conversation as well as explain that while we may have shared experience, it 
was different for each and I want to learn theirs.      
Another issue that became apparent, especially with illiterate patients or those who 
had a low educational level, is their perceived class difference. Some participants 
clearly stated their disadvantaged position compared to me (as an educated person 
who can read and write, and who is also a pharmacist): 
“You are a pharmacist, you can read and write and speak English, so you 
could easily understand these things (meaning detailed information 
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about medicines), whereas I don’t. I am just a simple person, I cannot 
speak English and I cannot read and write.” 
However, despite the perceived difference, participants were incredibly willing to 
me talk freely, and I did not feel they had reservations or intention to withhold 
information. In fact, I felt that participants were actually happy to have had the 
chance to speak for themselves and to be heard. They somehow thought of this 
research as an opportunity to raise their issues and concerns, hoping that the 
findings from this research would help to solve at least some of these problems. 
After completing data collection, I was in the process of analysing my interviews; I 
found one disagreement between the literature and the reports of participants 
related to the influence of family on medication-taking behaviours. While family 
support was associated with better medication adherence in the literature, some 
participants in my study described that family support may lead to suboptimal 
medication adherence. As I was becoming a carer and I saw my parents giving 
advice to each other and sometimes sharing their tablets, I started to question the 
applicability of generalisation and I recognised the need for a more differential 
approach to examine ‘extent of family support’ in different cultures. 
As I was going simultaneously through the processes of analysing the data and 
taking on some caring responsibilities, my insights and reflections of what I 
understood from the literature was gradually changing. Horsburgh (2003) indicates 
that findings of research represent the interpretation by the researcher of 
constructs developed and conveyed by participants. As I was taking some caring 
responsibilities, my way of understanding the issue of family involvement in 
patient’s medication-taking behaviours changed to expand my perspectives and 
include new dimensions of the roles and relationships between patients and their 
families from different cultures. I visited and revisited interviews that I analysed, 
looking at them thoroughly and finding differences to which I was blind before (e.g., 
whether patients receive help or assistance with their medication, and to describe 
the nature of support provided, how often, and in which circumstances or occasions 
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help is needed, and whether the support obtained from these sources was accurate 
to promote proper use of medications). 
Studying the unfamiliar, such as South Asian culture may also be a barrier to 
identifying appropriate themes or issues. A stranger to the culture may miss clues 
or problems that are clear to an ‘insider’. In analysing the interviews with South 
Asian participants, I compelled myself to diligent content analysis and made a 
deliberate effort to put myself in the role of a learner from my teacher, the 
participants, to develop reciprocity with participants for the goal of equalising the 
research relationship and conducting research ‘with’ rather than ‘on’ (Pillow, 2003).      
Reflexivity may be linked to issues of possible bias. For example, when researcher 
and participants share experiences, the assumption of researcher’s familiarity with 
participants’ realities carries the dangers of participants withholding information, 
they assume to be obvious to researcher and researcher’s taking for granted 
similarities and overlooking certain aspects of participants’ experience (Daly, 1992). 
However, attention was given to the issue of bias and the researcher received 
training about how to administer the questionnaire to participants in the exact 
same way. The importance of a non-judgmental tone of the researchers was 
emphasised, as was the importance of not influencing participants’ responses in any 
way. Probes were used only to aid in deeper exploration of the participant’s 
perspectives, and leading questions were avoided as they could introduce bias. In 
addition to training of the researcher, data gathered were examined for validity, 
internal reliability as well as what is known already from the literature in order to 
ensure that the data are authentic and reflect the experiences of all participants. 
Using a variety of sources for data gathering (i.e., mixed method approach and 
triangulation) and checking the audio-records and transcripts by the research team 
were also followed to avoid any possibility of bias. To secure that the data analysis 
was a trustworthy representation of the themes in the narratives rather than 
reflection of my biases, the research team was constantly consulted to consider the 
accuracy of the analysis. 
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11.3 Strengths and limitations of the study 
Strengths of the study 
• An important strength of this study was that the majority of study 
participants [MEs: 40 (100%), SAs 35 (88%)] used non-English speaking 
languages and were all from ethnic minority backgrounds, resulting in data 
which were rich in description of their views, concerns and needs regarding 
MRPs, especially given that medicine-related concerns and needs have not 
been addressed in any other study especially among SA and ME groups. 
Patel et al. (2003) reported that approaching ethnic monitories and non-
English speaking groups is one of the challenges in recruitment of research 
participants and these groups are often inadequately represented in 
research. 
• The methods employed in this research allowed access to participants’ views 
without using translators during interviews, thereby enhancing the quality of 
the data. 
• A further strength is the use of mixed methods and triangulation method 
(i.e., the process of synthesising data from multiple sources). Triangulation 
in the current study enhanced reliability and validation. It also captured a 
more complete, holistic and contextual representation of MRPs. Therefore it 
played an important role in eliciting data and suggesting conclusions to 
which other methods would have been blind. 
 
Limitations of the study 
• There are some disadvantages to using the daily consultation method in 
pharmacies. One of them is that if the prescription was taken to the 
pharmacy to be dispensed by a patient’s representative, the patient was not 
available for recruitment. This was particularly true for women from SA or 
ME backgrounds who usually sent their husband or daughter or son to order 
or collect their medicines either because they were busy, housebound or 
unable to speak English. 
• The sample of this research consisted of SA and ME patients with chronic 
diseases, therefore, results may not be transferrable to patients from other 
ethnic backgrounds. Although barriers related to healthcare providers or the 
healthcare system may be applicable to other ethnic groups living in the UK, 
careful attention must be paid before transferring the conclusions to other 
contexts. 
• There is a possibility that inequality in recruitment in this study occurred 
between ethnic groups because of the inability to support the range of 
minority languages. However, the number of people who were ineligible 
was few (n=18) and it is possible that they would have refused to take part 
in the study but we have no evidence to support this possibility.  
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11.4 Implications for practice and policy 
Findings of this research can be used to provide the foundation of programme 
development and aid in the design of culturally sensitive interventions to identify, 
solve and prevent MRPs. Where limited resources are available, targeted 
interventions may be most useful. It is recommended that interventions need to be 
guided by research findings, and that targeted interventions are formulated based 
on these findings (MRC, 2008). Results of this study show that MRPs may lead to 
medicine mismanagement and affect patients’ safety. If no action is taken into 
account to address MRPs and to support these patients, this will lead to poor 
chronic disease management and consequently more hospitalisation, co-
morbidities, and wasted resources. Therefore, it might be useful to adapt a 
preventive approach which identifies, resolves and prevents MRPs. Healthcare 
providers, especially pharmacists, should make MRPs identification and prevention 
a standard part of the consultation process. Targeted MUR for SA and ME groups, 
for example, should be prioritised. The targeted MUR can be developed further to 
focus on all the issues that were reported to be specific to SA and ME groups. For 
instance, a checklist which asks patients about their medication-taking behaviour 
while fasting should be included. Asking patients about medication-taking and 
obtaining practices while travelling is also recommended in MUR. It is also 
important to ask patients during consultation to declare whether they receive help 
or assistance with their medication and to describe the nature of support provided. 
Targeted interventions may be then tailored according to different patients’ need 
on an individual basis. 
The MRPs questionnaire has the potential to be advanced and developed as part of 
a medication use review for the detection of MRPs in patients with chronic disease 
from all ethnic backgrounds. One way of doing it, for example, is that the MRPs 
questionnaire could be developed into a simplified questionnaire loaded on 
computer and administered to patients by a HCP or it could be developed into a 
self-assessment questionnaire that is completed by patients. If the MRPs 
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questionnaire is completed personally by the patients, case scenarios can be 
developed and, after completing the results, these can be judged by a HCP. This 
method may also allow a HCP and a policy maker to measure the extent to which 
they are effectively addressing the needs and concerns of SA and ME groups in the 
community they serve. However, this method may work for some but not for 
others. 
Attempts should be made to increase patients’ education to address the knowledge 
deficits, particularly in relation to the nature of illnesses, seriousness of diseases, 
and their potential complications through a group session or lecture courses at 
clinics, GPs, community centres, local masjids and temples or through educational 
programmes via radio and television. Perhaps this can be achieved through 
interventions whereby patients are given the opportunity to live the experience of 
having illness complications before their occurrence. This may be achieved through 
joining disease-specific support groups (e.g., diabetes support groups) and sharing 
sound experiences with identified group leaders and other unfortunate members 
who have already developed advanced diabetes complications. Sharing experiences 
with those who have lost their sight or limbs due to diabetes may allow patients to 
appreciate the severity of diabetes complications and adopt preventive approaches 
and healthier lifestyles including better adherence to their medications.  
Proper pre-Ramadan and pre-Hajj month education and medical counselling should 
be encouraged. HCPs should be well informed about the religious practices of 
individuals practising a faith that can affect their chronic condition. A guide for pre-
Ramadan and pre-Hajj counselling should be designed. Each patient’s treatment 
plan should be individualised and reviewed on an annual basis as their health status 
may have differed from the previous year. Healthcare professionals should use 
Islamic leaders in the community as a source of support to convey key health 
messages. A guide that supports HCPs to understand the implications of, for 
example, fasting in chronic disease, the advice they can offer their patients in a 
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culturally sensitive manner and where to refer to for help and information should 
be designed. 
A family-centred approach to education would be beneficial as findings of the 
current study showed that the family constitutes a vital source of support to SA and 
ME patients. Involving family members in discussions and decisions about patients’ 
treatment plans would be beneficial to patients if they agreed to involving their 
families in their own care. Also, how family members view a medication should 
become a vital question in practice. Educational programmes via different media 
sources such as radio, television, and lecture courses are recommended and might 
be more useful within the SA and ME cultures. These can also help to correct the 
misconceptions and alter patients’ attitudes that have the potential to result in 
MRPs among SA and ME patients. 
The preferred language spoken and read by the patient should be monitored. 
Where there is a need, letters to patients should be provided in different languages 
according to their needs and more multilingual staff should be hired in areas which 
have a high percentage of SA and ME groups. Improving patients’ languages 
speaking literacy should be made through the use of audio material such as CDs, or 
visual materials (e.g., videos, cartoon instructions or pictorial diagrams). If written 
materials are required, they should use plain language at the fifth-grade level or 
lower. Providing written information in the most commonly spoken languages in 
the UK for key drugs and key diseases such as cardiovascular, diabetes, and cancer 
is recommended. Also, developing a PMR system where pharmacists can print out 
labels in different languages was seen as helpful. 
Adopting a patient-centred approach in delivering care is highly recommended, 
whereby doctors would involve patients as equal partners in all decisions about 
their treatment, especially in relation to medication selection and prescription. 
Eliciting patients’ priorities, identifying their expectations towards illness and its 
treatment and translating these into realistic objectives for the individual patient 
should be conducted. 
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Patients’ information on electronic databases should be accessed and shared 
among all healthcare providers involved in patients’ care. Religious, social and 
cultural beliefs and lifestyle priorities should be addressed and incorporated into 
patients’ medical records. 
HCPs need to be educated in the differences when dealing with a multi-cultural 
population. They need to be aware of the different social and cultural factors of the 
ethnic community and how it can influence their attitudes and behaviours towards 
complying with their medication regimen. 
Pharmacists have contributed significantly to the development and implementation 
of intervention strategies to reduce MRPs experienced by patients in the 
community. This is possibly because, at the community setting, the community 
pharmacists have the time and opportunity for face-to-face contact with the 
patient, which could be a factor that may be associated with better implementation 
of community pharmacy services. The findings of the current study strengthen the 
evidence that talking to patients and carrying out medication reviews through 
community pharmacy services can identify, solve and prevent MRPs. Nevertheless, 
interventions to identify and solve MRPs should be a shared responsibility of all 
HCPs. Mason and Bakus (2010) suggested an eight-structured process that can be 
adapted by all HCPs in identifying and resolving MRPs: 
• Obtaining an accurate medication list that truly reflects what the patient is 
taking. 
• Evaluating whether each medication is necessary or whether any other 
medication is required. 
• Determining whether each medication is the preferred one for its indication; 
• Assessing that dosage and regimen are correct. 
• Reviewing the medication list for ADRs and DIs. 
• Ensuring that proper monitoring and review takes place. 
• Assessing adherence and causes of non-adherence. 
• Resolving any discrepancies between the actual list and the one in the 
patients’ records. 
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For the SA and ME population, the researcher suggests an addition of another three 
points to the process: 
• Working with carers and patients in the monitoring, prevention and 
resolution of MRPs to deliver high-quality pharmaceutical care. 
• Empowering patients to be confident to take charge of their medications. 
• Encouraging patients to register with their community pharmacy for 
extended services like Chronic Medication Service to help ensure patients 
are on the right medicines and understand how to get the best out of their 
medicines. 
 
From April 2014, all elderly patients (age≥75) will be assigned a named GP to co-
ordinate their care. The responsibilities of these GPs will be to:  
• Take lead responsibility for ensuring that all appropriate services are 
delivered to the patient. 
• Where required, work with relevant associated health and social care 
professionals to deliver a multidisciplinary care package that meets the 
needs of the patient. 
• Ensure that the physical and psychological needs of the patient are 
recognised and responded to by the relevant clinicians in the practice; 
• Ensure that the patient has access to a health check if requested. 
 
This will enable patients to establish a continuity of care with one HCP. Research 
evidence shows that continuity of care is associated with better understanding of 
health condition and treatment, medicine usage and adherence, and with cost 
saving in prescribing, hospital admissions and referrals, and use of A&E and overall 
cost of healthcare (Alison and Freeman, 2011). It is also associated with increased 
trust, security in doctor-patient relationship and reduces unnecessary and harmful 
medical intervention (Alison and Freeman, 2011). It will also increase awareness of 
the religious, cultural and social aspects of ethnic minority groups among health 
professionals. It was suggested that such awareness would aid the provision of 
individually tailored health promotion advice to SAs and MEs. 
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11.5 Suggestions for future work 
• It would be interesting to evaluate the effect of interviewing patients inside 
a consultation room and outside a consultation room on number of MRPs 
identified.  
• The study had a cross-sectional design and thus the perceptions and 
experiences of patients and the data obtained on MRPs represented those 
at the time of the study. These are likely to change over time, thus 
conducting a longitudinal study design is highly recommended. A 
longitudinal study design might also be advantageous as repeated 
measurement would allow the assessment of the consistency of MRPs, 
adherence/non-adherence and patients’ perceptions and beliefs over time.  
• A review of MRPs in EMGs in the UK (Chapter 2 of this thesis) showed that 
there is a need for more research. Therefore, research on MRPs should be 
encouraged to identify the extent of the problems and to identify issues 
related to medicine use and service access. Also, research should be 
developed around a suitable theoretical framework as advised by Medical 
Research Council guidelines (Campbell, 2009) to help in understanding how 
different factors influence occurrence of MRPs, which would provide 
direction for the development of the best intervention to solve and prevent 
MRPs.  
• Researchers are also encouraged to identify specific variables that are 
predicative of MRPs among SA and ME patients such as demographic 
variables and clinical outcomes. For example, studying pattern or 
relationship between MRPs, age and presence of illness complications. 
Appropriate tailored interventions must be devised and targeted at these 
variables to prevent MRPs for this particular population and these 
interventions may need to be tested. 
• Tools to identify MRPs have been developed by previous researchers. To our 
knowledge, no tools have been developed to examine MRPs particularly in 
ethnic minority groups. Findings from this study will be valuable in this 
context; a rage of problems and their contributory factors were identified. 
Findings from the current study can be incorporated and developed into a 
generic tool and tested to confirm findings from this study and to examine 
the extent of problems in clinical practice.  
• With regard to the use of scales in languages other than those they were 
tested for, several solutions may be helpful for future research purposes. 
Refining scales and validating them fully in a culturally similar population 
before their use in a culturally different context may be needed. 
Alternatively, new scales can be developed from grounded qualitative 
research involving the same population. This has the advantage of 
eliminating the need for translation.   
• Cost-effectiveness studies of MRPs detecting and preventing interventions 
are also needed, as they would provide evidence for the importance of this 
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area of research and build the case for the need to direct health resources at 
decreasing MRPs.      
• Future research could focus on evaluating interventions targeted at 
identifying and resolving MRPs among SA and ME patients and assessing 
whether these would improve medicine-taking behaviour. As patient-
healthcare professional relationship was identified to be an issue, future 
research could examine the content of information provided and style of 
communication currently used by doctors involved in patients’ care. Results 
can then be used to inform the design of interventions targeted at 
improving the patient-HCP relationship. The impact of such intervention on 
MRPs could be then assessed.   
11.6 Research contributions 
What is already known on this topic? 
• Medicine-related problems may lead to significant medicine-related 
morbidity and mortality; 
• Up to date, there have been no studies which included the SA and ME 
patients’ perspectives on MRPs and their needs to address these problems. 
• There is no proposed tool that could be used for the identification of MRPs 
in SA and ME groups. 
• The extent of non-compliance with medications among SA and ME groups in 
the UK has never been estimated before. 
What does this research add? 
• This is the first study that explored and described medicine use and 
medicine-related problems experienced by SA and ME patients with chronic 
diseases in primary care in the UK, providing novel evidence that MRPs 
among these particular populations continues to be problematic across all 
chronic conditions, which may have life-threatening consequences. 
• This study is also the first to measure the extent of non-compliance with 
medication among SA and ME populations in the UK using 8-item MMAS, 
indicating that non-compliance constitutes a significant proportion in SA 
and ME patients. 
• The current study also highlighted differences between SAs and MEs 
participating in the study and so far it is the only one to propose a tool that 
can be used in SA and ME populations to identify MRPs and to detect 
factors that may contribute to the problems. 
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Chapter 12 Conclusion 
Based on Gordon’s coding frame the following types of MRPs were identified: 
adverse drug reactions and drug interactions; intentional non-compliance; 
cognitive, physical and sensory problems; and issues with concurrent use of herbal 
and alternative therapies. Problems with drug-prescribing; lack of information; 
monitoring and review; repeat prescriptions; GP surgery and pharmacy service were 
also identified. These problems influenced adherence and informed decision-
making among participants. 
Based on this study, a number of factors which may contribute to MRPs among SA 
and ME groups were found. Some factors were reported to be specific to these 
cultures; these included religious practices and beliefs, extent of family support, 
travelling abroad back to their homeland or to take religious journeys. Perceptions 
of healthcare providers, difficulty consulting a doctor of the same gender, lack of 
referrals to a specialised care, language and communication barriers, lack of 
translated resources, illiteracy, lack of involvement in the treatment decisions, lack 
of knowledge and understanding (e.g., problems with source, delivery, type and 
timing of information) may also contribute to the problems. However, other 
reported factors were similar to the general population. The relevance of these 
problems or factors to the wider population of SA and ME groups is still unknown at 
this point and further assessment is needed. The problems and factors identified in 
the current study needed to be tested in a larger sample and in a wider context. 
This thesis provided evidence that non-adherence to medications and poor health 
status among SA and ME patients is a significant problem of a striking magnitude. 
The Morisky quantitative survey showed 67% of SA and ME patients were non-
adherent with their medications.  
The current study provided a theoretical framework for MRPs. It also supports 
developing MUR further and adding the specific issues that were reported by SA 
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and ME groups to support these groups in their use of medicines. The findings also 
support the development of pharmaceutical care plans specific to SA and ME 
groups. Prioritising medication use review to SA and ME groups, increasing patient 
education and counselling, providing verbal and written information in patients’ 
preferred language and according to their needs and wants, and raising awareness 
of SA and ME cultures among HCPs are also recommended. Tailored interventions 
to patients’ needs and wants may be required to improve medication use and 
service access. There was also a need to move towards a more patient-centred 
approach and more involvement of patients in their disease management targets 
and strategies. Finally, it is also important to include family members in these plans, 
as the study showed that family members may be an important asset in a patient’s 
life.   
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Appendices 
Appendix 1: An overview of MRPs classification system. 
Article  Terminology Definition Classification Comments 
Strand, et al. 
(1990)  
DRP and DTP “Any undesirable event 
experienced by the 
patient that involves or 
is suspected to involve 
drug therapy and that 
actually or potentially 
interferes with a 
desired patient 
outcome”. 
(1) "Need additional drug therapy"; (2) "Unnecessary drug therapy"; (3) 
"Wrong drug"; (4) "Dosage too low"; (5) "Dosage too high"; (6) "ADR"; (7) 
"Compliance". 
 
1. This system used a clear definition; 
2. This classification system is not 
hierarchal; 
3. This classification system has no 
causes; 
4. This classification system has no 
interventions classifications to solve the 
identified DRPs; 
5. This system is usable in practice but 
has not been validated. 
Hanlon, et al. 
(1992) 
DRP None The criteria of Medication Appropriateness Index (MAI) include (1) 
indication; (2) effectiveness; (3) dosage; (4) correct direction; (5) practical 
directions; (6) drug-drug interaction; (7) drug-disease interaction; (8) 
duplication; (9) duration and (10) expense. 
1. This system used no clear definition; 
2. This classification system is not 
hierarchal; 
3. The causes of DRP integrated in the 
problem description; 
4. This classification system has no 
interventions classifications to solve the 
identified DRPs; 
5. This system is usable in practice but 
has not been validated. 
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Article  Terminology Definition Classification Comments 
The American 
Society of Health 
System Pharmacists 
(ASHP) classification 
(1996)    
 
MRP and MTP “An event or circumstances 
involving drug treatment that 
actually or potentially 
interferes with an optimum 
outcome for a specific 
patient”.  
 
(1) Medications with no medical indication; (2) 
Medical conditions for which there is no 
medication prescribed; (3) Medications 
prescribed inappropriately for a particular 
medical condition; (4) Inappropriate medication 
dose, dosage form, schedule, route of 
administration, or method of administration; 
(5)Therapeutic duplication; (6) Prescribing of 
medications to which the patient is allergic; (7) 
Actual and potential adverse drug events; (8) 
Actual and potential clinically significant drug–
drug, drug–disease, drug–nutrient, and drug–
laboratory test interactions; (9) Interference with 
medical therapy by social or recreational drug 
use; (10) Failure to receive the full benefit of 
prescribed medication therapy; (11) Problems 
arising from the financial impact of medication 
therapy on the patient; (12) Lack of 
understanding of the medication therapy by the 
patient; (13) Poor adherence. 
1. The classification used a clear definition; 
2. This classification system is not hierarchal; 
3. The causes of MRP integrated in the problem 
description; 
4. This classification system has no interventions 
classifications to solve the identified DRPs; 
5. This system is usable in practice but has not been 
validated. 
Granada Consensus 
II (2002) 
DTP “.. are health problems, 
understood as negative 
clinical outcomes, resulting 
from pharmacotherapy, that 
for different causes, either do 
not accomplish therapy 
objectives or produce 
undesirable effects”. 
Necessity: 
1. Untreated health problem; 
2. Effect of unnecessary drug.   
Effectiveness: 
3. Non-quantitative ineffectiveness problem; 
4. Quantitative ineffectiveness problem. 
Safety: 
5. Non-quantitative unsafe; 
6. Quantitative unsafe. 
1. The classification used a clear definition; 
2. This classification system is not hierarchal; 
3. The causes of MRP integrated in the problem 
description; 
4. This classification system has no interventions 
classifications to solve the identified DRPs; 
5. This system is usable in practice but has not been 
validated. 
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Article  Terminology Definition Classification Comments 
Krska, et al. system 
(2002) 
Pharmaceutical care 
issues 
“An element of a 
pharmaceutical care need 
which is addressed by the 
pharmacists”. 
(1) potential/suspected adverse reactions; (2) 
monitoring issues; (3) potential ineffective 
therapy; (4) education required; (5) 
inappropriate dosage regimen; (6) untreated 
indication; (7) no indication; (8) repeat 
prescription no longer required; (9) 
inappropriate duration of therapy; (10) 
discrepancy between doses prescribed and 
used; (11) potential drug-disease interaction; 
(12) other.    
1. The classification used a clear definition; 
2. This classification system is not hierarchal; 
3. This classification system has no causes 
classifications to solve the identified DRPs; 
4. The intervention to solve DRP integrated in the 
problem description; 
5. This system is usable in practice but has not 
been validated. 
Westerlund system 
(2002) 
DRP ‘‘A circumstance related to the 
patient’s use of a drug that 
actually or potentially prevents 
the patient from gaining the 
intended benefit of the drug”. 
(1) uncertainty about aim of the drug; (2) drug 
duplication; (3) drug-drug interaction; (4) 
contraindication; (5) therapy failure; (6) adverse 
effect; (8) underuse of drug; (9) overuse of 
drug; (10) other dosage problem; (11) difficulty 
swallowing tablet/capsule; (12) difficulty 
opening drug container; (13) other problem of 
administration/handling; and (14) other. 
1. The classification used a clear definition; 
2. This classification system is not hierarchal; 
3. The causes of DRPs integrated in the problem 
description; 
4. This classification system has interventions 
classifications to solve the identified DRPs; 
4. This system is usable in practice and has been 
validated. 
NCC-MERP 
Taxonomy of 
medication error 
(2003) 
Medication errors “any preventable event that 
may cause or lead to 
inappropriate medication use 
or patient harm while the 
medication is in the control of 
the healthcare professional, 
patient, or consumer’’. 
(1) Dose omission; (2) improper dose; (3) wrong 
strength/concentration; (4) wrong drug; (5) 
wrong dosage form; (6) wrong technique 
(includes inappropriate crushing tablets); (7) 
wrong route of administration; (8) wrong rate 
(probably relating to administration); (9) wrong 
duration; (10) wrong time; (11) wrong patient; 
(12) monitoring error (includes contraindicated 
drugs); (13) deteriorated drug error (dispensing 
drug that has been expired); (13) other. 
1. The classification used a clear definition; 
2. This classification system is not hierarchal; 
3. The causes of medication errors integrated in 
the problem description; 
4. This classification system has no clear 
interventions classifications to solve the identified 
medication error; 
4. This system is usable in practice and has not 
been validated. 
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Article  Terminology Definition Classification Comments 
Gordon, et al. (2005) DRP ‘‘Any problem that impacts on 
the patients’ ability to manage 
their medicines effectively’’. 
(1) Interactions; (2) non-compliance; (3) 
Cognitive, physical and sensory problems; 
(4) Drug-prescribing problems; (5) Interface, 
monitoring and review; (6) Lack of 
information or discussion; (7) Problems 
with repeat prescriptions; (8) GP surgery 
and pharmacy service problems. 
1. The classification used a clear definition; 
2. This classification system is not hierarchal; 
3. The causes of DRP integrated in the problem 
description; 
4. This classification system has no interventions 
classifications to solve the identified DRPs; 
5. This system is usable in practice and has been 
validated for use in pharmaceutical care research. 
AbuRuz, et al. (2006) Treatment-related 
problems 
‘‘An event or circumstance 
involving patient treatment 
that actually or potentially 
interferes with an optimum 
outcome for a specific patient’’ 
(1) Indication; (2) Effectiveness; (3) Safety, 
(4) Knowledge; (5) Adherence and (6) 
Miscellaneous. 
1. The classification used a clear definition; 
2. This classification system is hierarchal; 
3. This system consists of separate codes for problems, 
causes, and interventions; 
4. This system is usable in practice and has validated for 
use in teaching, practicing and researching 
pharmaceutical care; 
5. This classification is for use in research to identify the 
types, possible causes, interventions, nature, prevalence, 
and incidence of DRPs and also to indicate the 
pharmaceutical care outcomes in experimental studies. 
The PCNE 
classification system 
version 6 (2010) 
DRP "An event or circumstance 
involving drug therapy that 
actually or potentially 
interferes with desired health 
outcomes". 
(1) Treatment effectiveness; (2) adverse 
reactions; (3) treatment cost; (4) others. 
1. The classification used a clear definition; 
2. This classification system is hierarchal; 
3. This system consists of separate codes for problems, 
causes, and interventions; 
4. This system is usable in practice and has validated for 
use in pharmaceutical care research and practice; 
5. This classification is for use in research to identify the 
types, possible causes, interventions, nature, prevalence, 
and incidence of DRPs and also to indicate the 
pharmaceutical care outcomes in experimental studies. 
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Appendix 2: A list of search terms used for this review. 
Search terms for ‘Medicine-related problem’ And Search terms for ‘Ethnicity’ And Search terms for ‘United 
Kingdom’ 
"Drug related problem(s)" 
OR 
"Drug therapy problem(s)" 
OR 
"Drug self medication" 
OR 
"Drug self administration" 
OR 
"Drug toxicity" 
OR 
"Adverse drug reaction" 
OR 
"Drug interaction" 
OR 
" Drug intoxication" 
OR 
" drug contraindication" 
OR 
"Adverse drug effect" 
OR 
"Overdose" 
OR 
"Polypharmacy" 
OR 
"Drug evaluation" 
OR 
" Drug dose" 
OR 
"Drug monitoring" 
OR 
"Drug safety" 
OR 
"Drug screening" 
OR 
"Drug seeking behaviour" 
OR 
"Drug tolerability" 
OR 
"Drug tolerance" 
OR 
"Drug use" 
OR 
"Drug monitoring" 
OR 
"Drug utilisation" 
OR 
"Medicine related problem(s)"  
OR 
"Medication error(s)" 
OR 
"Medication adherence"  
OR 
"Medication compliance"  
OR 
"Medication therapy management" 
OR 
"Therapy related problem(s)" 
OR 
"Treatment related problem(s)" 
OR 
"Pharmaceutical care issue(s)" 
 "Ethnicity"  
OR 
"Ethnic group(s)" 
OR 
"Race" 
OR 
"Racial group(s)" 
OR 
"Religion” 
OR 
"Religious group(s)" 
OR  
"Minority group(s)" 
 
 "United Kingdom" 
OR 
"Great Britain" 
OR 
"England" 
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Appendix 3: Studies on medicine use and medicine-related problems experienced by ethnic minority patients in the UK. 
Primary 
author and 
date of 
publication 
Study design 
and study 
duration 
Age (years) Setting Sample Types of problems identified Potential causes of problems Interventions or 
recommendations to 
support patients in the use 
of medicines 
Wheatly and 
Shelly (1993) 
Not stated Not stated Intensive 
Care Unit 
(ICU) 
Not stated Problems with not taking 
medicines as advised. 
Religious beliefs and lack of 
information provided to patients 
on the use of medicines. 
Not stated. 
Chan C. 
(2000) 
Structured and 
semi-structured 
face-to-face 
interviews. 
20 to 45 years 
Chinese 
mothers. 
GP 
surgeries 
and 
patients’ 
homes. 
38 GPs, 26 
health visitors 
and 30 
Chinese 
mothers of 
pre-school 
children. 
Problems with access to health 
services, problems with poor 
compliance as well as problems 
with late in seeking antenatal 
care. 
Communication and language 
barriers; 
Problems with interpretation 
provided; 
Problems with non-prescription 
medicine; 
Limited knowledge of the medical 
and healthcare system;  
Lack of believes in the treatment 
they received. 
Increase involvement of 
ethnic minority groups in 
healthcare provision and 
utilisation.  
Lip et al. 
(2002) 
 
Cross sectional 
survey and 
questionnaire-
based 
interviews,  
(11 months). 
Mean age 69 
plus or minus 
9. 
Anticoag-
ulation 
clinics. 
44% White 
European, 
33% Indo-
Asian, 23% 
Afro-
Caribbean. 
Some patients had limited 
knowledge of Atrial Fibrillation 
(AF) as well as its consequences 
and therapy; 
Problems with not taking 
medicines as advised. 
Ethnic, cultural and religious 
differences; 
Communication and language 
barriers; 
Poor amount of counselling and 
information given to patients by 
healthcare professionals. 
Not stated. 
 364 
 
 
Primary 
author and 
date of 
publication 
Study design 
and study 
duration 
Age (years) Setting Sample Types of problems identified Potential causes of problems Interventions or 
recommendations to 
support patients in the use 
of medicines 
Horne et al. 
(2004) 
Exploratory, 
cross-sectional 
study using the 
Beliefs about 
Medicines 
Questionnaire 
(BMQ) and the 
Sensitive Soma 
scale. 
Mean age of 
European 
and Asian 
were 24.2 
and 22 
respectively. 
Not stated 500 UK 
undergraduate 
students of 
Asian (n=83) or 
European 
(n=417) origin. 
High risk of not taking medicines 
as advised. 
Students of South Asian origin 
had higher General Harm score 
than those of European origin 
(i.e., they perceived medicines as 
being intrinsically harmful, 
addictive substances that should 
be avoided (p<0.001) and they 
were significantly (p<0.001) less 
likely to endorse the benefits of 
modern medication). 
Cultural beliefs; 
Current and previous experience 
of taking medication. 
Not stated. 
Lip et al. 
(2004) 
Cross sectional 
survey and 
questionnaire-
based 
interviews,  
(3 months). 
Mean age of 
total cohort 
71 
Heart 
failure 
clinics. 
103 patients 
with CHF: 42 
White, 34 Indo-
Asian, 22 Afro-
Caribbean and 5 
Oriental 
Indo-Asians and Afro-Caribbeans 
were less aware of CHF as well as 
its consequences and therapy;  
Problems with not taking 
medicines as advised 
Ethnic, cultural and religious 
differences; 
Communication and language 
barriers; 
Poor amount of counselling and 
information given to patients. 
Not stated. 
Pardhan and 
Mahomed 
(2004) 
Survey, 
(22 months). 
>  40 Diabetic 
clinics. 
500 patients 
(268 South 
Asians and 232 
Europeans). 
South Asians were less aware of 
diabetes as well as its 
consequences; 
Problems with not taking 
medicines as advised and 
missing clinical appointments. 
Cultural and religious influences; 
Language and communication 
barriers; 
Problems with interpretation 
provided.  
Using pictorial flashcards to 
provide information for 
illiterate people instead of 
providing written 
information in a native 
language;  
Providing bilingual link-
workers. 
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Primary 
author and 
date of 
publication 
Study design 
and study 
duration 
Age (years) Setting Sample Types of problems identified Potential causes of problems Interventions or 
recommendations to 
support patients in the use 
of medicines 
Morgan and 
Figueoa-
Muñoz (2005) 
Focus-groups 
interviews. 
18 – 68 Communit
y centres. 
44 Africans. Health service barriers; 
Intentional and unintentional 
non-adherence with drug 
regime; 
Cognitive problems affecting use 
of medicines;  
Lack of knowledge of illness as 
well as its therapies; 
Concern of side effects of the 
drugs; 
Problems with accessing 
healthcare services. 
Cultural beliefs of illness, 
prescribed treatment and 
healthcare providers; 
Poor amount of counselling and 
information given to patients. 
Providing patients’ 
education; 
Improve provider-patient 
communication. 
Lawton et al. 
(2005) 
 
 
 
 
 
  
Observational 
cross sectional 
study using in-
depth 
interviews. 
30 to ≥71 Patients’ 
homes. 
32 Pakistani 
and Indian 
patients. 
Problems with not taking 
medicines as advised; 
Fear of dependency. 
Cultural beliefs of prescribed 
treatment and healthcare 
providers. 
Providing patient education 
and counselling;  
Improve provider-patient 
communication; 
Providing bilingual link 
workers. 
McDowll et 
al. (2006) 
Systematic 
review and 
meta-analysis. 
Not stated Not stated Blacks and 
East Asians. 
Risk of adverse drug reactions 
(ADRs) to cardiovascular drugs. 
Ethnic differences which are 
believed to affect response to 
drugs such as different 
distribution of cytochrome P450 
(CYP) genotype in different ethnic 
groups.   
Not stated. 
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Primary 
author and 
date of 
publication 
Study design and 
study duration 
Age 
(years) 
Setting Sample Types of problems identified Potential causes 
of problems 
Interventions or recommendations to 
support patients in the use of medicines 
Gordon et al. 
(2007) 
Face-to-face in-
depth interviews. 
≥18 Patients’ 
homes. 
83% White 
and 17% 
Black. 
Perceptions of side effects and 
methods of coping;  
Views and actions regarding the 
use of medicines; 
Cognitive, physical and sensory 
problems affecting use of 
medicines; 
Lack of information or 
understanding about use of 
medicines; 
Problems in services access. 
• Under-
estimating 
patients’ 
desire for 
informatio
n. 
• Involve patients in evidence-
informed decision making for safer 
and more effective disease and 
medicine managements.  
• Encourage pharmacists and patients 
to work together and share their 
experiences regarding the use of 
medicines and exchange information 
that will support patients in 
achieving optimal outcomes from 
their medications. 
• Encourage effective communication 
between secondary and primary 
care and patients for the continuity 
of safe and effective therapy. 
Kumar et al. 
(2008) 
Face-to-face 
interviews using the 
Beliefs about 
Medicine 
Questionnaire, the 
SF-36 health survey 
and the Health 
Assessment 
Questionnaire. 
Not 
stated 
Outpatient 
Rheumatology 
Departments. 
100 patients 
of South Asian 
origin and 100 
patients of 
White 
British/Irish 
origin. 
Patients of South Asian origin had 
Specific Concern, General 
Overuse and the General Harm 
scores (i.e., Asian patients 
believed that drugs in general 
were more overused and more 
harmful than White participants 
and they were also more 
concerned about their DMARDs). 
• Cultural 
beliefs. 
• Not stated. 
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Primary 
author and 
date of 
publication 
Study design 
and study 
duration 
Age (years) Setting Sample Types of problems identified Potential causes of problems Interventions or 
recommendations to 
support patients in the use 
of medicines 
Ormerod et 
al. (2008) 
Systematic 
review and 
meta-analysis. 
Not stated Not stated Different 
ethnic groups. 
High risk of ADRs in patients 
treated with antipsychotics. 
Not stated. Not stated. 
Sidi et al. 
(2009) 
Face-to-face 
interviews 
using general 
health status 
(SF-36), MRP 
screening tool 
and Satisfaction 
with 
information 
about 
medicines 
(SIMS). 
18 – 85 Communit
y 
pharmacy 
32 South 
Asians. 
Lack of information on 
medicines;  
Intentional non-compliance;  
Lack of monitoring and review of 
medicines. 
Pharmacy lack of information or 
opportunity to discuss 
medication-related issues or 
concerns;   
Language issues. 
Not stated. 
Opara et al. 
(2010) 
Face-to-face 
interviews 
using MRP 
screening tool 
and SIMS tool. 
18 – 85 Communit
y 
pharmacie
s. 
South Asians. Intentional non-adherence and 
lack of regular monitoring or 
review. 
Cultural and language issues; 
‘Blind belief’ and not recognising 
the pharmaceutical role of 
pharmacist;  
Limited understanding of 
patients’ medicines.  
Not stated. 
Tsang et al. 
(2010) 
Descriptive 
analyses  
12 months 
0-104 GP 
practices. 
White and 
Asians. 
Adverse events, ADRs and 
adverse effects. 
Cuts puncture perforation or 
haemorrhage during medical 
care; 
Systemic antibiotic affecting ANS 
and CVS 
Not stated. 
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Appendix 4: Patient records review in pharmacy. 
Current medication (including prescription, OTC and homeopathic medicines dispensed and sold in past year) 
 
 Drug name Strength Form Directions for 
use 
Quantities Frequency of 
repeat 
Start-Stop date (if 
applicable) 
Comments 
1  
 
       
2  
 
       
3  
 
       
4  
 
       
5  
 
       
6  
 
       
7  
 
       
8  
 
       
9  
 
       
10  
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Appendix 5: MRPs tool for Gordon (English and Arabic versions). 
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Appendix 6: Morisky 8-items tool (English and Arabic versions). 
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Appendix 7: EQ-5D-3L tool (English and Arabic versions). 
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Appendix 8: Pharmacist invitation letter. 
 390 
 
Appendix 9: A summary of the study to be sent to the community pharmacists. 
 
 391 
 
 
 392 
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Appendix 10: A letter to thank pharmacist for taking part in the study. 
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Appendix 11: Patient invitation letter.
 
 395 
 
Appendix 12: Patient information sheet. 
 
 
 396 
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Appendix 13: Patient consent form.
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Appendix 14: Gordon et al 2005 categorisation sheet. 
Medicine related problems Service related problems 
Interactions Drug-prescribing problems 
Type A ADR – side effect known Drug missing from regime 
Type B ADR – hypersensitivity Therapeutic duplication 
Drug-drug interaction Use of drug to treat adverse effect of 
another 
Drug-disease interaction Inappropriate dose (too high or low) 
Drug-laboratory test interaction No directions given for medicines 
Drug-food interaction Interface, monitoring and review 
Intentional non-compliance Inadequate monitoring or review (identify 
by researcher) 
Under-use of POMs Inadequate monitoring or review (identify 
by patient) 
Over-use of POMs Inadequate transfer of information from 
hospital to GP 
Duplication of POMs Lack of information or discussion 
Mixing different preparations in the 
same container 
Inadequate information on medicines 
Use of expired medicines Inadequate information on illness 
Inappropriate storage of medicines Inadequate discussion with 
doctors/nurses/pharmacists/hospital staff 
Unsure of dosing Problems with repeat prescriptions 
Stopped taking medicines Poorly synchronised quantities of repeats 
Cognitive, physical and sensory 
problems 
Over-ordering and stored at home 
(hoarding) 
Forgetting to take medicines Ran out of medicine and did not order 
anymore 
Difficulty opening containers/packs Medicines no longer used remain on form 
Difficulty reading labels Renew once only medicine 
Difficulty hearing instructions Delay renewals after supplies run out 
Problems with non-prescription 
medicines 
Old medicines remain on form 
Over-use GP surgery and pharmacy service 
problems 
Interaction with POMs Difficulty getting appointments to see GP 
Contra-indication Long waiting times in GP surgery 
Use of expired medicines Difficulty consulting the practice nurse 
 Difficulty consulting the pharmacist 
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Appendix 15: Research Ethics Committee (REC) application form. 
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Appendix 16: The provisional decision letter from NHS REC. 
 433 
 
 
 
 434 
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Appendix 17: The response letter to NHS REC. 
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Appendix 18: The letter of favourable opinion from the NHS REC. 
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Appendix 19: NHS R & D form. 
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Appendix 20: NHS Site Specific Information (SSI) Form. 
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Appendix 21: R&D approvals from North West London and North Central London R&D offices. 
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Appendix 22: Pharmacies visiting timetables by Months. 
Day Mon 7th May Tu 8th May We 9th May Th 10th May Fri 11th May No. of visit 
Pharmacy  Pharm 5 Pharm 3  Pharm 1 1 
Day Mon 14th May Tu 15th May We 16th May Th 17th May Fri 18th May No. of visit 
Pharmacy  Pharm 7 Pharm 6 Pharm 4  1 
Day Mon 21st May Tu 22nd May We 23rd May Th 24th May Fri 25th May No. of visit 
Pharmacy  Pharm 5 Pharm 3 Pharm 2 Pharm 1 2 
Day Mon 28th May Tu 29th May We 30th May Th 31st May Fri 1st June No. of visit 
Pharmacy  Pharm 7 Pharm 6 Pharm 4  2 
       
Day Mon 4th June Tu 5th June We 6th June Th 7th June Fri 8th June No. of visit 
Pharmacy   Pharm 3 Pharm 2 Pharm 1 3 
Day Mon 11th June Tu 12th June We 13th June Th 14th June Fri 15th June No. of visit 
Pharmacy Fairview Pharmacy Pharm 7 Pharm 6 Pharm 4  3 
Day Mon 18th June Tu 19th June We 20th June Th 21st June Fri 22nd June No. of visit 
Pharmacy  Pharm 5 Pharm 3 Pharm 2 Pharm 1 4 
Day Mon 25th June Tu 26th June We 27th June Th 28th June Fri 29th June No. of visit 
Pharmacy  Pharm 7 Pharm 6 Pharm 4  4 
       
Day Mon 2nd July Tu 3rd July We 4th July Th 5th July Fri 6th July No. of visit 
Pharmacy  Pharm 5 Pharm 3 Pharm 2 Pharm 1 5 
Day Mon 9th July Tu 10th July We 11th July Th 12th July Fri 13th July No. of visit 
Pharmacy  Pharm 7 Pharm 6 Pharm 4  5 
Day Mon 16th July Tu 17th July We 18th July Th 19th July Fri 20th July No. of visit 
Pharmacy  Pharm 5 Pharm 3 Pharm 2 Pharm 1 6 
Day Mon 23rd July Tu 24th July We 25th July Th 26th July Fri 27th July No. of visit 
Pharmacy  Pharm 7 Pharm 6 Pharm 4  6 
 496 
 
Appendix 23: Gantt chart for the study. 
 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 
Months 1 2 3 4 5 6 7 8 9 10 11 12 
General activities              
PhD Induction 
courses 
            
Postgraduate 
training programme 
            
Attend PhD 
Research Days 
            
1st year report 
submission                         
            
First Year Viva 
examination 
            
Attend a national 
conference                                 
            
Attend an 
international 
conference 
            
Research             
Literature search 
and background 
reading 
            
Prepare & develop 
research protocol 
            
Submit research 
protocol for Ethics 
Committee approval 
            
Obtain Ethics 
Committee approval   
            
Research and 
development 
approval (R&D) 
            
Recruiting 
community 
pharmacies 
            
Pilot work             
Data collection 
(recruiting patients 
+ interviews) 
            
Data analysis                                                                 
Thesis write-up             
Submit draft thesis             
Correction & 
submission of final 
thesis 
            
PhD examination             
Publishing 1st article             
Publishing 2nd 
article 
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 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 
Months 13 14 15 16 17 18 19 20 21 22 23 24 
General activities              
PhD Induction 
courses 
            
Postgraduate 
training 
programme 
            
Attend PhD 
Research Days 
           Poster 
1st year report 
submission                         
            
First Year Viva 
examination 
            
Attend a national 
conference                                 
         Talk   
Attend an 
international 
conference 
            
Research             
Literature search 
and background 
reading 
            
Prepare & develop 
research protocol 
            
Submit research 
protocol for Ethics 
Committee 
approval 
            
Obtain Ethics 
Committee 
approval   
            
Research and 
development 
approval (R&D) 
            
Recruiting 
community 
pharmacies 
            
Pilot work             
Data collection 
(recruiting patients 
+ interviews) 
            
Data analysis                                                                 
Thesis write-up             
Submit draft thesis             
Correction & 
submission of final 
thesis 
            
PhD examination             
Publishing 1st 
article 
            
Publishing 2nd 
article 
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 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 
Months 25 26 27 28 29 30 31 32 33 34 35 36 
General activities              
PhD Induction 
courses 
            
Postgraduate 
training 
programme 
            
Attend PhD 
Research Days 
            
1st year report 
submission                         
            
First Year Viva 
examination 
            
Attend a national 
conference                                 
            
Attend an 
international 
conference 
         Poster   
Research             
Literature search 
and background 
reading 
            
Prepare & develop 
research protocol 
            
Submit research 
protocol for Ethics 
Committee 
approval 
            
Obtain Ethics 
Committee 
approval   
            
Research and 
development 
approval (R&D) 
            
Recruiting 
community 
pharmacies 
            
Pilot work             
Data collection 
(recruiting patients 
+ interviews) 
            
Data analysis                                                                
Thesis write-up             
Submit draft thesis             
Correction & 
submission of final 
thesis 
            
PhD examination             
Publishing 1st 
article 
            
Publishing 2nd 
article 
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 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 
Months 37 38 39 40 41 42 43 44 45 46 47 48 
General activities              
PhD Induction 
courses 
            
Postgraduate 
training programme 
            
Attend PhD 
Research Days 
   Talk         
1st year report 
submission                         
            
First Year Viva 
examination 
            
Attend a national 
conference                                 
            
Attend an 
international 
conference 
            
Research             
Literature search 
and background 
reading 
            
Prepare & develop 
research protocol 
            
Submit research 
protocol for Ethics 
Committee approval 
            
Obtain Ethics 
Committee approval   
            
Research and 
development 
approval (R&D) 
            
Recruiting 
community 
pharmacies 
            
Pilot work             
Data collection 
(recruiting patients 
+ interviews) 
            
Data analysis                                                               
Thesis write-up             
Submit draft thesis             
Correction & 
submission of final 
thesis 
            
PhD examination             
Publishing 1st article             
Publishing 2nd 
article 
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Appendix 24: Case studies of 80 participants. 
Case studies of 20 participants identified as having medicine-use issues only. 
Case study 
Case 102-PAK-M-65 was a 65 year old Pakistani male taking Ramipril, Amlodipine, Atorvastatin. He 
reported forgetting to take his medicines once or twice a year (‘rarely’ on the Likert scale) (301). 
Case 103-BNG-M-45 was a 45 year old Bangladeshi male taking Metformin, Atorvastatin, Citalopram, 
Co-dydramol, Tamsulosin, Omeprazole. He reported reducing the dose of Metformin from 2 tablets 
three times a day to 1 tablet after breakfast and after lunch and 2 tablets after dinner (‘sometimes’ 
on the Likert scale) (201) because of experiencing tiredness, legs’ weakness and stomach problem as 
side effects of taking Metformin (101). He also revealed reducing the dose of Atrovastatin from one 
tablet at night to none at night (‘sometimes’ on the Likert scale) because of having shortness of 
breath as a side effect of taking Atorvastatin. He declared forgetting to take his medicines (‘often’ on 
the Likert scale) (301). He took over-the-counter (OTC) Paracetamol when required and prescription-
only medicine (POM) Co-dydramol which was prescribed in a hospital A&E department (402).   
Case 215-AR-M-40 was a 40 year old Arabic male taking Risperidone, Mirtazapine, Lansoprazole. He 
revealed that he was increasing the doses of Risperidone, Mirtazapine, Lansoprazole once or twice a 
month from 1 tab a day to 2 tab a day (‘sometimes’ on the Likert scale) when he was feeling unwell 
(202). He reported forgetting to take his medicines once a month (‘sometimes’ on the Likert scale) 
(301). 
Case 304-IN-F-77 was a 77 year old Indian female taking Amlodipine, Aspirin, Rosuvastatin, 
Ezetimibe. She reported experiencing hair loss as a side effect of taking Simvastatin (101). She 
revealed forgetting to take her medicines once or twice a year (‘rarley’ on the Likert scale) (301). 
Case 307-AR-M-52 was a 52 year old Arabic male taking Diclofenac tabs, Diclofenac gel, 
Amitriptyline, Tramadol, Paracetamol, Omeprazole. He reported experiencing stomach pain as a side 
effect of taking Diclofenac (101). He revealed forgetting to take his medicines once or twice a week 
(‘sometimes’ on the Likert scale) (301). 
Case 309-AR-F-44 was a 44 year old Arabic female taking Humalin S, Humalin I, Novomix 30, 
Metformin, Pregabalin, Perindopril, Sertraline, Salbutamol inh, Salmeterol inh, Beclometasone inh, 
montelukast, Aspirin, Atrovastatin, Omeprazole, Colecaciferol, Ferrous fumarate, Paracetamol. It 
was identified that she was taking Salbutamol regularly (2 puffs twice a day) instead of taking it 
when required (202). She reported taking 1 puff twice or three times a day from Beclometasone and 
Salmeterol inhalers. She was instructed to take 2 puffs twice a day from Beclometasone and 
Salmeterol inhalers (201). It was also identified that she reduced the dose of Humalin I from 10units 
in the morning and 14 units in the evening to only 12 units in the evening. She reported experiencing 
weight gain as a side effect of taking Insulin (101). She revealed having difficulties opening 
containers (302).   
Case 314-AR-M-61 was a 61 year old Arabic male taking Metformin, Gliclazide, Simvastatin, 
Omeprazole, Ibuprofen, Tramadol, Senna. He reported taking one tablet after breakfast and two 
tablets after lunch from Metformin (213). He was prescribed one tablet to be taken three times a 
day. 
Case 403-AR-F-60 was a 60 year old Arabic female taking Amitriptyline, Pravastatin, Tramadol, 
Trazodone, ProD3, Gaviscon, Colecalciferol, Diclofenac. She revealed forgetting to take her night 
medicines especially painkillers (‘sometimes’ on the Likert scale) (301). She reported that she 
sometimes had difficulties opening containers or pulling out tablets because of her arthritic pain 
(302).   
Case 405-AR-M-64 was a 64 year old Arabic male taking Novomix, Metformin, Losartan, 
Benzafibrate, Simvastatin, Paroxetine, Risperidone, Paracetamol. He had been feeling tired and had 
been sweating and shaking since he started taking Insulin (101). When asked about why he was 
taking Cod liver oil and Garlic tablets, he could not recall the right reasons (405). 
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Case study 
Case 406-AR-M-67 was a 67 year old Arabic male taking Metformin, Gliclazide, Lisinopril, Aspirin, 
Simvastatin, Co-dydramol, Amitriptyline, Salbutamol, Tiotropium, Budesonide/Formoterol, 
Montelukast, Omeprazole, Calcium carbonate, Senna, Lactulose, Aqueous cream. He reported taking 
One tablet 80 mg of Gliclazide twice a day (202) after food (214). He was prescribed half a tablet to 
be taken twice a day 30 minutes before food. He declared difficulties opening containers/packs 
because of his arthritic pain(302). 
Case 501-PAK-M-68 was a 68 year old Pakistani male taking Novomix, Metformin, Gliclazide, 
Ramipril, Budesonide + Formoterol (Symbicort®), Simvastatin. He disclosed that he had been taking 
Metformin sometimes 2 tablets twice a day and sometimes 1 tablet twice a day (201). Metformin 
was prescribed to be taken as 2 tablets twice a day. He also reported stop taking his medicines in 
Ramadan and when travelling abroad. 
Case 506-PAK-F-78 was a 78 year old Pakistani female taking Metformin, Sexaglibtin, Perindopril, 
Amlodipine, Omeprazole, Simvastatin, Aspirin, Co-dydramol. She reported feeling sick and noxious as 
a side effect of taking Metformin (101). She declared forgetting to take pain killer medicine [Co-
dydramol] once or twice a year (‘rarely’ on the Likert scale) (301). 
Case 609-OSA-M-80 was an 80 year old male from other South Asian background taking Warfarin, 
Isosorbide mononitrate, Furosemide, Amlodipine, Lansoprazole, Penicillin v, Calcium carbonate and 
colecalciferol. He reported experiencing itch rash as a side effect of taking Alendronic acid (101). He 
reported stop taking ISMN and Lanzoprazole for 3 days last month (201). He reported forgetting to 
take his medicines once a month (‘sometimes’ on the Likert scale) (301). 
Case 610-IN-M-80 was an 80 year old Indian male taking Irbesartan, Ramipril, Metformin, 
Simvastatin, Aspirin, Folic acid, Cyanocobolamin, Omega-3. He reported experiencing constipation as 
a side effect of taking Irbesartan and Metformin (101). 
Case 612-IN-M-45 was a 45 year old Indian male taking Pioglitazone+Metformin, Gliclazide, 
Simvastatin, Cyanocobalamin. It was identified that he was taking Gliclazide tablet after food (214). 
Gliclazide is best to be taken 30 minutes before breakfast. He revealed forgetting to take his 
afternoon tablet (301). 
Case 615-IN-M-74 was a 74 year old Indian male taking Amlodipine, Irbesartan, Allopurinol, Folic 
acid, Calcium carbonate + colecalciferol, Cyanocobalamine, Paracetamol, Tamsulosin, White soft 
paraffin and liquid paraffin cream. He reported experiencing dizziness sometimes as a side effect of 
taking Amlodipine (101) 
Case 702-IN-M-57 was a 57 year old Indian male taking Metformin, Pioglitazone, Gliclazide, 
Ezetimibe, Keppra, Sodium Valproate, Dosulepin, Aspirin, Adcal-D3, Co-codamol, Dutasteride, 
Omeprazole, Ventolin, Viscotears, Ganfort. He revealed experiencing indigestion as side effects of 
taking Tegretol (101). He declared forgetting to take his medicines (‘very often’ on the Likert scale) 
(301). 
Case 705-IN-M-64 was a 64 year old Indian male taking Novomix, Metformin, Losartan, Aspirin, 
Simvastatin. He declared forgetting to take his medicines once a year (‘sometimes’ on the Likert 
scale) (301). 
Case 706-IN-F-62 was a 62 year old Indian female taking Bendroflumethiazide, Enalapril, 
Methotrexate, Co-codamol, Calcipotriol+betamethasone oint, Mometasone, Loratidine, Folic acid, 
Omeprazole. She revealed forgetting to take her medicines (‘rarely’ on Likert scale) (301). She 
declared difficulties pulling out Omeprazole tablets (302). 
Case 707-IN-F-67 was a 67 year old Indian female taking Amlodipine, Candesartan, Simvastatin, 
Adcal-D3. She revealed experiencing stomach upset as side effects of taking uncoated Simvastatin 
(101) and she requested to have a coated statin.  
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Case studies of four participants identified as having service-use issues only. 
Case study 
Case 207-AR-F-40 was a 40 year old Arabic female taking Warfarin and co-codamol. She had been 
prescribed Warfarin for a year and a half (507). However, she had DVT and PE induced by surgery, 
which required only 3 months of Warfarin therapy. She reported poor communication between 
hospital doctor and GP regarding whether she had to stop or continue taking Warfarin (603). 
Case 504-PAK-M-81 was an 81 year old Pakistani male taking Amlodipine, Valsartan, Atenolol, GTN, 
Salbutamol, Clenil modulate inhaler, Aspirin, Clopidogrel, Simvastatin, Co-codamol, Paracetamol, 
Quinine sulphate, Amitriptyline, Cyanocobalamin, Ranitidine, Gaviscon advance, Piroxicam gel, 
Celluvisc eye drops, Hypromellose eye drops. When asked about why he was taking Clenil modulate, 
Amitriptyline and Cyanocobalamin, he couldn’t state the reasons (701). He reported difficulties 
making appointments to consult his regular GP (909). It was identified that he was prescribed two 
analgesics containing Paracetamol as an active ingredient [Co-codamol and Paracetamol] (502). He 
was also prescribed two eye drops to treat tear deficiency which were in the same BNF group 8.11 
[Celluvisc eye drops and Hypromellose eye drops] (502). 
Case 505-PAK-M-57 was a 57 year old Pakistani male taking Atenolol, Ramipril, Bendroflumethiazide, 
GTN, ISMN, Insulin Detemir, NovoRapid Insulin, Metformin, Vildagliptin, Omeprazole, Paracetamol, 
Atrovastatin, Amitriptyline, Prochlorperazine, Betamethasone, Viscotears liquid gel. He reported 
experiencing problems with the attitude of receptionists in the GP surgery (913). He revealed poor 
communication between hospital doctors and GPs regarding changes to medicines (603). He 
declared delay renewal of repeat prescription after his supply of medicines run out on different 
occasions (806).  
Case 703-IN-M-60 was a 60 year old Indian male Furosemide, Ramipril, Cardvedilol, Spironolactone, 
Aspirin, Simvastatin, Novomix, Humalog mix, Metformin, Ventolin, Fluticasone, Eltroxin, 
Omeprazole. He declared that he sometimes delayed renewal of repeat prescription after his supply 
of medicines run out (806). 
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Case studies of 49 participants identified as having both medicine-use and service-use issues 
combined. 
Case study 
Case 101-BNG-M-48 was a 48 year old Bangladeshi male taking Bendroflumethiazide, Omeprazole, Simvastatin. 
He disclosed that he had been taking Omeprazole only when needed, rather than taking one tablet a day (201) 
as prescribed. He reported difficulties getting an appointment to see the GP (901). 
Case 105-TRK-F-33 was a 33 year old Turkish female taking Metformin, Simvastatin, Calcichew-D3, Aripiprazole. 
She was experiencing difficulties remembering to take her medicines because she had mental problem 
(‘sometimes’ on the Likert scale) (301). It was identified that she was reducing the dose of Metformin from one 
tablet three times a day to one tablet twice a day (201). She would like to have more information on her illness 
(702) and on her medicines (701).  
Case 106-BNG-M-66 was a 66 year old Bangladeshi male taking Amlodipine, Atenolol, Ramipril, GTN, Insultard 
Innolet, Metformin, Aspirin, Simvastatin, Paracetamol. He disclosed that he was taking two tablets twice a day 
from Metformin instead of taking one tablet twice a day (202). In addition, it was identified that he was taking 
one puff from GTN every morning. He also revealed that he was taking Simvastatin in the morning (214). When 
asked about why he was taking Simvastatin, GTN and Ramipril, he could not state the correct reasons (701). 
Case 107-OSA-M-57 was a 57 year old Sri Lankan male taking Insulin Novorapid, Insulin Glargine, Metformin, 
Doxazosin, Propranolol, Ramipril, Simvastatin, Amitriptyline, Zoplicone, Citalopram, Tramadol, Co-codamol, 
Macrogol compound, Senna, Docusate. He was prescribed two stimulant laxatives which were in the same BNF 
group 1.6.2 [Senna and Docusate] (502). He disclosed that she had been taking Propranolol one tablet in the 
morning, rather than taking one twice a day as instructed (201). When asked about why he was taking Cod liver 
oil, Multivitamins and Garlic tablets, he stated that his wife asked him to take those tablets (405). He reported 
experiencing swelling in the legs as a side effect of taking Amlodipine (101). It was identified that he was unsure 
of the Doxazosin dosing frequency (207). At the beginning, he took one tablet three times a day and then his GP 
told him to take two tablets in the morning only. The dosing frequency recoded in the records was one tablet 
three times daily. He revealed forgetting to take his medicines once a month (‘sometimes’ on the Likert scale) 
(301). He declared delay renewal of repeat prescription twice or three times a year after his supply of medicines 
[Other than diabetic and BP] run out (806). 
Case 201-AR-F-62 was a 62 year old Arabic female. She disclosed that she had been taking Omeprazole only 
when needed, rather than taking one tablet a day (201) and when she had a strong stomach pain, she took 2 to 
3 tablets a day. She reported taking antidepressant tablets when required. However, she was prescribed one 
tablet to be taken daily. She revealed forgetting to take her medicines (‘often’ on the Likert scale) (301). She 
declared difficulties reading labels (303), hearing instructions (304) and opening containers/packs (302). When 
asked about why she was taking Omega-3 tablets, she could not disclose the exact reason (405). She reported 
difficulties consulting the same GP (909), getting an appointment to see the GP (901), consulting GP (904) and 
pharmacist (903). She stated that the pharmacy had never had complete stock (906). 
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Case study 
Case 202-AR-F-61 was a 61 year old Arabic female taking Lisinopril, Ibuprofen, Co-codamol, Mirtazapin, 
Prochlorperazine, Ispaghula, Calcichew D3, Orlistat, Anusol cream. It was identified that Omeprazole had been 
missing from her regime (501). She reported taking Ibuprofen, Mirtazapin and Prochlorperazine only when 
needed (201). She was prescribed one tablet daily from Mirtazapin and one tablet three times a day from both 
Ibuprofen and Prochlorperazine. She revealed difficulty opening containers because of her arthritis pain (302). 
She reported lack of hospital referral for her dizziness and legs problems (910). When asked about how well this 
arrangement at her GP surgery suited her, she disclosed problems with waiting time in the GP (911), getting 
appointment to see GP (901), attitude of receptionists (913) and length of consultations (912). She reported 
that she required more information on the reasons for her legs problems (702).  
Case 203-AR-M-63 was a 63 year old Arabic male taking Metformin, Gliclazide, Pioglitazone, Ramipril, 
Atorvastatin, Bezafibrate and Etoricoxib. He reported stop taking Pioglitazone (208) because of experiencing 
rash on his hands that he thought the Pioglitazone might be a possible cause of it (101). He disclosed that he 
sometimes was taking one tablet three times a day from Metformin instead of taking two tablets three times a 
day (201). He also revealed that he sometimes took Metformin before food rather than with food or after food 
(214). He also declared taking Aspirin as an OTC medicine one tablet a day. Concomitant use of low dose Aspirin 
with Etoricoxib, which he was prescribed, may result in an increased rate GI ulceration or disorder (402). When 
asked about when he took his Metformin tablets, he stated taking them before or after food (701).  
Case 204-AR-F-45 was a 45 year old Arabic female taking Methotrexate, Diclofenac sodium, Folic acid, 
Calcichew-D3 and Alendronic acid. She reported suffering itchy rash and redness of the skin as a side effect of 
Humira® (101). She revealed under using her Diclofenac tablets because of having ulcer caused by Diclofenac. 
Thus, her doctor changed the dosage form of Diclofenac from tablets to suppositories (212) and prescribed 
Omeprazole (503). She reported feeling sick, dizzy, drowsy and nauseated as side effects of taking 
Methotrexate. She disclosed difficulties opening Calcichew-D3 container when she had arthritis flare-ups (302). 
She reported that she forgot to take her Diclofenac and Calicichew-D3 sometimes (301). She also revealed that 
she had not been given enough information on illness and medicine (701,702) and that she wanted more 
discussion with her consultant. She stated having difficulties getting appointments to see the GP (901). 
Case 205-AR-F-57 was a 57 year old Arabic female taking Metformin, Ompeprazole, Simvastatin, Adcal-D3, 
Zoiclone, Venlafaxine, Fesoterodine, Tramadol and Paracetamol. She reported experiencing dryness all over her 
body including her mouth and skin, that she thought the Fesoterodine and Venlafaxine might be potential 
causes of it (101). She also revealed having hair loss as a side effect of taking her medicines and not drinking 
enough water. She also reported having itchy spots around her tummy which she expected to be a possible side 
effect of taking Simvastatin. She disclosed difficulties dissolving the Fesoterodine tablets easily in her mouth 
(212). She declared underusing her medicines in Ramadan especially Metformin, which she was taking 2 tablets 
a day from it rather than 3 tablets (201). She revealed forgetting to take her medicines once or twice a day 
(‘very often’ on the Likert scale) (301). She requested more information on diabetes, new and current medicines 
and on how to manage her medicines in Ramadan (701,702). When asked about how well this arrangement at 
her GP surgery suited her, she disclosed problems with bad attitude from receptionist (913) and short length of 
consultations (912) which inhibited her from fully disclosing her problems with the GP regarding the use of her 
medicines. 
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Case study 
Case 206-AR-M-66 was a 66 year old Arabic male taking Furosemide, Bendrofulmethiazide, Ramirpil, Bisoprolol, 
Spironolactone, Doxazosin, Isosorbide mononitrate (ISM), Novomix 30, Metformin, Atorvastatin, Clopidogrel, 
Omeprazole, Ipratropium, Ferrous fumarate, Amitriptyline, Pregabalin, Cinnarizine, Dihydrocodiene, 
Paracetamol, Allopurinol, Movelat cream. He reported that he underused his Insulin when his sugar level was 
normal (‘sometimes’ on the Likert scale) (201) and because he did not feel comfortable using a needle and 
syringe (212). When asked about why he was taking Ipratropium, Amitriptyline and ISMN, he couldn’t state the 
reasons (701). Finally, he had not received an information leaflet from the pharmacy when one of his medicines 
was dispensed during the interview (907).  
Case 208-PAK-F-35 was a 35 year old Pakistani female taking Ventolin, Seretide 250, Singulair, Lansoprazole, 
Levothyroxine, Diazepam. She reported taking Salbutamol regularly (around 20 puffs) each day instead of taking 
it when required (202). She reported difficulties making appointment at the GP surgery (901) and consulting the 
same GP (909). She also disclosed problems with long waiting time (911) and lack of hospital referral (910). She 
revealed taking Ibuprofen as an OTC medicine which is contraindicated in asthmatic patients (403) and may 
increase the risk of bleeding when Ibuprofen is taken with SSRIs such as Citalopram that the patient was using 
(402). 
Case 209-AR-M-49 was a 49 year old Arabic male taking Amlodipine, Atenolol, Ramipril, Metformin, Gliclazide, 
Simvastatin, Lansoprazole, Zopiclone, Gabapentin, Dosulepin, Diethylamine salicylate cream, Capsaicin cream. 
He had been told to take his Metformin tablets twice daily but on the pharmacy records it was read ‘take one 
three times a day’ and as a result was unsure of the dosing (207). He reported forgetting to take his medicines 
(‘Sometimes’ on Likert scale) and 4-5 times in the last month (301). He stated experiencing headache as a side 
effect of Atenolol (101). He revealed delay renewal of repeat prescription after his supply of diabetic and BP 
medicines run out on different occasions (806) which made him take diabetic and BP medicines that were 
prescribed for his mother until he ordered a repeat prescription (216). 
Case 210-AR-M-55 was a 55 year old Arabic male taking Metoprolol, GTN, Isosorbide dinitrate, Aspirin, 
Atorvastatin, Metformin, Ranatidine, Etoricoxib, Amitriptyline, Co-codamol, Doxazosin, Zoplidem, Saxagliptin, 
Tamsulosin. It was identified that he was taking Metformin 850 mg one tablet a day rather than taking twice 
tablet a day and taking 20 mg a day from Atorvastatin instead of taking 40 mg a day (201) and the GP was not 
informed of this alteration. When asked about why and how many tablet he was taking from Doxazosin, he 
couldn’t state the reasons and the amount (701). He required information on whether Metformin had a bad 
effect on the Heart. He revealed that since he had an open heart surgery done for him 10 years ago, he had not 
had a heart catheterization and he uncovered that he did not regularly visit his GP at the surgery (602). He 
reported forgetting to take his medicines about twice a month (‘sometimes’ on Likert scale) (301). He declared 
difficulties getting an appointment to see the GP (901) and problems with long waiting time inside the GP 
surgery (911). He stated that the pharmacy had never had complete stock (906). 
Case 211-IN-M-59 was a 59 year old Indian male taking Ramipril, Simvastatin, Colecalciferol and Escitalopram.  
He reported forgetting to take his Simvastatin about twice a year (‘rarley’ on Likert scale) (301).   
Case 212-AR-M-80 was an 80 year old Arabic male taking Salbutamol, Qvar, Simvastatin, Omeprazole, 
Betahistine, Tramadol, Vitamins, Paracetamol, Lidocaine hydrocortisone, hypromellose eye drops. He reported 
taking all his medicines when required apart from Simvastatin, although he was instructed to take Qvar, 
Omeprazole, Vitamins, Betahistine, Lidocaine hydrocortisone regularly (201). When asked about why he was 
taking Omeprazole, he couldn’t state the reason and he was not sure whether he had to take Omperazole tablet 
before or after food (701). He disclosed problems with short length of consultations with his GP (912). 
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Case study 
Case 213-AR-F-60 was a 60 year old Arabic female taking Humulin M3 insulin, Metformin, Lisinopril, Simvastatin, 
Ibuprofen, Paracetamol. She revealed taking two Metformin tablets per day and 30units of Insulin in the 
morning and 20units at night, although she was prescribed three Metformin tablets to be taken daily and 
40units of Insulin to be taken in the morning and in the evening (201). She declared difficulties getting an 
appointment to see the GP (901), and problems with short length of consultations with her GP (912). 
Case 214-AR-M-45 was a 45 year old Arabic male taking Furosemide, Ramipril, Bisoprolol, Amlodipine, Aspirin, 
Metformin, Clopidogrel, Atorvastatin, Orlistat. He reported that he stopped taking Atrovastatin because he did 
not think it was necessary (208). He also revealed that he was reducing the dose of Metformin once or twice a 
month from 2 tabs a day to 1 tab a day (‘sometimes’ on the Likert scale) (201) because of forgetfulness and 
experiencing tachycardia and tiredness that he thought that Metformin might be a potential cause of these side 
effects (101). He reported forgetting to take his medicines once or twice a week (‘often’ on the Likert scale) 
(301). He declared requiring more information on medicines (701) and more regular monitoring and review 
from his GP (602). When asked about why he was taking from Bisoprolol, Atorvastatin and Furosemide, he 
couldn’t state the right reasons. He reported difficulties getting an appointment to see the GP (901), and 
problems with long waiting time in the GP surgery (911). 
Case 216-AR-M-50 was a 50 year old Arabic male taking Bisoprolol, Aspirin, Simvastatin, GTN, Isosorbide 
mononitrate, Co-dydramol. He declared taking Simvastatin tablet in the morning rather than evening (214). He 
reported stop taking his medicines once or twice a month for 3 or 4 days when he was feeling better 
(‘sometimes’ on the Likert scale) (208). He revealed forgetting to take his medicines once or twice a week 
(‘often’ on the Likert scale) (301). He revealed delay renewal of repeat prescription two months ago after his 
supply of medicines run out which made him skip taking his medicines for two days (806). 
Case 302-AR-M-83 was an 83 year old Arabic male taking Furosemide, Bendroflumethiazide, Perindopril, 
Amlodipine, Doxazosin, Aspirin, Novomix 30 flexepen insulin, Metformin, Salbutamol inhaler, Beclometasone 
CFC-f inhaler, Omeprazole, Simvastatin. It was identified that he was taking Salbutamol regularly (2 puffs four 
times a day) instead of taking it when required (202). He revealed delay renewal of repeat prescription 
sometimes after his supply of medicines run out (806). 
Case 303-AR-F-53 was a 53 year old Arabic female taking Aspirin, Diazepam, Zoplicone, Gabapentin, Fluoxetine, 
Gaviscon, Omeprazole, Atrovastatin, Fesoterodine fumarate, co-codamol, Diclofenac tabs, Ibuprofen gel, 
Transvasin heat rub, Prochlorperazine, Adcal-D3. She had been prescribed Zopiclone for 17 years and Diazepam 
for 8 years (507). However, both Zopiclone and Diazepam are licensed for short-term use up to 4 weeks. She 
reported taking one tablet three times a day from Diazepam and Co-codamol regularly; although Diazepam and 
co-codamol were prescribed to be taken three times a day when required (202). She revealed stop taking 
Atrovastatin when she was feeling well (208). She revealed forgetting to take her medicines every day (‘very 
often’ on the Likert scale) (301). She declared difficulties getting an appointment to see the GP (901), and 
problems with length of consultations with her GP (912). 
Case 305-AR-F-32 was a 32 year old Arabic female taking Propranolol, Metoclopromide, Folic acid, Amitriptyline, 
Adcal-D3, Diclofenac. She revealed that she was taking one tablet only when needed from Amitriptyline. She 
was prescribed one tablet to be taken at night regularly (201). It was also identified that she was reducing the 
dose of Adcal-D3 to one tablet a day or none a day, although she was instructed to take Adcal-D3 twice a day. 
She reported experiencing vomiting and felling unwell as a result of the side effect of taking Diclofenac (101). 
She also revealed taking Metoclopromide, prescribed by her GP, for nausea and vomiting (503). She declared 
difficulties with long waiting time in the GP surgery (901), and problems with short length of consultations with 
her GP (912). She revealed delay renewal of repeat prescription last month after his supply of medicines run out 
because of not having enough money to pay for her prescription (806). 
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Case study 
Case 306-AR-M-47 was a 47 year old Arabic male taking Pioglitazone+Metformin, Gliclazide, Simvastatin, 
Omeprazole. He revealed that he was increasing the doses of Pioglitazone+Metformin and Gliclazide from 1 tab 
twice a day and 2 tablets twice a day respectively to 1 tabs three time a day and 2 tablets three times a day 
respectively, when his sugar level was elevating (202). He reported experiencing heartburn as a result of the 
side effect of taking Metformin (101). He also revealed taking Omeprazole, prescribed by her GP, for heartburn 
(503). He declared difficulties getting an appointment to see the GP (901). 
Case 308-AR-F-55 was a 55 year old Arabic female taking Propranolol, Simvastatin, Omeprazole, Adcal-D3, 
Naproxen. She reported forgetting to take her medicines once a week (‘sometimes’ on the Likert scale) (301). 
She declared difficulties getting an appointment to see the GP (901) and difficulties in consulting the same GP 
(909). 
Case 310-AR-F-43 was a 43 year old Arabic female taking Metformin, Gliclazide, Exenatide, Symbicort, 
Omeprazole. She had developed upset stomach and dry mouth, as a side effect of Insulin (101). She reported 
reducing the dose of Metformin from three tablets a day to two tablets a day during Ramadan (201). She 
reported forgetting to take Exenatide injection twice or three times a month (‘often’ on the Likert scale) (301). 
She declared difficulties getting an appointment to see her regular GP (909). 
Case 311-AR-F-45 was a 45 year old Arabic female taking Naproxen, Tranexamic acid, Fentanyl patches, 
Gabapentin, Mirtazapine, Fluoxetine, Amitriptyline, Omeprazole, Ranitidine. It was identified that she splitted 
the dose of Fluoxetine to one tablet three times a day when should be taken as three tablets in the morning 
(209). The use of a tricyclic antidepressant [Amitriptyline] may result in increase in plasma antidepressant 
concentrations and possibly antidepressant toxicity when fluoxetine is added (103). She declared difficulties 
opening containers or applying patches on her back because of her arthritic pain (302). She revealed under 
using Fluoxetine and Amitriptyline tablets, which should be taken regularly, when her pain was under control 
(201). She reported forgetting to take her medicines (‘sometimes’ on the Likert scale) (301). It was identified 
that she was taking both ranitidine and omeprazole (502). She revealed delay renewal of repeat prescription for 
Fentanyl patches twice after her supply run out (806). 
Case 312-AR-M-50 was a 50 year old Arabic male taking Bisoprolol, Ramipril, Atorvastatin, Aspirin, Fluoxetine. 
He reported forgetting to take his Aspirin once a month (‘sometimes’ on the Likert scale) (301). Because his 
Aspirin was in a form of dispersible tablets so while he was waiting for the tablet to dissolve in the water, he 
took his other medicines and forgot to take Aspirin.  
Case 313-AR-F-44 was a 44 year old Arabic female taking Salbutamol, Seretide, Paracetamol. She revealed 
taking Seretide only when needed, although it was prescribed to be taken as tow puffs twice a day (201).  She 
declared difficulties getting an appointment to see the GP (901), difficulties in consulting the same GP (909) and 
problems with short length of consultations with the GP (912). She reported a lack of on formation on 
medicines from the GP and she requested more information on her medicines (701). 
Case 401-AR-F-40 was a 40 year old Arabic female taking Ventolin, Clenil modulate, Humira injection, 
Methotrextae, Co-dydramol, Diclofenac, Colecalciferol, Folic acid, Oilatum emollient, Lansoprazole, Ispaghula, 
Diazepam. She reported experiencing stress and mode changes as side effects of taking Methotrexate (101). She 
took one puff twice a day from Beclometasone inhaler and on some occasions took one puff once a day (201). 
She revealed having problems with opening containers and pulling out tablets especially when experiencing 
flares (302). She had problems with the lack of referral to a hospital specialist (910). She revealed forgetting to 
take her medicines (‘sometimes’ on the Likert scale) (301). She declared difficulties getting an appointment to 
see the same GP (909), and problems with long waiting time in the GP surgery (911). She revealed delay 
renewal of repeat prescription on different occasions after her supply of medicines run out (806). 
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Case study 
Case 402-AR-M-65 was a 65 year old Arabic male taking Metformin, Salbutamol, Co-dydramol, Cetomacrogol 
cream. He reported taking one tablet three times a day from Metformin; although Metformin was prescribed to 
be taken as one tablet twice a day (202). He declared forgetting to take his medicines especially when he was 
going out (‘rarely’ on the Likert scale) (301). He revealed delay renewal of repeat prescription on different 
occasions after his supply of medicines run out (806). She disclosed difficulties getting an appointment to see 
the doctor (901). 
Case 404-AR-M-45 was a 45 year old Arabic male taking Metformin, Fluoxetine, Temazepam, Co-dydramol, 
Ibugel, Folic acid. He reported taking 2 tablets from Temazepam at night, 2 tablets from Fluoxetine in the 
afternoon and 2 tablets from Simvastatin one in the afternoon and one in the evening. He was prescribed one 
tablet from each to be taken daily (202). It was identified that he took one tablet daily from Metformin rather 
than 3 tablets daily as prescribed (201). He revealed forgetting to take his medicines (‘sometimes’ on the Likert 
scale) (301). He had been prescribed Temazepam for almost 10 years (507). He requested more information on 
his medicines (701). He reported delay renewal of repeat prescription on different occasions after his supply of 
medicines run out (806). 
Case 407-AR-M-56 was a 56 year old Arabic male taking Atenolol, Amlodipine, Benzafibrate, Simvastatin, 
Aspirin. He revealed forgetting to take his medicines three or four times a year (‘sometimes’ on the Likert scale) 
(301). He reported delay renewal of repeat prescription on different occasions after his supply of medicines run 
out because he was a full-time worker (806). 
Case 502-AR-F-65 was a 65 year old Arabic female taking Bisoprolol, Irbesartan, Clopidogrel, Fluticasone+ 
Salmeterol, Calcichew-D3, Rosuvastatin, Ezetimibe, Diclofenac, Esmoprazole. She reported experiencing muscle 
pain and weakness as a side effect of taking Rosuvastatin (101). She revealed forgetting to take her evening 
tablets [Rosuvastatin and Bisoprolol] (‘rarely’ on the Likert scale) (301). She declared that she had stopped 
ordering further supplies of Salbutamol inhaler which was prescribed and was on her repeat form, because she 
did not need it (803). 
Case 503-IRN-F-63 was a 63 year old Iranian female taking Aspirin, Cholecalciferol + Calcium carbonate, 
Levothyroxin, Simvastatin. She reported taking 2 tablets of Cholecalciferol + Calcium carbonate at once when 
should be taken as one tablet twice daily (213). She revealed delay renewal of repeat prescription on different 
occasions after her supply of medicines run out (806). She declared difficulties getting an appointment to see 
the GP (901), and problems with long waiting time in the GP surgery (911). 
Case 507-AR-F-39 was a 39 year old Arabic female taking Diazepam, Fluoxetine, Zolpidem, Omeprazole, 
Diclofenac, Piroxicam. She had been prescribed Zolpidem for three years (507). Although, Zolpidem is not 
licensed for long term use and it should not be used for more than 4 weeks. Therefore, Zolpidem should not 
have been in her prescribed regime for more than 4 weeks (506). The problem was as a result of her GP. She 
reported experiencing internal skin rash as a side effect of taking Diazepam and Zolpidem (101). She revealed 
taking Omeprazole sometimes three tablets a day (202) and sometimes one or none a day depending on 
whether she had strong stomach pain or not (201). She was prescribed 20 mg Omeprazole tablets to be taken 
twice a day. She also declared increasing the dose of Zolpidem once a month from one tablet at night to 2 or 3 
tablets at night especially before the period when she was feeling unwell. She disclosed feeling neglected, 
stressed and depressed because of the attitude of her GP (913). She had problems with the lack of referral to a 
mental health specialist (910). 
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Case study 
Case 601-PAK-F-65 was a 65 year old Pakistani female taking Bendroflumethiazide, Metoprolol, Ramipril, 
Atorvastatin, Folic acid, Paracetamol. She had stopped taking Ramipril without informing her GP because she 
thought the Ramipril might be a potential cause of her stomach pain (208). She declared asking the GP before to 
stop taking her BP tablet but he advised her to avoid doing that. She reported taking a tablet and a half from the 
Metoprolol in the morning all at once (213). However, she should take half tablet three times a day. It was 
identified that Omeprazole had been missing from her regime (501); although she had told her GP that she was 
experiencing stomach pain. When asked about why she was taking Atorvastatin, she stated for ulcer (701).  
Case 602-PAK-M-54 was a 54 year old Pakistani male taking Perindopril, Amlodipine, Bisoprolol, Atorvastatin, 
Aspirin, Clopidogrel, Lansoprazole. He was prescribed antihistamine for allergy (503), which had been attributed 
to aspirin sensitivity. He revealed having stomach bleeding because of taking Aspirin on an empty stomach 
(101).  
Case 603-IN-M-51 was a 51 year old Indian male taking Bendroflumethiazide, Amlodipine, Perindopril, 
Omeprazole, Latanoprost eye drops, Diclofenac gel.  He was prescribed diclofenac gel for aches and pains (503), 
which may have been attributed to a potential side effect of taking Mesalazine (Pantasa®). He had developed 
swollen legs and lethargy, as a side effect of Amlodipine (101). He revealed delay renewal of repeat prescription 
once or twice last year after his supply of medicines run out (806) which made him skipped taking his medicines 
because of not having extra supply at home (201). He required information on the reason for why all these 
aches and pains were occurring to him (702). 
Case 604-AR-F-52 was a 52 year old Arabic female taking Metformin, Gliclazide, Simvastatin, 
Hydroxychloroquine, Ibuprofen gel, Betahistin and Otomize spray. She reported having frequent headache, 
earache, vertigo and dizziness as a result of the side effect of taking Hydroxychloroquine (101). She also 
revealed taking Betahistin and Otomize spray, prescribed by her GP, for vertigo and earache (503). She declared 
experiencing a weight loss as a side effect of taking Metformin. She reported taking Hydroxychloroquine, 200 
mg twice or three times a day sometimes depending on the level of arthritis pain, instead of 200 mg once a day 
and the GP was not informed of this alteration (202). She also stated taking Simvastatin in the morning rather 
than evening (214). She reported forgetting to take her medicines (‘often’ on Likert scale) (301). When asked 
about why she was taking Simvastatin, she got confused whether it was used for diabetes or for cholesterol 
(701). Finally, she had not received an information leaflet last time from the pharmacy when an antibiotic was 
dispensed to her (907).  
Case 605-IN-M-66 was a 66 year old Indian male taking Indapamide, Perindopril, Amlodipine, Doxazosin, 
Bisoprolol, GTN spray, Isosorbide mononitrate (ISMN), Aspirin, Clopidogrel, Atorvastatin, Lansoprazole. When 
asked about why he was taking Isosorbide mononitrate, he couldn’t tell the reason and he got confused 
between ISMN and Bisoprolol and ISMN and Amlodipine (701). He revealed delay prescription renewal, 2 or 3 
times last year after his supply of medicines run out especially with Amlodpine because it was the only medicine 
that was prescribed for one month repeat supply whereas all his other medicines were for 2 months repeat 
supply (806). Thus, he wanted the repeat prescription service to be introduced at the pharmacy. He declared 
difficulties getting an appointment to see the GP (901) and that the GP didn’t like to discuss more than one 
problem at a time. 
Case 606-IN-M-81 was an 81 year old Indian Male taking Bumetanide, Carvedilol, Isosorbide mononitrate, 
Aspirin, Humalog Mix25, Pravastatin, Omeprazole, Levothyroxine, Allopurinol, Citalopram, Maxepa. It was 
difficult for him to identify medicines he was taking currently on his repeat form (804). He reported having 
hearing (303) and reading difficulties (304). He had been experiencing stomach upset and nausea because of 
taking Senna (101).  
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Case study 
Case 607-IN-F-75 was a 75 year old Indian female taking Doxazosin, Losartan, Metformin, Atorvastatin, 
Omeprazole, Betahistine, Co-codamol, Forceval caps, and hypromellose eye drops. She reported under using 
her medicines (‘often’ on Likert scale), mostly with Metformin and Insulin because of having stomach problems 
that prevent her from eating her food and medicines (201). She declared taking Senna; however, Senna was 
prescribed for her husband not for her (216). It was indicated that Insulin was no longer used although it was 
remaining on form (804). She reported having difficulties in reading because she was illiterate and could not 
speak, read or write English (303). She revealed having problems with opening containers due to her arthritis 
pain (302) and problems with swallowing big tablets (305). When asked about why she was taking Losartan, she 
couldn’t tell the reason (701). When asked whether she had enough information on her medicines, her 
daughter reported that her mother could not remember and got confused about why she should take each 
medicine. She declared delay taking her prescription to the pharmacy after her supply of medicines run out 
(806). She also reported experiencing lots of side effects with her medicines (101) because there was a problem 
with the pharmacy supplying medicines from various manufacturers and different brands (905) and thus the 
quality of her medicines may differ each month. She announced that the arrangement at the GP surgery was 
not bad but there were difficulties consulting the GP and diabetic nurse (902) and making appointment at the 
GP surgery generally (901). She revealed that the GPs would not conduct emergency home visits in Brent, 
whereas in Barent, where she had been living previously, he would because the area was full of White British. 
She also reported that the length of time spent on consultation was in and out (912). She believed that the 
doctors didn’t know what they were doing. For example, she declared that diabetes team did not understand 
that she had other problems that may lead to uncontrolled sugar level. Miscommunication on behalf of the 
team and lack of cultural understanding were reported by the participant. She also disclosed nurse’s lack of 
knowledge of diabetes and diabetes medications. Her daughter revealed having difficulties dealing with GP staff 
and that the GP staff did not make the effort to make her life easier (913).  
Case 608-IN-F-50 was a 50 year old Indian female taking Gliclazide, Sitagliptin, Repaglinide, Amlodipine, 
Candesartan and Colecalciferol+calcium carbonate. She reported forgetting to take her medicines twice every 6 
months (‘sometimes’ on the Likert scale) when she was rushing out to work (301). She revealed suffering 
abdominal pain and bloating as side effects of taking Metformin and Gliclazide (101). She reported that she had 
refused to use Insulin, which was recommended by her GP, because she did not feel comfortable using a needle 
and syringe in public and at work and because she was the only carer for her parents (212). She disclosed 
experiencing dizziness when taking repaglinide and gliclazide half an hour before food, because she forgot to 
eat after taking repaglinide and gliclazide. She declared not having regular monitoring or review (602). She 
reported difficulties making appointment at the GP surgery (901) and problems with short length of 
consultation (912). She wanted more information on side effects, drug-drug interactions long term effects of 
her current medicines (701). She revealed difficulty getting a hospital referral (910). 
Case 611-IN-M-64 was a 64 year old Indian male taking Metformin, Gliclazide, Irbesartan, Amlodipine, Aspirin, 
Simvastatin. He reported taking one tablet twice a day from Metformin; although it was prescribed to be taken 
as one tablet once a day (202). When asked about how well this arrangement at his GP surgery suited him, he 
disclosed problems with attitude of receptionists (913). 
Case 613-IN-M-64 was a 64 year old Indian male taking Novomix, Metformin, Gliclazide, Atenolol, Losartan, 
Aspirin, Atorvastatin, Amitriptyline. He revealed having external allergy from heat patches (102). He reported 
forgetting to take his afternoon and evening medicines once or twice a month (‘Rarely’ on the Likert scale) 
(301). He declared difficulties getting an appointment to see the same GP (909), and problems with short length 
of consultations with the GP (912). He disclosed delay taking his prescription to the pharmacy after her supply 
of medicines run out once or twice this year during the bank holidays’ time (806). 
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Case study 
Case 701-IN-M-77 was a 77 year old Indian male taking Amiodarone, Furosemide, Bisoprolol, Amlodipine, 
Losartan, Metformin, Pioglitazone, Glimepiride, Aspirin, Atorvastatin, Omeprazole, Paracetamol, Goserelin, 
Tamsulosin, Quinine sulphate, Folic acid, Ferrous fumarate, Vitamin A+D. He was prescribed by the GP surgery 
the wrong dose of Amiodarone [200 mg three times daily] (504). He reported forgetting to take his morning and 
afternoon medicines once or twice a month (‘sometimes’ on the Likert scale) (301). 
Case 709-IN-M-66 was a 66 year old Indian male taking Furosemide, Nicorandil, Losartan, Bisoprolol, ISMN, 
Clopidogrel, Aspirin, Metformin, Rosuvastatin, Paracetamol, Omeprazole. He had told the specialist that he felt 
dizzy when taking Nicorandil and had skin pigmentations when taking Rosuvastatin and subsequently to these 
the Nicorandil dose was reduced and Rosuvastatin was still prescribed (101). He reported forgetting to take his 
morning tablets once to three times a year (‘sometimes’ on the Likert scale) (301). He requested more 
information about his medicines especially the side effects (701). He declared delay renewal of repeat 
prescription several times after his supply of medicines run out (806). When asked about how well this 
arrangement at his GP surgery suited him, he disclosed problems with getting appointment to see GP (901) and 
short length of consultations (912). 
Case 710-IN-M-58 was a 58 year old Indian male taking Carvedilol, Candesartan, Atorvastatin, Adcal-D3. He 
revealed forgetting to take his evening tablets twice a year (‘rarely’ on Likert scale) (301). He reported getting 
confused between two medicines because the pharmacy was supplying medicines from various manufacturers 
and suppliers (905). 
Case 711-AR-F-18 was an 18 year old Arabic female taking Ventolin, Symbicort, Quetiapine, Azelaic acid cream, 
Tretinoin. She reported forgetting to take her medicines every other day (‘often’ on Likert scale) (301). She 
revealed under using Quetiapine, Azelaic acid cream, Tretinoin (‘sometimes’ on Likert scale) (201). She also 
disclosed problems with long waiting time (911) and getting appointments to see GP (901). She declared delay 
renewal of repeat prescription several times after her supply of medicines run out which made her skip taking 
her medicines on time as instructed (806). She requested more information about the inflammation in her body 
(702). 
Case 713-IN-M-64 was a 64 year old Indian male taking Amlodipine, Irbesratan, Alendronic acid, Vitamin D3, 
Prednisolone, Co-codamol, Paracetamol. He reported experiencing fever, shortness of breath and abdominal 
pain as a side effect of taking Alendronic acid (101). It was identified that Omeprazole had been missing from his 
regime (501). Although, he was taking Alendronic acid and Prednisolone which are both linked with peptic 
ulceration and stomach discomfort. He declared suffering from stomach pain. It was identified that he was 
prescribed two analgesics containing Paracetamol as an active ingredient [Co-codamol and Paracetamol] (502). 
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